WO2019125974A1 - Cyclic di-nucleotide compounds as sting agonists - Google Patents

Cyclic di-nucleotide compounds as sting agonists Download PDF

Info

Publication number
WO2019125974A1
WO2019125974A1 PCT/US2018/065902 US2018065902W WO2019125974A1 WO 2019125974 A1 WO2019125974 A1 WO 2019125974A1 US 2018065902 W US2018065902 W US 2018065902W WO 2019125974 A1 WO2019125974 A1 WO 2019125974A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
alkyl
independently selected
base
cycloalkyl
Prior art date
Application number
PCT/US2018/065902
Other languages
French (fr)
Inventor
Brian M. Andresen
Frank Bennett
Wonsuk Chang
Matthew Lloyd CHILDERS
Jared N. Cumming
Jongwon Lim
Min Lu
Benjamin Wesley TROTTER
Wen-Lian Wu
Original Assignee
Merck Sharp & Dohme Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.
Priority to US16/771,814 priority Critical patent/US11685761B2/en
Priority to EP18890472.6A priority patent/EP3727401A4/en
Publication of WO2019125974A1 publication Critical patent/WO2019125974A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Definitions

  • the present disclosure relates to cyclic di-nucleotide compounds and derivatives thereof that may be useful as STING (Stimulator of Interferon Genes) agonists that activate the STING pathway.
  • STING Stimulator of Interferon Genes
  • the present disclosure also relates to processes for the synthesis and to uses of such cyclic di-nucleotide compounds. REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY
  • sequence listing of the present application is submitted electronically via EFS- Web as an ASCII-formatted sequence listing, with a file name of
  • the immune system has evolved to recognize and neutralize different types of threats in order to maintain the homeostasis of the host, and it is generally broken down into two arms: adaptive and innate.
  • the adaptive immune system is specialized to recognize as foreign those antigens not naturally expressed in the host and to mount an anti-antigen response through the coordinated actions of many leukocyte subsets.
  • the hallmark of adaptive immune responses is their ability to provide“memory” or long-lasting immunity against the encountered antigen. While this specific and long-lasting effect is critical to host health and survival, the adaptive immune response requires time to generate a full-blown response.
  • the innate immune system compensates for this time delay and is specialized to act quickly against different insults or danger signals. It provides the first line of defense against bacteria, viruses, parasites and other infectious threats, but it also responds strongly to certain danger signals associated with cellular or tissue damage.
  • the innate immune system has no antigen specificity but does respond to a variety of effector mechanisms. Opsonization, phagocytosis, activation of the complement system, and production of soluble bioactive molecules such as cytokines or chemokines are all mechanisms by which the innate immune system mediates its response. By responding to these damage-associated molecular patterns (DAMPs) or pathogen-associated molecular patterns (PAMPs) described above, the innate immune system is able to provide broad protection against a wide range of threats to the host.
  • DAMPs damage-associated molecular patterns
  • PAMPs pathogen-associated molecular patterns
  • cytosolic DNA and RNA are among these PAMPs and DAMPs. It has recently been demonstrated that the main sensor for cytosolic DNA is cGAS (cyclic GMP-AMP synthase). Upon recognition of cytosolic DNA, cGAS catalyzes the generation of the cyclic- dinucleotide 2’3’-cGAMP, an atypical second messenger that strongly binds to the ER- transmembrane adaptor protein STING. A conformational change is undergone by cGAMP- bound STING, which translocates to a perinuclear compartment and induces the activation of critical transcription factors IRF-3 and NF- ⁇ B. This leads to a strong induction of type I interferons and production of pro-inflammatory cytokines such as IL-6, TNF- ⁇ and IFN- ⁇ .
  • pro-inflammatory cytokines such as IL-6, TNF- ⁇ and IFN- ⁇ .
  • type I interferons and pro-inflammatory cytokines have been very well established.
  • these molecules strongly potentiate T-cell activation by enhancing the ability of dendritic cells and macrophages to uptake, process, present and cross-present antigens to T-cells.
  • the T-cell stimulatory capacity of these antigen-presenting cells is augmented by the up-regulation of critical co-stimulatory molecules, such as CD80 or CD86.
  • type I interferons can rapidly engage their cognate receptors and trigger the activation of interferon-responsive genes that can significantly contribute to adaptive immune cell activation.
  • type I interferons are shown to have antiviral activities by directly inhibiting human hepatitis B virus and hepatitis C virus replication, and by stimulating immune responses to virally infected cells.
  • Compounds that can induce type I interferon production are used in vaccines, where they act as adjuvants, enhancing specific immune responses to antigens and minimizing side effects by reducing dosage and broadening the immune response.
  • interferons and compounds that can induce interferon production, have potential use in the treatment of human cancers. Such molecules are potentially useful as anti- cancer agents with multiple pathways of activity. Interferons can inhibit human tumor cell proliferation directly and may be synergistic with various approved chemotherapeutic agents. Type I interferons can significantly enhance anti-tumor immune responses by inducing activation of both the adaptive and innate immune cells. Finally, tumor invasiveness may be inhibited by interferons by modulating enzyme expression related to tissue remodeling.
  • the present disclosure relates to novel compounds of general formula (I).
  • the present disclosure relates to compounds having the general structural formula (I):
  • Embodiments of the disclosure include compounds of general formula (I), and pharmaceutically acceptable salts, hydrates, solvates, or prodrugs thereof, as well as synthesis and isolation of compounds of general formula (I), and pharmaceutically acceptable salts, hydrates, solvates, or prodrugs thereof.
  • the compounds of general formula (I), and their pharmaceutically acceptable salts, hydrates, solvates, and/or prodrugs may be useful as agents to induce immune responses, to induce STING-dependent type I interferon production, and/or to treat a cell proliferation disorders, such as cancers, in a subject.
  • the compounds of general formula (I) could further be used in combination with other therapeutically effective agents, including but not limited to, other drugs useful for the treatment of cell proliferation disorders, such as cancers.
  • the invention further relates to processes for preparing compounds of general formula (I), and pharmaceutical compositions that comprise compounds of general formula (I) and pharmaceutically acceptable salts thereof.
  • the present disclosure includes compounds of general formula (I), and
  • the present disclosure includes compounds of general formula (I), and
  • Embodiments disclosed herein relate to compounds of general formula (I) or pharmaceutically acceptable salts, hydrates, solvates, or prodrugs thereof, wherein Base 1 and
  • Base 2 are each independently selected from the group consisting of , ,
  • R 2 and R 2a C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 haloalkyl, C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, -O-C 1 -C 6 alkyl, -O-C 2 -C 6 alkenyl, and
  • R 3 is selected from the group consisting of H, F, Cl, Br, I, OH, CN, N 3 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 haloalkyl, C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, -O-C 1 -C 6 alkyl, -O-C 2 -C 6 alkenyl, and -O-C 2 -C 6 alkynyl, where said R 3 C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 haloalkyl, C 2
  • each R 9 C 1 -C 20 alkyl is optionally substituted by 0 to 3 substituents independently selected from the group consisting of OH, -O-C 1 -C 20 alkyl,-S-C(O)C 1 -C 6 alkyl, and C(O)OC 1 -C 6 alkyl; optionally R 1a and R 3 are connected to form C 1 -C 6 alkylene, C 2 -C 6 alkenylene, -O-C 1 -C 6 alkylene, or -O-C 2 -C 6 alkenylene, such that where R 1a and R 3 are connected to form -O-C 1 -C 6 alkylene, or -O-C 2 -C 6 alkenylene, said O is bound at the R 3 position; optionally R 2a and R 3 are connected to form C 1 -C 6 alkylene, C 2 -C 6 alkenylene, -O-C 1 -C 6 alkylene, or -O-C 2 -
  • At least one of Base 1 and Base 2 is each independently selected
  • variables Base 1 , Base 2 , Y, Y a , X a , X a1 , X b , X b1 , X c , X c1 , X d , X d1 , R 1 , R 1a , R 2 , R 2a , R 3 , R 4 , R 4a , R 5 , R 6 , R 6a , R 7 , R 7a , R 8 , R 8a , and R 9 of general formula (I), and the various aspects thereof, are each selected independently from each other.
  • Base 1 and Base 2 are each independently selected from the
  • Base 1 and Base 2 are each independently selected from the group consisting of
  • Base 1 and Base 2 each may be independently substituted by 0-3 substituents R 10 , where each R 10 is independently selected from the group consisting of F, Cl, I, Br, OH, SH, NH 2 , C 1-3 alkyl, C 3-6 cycloalkyl, O(C 1-3 alkyl), O(C 3-6 cycloalkyl), S(C 1-3 alkyl), S(C 3-6 cycloalkyl), NH(C 1-3 alkyl), NH(C 3-6 cycloalkyl), N(C 1-3 alkyl) 2 , and N(C 3-6 cycloalkyl) 2 .
  • R 10 is independently selected from the group consisting of F, Cl, I, Br, OH, SH, NH 2 , C 1-3 alkyl, C 3-6 cycloalkyl, O(C 1-3 alkyl), O(C 3-6 cycloalkyl), S(C 1-3 alkyl), S(C 3-6 cycloalkyl),
  • Base 1 and Base 2 are each independently selected from the group consisting of
  • Base 1 and Base 2 are each
  • Base 1 and Base 2 each may be independently substituted by 0-3 substituents R 10 , where each R 10 is independently selected from the group consisting of F, Cl, I, Br, OH, SH, NH 2 , C 1-3 alkyl, C 3-6 cycloalkyl, O(C 1-3 alkyl), O(C 3-6 cycloalkyl), S(C 1-3 alkyl), S(C 3-6 cycloalkyl), NH(C 1-3 alkyl), NH(C 3-6 cycloalkyl), N(C 1-3 alkyl) 2 , and N(C 3-6 cycloalkyl) 2 .
  • Base 1 and Base 2 are each independently selected from the group consisting of
  • Base 1 and Base 2 are each independently selected from Base 1 and Base 2 independently
  • Base 1 and Base 2 each may be independently substituted by 0-3 substituents R 10 , where each R 10 is independently selected from the group consisting of F, Cl, I, Br, OH, SH, NH 2 , C 1-3 alkyl, C 3-6 cycloalkyl, O(C 1-3 alkyl), O(C 3-6 cycloalkyl), S(C 1-3 alkyl), S(C 3-6 cycloalkyl), NH(C 1-3 alkyl), NH(C 3-6 cycloalkyl), N(C 1-3 alkyl) 2 , and N(C 3-6 cycloalkyl) 2 .
  • R 10 is independently selected from the group consisting of F, Cl, I, Br, OH, SH, NH 2 , C 1-3 alkyl, C 3-6 cycloalkyl, O(C 1-3 alkyl), O(C 3-6 cycloalkyl), S(C 1-3 alkyl), S(C 3-6 cycloalkyl),
  • Base 1 and Base 2 are each independently selected from the group consisting of
  • Base 1 and Base 2 are each
  • Base 1 and Base 2 each may be independently substituted by 0-3 substituents R 10 , where each R 10 is independently selected from the group consisting of F, Cl, I, Br, OH, SH, NH 2 , C 1-3 alkyl, C 3-6 cycloalkyl, O(C 1-3 alkyl), O(C 3-6 cycloalkyl), S(C 1-3 alkyl), S(C 3-6 cycloalkyl), NH(C 1-3 alkyl), NH(C 3-6 cycloalkyl), N(C 1-3 alkyl) 2 , and N(C 3-6 cycloalkyl) 2 .
  • Base 1 and Base 2 are each independently selected from the group consisting of F, Cl, I, Br, OH, SH, NH 2 , C 1-3 alkyl, C 3-6 cycloalkyl, O(C 1-3 alkyl), O(C 3-6 cycloalkyl), S(C 1-3 alkyl), S(C 3-6 cycloal
  • Base 1 and Base 2 are each independently selected from the group consisting of
  • Base 1 and Base 2 each may be independently substituted by 0-3 substituents R 10 , where each R 10 is independently selected from the group consisting of F, Cl, I, Br, OH, SH, NH 2 , C 1-3 alkyl, C 3-6 cycloalkyl, O(C 1-3 alkyl), O(C 3-6 cycloalkyl), S(C 1-3 alkyl), S(C 3-6 cycloalkyl), NH(C 1-3 alkyl), NH(C 3-6 cycloalkyl), N(C 1-3 alkyl) 2 , and N(C 3-6 cycloalkyl) 2 .
  • R 10 is independently selected from the group consisting of F, Cl, I, Br, OH, SH, NH 2 , C 1-3 alkyl, C 3-6 cycloalkyl, O(C 1-3 alkyl), O(C 3-6 cycloalkyl), S(C 1-3 alkyl), S(C 3-6 cycloalkyl),
  • Base 2 is selected from the group
  • Base 1 and Base 2 is each independently selected from the group consisting of
  • Base 1 and Base 2 each may be independently substituted by 0-3 substituents R 10 , where each R 10 is independently selected from the group consisting of F, Cl, I, Br, OH, SH, NH 2 , C 1-3 alkyl, C 3-6 cycloalkyl, O(C 1-3 alkyl), O(C 3-6 cycloalkyl), S(C 1-3 alkyl), S(C 3-6 cycloalkyl), NH(C 1-3 alkyl), NH(C 3-6 cycloalkyl), N(C 1-3 alkyl) 2 , and N(C 3-6 cycloalkyl) 2 .
  • R 10 is independently selected from the group consisting of F, Cl, I, Br, OH, SH, NH 2 , C 1-3 alkyl, C 3-6 cycloalkyl, O(C 1-3 alkyl), O(C 3-6 cycloalkyl), S(C 1-3 alkyl), S(C 3-6 cycloalkyl),
  • Y and Y a are each independently selected from the group consisting of -O- and -S-. In this embodiment, all other groups are as provided in the general formula (I) above or in the first embodiment described above.
  • X a and X a1 are each independently selected from the group consisting of -O- and -S-. In this embodiment, all other groups are as provided in the general formula (I) above or in the first through second embodiments described above.
  • X b and X b1 are each independently selected from the group consisting of -O- and -S-. In this embodiment, all other groups are as provided in the general formula (I) above or in the first through third embodiments described above.
  • X c and X c1 are each independently selected from the group consisting of -OR 9 , -SR 9 , and -NR 9 R 9 , where each R 9 is independently selected from the group
  • X c and X c1 are each independently selected from the group consisting of -OH,
  • X c and X c1 are each independently selected from the group consisting of -OH and -SH. In all aspects of this embodiment, all other groups are as provided in the general formula (I) above or in the first through fourth embodiment described above.
  • X d and X d1 are each independently selected from the group consisting of O and S.
  • all other groups are as provided in the general formula (I) above or in the first through fifth embodiments described above.
  • R 1 and R 1a are each H.
  • all other groups are as provided in the general formula (I) above or in the first through sixth embodiments described above.
  • R 2 and R 2a are each independently selected from the group consisting of H, F, Cl, I, Br, OH, CN, N 3 , C 1 -C 6 alkyl, and C 1 -C 6 haloalkyl, where said R 2 and R 2a C 1 -C 6 alkyl or C 1 -C 6 haloalkyl are substituted by 0 to 3 substituents selected from the group consisting of OH, CN, and N 3 .
  • R 2 and R 2a are each independently selected from the group consisting of H, F, Cl, I, Br, OH, CN, N 3 , -CF 3 , -CH 3 , -CH 2 OH, and -CH 2 CH 3 .
  • R 2 and R 2a are each independently selected from the group consisting of H, F, Cl, OH, CN, N 3 , and -CH 3 .
  • R 2 and R 2a are each independently selected from the group consisting of H, F, and OH. In all aspects of this embodiment, all other groups are as provided in the general formula (I) above or in the first through seventh embodiments described above.
  • R 3 is selected from the group consisting H, F, Cl, I, Br, OH, CN, N 3 , C 1 -C 6 alkyl, and C 1 -C 6 haloalkyl, where said R 3 C 1 -C 6 alkyl or C 1 -C 6 haloalkyl are substituted by 0 to 3 substituents selected from the group consisting of OH, CN, and N 3 .
  • R 3 is selected from the group consisting of H, F, Cl, I, Br, OH, CN, N 3 , -CF 3 , -CH 3 , -CH 2 OH, and -CH 2 CH 3 .
  • R 3 is selected from the group consisting of H, F, Cl, OH, CN, N 3 , and -CH 3 . In even more particular aspects, R 3 is selected from the group consisting of H, F, and OH. In all aspects of this embodiment, all other groups are as provided in the general formula (I) above or in the first through eighth embodiments described above.
  • R 4 and R 4a are each independently selected from the group consisting of H, F, Cl, I, Br, CN, OH, N 3 , C 1 -C 6 alkyl, and C 1 -C 6 haloalkyl, where said R 4 and R 4a C 1 -C 6 alkyl or C 1 -C 6 haloalkyl are substituted by 0 to 3 substituents selected from the group consisting of OH, CN, and N 3 .
  • R 4 and R 4a are each independently selected from the group consisting of H, F, Cl, I, Br, OH, CN, N 3 , -CF 3 , -CH 3 , -CH 2 OH, and -CH 2 CH 3 .
  • R 4 and R 4a are each independently selected from the group consisting of H, F, Cl, OH, CN, N 3 , and -CH 3 .
  • R 4 and R 4a are each independently selected from the group consisting of H, F, and OH. In all aspects of this embodiment, all other groups are as provided in the general formula (I) above or in the first through ninth embodiments described above.
  • R 5 is selected from the group consisting of H, F, Cl, I, Br, OH, CN, N 3 , C 1 -C 6 alkyl, and C 1 -C 6 haloalkyl, where said R 5 C 1 -C 6 alkyl or C 1 -C 6 haloalkyl are substituted by 0 to 3 substituents selected from the group consisting of OH, CN, and N 3 .
  • R 5 is selected from the group consisting of H, F, Cl, I, Br, OH, CN, N 3 , -CF 3 , -CH 3 , -CH 2 OH, and -CH 2 CH 3 .
  • R 5 is selected from the group consisting of H, F, Cl, OH, CN, N 3 , and CH 3 . In even more particular aspects, R 5 is selected from the group consisting of H, F, and OH. In all aspects, all other groups are as provided in the general formula (I) above or in the first through tenth embodiments described above.
  • R 6 and R 6a are each independently selected from the group consisting of H, F, Cl, I, Br, OH, CN, N 3 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, and C 2 -C 6 alkynyl, where said R 6 and R 6a C 1 -C 6 alkyl, C 2 -C 6 alkenyl, and C 2 -C 6 alkynyl are substituted by 0 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, CN, and N 3 .
  • R 6 and R 6a are each H. In all aspects of this embodiment, all other groups are as provided in the general formula (I) above or in the first through eleventh embodiments described above.
  • R 7 and R 7a are each independently selected from the group consisting of H, C 1 -C 6 alkyl, and C 1 -C 6 haloalkyl, where said R 7 and R 7a C 1 -C 6 alkyl or C 1 -C 6 haloalkyl are substituted by 0 to 3 substituents selected from the group consisting of OH, CN, and N 3 .
  • R 7 and R 7a are each independently selected from the group consisting of H, -CF 3 , -CH 3 , and -CH 2 CH 3 .
  • R 7 and R 7a are each H.
  • all other groups are as provided in the general formula (I) above or in the first through twelfth embodiments described above.
  • R 8 and R 8a are each independently selected from the group consisting of H, C 1 -C 6 alkyl, and C 1 -C 6 haloalkyl, where said R 8 and R 8a C 1 -C 6 alkyl or C 1 -C 6 haloalkyl are substituted by 0 to 3 substituents selected from the group consisting of OH, CN, and N 3 .
  • R 8 and R 8a are each independently selected from the group consisting of H, -CF 3 , -CH 3 , and -CH 2 CH 3 .
  • R 8 and R 8a are each H.
  • all other groups are as provided in the general formula (I) above or in the first through thirteenth embodiments described above.
  • R 1a and R 3 are connected to form C 1 -C 6 alkylene, C 2 -C 6 alkenylene, -O-C 1 -C 6 alkylene, or -O-C 2 -C 6 alkenylene, such that where R 1a and R 3 are connected to form -O-C 1 -C 6 alkylene or -O-C 2 -C 6 alkenylene, said O is bound at the R 3 position.
  • all other groups are as provided in the general formula (I) above or in the first through fourteenth embodiments described above.
  • R 2a and R 3 are connected to form C 1 -C 6 alkylene, C 2 -C 6 alkenylene, -O-C 1 -C 6 alkylene, or -O-C 2 -C 6 alkenylene, such that where R 2a and R 3 are connected to form -O-C 1 -C 6 alkylene or -O-C 2 -C 6 alkenylene, said O is bound at the R 3 position.
  • all other groups are as provided in the general formula (I) above or in the first through fourteenth embodiments described above.
  • R 3 and R 6a are connected to form C 2 -C 6 alkylene, C 2 -C 6 alkenylene, -O-C 1 -C 6 alkylene, or -O-C 2 -C 6 alkenylene,, such that where R 3 and R 6a are connected to form -O-C 1 -C 6 alkylene or -O-C 2 -C 6 alkenylene, said O is bound at the R 3 position.
  • all other groups are as provided in the general formula (I) above or in the first through fourteenth embodiments described above.
  • R 4 and R 5 are connected to form C 1 -C 6 alkylene, C 2 -C 6 alkenylene, -O-C 1 -C 6 alkylene, or -O-C 2 -C 6 alkenylene, such that where R 4 and R 5 are connected to form -O-C 1 -C 6 alkylene or -O-C 2 -C 6 alkenylene, said O is bound at the R 5 position.
  • all other groups are as provided in the general formula (I) above or in the first through fourteenth embodiments described above.
  • R 5 and R 6 are connected to form C 1 -C 6 alkylene, C 2 -C 6 alkenylene, -O-C 1 -C 6 alkylene, or -O-C 2 -C 6 alkenylene, such that where R 5 and R 6 are connected to form -O-C 1 -C 6 alkylene or -O-C 2 -C 6 alkenylene, said O is bound at the R 5 position.
  • all other groups are as provided in the general formula (I) above or in the first through fourteenth embodiments described above.
  • R 7 and R 8 are connected to form C 1 -C 6 alkylene or C 2 -C 6 alkenylene.
  • all other groups are as provided in the general formula (I) above or in the first through fourteenth embodiments described above.
  • R 7a and R 8a are connected to form C 1 -C 6 alkylene or C 2 -C 6 alkenylene.
  • all other groups are as provided in the general formula (I) above or in the first through fourteenth embodiments described above.
  • Base 1 and Base 2 are each independently selected
  • Base 1 and Base 2 are each
  • Base 1 and Base 2 are each independently selected from the group consisting of
  • Base 1 and Base 2 are each independently selected
  • Base 1 and Base 2 are each independently
  • R 9 C 1 -C 6 alkyl is optionally substituted by 1 to 2 substituents independently selected from the group consisting of OH, -O-C 1 -C 20 alkyl,-S-C(O)C 1 -C 6 alkyl, and -C(O)OC 1 -C 6 alkyl; optionally R 3 and R 6a are connected to form C 2 -C 6 alkylene, C 2 -C 6 alkenylene,-O-C 1 -C 6 alkylene, or -O-C 2 - C 6 alkenylene, such that where R 3 and R 6a are connected to form -O-C 1 -C 6 alkylene or -O-C 2 -C 6 alkenylene, said O is bound at the R 3 position; and optionally R 5 and R 6 are connected to form C 1 -C 6 alkylene, C 2 -C 6 alkenylene, -O-C 1 -C
  • Base 1 and Base 2 are each independently selected
  • Base 1 and Base 2 are each independently selected from the group consisting of wherein at least one of Base 1 and Base 2 is each independently selected from the group consisting of wherein at least one of Base 1 and Base 2 is each independently
  • R 3 and R 6a are connected to C 2 -C 6 alkylene, C 2 -C 6 alkenylene, -O-C 1 -C 6 alkylene, or -O-C 2 -C 6 alkenylene, such that where R 3 and R 6a are connected to form -O-C 1 -C 6 alkylene or -O-C 2 -C 6 alkenylene, said O is bound at the R 3 position; and optionally R 5 and R 6 are connected to form C 1 -C 6 alkylene, C 2 -C 6 alkenylene, -O-C 1 -C 6 alkylene, or -O-C 2 -C 6 alkenylene, such that where R 5 and R 6 are connected to form -O-C 1 -C 6 alkylene or -O-C 2 -C 6 alkenylene, said O is bound at the R 5 position.
  • all other groups are as provided in the general formula (I) above or in the first through fourteenth embodiments
  • Base 1 and Base 2 are each independently selected
  • Base 2 is each independently selected from the group consisting of
  • Base 1 and Base 2 are each independently selected
  • Base 1 and Base 2 are each
  • Base 1 and Base 2 are each independently selected from the group consisting of
  • Base 1 and Base 2 are each independently selected
  • Base 1 and Base 2 are each independently selected from the group consisting of
  • Base 1 and Base 2 are each independently selected from
  • Base 1 and Base 2 are each independently selected from the group consisting of
  • Base 1 is selected from the group consisting of
  • Base 2 is selected from the group consisting of
  • a thirty-second embodiment relates to a compound selected from the group
  • a thirty-third embodiment relates to a pharmaceutical composition, said
  • composition comprising (a) a compound according to any one of general formula (I) above or the first through thirty-second embodiments above or a pharmaceutically acceptable salt thereof; and (b) a pharmaceutically acceptable carrier.
  • a thirty-fourth embodiment relates to methods of inducing an immune response in a subject, comprising administering a therapeutically effective amount of a compound according to any one of general formula (I) above or the first through thirty-second embodiments above or a pharmaceutically acceptable salt thereof to the subject.
  • a thirty-fifth embodiment relates to methods of inducing an immune response in a subject, comprising administering a therapeutically effective amount of a composition according to the thirty-third embodiment above to the subject.
  • a thirty-sixth embodiment relates to methods of inducing STING-dependent type I interferon production in a subject, comprising administering a therapeutically effective amount of a compound according to any one of general formula (I) above or the first through thirty- second embodiments above or a pharmaceutically acceptable salt thereof to the subject.
  • a thirty-seventh embodiment relates to methods of inducing STING-dependent type I interferon production in a subject, comprising administering a therapeutically effective amount of a composition according to the thirty-third embodiment above to the subject.
  • a thirty-eighth embodiment relates to methods of inducing STING-dependent cytokine production in a subject, comprising administering a therapeutically effective amount of a compound according to any one of general formula (I) above or the first through thirty-second embodiments above or a pharmaceutically acceptable salt thereof to the subject.
  • a thirty-ninth embodiment relates to methods of inducing a STING-dependent cytokine production in a subject, comprising administering a therapeutically effective amount of a composition according to the thirty-third embodiment above to the subject.
  • a fortieth embodiment relates to a compound selected from the exemplary species depicted in Examples 1 through 54 shown below.
  • a forty-first embodiment relates to a pharmaceutical composition, said
  • composition comprising (a) a compound according to the fortieth embodiment above or a pharmaceutically acceptable salt thereof; and (b) a pharmaceutically acceptable carrier.
  • a forty-second embodiment relates to methods of inducing an immune response in a subject, comprising administering a therapeutically effective amount of a compound according to the fortieth embodiment above or a pharmaceutically acceptable salt thereof to the subject.
  • a forty-third embodiment relates to methods of inducing an immune response in a subject, comprising administering a therapeutically effective amount of a composition according to the forty-first embodiment above to the subject.
  • a forty-fourth embodiment relates to methods of inducing STING-dependent type I interferon production in a subject, comprising administering a therapeutically effective amount of a compound according to the fortieth embodiment above or a pharmaceutically acceptable salt thereof to the subject.
  • a forty-fifth embodiment relates to methods of inducing STING-dependent type I interferon production in a subject, comprising administering a therapeutically effective amount of a composition according to the forty-first embodiment above to the subject.
  • a forty-sixth embodiment relates to methods of inducing STING-dependent cytokine production in a subject, comprising administering a therapeutically effective amount of a compound according to the fortieth embodiment above or a pharmaceutically acceptable salt thereof to the subject.
  • a forty-seventh embodiment relates to methods of inducing STING-dependent cytokine production in a subject, comprising administering a therapeutically effective amount of a composition according to the forty-first embodiment above to the subject.
  • composition comprising an effective amount of a compound of general formula (I), or a pharmaceutically acceptable salt thereof, and a
  • an active agent selected from the group consisting of STING agonist compounds, anti-viral compounds, antigens, adjuvants, CTLA-4 and PD-1 pathway antagonists and other immunomodulatory agents, lipids, liposomes, peptides, anti-cancer and chemotherapeutic agents.
  • a pharmaceutical combination that is (i) a compound of general formula (I), or a pharmaceutically acceptable salt thereof, and (ii) an active agent selected from the group consisting of STING agonist compounds, anti-viral compounds, antigens, adjuvants, CTLA-4 and PD-1 pathway antagonists and other immunomodulatory agents, lipids, liposomes, peptides, anti-cancer and chemotherapeutic agents; wherein the compound of general formula (I), or pharmaceutically acceptable salt thereof, and the active agent are each employed in an amount that renders the combination effective for inducing an immune response in a patient.
  • a method of inducing an immune response in a patient which comprises administering to the subject a therapeutically effective amount of a composition of (a), a composition of (b), or a combination of (c).
  • a method of inducing STING-dependent type I interferon production in a patient which comprises administering to the subject a therapeutically effective amount of a composition of (a), a composition of (b), or a combination of (c).
  • a method of inducing STING-dependent cytokine production in a patient which comprises administering to the subject a therapeutically effective amount of a compound of general formula (I), or a pharmaceutically acceptable salt thereof.
  • a method of inducing STING-dependent cytokine production in a patient which comprises administering to the subject a therapeutically effective amount of a composition of (a), a composition of (b), or a combination of (c).
  • the present disclosure also includes a compound of the present disclosure for use (i) in, (ii) as a medicament for, or (iii) in the preparation of a medicament for: (a) inducing an immune response in a patient, or (b) inducing STING-dependent cytokine production in a patient.
  • the compounds of the present disclosure can optionally be employed in combination with one or more active agents selected from STING agonist compounds, anti-viral compounds, antigens, adjuvants, CTLA-4 and PD-1 pathway antagonists and other active agents selected from STING agonist compounds, anti-viral compounds, antigens, adjuvants, CTLA-4 and PD-1 pathway antagonists and other active agents selected from STING agonist compounds, anti-viral compounds, antigens, adjuvants, CTLA-4 and PD-1 pathway antagonists and other active agents selected from STING agonist compounds, anti-viral compounds, antigens, adjuvants, CTLA-4 and PD-1 pathway antagonists and other active agents selected from STING agonist
  • immunomodulatory agents lipids, liposomes, peptides, anti-cancer agents, and chemotherapeutic agents.
  • Additional embodiments of the disclosure include the pharmaceutical compositions, combinations and methods set forth in (a) through (l) above and the uses set forth in the preceding paragraph, wherein the compound of the present disclosure employed therein is a compound of one of the embodiments, aspects, instances, occurrences, or features of the compounds described above. In all of these embodiments, the compound may optionally be used in the form of a pharmaceutically acceptable salt, as appropriate.
  • each embodiment may be combined with one or more other embodiments, to the extent that such a combination provides a stable compound and is consistent with the description of the embodiments. It is further to be understood that the embodiments of compositions and methods provided as (a) through (l) above are understood to include all embodiments of the compounds, including such embodiments as result from combinations of embodiments.
  • the term“subject” refers to a mammal that has been the object of treatment, observation, or experiment.
  • the mammal may be male or female.
  • the mammal may be one or more selected from the group consisting of humans, bovine (e.g., cows), porcine (e.g., pigs), ovine (e.g., sheep), capra (e.g., goats), equine (e.g., horses), canine (e.g., domestic dogs), feline (e.g., house cats), Lagomorpha (rabbits), rodents (e.g., rats or mice), Procyon lotor (e.g., raccoons).
  • the subject is human.
  • immune response relates to any one or more of the following: specific immune response, non-specific immune response, both specific and non- specific response, innate response, primary immune response, adaptive immunity, secondary immune response, memory immune response, immune cell activation, immune cell proliferation, immune cell differentiation, and cytokine expression.
  • a compound of general formula (I), or a pharmaceutically acceptable salt of the foregoing is administered in conjunction with one or more additional therapeutic agents including anti-viral compounds, vaccines intended to stimulate an immune response to one or more predetermined antigens, adjuvants, CTLA-4 and PD-1 pathway antagonists and other immunomodulatory agents, lipids, liposomes, peptides, anti-cancer agents, and chemotherapeutic agents, etc.
  • additional therapeutic agents including anti-viral compounds, vaccines intended to stimulate an immune response to one or more predetermined antigens, adjuvants, CTLA-4 and PD-1 pathway antagonists and other immunomodulatory agents, lipids, liposomes, peptides, anti-cancer agents, and chemotherapeutic agents, etc.
  • a compound of general formula (I), or a pharmaceutically acceptable salt of the foregoing is administered in conjunction with one or more additional compositions including anti-viral compounds, vaccines intended to stimulate an immune response to one or more predetermined antigens, adjuvants, CTLA-4 and PD-1 pathway antagonists and other immunomodulatory agents, lipids, liposomes, peptides, anti-cancer agents, and chemotherapeutic agents, etc.
  • additional compositions including anti-viral compounds, vaccines intended to stimulate an immune response to one or more predetermined antigens, adjuvants, CTLA-4 and PD-1 pathway antagonists and other immunomodulatory agents, lipids, liposomes, peptides, anti-cancer agents, and chemotherapeutic agents, etc.
  • alkyl refers to a monovalent straight or branched chain, saturated aliphatic hydrocarbon radical having a number of carbon atoms in the specified range.
  • “C 1-6 alkyl” refers to any of the hexyl alkyl and pentyl alkyl isomers as well as n-, iso-, sec- and tert-butyl, n- and iso-propyl, ethyl, and methyl.
  • C 1-4 alkyl refers to n-, iso-, sec- and tert-butyl, n- and isopropyl, ethyl, and methyl.
  • alkylene refers to a bivalent straight chain, saturated aliphatic hydrocarbon radical having a number of carbon atoms in the specified range.
  • alkenyl refers to a monovalent straight or branched chain, unsaturated aliphatic hydrocarbon radical having a number of carbon atoms in the specified range and including one or more double bond.
  • alkenylene refers to a bivalent straight chain, unsaturated aliphatic hydrocarbon radical having a number of carbon atoms in the specified range and including one or more double bond.
  • the term“alkynyl” refers to a monovalent straight or branched chain, unsaturated aliphatic hydrocarbon radical having a number of carbon atoms in the specified range and including one or more triple bond.
  • the term“alkynylene” refers to a bivalent straight chain, unsaturated aliphatic hydrocarbon radical having a number of carbon atoms in the specified range and including one or more triple bond.
  • halogen refers to fluorine, chlorine, bromine, and iodine (alternatively referred to as fluoro, chloro, bromo, and iodo or F, Cl, Br, and I).
  • haloalkyl refers to an alkyl group as defined above in which one or more of the hydrogen atoms have been replaced with a halogen.
  • “C 1-6 haloalkyl” refers to a C 1 to C 6 linear or branched alkyl group as defined above with one or more halogen substituents.
  • fluoroalkyl has an analogous meaning except the halogen substituents are restricted to fluoro.
  • Suitable fluoroalkyls include the series (CH 2 ) 0-4 CF 3 (i.e., trifluoromethyl, 2,2,2-trifluoroethyl, 3,3,3-trifluoro-n-propyl, etc.).
  • haloalkenyl refers to an alkenyl group as defined above in which one or more of the hydrogen atoms have been replaced with a halogen.
  • haloalkynyl refers to an alkynyl group as defined above in which one or more of the hydrogen atoms have been replaced with a halogen.
  • alkoxy as used herein, alone or in combination, includes an alkyl group connected to the oxy connecting atom.
  • the term“alkoxy” also includes alkyl ether groups, where the term“alkyl” is defined above, and“ether” means two alkyl groups with an oxygen atom between them.
  • suitable alkoxy groups include methoxy, ethoxy, n- propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy, methoxymethane (also referred to as “dimethyl ether”), and methoxyethane (also referred to as“ethyl methyl ether”).
  • cycloalkyl refers to a saturated hydrocarbon containing one ring having a specified number of carbon atoms.
  • examples of cycloalkyl include
  • heterocycle represents a stable 3- to 6-membered monocyclic that is either saturated or unsaturated, and that consists of carbon atoms and from one to two heteroatoms selected from the group consisting of N, O, and S.
  • the heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure.
  • the term includes heteroaryl moieties.
  • heterocyclic elements include, but are not limited to, azepinyl, benzimidazolyl, benzisoxazolyl, benzofurazanyl, benzopyranyl, benzothiopyranyl, benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, cinnolinyl, dihydrobenzofuryl, dihydrobenzothienyl, dihydrobenzothiopyranyl, dihydrobenzothiopyranyl sulfone, 1,3-dioxolanyl, furyl, imidazolidinyl, imidazolinyl, imidazolyl, indolinyl, indolyl, isochromanyl, isoindolinyl, isoquinolinyl, isothiazolidinyl, isothiazolyl, isothiazolidinyl, morpholinyl, naphthyrid
  • spirocycle or“spirocyclic ring” refers to a pendant cyclic group formed by substituents on a single atom.
  • the term“compound” refers to the compound and, in certain embodiments, to the extent they are stable, any hydrate or solvate thereof.
  • a hydrate is the compound complexed with water
  • a solvate is the compound complexed with a solvent, which may be an organic solvent or an inorganic solvent.
  • A“stable” compound is a compound that can be prepared and isolated and whose structure and properties remain or can be caused to remain essentially unchanged for a period of time sufficient to allow use of the compound for the purposes described herein (e.g., therapeutic administration to a subject).
  • the compounds of the present invention are limited to stable compounds embraced by general formula (I), or pharmaceutically acceptable salts thereof.
  • ranges cited herein are inclusive; i.e., the range includes the values for the upper and lower limits of the range as well as all values in between.
  • temperature ranges, percentages, ranges of equivalents, and the like described herein include the upper and lower limits of the range and any value in the continuum there between.
  • Numerical values provided herein, and the use of the term“about”, may include variations of ⁇ 1%, ⁇ 2%, ⁇ 3%, ⁇ 4%, ⁇ 5%, ⁇ 10%, ⁇ 15%, and ⁇ 20% and their numerical equivalents.
  • the term“one or more” item includes a single item selected from the list as well as mixtures of two or more items selected from the list.
  • the atoms may exhibit their natural isotopic abundances, or one or more of the atoms may be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominantly found in nature.
  • the present disclosure is meant to include all suitable isotopic variations of the compounds of general formula (I), and pharmaceutically acceptable salts of the foregoing.
  • different isotopic forms of hydrogen (H) include protium ( 1 H), deuterium ( 2 H), and tritium ( 3 H).
  • Protium is the predominant hydrogen isotope found in nature. Enriching for deuterium may afford certain therapeutic advantages, such as increasing in vivo half-life or reducing dosage requirements, or may provide a compound useful as a standard for
  • the compounds are isotopically enriched with deuterium.
  • one or more of Base 1 , Base 2 , Y, Y a , X a , X a1 , X b , X b1 , R 1 , R 1a , R 2 , R 2a , R 3 , R 4 , R 4a , R 5 , R 6 , R 6a , R 7 , R 7a , R 8 , R 8a , and R 9 may include deuterium.
  • a straight line at a chiral center includes both (R) and (S) stereoisomers and mixtures thereof.
  • the invention includes all possible enantiomers and diastereomers and mixtures of two or more stereoisomers, for example mixtures of enantiomers and/or diastereomers, in all ratios.
  • enantiomers are a subject of the invention in enantiomerically pure form, both as levorotatory and as dextrorotatory antipodes, in the form of racemates and in the form of mixtures of the two enantiomers in all ratios.
  • the invention includes both the cis form and the trans form, as well as mixtures of these forms in all ratios.
  • the preparation of individual stereoisomers can be carried out, if desired, by separation of a mixture by customary methods, for example by chromatography or crystallization, by the use of stereochemically uniform starting materials for the synthesis or by stereoselective synthesis.
  • a derivatization can be carried out before a separation of stereoisomers.
  • the separation of a mixture of stereoisomers can be carried out at an intermediate step during the synthesis of a compound of general formula (I), or a pharmaceutically acceptable salt of the foregoing, or it can be done on a final racemic product.
  • Absolute stereochemistry may be determined by X-ray crystallography of crystalline products or crystalline intermediates that are derivatized, if necessary, with a reagent containing a stereogenic center of known configuration. Unless a particular isomer, salt, solvate (including hydrates) or solvated salt of such racemate, enantiomer, or diastereomer is indicated, the present invention includes all such isomers, as well as salts, solvates (including hydrates), and solvated salts of such racemates, enantiomers, diastereomers, and mixtures thereof.
  • the compounds of the present invention can be employed in the form of pharmaceutically acceptable salts.
  • Those skilled in the art will recognize those instances in which the compounds of the invention may form salts. Examples of such compounds are described herein by reference to possible salts. Such reference is for illustration only.
  • compositions for treating patients can be used with compounds for treating patients.
  • Non- pharmaceutical salts may, however, be useful in the preparation of intermediate compounds.
  • pharmaceutically acceptable salt refers to a salt (including an inner salt such as a zwitterion) that possesses effectiveness similar to the parent compound and that is not biologically or otherwise undesirable (e.g., is neither toxic nor otherwise deleterious to the recipient thereof).
  • an embodiment of the invention provides pharmaceutically acceptable salts of the compounds of the invention.
  • the term“salt(s)”, as employed herein, denotes any of the following: acidic salts formed with inorganic and/or organic acids, as well as basic salts formed with inorganic and/or organic bases.
  • Salts of compounds of the invention may be formed by methods known to those of ordinary skill in the art, for example, by reacting a compound of the invention with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in aqueous medium followed by lyophilization.
  • Exemplary acid addition salts include acetates, ascorbates, benzoates,
  • Suitable salts include acid addition salts that may, for example, be formed by mixing a solution of a compound with a solution of a pharmaceutically acceptable acid such as
  • hydrochloric acid sulfuric acid, acetic acid, trifluoroacetic acid, or benzoic acid.
  • acids that are generally considered suitable for the formation of pharmaceutically useful salts from basic pharmaceutical compounds are discussed, for example, by P. Stahl et al, Camille G. (eds.), Handbook of Pharmaceutical Salts. Properties, Selection and Use. (2002) Zurich: Wiley- VCH; S. Berge et al, Journal of Pharmaceutical Sciences (1977) 66(1) 1-19; P. Gould,
  • Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (for example, organic amines) such as dicyclohexylamine, t-butyl amine, choline, and salts with amino acids such as arginine, lysine and the like.
  • alkali metal salts such as sodium, lithium, and potassium salts
  • alkaline earth metal salts such as calcium and magnesium salts
  • salts with organic bases for example, organic amines
  • organic bases for example, organic amines
  • amino acids such as arginine, lysine and the like.
  • Basic nitrogen- containing groups may be quarternized with agents such as lower alkyl halides (e.g., methyl, ethyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g., dimethyl, diethyl, and dibutyl sulfates), long chain halides (e.g., decyl, lauryl, and stearyl chlorides, bromides and iodides), aralkyl halides (e.g., benzyl and phenethyl bromides), and others.
  • lower alkyl halides e.g., methyl, ethyl, and butyl chlorides, bromides and iodides
  • dialkyl sulfates e.g., dimethyl, diethyl, and dibutyl sulfates
  • long chain halides e.g., decyl, lauryl, and
  • Compounds carrying an acidic moiety can be mixed with suitable pharmaceutically acceptable salts to provide, for example, alkali metal salts (e.g., sodium or potassium salts), alkaline earth metal salts (e.g., calcium or magnesium salts), and salts formed with suitable organic ligands such as quaternary ammonium salts.
  • suitable pharmaceutically acceptable salts for example, alkali metal salts (e.g., sodium or potassium salts), alkaline earth metal salts (e.g., calcium or magnesium salts), and salts formed with suitable organic ligands such as quaternary ammonium salts.
  • suitable organic ligands such as quaternary ammonium salts.
  • pharmaceutically acceptable esters can be employed to modify the solubility or hydrolysis characteristics of the compound.
  • zwitterions inner salts
  • inner salts may be formed and are included within the terms“salt(s)” as used herein. It is understood that certain compounds of the invention may exist in zwitterionic form, having both anionic and cationic centers within the same compound and a net neutral charge. Such zwitterions are included within the invention.
  • PG 1 or PG 2 represents a protecting group for an amino group in a nucleobase, which may be a phenyl carbonyl group including benzoyl group, an alkyl carbonyl group including isobutyl carbonyl group and 2-(4-(tert-butyl)phenoxy) acetyl group or a formamidine group including N,N-dimethyl-formamidine. All other variables have the same meaning as provided above. [0105] Method 1
  • Compounds described herein having therapeutic applications may be administered to a patient for the purpose of inducing an immune response, inducing STING-dependent cytokine production and/or inducing anti-tumor activity.
  • administration and variants thereof (e.g., “administering” a compound) means providing the compound to the individual in need of treatment.
  • compositions are provided in combination with one or more additional active agents (e.g., antiviral agents useful for treating HCV infection or anti-tumor agents for treating cancers),“administration” and its variants are each understood to include concurrent and sequential provision of the compound or salt and other agents.
  • additional active agents e.g., antiviral agents useful for treating HCV infection or anti-tumor agents for treating cancers
  • administration and its variants are each understood to include concurrent and sequential provision of the compound or salt and other agents.
  • additional active agents e.g., antiviral agents useful for treating HCV infection or anti-tumor agents for treating cancers
  • additional active agents e.g., antiviral agents useful for treating HCV infection or anti-tumor agents for treating cancers
  • administration are each understood to include concurrent and sequential provision of the compound or salt and other agents.
  • the compounds disclosed herein may be STING agonists. These compounds are potentially useful in treating diseases or disorders including, but not limited to, cell proliferation disorders.
  • Cell-proliferation disorders include,
  • papillomatosis papillomatosis
  • gestational trophoblastic diseases papillomatosis
  • benign neoplastic diseases such as skin papilloma (warts) and genital papilloma.
  • the disease or disorder to be treated is a cell proliferation disorder.
  • the cell proliferation disorder is cancer.
  • the cancer is selected from brain and spinal cancers, cancers of the head and neck, leukemia and cancers of the blood, skin cancers, cancers of the reproductive system, cancers of the gastrointestinal system, liver and bile duct cancers, kidney and bladder cancers, bone cancers, lung cancers, malignant mesothelioma, sarcomas, lymphomas, glandular cancers, thyroid cancers, heart tumors, germ cell tumors, malignant neuroendocrine (carcinoid) tumors, midline tract cancers, and cancers of unknown primary (i.e., cancers in which a metastasized cancer is found but the original cancer site is not known).
  • the cancer is present in an adult patient; in additional embodiments, the cancer is present in a pediatric patient.
  • the cancer is AIDS-related.
  • the cancer is selected from brain and spinal cancers.
  • the cancer is selected from the group consisting of anaplastic
  • the brain cancer is selected from the group consisting of astrocytic tumor (e.g., pilocytic astrocytoma, subependymal giant-cell astrocytoma, diffuse astrocytoma, pleomorphic xanthoastrocytoma, anaplastic astrocytoma, astrocytoma, giant cell glioblastoma, glioblastoma, secondary glioblastoma, primary adult glioblastoma, and primary pediatric glioblastoma), oligodendroglial tumor (e.g., oligodendroglioma, and anaplastic oligodendroglioma), oligoastrocytic tumor (e.g., oligoastrocytoma, and anaplastic
  • ependymoma e.g., myxopapillary ependymoma, and anaplastic
  • the brain cancer is selected from the group consisting of glioma, glioblastoma multiforme, paraganglioma, and suprantentorial primordial neuroectodermal tumors (sPNET).
  • the cancer is selected from cancers of the head and neck, including nasopharyngeal cancers, nasal cavity and paranasal sinus cancers, hypopharyngeal cancers, oral cavity cancers (e.g., squamous cell carcinomas, lymphomas, and sarcomas), lip cancers, oropharyngeal cancers, salivary gland tumors, cancers of the larynx (e.g., laryngeal squamous cell carcinomas, rhabdomyosarcomas), and cancers of the eye or ocular cancers.
  • the ocular cancer is selected from the group consisting of intraocular melanoma and retinoblastoma.
  • the cancer is selected from leukemia and cancers of the blood.
  • the cancer is selected from the group consisting of myeloproliferative neoplasms, myelodysplastic syndromes, myelodysplastic/myeloproliferative neoplasms, acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelogenous leukemia (CML), myeloproliferative neoplasm (MPN), post-MPN AML, post- MDS AML, del(5q)-associated high risk MDS or AML, blast-phase chronic myelogenous leukemia, angioimmunoblastic lymphoma, acute lymphoblastic leukemia, Langerans cell histiocytosis, hairy cell leukemia, and plasma cell neoplasms including plasmacytomas and multiple myelomas.
  • Leukemias referenced herein may be acute or chronic.
  • the cancer is selected from skin cancers.
  • the skin cancer is selected from the group consisting of melanoma, squamous cell cancers, and basal cell cancers.
  • the cancer is selected from cancers of the reproductive system.
  • the cancer is selected from the group consisting of breast cancers, cervical cancers, vaginal cancers, ovarian cancers, prostate cancers, penile cancers, and testicular cancers.
  • the cancer is a breast cancer selected from the group consisting of ductal carcinomas and phyllodes tumors.
  • the breast cancer may be male breast cancer or female breast cancer.
  • the cancer is a cervical cancer selected from the group consisting of squamous cell carcinomas and adenocarcinomas.
  • the cancer is an ovarian cancer selected from the group consisting of epithelial cancers.
  • the cancer is selected from cancers of the gastrointestinal system.
  • the cancer is selected from the group consisting of esophageal cancers, gastric cancers (also known as stomach cancers), gastrointestinal carcinoid tumors, pancreatic cancers, gallbladder cancers, colorectal cancers, and anal cancer.
  • the cancer is selected from the group consisting of esophageal squamous cell carcinomas, esophageal adenocarcinomas, gastric adenocarcinomas, gastrointestinal carcinoid tumors, gastrointestinal stromal tumors, gastric lymphomas, gastrointestinal lymphomas, solid pseudopapillary tumors of the pancreas, pancreatoblastoma, islet cell tumors, pancreatic carcinomas including acinar cell carcinomas and ductal adenocarcinomas, gallbladder adenocarcinomas, colorectal adenocarcinomas, and anal squamous cell carcinomas.
  • the cancer is selected from liver and bile duct cancers.
  • the cancer is liver cancer (also known as hepatocellular carcinoma).
  • the cancer is bile duct cancer (also known as cholangiocarcinoma); in instances of these embodiments, the bile duct cancer is selected from the group consisting of intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma.
  • the cancer is selected from kidney and bladder cancers.
  • the cancer is a kidney cancer selected from the group consisting of renal cell cancer, Wilms tumors, and transitional cell cancers.
  • the cancer is a bladder cancer selected from the group consisting of urethelial carcinoma (a transitional cell carcinoma), squamous cell carcinomas, and adenocarcinomas.
  • the cancer is selected from bone cancers.
  • the bone cancer is selected from the group consisting of osteosarcoma, malignant fibrous histiocytoma of bone, Ewing sarcoma, chordoma (cancer of the bone along the spine).
  • the cancer is selected from lung cancers.
  • the lung cancer is selected from the group consisting of non-small cell lung cancer, small cell lung cancers, bronchial tumors, and pleuropulmonary blastomas.
  • the cancer is selected from malignant mesothelioma.
  • the cancer is selected from the group consisting of epithelial
  • mesothelioma and sarcomatoids are mesothelioma and sarcomatoids.
  • the cancer is selected from sarcomas.
  • the sarcoma is selected from the group consisting of central chondrosarcoma, central and periosteal chondroma, fibrosarcoma, clear cell sarcoma of tendon sheaths, and Kaposi's sarcoma.
  • the cancer is selected from lymphomas.
  • the cancer is selected from the group consisting of Hodgkin lymphoma (e.g., Reed-Sternberg cells), non-Hodgkin lymphoma (e.g., diffuse large B-cell lymphoma, follicular lymphoma, mycosis fungoides, Sezary syndrome, primary central nervous system lymphoma), cutaneous T-cell lymphomas, primary central nervous system lymphomas.
  • the cancer is selected from glandular cancers.
  • the cancer is selected from the group consisting of adrenocortical cancer (also known as
  • adrenocortical carcinoma or adrenal cortical carcinoma adrenocortical carcinoma or adrenal cortical carcinoma
  • pheochromocytomas adrenocortical carcinoma or adrenal cortical carcinoma
  • paragangliomas adrenocortical carcinoma or adrenal cortical carcinoma
  • pituitary tumors thymoma
  • thymic carcinomas adrenocortical carcinoma or adrenal cortical carcinoma
  • the cancer is selected from thyroid cancers.
  • the thyroid cancer is selected from the group consisting of medullary thyroid carcinomas, papillary thyroid carcinomas, and follicular thyroid carcinomas.
  • the cancer is selected from germ cell tumors.
  • the cancer is selected from the group consisting of malignant extracranial germ cell tumors and malignant extragonadal germ cell tumors.
  • the malignant extragonadal germ cell tumors are selected from the group consisting of nonseminomas and seminomas.
  • the cancer is selected from heart tumors.
  • the heart tumor is selected from the group consisting of malignant teratoma, lymphoma, rhabdomyosacroma, angiosarcoma, chondrosarcoma, infantile fibrosarcoma, and synovial sarcoma.
  • the cell-proliferation disorder is selected from benign papillomatosis, benign neoplastic diseases and gestational trophoblastic diseases.
  • the benign neoplastic disease is selected from skin papilloma (warts) and genital papilloma.
  • the gestational trophoblastic disease is selected from the group consisting of hydatidiform moles, and gestational trophoblastic neoplasia (e.g., invasive moles, choriocarcinomas, placental-site trophoblastic tumors, and epithelioid trophoblastic tumors).
  • treatment and“treating” refer to all processes in which there may be a slowing, interrupting, arresting, controlling, or stopping of the progression of a disease or disorder described herein. The terms do not necessarily indicate a total elimination of all disease or disorder symptoms.
  • administration of and or“administering” a compound should be understood to include providing a compound described herein, or a pharmaceutically acceptable salt thereof, and compositions of the foregoing to a subject.
  • the amount of a compound administered to a subject is an amount sufficient to induce an immune response and/or to induce STING-dependent type I interferon production in the subject.
  • the amount of a compound can be an“effective amount” or “therapeutically effective amount,” such that the subject compound is administered in an amount that will elicit, respectively, a biological or medical (i.e., intended to treat) response of a tissue, system, animal, or human that is being sought by a researcher, veterinarian, medical doctor, or other clinician.
  • An effective amount does not necessarily include considerations of toxicity and safety related to the administration of a compound.
  • An effective amount of a compound will vary with the particular compound chosen (e.g., considering the potency, efficacy, and/or half-life of the compound); the route of administration chosen; the condition being treated; the severity of the condition being treated; the age, size, weight, and physical condition of the subject being treated; the medical history of the subject being treated; the duration of the treatment; the nature of a concurrent therapy; the desired therapeutic effect; and like factors and can be routinely determined by the skilled artisan.
  • the compounds disclosed herein may be administered by any suitable route including oral and parenteral administration.
  • Parenteral administration is typically by injection or infusion and includes intravenous, intramuscular, intratumoral, and subcutaneous injection or infusion.
  • the compounds disclosed herein may be administered once or according to a dosing regimen where a number of doses are administered at varying intervals of time for a given period of time. For example, doses may be administered one, two, three, or four times per day. Doses may be administered until the desired therapeutic effect is achieved or indefinitely to maintain the desired therapeutic effect. Suitable dosing regimens for a compound disclosed herein depend on the pharmacokinetic properties of that compound, such as absorption, distribution and half-life, which can be determined by a skilled artisan.
  • suitable dosing regimens including the duration such regimens are administered, for a compound disclosed herein depend on the disease or condition being treated, the severity of the disease or condition, the age and physical condition of the subject being treated, the medical history of the subject being treated, the nature of concurrent therapy, the desired therapeutic effect, and like factors within the knowledge and expertise of the skilled artisan. It will be further understood by such skilled artisans that suitable dosing regimens may require adjustment given an individual subject's response to the dosing regimen or over time as the individual subject needs change. Typical daily dosages may vary depending upon the particular route of administration chosen.
  • One embodiment of the present disclosure provides for a method of treating a cell proliferation disorder comprising administration of a therapeutically effective amount of a compound of general formula (I), or a pharmaceutically acceptable salt of the foregoing, to a subject in need of treatment thereof.
  • the disease or disorder to be treated is a cell proliferation disorder.
  • the cell proliferation disorder is cancer.
  • the cancer is selected from brain and spinal cancers, cancers of the head and neck, leukemia and cancers of the blood, skin cancers, cancers of the reproductive system, cancers of the gastrointestinal system, liver and bile duct cancers, kidney and bladder cancers, bone cancers, lung cancers, malignant mesothelioma, sarcomas, lymphomas, glandular cancers, thyroid cancers, heart tumors, germ cell tumors, malignant neuroendocrine (carcinoid) tumors, midline tract cancers, and cancers of unknown primary.
  • a compound of general formula (I), or a pharmaceutically acceptable salt of the foregoing in a therapy.
  • the compound may be useful in a method of inducing an immune response and/or inducing STING-dependent type I interferon production in a subject, such as a mammal in need of such inhibition, comprising administering an effective amount of the compound to the subject.
  • a pharmaceutical composition comprising at least one compound of general formula (I), or at least one pharmaceutically acceptable salt of the foregoing, for use in potential treatment to induce an immune response and/or to induce STING- dependent type I interferon production.
  • One embodiment disclosed herein is the use of a compound of general formula (I), or a pharmaceutically acceptable salt of the foregoing, in the manufacture of a medicament to induce an immune response and/or to induce STING-dependent type I interferon production.
  • the disease or disorder to be treated is a cell proliferation disorder.
  • the cell proliferation disorder is cancer.
  • the cancer is selected from brain and spinal cancers, cancers of the head and neck, leukemia and cancers of the blood, skin cancers, cancers of the reproductive system, cancers of the gastrointestinal system, liver and bile duct cancers, kidney and bladder cancers, bone cancers, lung cancers, malignant mesothelioma, sarcomas, lymphomas, glandular cancers, thyroid cancers, heart tumors, germ cell tumors, malignant neuroendocrine (carcinoid) tumors, midline tract cancers, and cancers of unknown primary.
  • Compositions include brain and spinal cancers, cancers of the head and neck, leukemia and cancers of the blood, skin cancers, cancers of the reproductive system, cancers of the gastrointestinal system, liver and bile duct cancers, kidney and bladder cancers, bone cancers, lung cancers, malignant mesothelioma, sarcomas, lymphomas, glandular cancers, thyroid cancers, heart tumors, germ cell tumors,
  • composition as used herein is intended to encompass a dosage form comprising a specified compound in a specified amount, as well as any dosage form that results, directly or indirectly, from combination of a specified compound in a specified amount. Such term is intended to encompass a dosage form comprising a compound of general formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug of the foregoing, and one or more pharmaceutically acceptable carriers or excipients.
  • the dosage form comprises compounds of general structural formula (I), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and one or more pharmaceutically acceptable carriers or excipients.
  • the dosage form comprises compounds of general structural formula (I), or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or excipients.
  • the compositions of the present disclosure encompass any composition made by admixing a compound of the present disclosure and one or more pharmaceutically acceptable carrier or excipients.
  • pharmaceutically acceptable it is meant the carriers or excipients are compatible with the compound disclosed herein and with other ingredients of the composition.
  • compositions of the foregoing can be administered by means that produces contact of the active agent with the agent’s site of action.
  • the compounds can be administered by conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in a combination of therapeutic agents.
  • the compounds can be
  • composition comprising a compound of general formula (I), or a pharmaceutically acceptable salt of the foregoing, and one or more pharmaceutically acceptable carriers or excipients.
  • the composition may be prepared and packaged in bulk form in which a therapeutically effective amount of a compound of the disclosure can be extracted and then given to a subject, such as with powders or syrups.
  • composition may be prepared and packaged in unit dosage form in which each physically discrete unit contains a therapeutically effective amount of a compound of general formula (I), or a pharmaceutically acceptable salt of the foregoing.
  • dosage forms include those adapted for (1) oral administration, such as tablets, capsules, caplets, pills, troches, powders, syrups, elixirs, suspensions, solutions, emulsions, sachets, and cachets; and (2) parenteral administration, such as sterile solutions, suspensions, and powders for reconstitution.
  • suitable pharmaceutically acceptable carriers or excipients will vary depending upon the particular dosage form chosen.
  • suitable pharmaceutically acceptable carriers or excipients may be chosen for a particular function that they may serve in the composition. For example, certain
  • pharmaceutically acceptable carriers or excipients may be chosen for their ability to facilitate the production of uniform dosage forms. Certain pharmaceutically acceptable carriers or excipients may be chosen for their ability to facilitate the production of stable dosage forms. Certain pharmaceutically acceptable carriers or excipients may be chosen for their ability to facilitate the carrying or transporting of a compound disclosed herein, once administered to the subject, from one organ or portion of the body to another organ or another portion of the body. Certain pharmaceutically acceptable carriers or excipients may be chosen for their ability to enhance patient compliance.
  • Suitable pharmaceutically acceptable excipients include the following types of excipients: diluents, lubricants, binders, disintegrants, fillers, glidants, granulating agents, coating agents, wetting agents, solvents, co-solvents, suspending agents, emulsifiers, sweeteners, flavoring agents, flavor masking agents, coloring agents, anti-caking agents, hemectants, chelating agents, plasticizers, viscosity increasing agents, antioxidants, preservatives, stabilizers, surfactants, and buffering agents.
  • compositions of the disclosure are prepared using techniques and methods known to those skilled in the art. Some methods commonly used in the art are described in REMINGTON'S PHARMACEUTICAL SCIENCES (Mack Publishing Company).
  • the disclosure is directed to a solid oral dosage form such as a tablet or capsule comprising a therapeutically effective amount of a compound of general formula (I), or a pharmaceutically acceptable salt of the foregoing, and a diluent or filler.
  • a solid oral dosage form such as a tablet or capsule comprising a therapeutically effective amount of a compound of general formula (I), or a pharmaceutically acceptable salt of the foregoing, and a diluent or filler.
  • Suitable diluents and fillers include lactose, sucrose, dextrose, mannitol, sorbitol, starch (e.g., corn starch, potato starch, and pre-gelatinized starch), cellulose and its derivatives, (e.g., microcrystalline cellulose), calcium sulfate, and dibasic calcium phosphate.
  • the solid oral dosage form may further comprise a binder.
  • Suitable binders include starch (e.g., corn starch, potato starch, and pre-gelatinized starch) gelatin, acacia, sodium alginate, alginic acid, tragacanth, guar gum, povidone, and cellulose and its derivatives (e.g., microcrystalline cellulose).
  • the solid oral dosage form may further comprise a disintegrant.
  • Suitable disintegrants include crospovidone, sodium starch glycolate, croscarmelose, alginic acid, and sodium carboxymethyl cellulose.
  • the solid oral dosage form may further comprise a lubricant. Suitable lubricants include stearic acid, magnesium stearate, calcium stearate, and talc.
  • dosage unit formulations for oral administration can be microencapsulated.
  • the composition can also be prepared to prolong or sustain the release as, for example, by coating or embedding particulate material in polymers, wax, or the like.
  • the compounds disclosed herein may also be coupled with soluble polymers as targetable drug carriers.
  • soluble polymers can include polyvinylpyrrolidone, pyrancopolymer, polyhydroxypropylmethacrylamidephenol, polyhydroxyethylaspartamidephenol, or
  • the compounds of the disclosure may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example polylactic acid, polepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanacrylates, and cross- linked or amphipathic block copolymers of hydrogels.
  • the disclosure is directed to a liquid oral dosage form. Oral liquids such as solutions, syrups, and elixirs can be prepared in dosage unit form so that a given quantity contains a predetermined amount of a compound or a pharmaceutically acceptable salt thereof disclosed herein.
  • Syrups can be prepared by dissolving the compound of the disclosure in a suitably flavored aqueous solution; elixirs are prepared through the use of a non-toxic alcoholic vehicle.
  • Suspensions can be formulated by dispersing a compound disclosed herein in a non- toxic vehicle.
  • Solubilizers and emulsifiers such as ethoxylated isostearyl alcohols and polyoxy ethylene sorbitol ethers, preservatives, flavor additives such as peppermint oil, or other natural sweeteners or saccharin or other artificial sweeteners and the like can also be added.
  • compositions for parenteral administration include aqueous and non- aqueous sterile injection solutions that may contain anti-oxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions that may include suspending agents and thickening agents.
  • the compositions may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules, and tablets.
  • the compounds of general formula (I), and/or pharmaceutically acceptable salts of the foregoing may be administered in combination with one or more additional active agents.
  • one or more compounds of general formula (I), or one or more pharmaceutically acceptable salts of the foregoing, and the one or more additional active agents may be co- administered.
  • the additional active agent(s) may be administered in a single dosage form with the compound of general formula (I), or pharmaceutically acceptable salt of the foregoing, or the additional active agent(s) may be administered in separate dosage form(s) from the dosage form containing the compound of general formula (I), or pharmaceutically acceptable salt of the foregoing.
  • the additional active agent(s) may be one or more agents selected from the group consisting of STING agonist compounds, anti-viral compounds, antigens, adjuvants, anti-cancer agents, CTLA-4, LAG-3, and PD-1 pathway antagonists, lipids, liposomes, peptides, cytotoxic agents, chemotherapeutic agents, immunomodulatory cell lines, checkpoint inhibitors, vascular endothelial growth factor (VEGF) receptor inhibitors, topoisomerase II inhibitors, smoothen inhibitors, alkylating agents, anti-tumor antibiotics, anti-metabolites, retinoids, and
  • immunomodulatory agents including but not limited to anti-cancer vaccines. It will be understood the descriptions of the above additional active agents may be overlapping. It will also be understood that the treatment combinations are subject to optimization, and it is understood that the best combination to use of the compounds of general formula (I), or pharmaceutically acceptable salts of the foregoing, and one or more additional active agents will be determined based on the individual patient needs.
  • a compound disclosed herein may be used in combination with one or more other active agents, including but not limited to, other anti-cancer agents that are used in the prevention, treatment, control, amelioration, or reduction of risk of a particular disease or condition (e.g., cell proliferation disorders).
  • a compound disclosed herein is combined with one or more other anti-cancer agents for use in the prevention, treatment, control amelioration, or reduction of risk of a particular disease or condition for which the compounds disclosed herein are useful.
  • Such other active agents may be administered, by a route and in an amount commonly used therefor, contemporaneously or sequentially with a compound of the present disclosure.
  • compositions of the present disclosure include those that also contain one or more other active ingredients, in addition to a compound disclosed herein.
  • a compound disclosed herein may be administered either simultaneously with, or before or after, one or more other active agent(s).
  • a compound disclosed herein may be administered separately, by the same or different route of administration, or together in the same pharmaceutical composition as the other agent(s).
  • Products provided as combinations may include a composition comprising a compound of general formula (I), or a pharmaceutically acceptable salt of the foregoing, and one or more other active agent(s) together in the same pharmaceutical composition, or may include a composition comprising a compound of general formula (I), or a pharmaceutically acceptable salt of the foregoing, and a composition comprising one or more other active agent(s) in separate form, e.g. in the form of a kit or in any form designed to enable separate administration either concurrently or on separate dosing schedules.
  • the weight ratio of a compound of general formula (I), or a pharmaceutically acceptable salt of the foregoing, to a second active agent may be varied and will depend upon the therapeutically effective dose of each agent. Generally, a therapeutically effective dose of each will be used. Combinations of a compound disclosed herein and other active agents will generally also be within the aforementioned range, but in each case, a therapeutically effective dose of each active agent should be used. In such combinations, the compound disclosed herein and other active agents may be administered separately or in conjunction. In addition, the administration of one element may be prior to, concurrent to, or subsequent to the administration of other agent(s).
  • this disclosure provides a composition comprising a compound of general formula (I), or a pharmaceutically acceptable salt thereof, and at least one other active agent as a combined preparation for simultaneous, separate or sequential use in therapy.
  • the therapy is the treatment of a cell proliferation disorder, such as cancer.
  • the disclosure provides a kit comprising two or more separate pharmaceutical compositions, at least one of which contains a compound of general formula (I), or a pharmaceutically acceptable salt of the foregoing.
  • the kit comprises means for separately retaining said compositions, such as a container, divided bottle, or divided foil packet.
  • An example of such a kit is a blister pack, as typically used for the packaging of tablets, capsules, and the like.
  • kits of this disclosure may be used for administration of different dosage forms, for example, oral and parenteral, for administration of the separate compositions at different dosage intervals, or for titration of the separate compositions against one another.
  • a kit of the disclosure typically comprises directions for administration.
  • the disclosure also provides the use of another active agent for treating a cell proliferation disorder, where the medicament is administered with a compound of general formula (I), or a pharmaceutically acceptable salt of the foregoing.
  • the disclosure also provides the use of a compound of general formula (I), or a pharmaceutically acceptable salt of the foregoing, for treating a cell proliferation disorder, where the patient has previously (e.g., within 24 hours) been treated with another active agent.
  • the disclosure also provides the use of another active agent for treating a cell proliferation disorder, where the patient has previously (e.g., within 24 hours) been treated with a compound of general formula (I), or a pharmaceutically acceptable salt of the foregoing.
  • the second agent may be administered a week, several weeks, a month, or several months after the administration of a compound disclosed herein.
  • STING agonist compounds that may be used in combination with the compounds of general formula (I), or pharmaceutically acceptable salts of the foregoing, disclosed herein include but are not limited to cyclic di-nucleotide compounds.
  • Anti-viral compounds that may be used in combination with the compounds of general formula (I), or pharmaceutically acceptable salts of the foregoing, disclosed herein include hepatitis B virus (HBV) inhibitors, hepatitis C virus (HCV) protease inhibitors, HCV polymerase inhibitors, HCV NS4A inhibitors, HCV NS5A inhibitors, HCV NS5b inhibitors, and human immunodeficiency virus (HIV) inhibitors.
  • HBV hepatitis B virus
  • HCV hepatitis C virus
  • HCV polymerase inhibitors HCV NS4A inhibitors
  • HCV NS5A inhibitors HCV NS5b inhibitors
  • HCV NS5b inhibitors human immunodeficiency virus
  • Antigens and adjuvants that may be used in combination with the compounds of general formula (I), or the pharmaceutically acceptable salts of the foregoing, include B7 costimulatory molecule, interleukin-2, interferon-y, GM-CSF, CTLA-4 antagonists, OX-40/0X- 40 ligand, CD40/CD40 ligand, sargramostim, levamisol, vaccinia virus, Bacille Calmette-Guerin (BCG), liposomes, alum, Freund's complete or incomplete adjuvant, detoxified endotoxins, mineral oils, surface active substances such as lipolecithin, pluronic polyols, polyanions, peptides, and oil or hydrocarbon emulsions.
  • BCG Bacille Calmette-Guerin
  • Adjuvants such as aluminum hydroxide or aluminum phosphate
  • Adjuvants can be added to increase the ability of the vaccine to trigger, enhance, or prolong an immune response.
  • Additional materials such as cytokines, chemokines, and bacterial nucleic acid sequences, like CpG, a toll-like receptor (TLR) 9 agonist as well as additional agonists for TLR 2, TLR 4, TLR 5, TLR 7, TLR 8, TLR9, including lipoprotein, LPS, monophosphoryllipid A, lipoteichoic acid, imiquimod, resiquimod, and in addition retinoic acid- inducible gene I (RIG-I) agonists such as poly I:C, used separately or in combination with the described compositions are also potential adjuvants.
  • TLR toll-like receptor
  • CLTA-4 and PD-1 pathways are important negative regulators of immune response.
  • Activated T-cells up-regulate CTLA-4, which binds on antigen-presenting cells and inhibits T- cell stimulation, IL-2 gene expression, and T-cell proliferation; these anti-tumor effects have been observed in mouse models of colon carcinoma, metastatic prostate cancer, and metastatic melanoma.
  • PD-1 binds to active T-cells and suppresses T-cell activation; PD-1 antagonists have demonstrated anti-tumor effects as well.
  • CTLA-4 and PD-1 pathway antagonists that may be used in combination with the compounds of general formula (Ia), the compounds of general formula (Ib), the compounds of general formula (I), or the pharmaceutically acceptable salts of the foregoing, disclosed herein, include ipilimumab, tremelimumab, nivolumab, pembrolizumab, CT-011, AMP-224, and MDX-1106.
  • PD-1 antagonist or“PD-1 pathway antagonist” means any chemical compound or biological molecule that blocks binding of PD-L1 expressed on a cancer cell to PD-1 expressed on an immune cell (T-cell, B-cell, or NKT-cell) and preferably also blocks binding of PD-L2 expressed on a cancer cell to the immune-cell expressed PD-1.
  • Alternative names or synonyms for PD-1 and its ligands include: PDCD1, PD1, CD279, and SLEB2 for PD-1; PDCD1L1, PDL1, B7H1, B7-4, CD274, and B7-H for PD-L1; and PDCD1L2, PDL2, B7-DC, Btdc, and CD273 for PD-L2.
  • the PD-1 antagonist blocks binding of human PD-L1 to human PD-1, and preferably blocks binding of both human PD-L1 and PD-L2 to human PD-1.
  • Human PD-1 amino acid sequences can be found in NCBI Locus No.: NP_005009.
  • Human PD- L1 and PD-L2 amino acid sequences can be found in NCBI Locus No.: NP_054862 and
  • PD-1 antagonists useful in any of the treatment method, medicaments and uses of the present disclosure include a monoclonal antibody (mAb), or antigen binding fragment thereof, which specifically binds to PD-1 or PD-L1, and preferably specifically binds to human PD-1 or human PD-L1.
  • the mAb may be a human antibody, a humanized antibody, or a chimeric antibody and may include a human constant region.
  • the human constant region is selected from the group consisting of IgG1, IgG2, IgG3, and IgG4 constant regions, and in preferred embodiments, the human constant region is an IgG1 or IgG4 constant region.
  • the antigen binding fragment is selected from the group consisting of Fab, Fab'-SH, F(ab') 2 , scFv, and Fv fragments.
  • mAbs that bind to human PD-L1 are described in PCT International Patent Application Nos. WO2013/019906 and WO2010/077634 A1 and in U.S. Patent No. US8383796.
  • Specific anti-human PD-L1 mAbs useful as the PD-1 antagonist in the treatment method, medicaments and uses of the present disclosure include MPDL3280A, BMS-936559,
  • MEDI4736 MSB0010718C
  • PD-1 antagonists useful in any of the treatment method, medicaments, and uses of the present disclosure include an immune-adhesion that specifically binds to PD-1 or PD- L1, and preferably specifically binds to human PD-1 or human PD-L1, e.g., a fusion protein containing the extracellular or PD-1 binding portion of PD-L1 or PD-L2 fused to a constant region such as an Fc region of an immunoglobulin molecule.
  • immune-adhesion molecules that specifically bind to PD-1 are described in PCT International Patent Application Publication Nos. WO2010/027827 and WO2011/066342.
  • AMP-224 also known as B7-DCIg
  • B7-DCIg a PD-L2-FC fusion protein and binds to human PD-1.
  • cytotoxic agents examples include, but are not limited to, arsenic trioxide (sold under the tradename TRISENOX ® ), asparaginase (also known as L- asparaginase, and Erwinia L-asparaginase, sold under the tradenames ELSPAR ® and
  • Chemotherapeutic agents that may be used in combination with the compounds of general formula (I), or pharmaceutically acceptable salts of the foregoing, disclosed herein include abiraterone acetate, altretamine, anhydrovinblastine, auristatin, bexarotene, bicalutamide, BMS 184476, 2,3,4,5,6-pentafluoro-N-(3-fluoro-4-methoxyphenyl)benzene sulfonamide, bleomycin, N,N-dimethyl-L-valyl-L-valyl-N-methyl-L-valyl-L-prolyl- 1-Lproline-t-butylamide, cachectin, cemadotin, chlorambucil, cyclophosphamide, 3',4'-didehydro-4'deoxy-8'-norvin- caleukoblastine, docetaxol, doxetaxel, cyclophospham
  • vascular endothelial growth factor (VEGF) receptor inhibitors include, but are not limited to, bevacizumab (sold under the trademark AVASTIN by Genentech/Roche), axitinib (described in PCT International Patent Publication No.
  • Brivanib Alaninate ((S)-((R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1- f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate, also known as BMS-582664), motesanib (N-(2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-[(4-pyridinylmethyl)amino]-3- pyridinecarboxamide. and described in PCT International Patent Application Publication No. WO02/068470), pasireotide (also known as SO 230, and described in PCT International Patent Publication No. WO02/010192), and sorafenib (sold under the tradename NEXAVAR).
  • topoisomerase II inhibitors include but are not limited to, etoposide (also known as VP-16 and Etoposide phosphate, sold under the tradenames TOPOSAR,
  • VEPESID VEPESID
  • ETOPOPHOS teniposide
  • VUMON teniposide
  • alkylating agents include but are not limited to, 5-azacytidine (sold under the trade name VIDAZA), decitabine (sold under the trade name of DECOGEN), temozolomide (sold under the trade names TEMODAR and TEMODAL by Schering- Plough/Merck), dactinomycin (also known as actinomycin-D and sold under the tradename COSMEGEN), melphalan (also known as L-PAM, L-sarcolysin, and phenylalanine mustard, sold under the tradename ALKERAN), altretamine (also known as hexamethylmelamine (HMM), sold under the tradename HEXALEN), carmustine (sold under the tradename BCNU), bendamustine (sold under the tradename TREANDA), busulfan (sold under the tradenames BUSULFEX ® and MYLERAN ® ), carboplatin (sold under the tradename PARAPLATIN ® ), lo
  • anti-tumor antibiotics include, but are not limited to, doxorubicin (sold under the tradenames ADRIAMYCIN ® and RUBEX ® ), bleomycin (sold under the tradename LENOXANE ® ), daunorubicin (also known as dauorubicin hydrochloride, daunomycin, and rubidomycin hydrochloride, sold under the tradename CERUBIDINE ® ), daunorubicin liposomal (daunorubicin citrate liposome, sold under the tradename DAUNOXOME ® ), mitoxantrone (also known as DHAD, sold under the tradename NOVANTRONE ® ), epirubicin (sold under the tradename ELLENCETM), idarubicin (sold under the tradenames IDAMYCIN ® , IDAMYCIN PFS ® ), and mitomycin C (sold under the tradename MUTAMY
  • anti-metabolites include, but are not limited to, claribine (2- chlorodeoxyadenosine, sold under the tradename LEUSTATIN ® ), 5-fluorouracil (sold under the tradename ADRUCIL ® ), 6-thioguanine (sold under the tradename PURINETHOL ® ), pemetrexed (sold under the tradename ALIMTA ® ), cytarabine (also known as arabinosylcytosine (Ara-C), sold under the tradename CYTOSAR-U ® ), cytarabine liposomal (also known as Liposomal Ara-C, sold under the tradename DEPOCYTTM), decitabine (sold under the tradename DACOGEN ® ), hydroxyurea and (sold under the tradenames HYDREA ® , DROXIATM and MYLOCELTM), fludarabine (sold under the tradename FLUDARA ® ), flo
  • retinoids include, but are not limited to, alitretinoin (sold under the tradename PANRETIN ® ), tretinoin (all-trans retinoic acid, also known as ATRA, sold under the tradename VESANOID ® ), Isotretinoin (13-c/s-retinoic acid, sold under the tradenames
  • ACCUTANE ® AMNESTEEM ® , CLARAVIS ® , CLARUS ® , DECUTAN ® , ISOTANE ® , IZOTECH ® ,
  • the individual compounds described in the Examples herein are defined as STING agonists by (i) binding to the STING protein as evidenced by a reduction in binding of tritiated cGAMP ligand to the STING protein by at least 20% at 20uM (concentration of compound being tested) in a STING Biochemical [3H]cGAMP Competition Assay and (ii) demonstrating interferon production with a 6% or greater induction of IFN- ⁇ secretion at 30uM in the THP1 cell assay (where induction caused by cGAMP at 30uM was set at 100%).
  • the ability of compounds to bind STING is quantified by the ability to compete with tritiated cGAMP ligand for human STING receptor membrane using a radioactive filter- binding assay.
  • the binding assay employs STING receptor obtained from Hi-Five cell membranes overexpressing full-length HAQ STING prepared in-house and tritiated cGAMP ligand also purified in-house.
  • Bq Becquerel, the SI unit of radioactivity, equivalent to 1 disintegration per second (dps)
  • i-PrMgCl-LiCl Isopropylmagnesium chloride– lithium chloride
  • i-PrOH Isopropanol, isopropyl alcohol
  • Step 1 (3aR,4R,12R,12aR)-2,2,2-triphenyl-3a,4,12,12a-tetrahydro-5H,8H-2l5- 4,12-epoxy[1,3,2]dioxaphospholo[4,5-e]pyrimido[2,1-b][1,3]oxazocin-8-one
  • Step 2 (6R,7R,8S,9R)-7,8-dihydroxy-7,8,9,10-tetrahydro-2H,6H-6,9- epoxypyrimido[2,1-b][1,3]oxazocin-2-one
  • Step 4 8-( ⁇ -D-ribofuranosyl)-8,8a-dihydroimidazo[1,2-a]pyrimidin-5(1H)-one
  • Step 2 4-bromo-6-chloropyridazin-3-amine
  • 6-chloropyridazin-3-amine 179g, 1.38mol
  • MeOH MeOH
  • NaHCO 3 232g, 2.76mol
  • Br 2 265g, 1.66mol
  • Step 6 5-[2,3,5-tris-O-(phenylcarbonyl)- ⁇ -D-ribofuranosyl]imidazo[1,2- b]pyridazin-8(5H)-one
  • Step 7 5-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2- yl)imidazo[1,2-b]pyridazin-8(5H)-one
  • Step 8 5-((2R,3R,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-3,4- dihydroxytetrahydrofuran-2-yl)imidazo[1,2-b]pyridazin-8(5H)-one
  • Step 9 5-((2R,3R,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-3- hydroxy-4-((triisopropylsilyl)oxy)tetrahydrofuran-2-yl)imidazo[1,2-b]pyridazin-8(5H)-one and 5-((2R,3R,4R,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxy-3- ((triisopropylsilyl)oxy)tetrahydrofuran-2-yl)imidazo[1,2-b]pyridazin-8(5H)-one
  • Step 10 (2R,3R,4R,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-2-(8- oxoimidazo[1,2-b]pyridazin-5(8H)-yl)-4-((triisopropylsilyl)oxy)tetrahydrofuran-3-yl hydrogen phosphonate
  • Step 11 (2R,3R,4R,5R)-5-(hydroxymethyl)-2-(8-oxoimidazo[1,2-b]pyridazin- 5(8H)-yl)-4-((triisopropylsilyl)oxy)tetrahydrofuran-3-yl hydrogen phosphonate
  • Step 1 ((3aS,4R,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2-dimethyltetrahydrothieno [3,4-d][1,3]dioxol-4-yl)methanol
  • Step 2 N-(9-((3aR,4R,6R,6aS)-6-(hydroxymethyl)-2,2-dimethyltetrahydrothieno [3,4-d][1,3]dioxol-4-yl)-9H-purin-6-yl)benzamide
  • Step 3 N-(9-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrothiophen- 2-yl)-9H-purin-6-yl)benzamide
  • Step 4 N-(9-((2R,3R,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-3,4- dihydroxytetrahydrothiophen-2-yl)-9H-purin-6-yl)benzamide
  • Step 5 N-(9-((2R,3R,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4- hydroxy-3-((triisopropylsilyl)oxy)tetrahydrothiophen-2-yl)-9H-purin-6-yl)benzamide
  • N-(9-((2R,3R,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-3,4- dihydroxytetrahydrothiophen-2-yl)-9H-purin-6-yl)benzamide (1.23g, 1.78mmol)
  • (2R,4S)-4- isopropyl-2-methoxy-3-((R)-2-methyl-1-(1-methyl-1H-imidazol-2-yl)propyl)oxazolidine 0.53g, 2.67mmol
  • N-ethyl-N-isopropylpropan-2-aminium chloride (8.9mg, 0.053mmol) were co-evaporated with THF (3 ⁇ 10mL) and then re-dissolved in THF (80mL) under Ar.
  • N-ethyl-N-isopropylpropan-2-amine (0.691g, 5.35mmol). It was stirred at RT for 5min, and then TIPSOTf (1.64g, 5.35mmol) was added dropwise. The mixture was stirred at RT for 16h. Then, the solution was diluted with EtOAc (50mL) and washed with Na 2 CO 3 (3 ⁇ 50mL). The organic layer was dried (MgSO 4 ) and concentrated to give a crude containing the product. The residue was used for the next reaction step without further purification. LCMS (ES, m/z): 846.3 [M+H] + .
  • Step 6 (2R,3S,4R,5R)-5-(6-benzamido-9H-purin-9-yl)-2-((bis(4- methoxyphenyl)(phenyl)methoxy)methyl)-4-((triisopropylsilyl)oxy)tetrahydrothiophen-3-yl (2- cyanoethyl) diisopropylphosphoramidite
  • Step 1 ((2R,3S,4S)-4-acetoxy-3-fluoro-5-(4-oxo-4,5-dihydro-1H-imidazo[4,5- c]pyridin-1-yl)tetrahydrofuran-2-yl)methyl benzoate
  • TIPSOTf (3.92g, 17.7mmol) was added to the solution, and it was stirred at 0°C for 30min. Then, the solution was heated to 80°C for 16h. Then, the reaction mixture was cooled to 0°C, and sat aq NaHCO 3 (10mL) and H 2 O (30mL) were added. Layers were separated, and the aq layer was extracted with EtOAc (3 ⁇ 50mL). The combined organic layers were washed with brine (100mL), dried (Na 2 SO 4 ), and concentrated. The residue was purified by silica gel column chromatography, eluted with 1 to 10% MeOH in DCM to afford the product. LCMS (ES, m/z): 416.3 [M+H] + .
  • Step 2 1-((3S,4R,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)- 1,5-dihydro-4H-imidazo[4,5-c]pyridin-4-one
  • Step 3 1-((3S,4R,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-fluoro- 3-hydroxytetrahydrofuran-2-yl)-1,5-dihydro-4H-imidazo[4,5-c]pyridin-4-one
  • Step 1 ((2S,4R,5R)-4-acetoxy-5-(4-(benzyloxy)-1H-imidazo[4,5-c]pyridin-1- yl)tetrahydrofuran-2-yl)methyl 4-methylbenzoate and ((2S,4R,5R)-4-acetoxy-5-(4-oxo-4,5- dihydro-1H-imidazo[4,5-c]pyridin-1-yl)tetrahydrofuran-2-yl)methyl 4-methylbenzoate
  • Step 2 ((2S,4R,5R)-4-acetoxy-5-(4-oxo-4,5-dihydro-1H-imidazo[4,5-c]pyridin-1- yl)tetrahydrofuran-2-yl)methyl 4-methylbenzoate
  • Step 3 1-((2R,3R,5S)-3-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,5- dihydro-4H-imidazo[4,5-c]pyridin-4-one
  • Step 4 1-((2R,3R,5S)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-3- hydroxytetrahydrofuran-2-yl)-1,5-dihydro-4H-imidazo[4,5-c]pyridin-4-one
  • Step 1 N-(9-((2R,3R,4R,5R)-3,4-bis((tert-butyldimethylsilyl)oxy)-5-(((tert- butyldimethylsilyl)oxy)methyl)tetrahydrofuran-2-yl)-6-oxo-6,9-dihydro-1H-purin-2-yl)-2- chloroacetamide
  • Step 2 3-((2R,3R,4R,5R)-3,4-bis((tert-butyldimethylsilyl)oxy)-5-(((tert- butyldimethylsilyl)oxy)methyl)tetrahydrofuran-2-yl)-3,5-dihydro-9H-imidazo[1,2-a]purine- 6,9(7H)-dione
  • Step 3 3-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)- 3,5-dihydro-9H-imidazo[1,2-a]purine-6,9(7H)-dione
  • Step 1 2-amino-1-(2,2-diethoxyethyl)-9-((2R,3R,4S,5R)-3,4-dihydroxy-5- (hydroxymethyl)tetrahydrofuran-2-yl)-1,9-dihydro-6H-purin-6-one
  • K 2 CO 3 11.0g, 79.0mmol
  • 2-bromo-1,1-diethoxyethane (12.3mL, 79.0mmol) was added over 10min. The reaction was heated at 90°C for 72h.
  • Step 2 3-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)- 3,5-dihydro-9H-imidazo[1,2-a]purin-9-one
  • Step 1 N-(9-((2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)tetrahydrofuran- 2-yl)-6-oxo-6,9-dihydro-1H-purin-2-yl)isobutyramide
  • Step 2 N-(9-((2R,3S,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4- fluoro-3-hydroxytetrahydrofuran-2-yl)-6-oxo-6,9-dihydro-1H-purin-2-yl)isobutyramide
  • N-(9-((2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)- 6-oxo-6,9-dihydro-1H-purin-2-yl)isobutyramide (1.30g, 3.66mmol) was co-evaporated with Py (3 ⁇ 10mL) and re-dissolved in Py (26mL). To the solution at 0°C-5°C was added DMTrCl (1.36g, 4.02mmol). It was stirred at RT for 3h and then concentrated.
  • Step 3 (2R,3S,4R,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-fluoro- 2-(2-isobutyramido-6-oxo-1,6-dihydro-9H-purin-9-yl)tetrahydrofuran-3-yl (2-cyanoethyl) diisopropylphosphoramidite
  • Step 1 2-amino-1-(2,2-diethoxyethyl)-9-((2R,3S,4S,5R)-4-fluoro-3-hydroxy-5- (hydroxymethyl)tetrahydrofuran-2-yl)-1,9-dihydro-6H-purin-6-one
  • Step 2 3-((2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2- yl)-3,5-dihydro-9H-imidazo[1,2-a]purin-9-one
  • Step 3 3-((2R,3S,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4- fluoro-3-hydroxytetrahydrofuran-2-yl)-5-(bis(4-methoxyphenyl)(phenyl)methyl)-3,5-dihydro-9H- imidazo[1,2-a]purin-9-one
  • Step 4 (2R,3S,4R,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-2-(5- (bis(4-methoxyphenyl)(phenyl)methyl)-9-oxo-5,9-dihydro-3H-imidazo[1,2-a]purin-3-yl)-4- fluorotetrahydrofuran-3-yl phenyl phosphonate
  • Step 5 (2R,3S,4R,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-2-(5- (bis(4-methoxyphenyl)(phenyl)methyl)-9-oxo-5,9-dihydro-3H-imidazo[1,2-a]purin-3-yl)-4- fluorotetrahydrofuran-3-yl hydrogen phosphonate
  • Step 6 (2R,3S,4R,5R)-4-fluoro-5-(hydroxymethyl)-2-(9-oxo-5,9-dihydro-3H- imidazo[1,2-a]purin-3-yl)tetrahydrofuran-3-yl hydrogen phosphonate
  • Step 1 (2R,3R,4S,5R)-5-(7-amino-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-2- ((benzoyloxy)methyl)-4-fluorotetrahydrofuran-3-yl benzoate
  • Step 2 (2R,3R,4S,5R)-5-(7-amino-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-4- fluoro-2-(hydroxymethyl)tetrahydrofuran-3-ol
  • Step 3 N-(3-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran- 2-yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl)benzamide
  • Step 4 N-(3-((2R,3S,4R,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-3- fluoro-4-hydroxytetrahydrofuran-2-yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl)benzamide
  • Step 5 (2R,3R,4S,5R)-5-(7-benzamido-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-2- ((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-fluorotetrahydrofuran-3-yl (2-cyanoethyl) diisopropylphosphoramidite
  • Step 1 (3R,4R,5R)-2-(4-aminoimidazo[2,1-f][1,2,4]triazin-7-yl)-3,4- bis(benzyloxy)-5-((benzyloxy)methyl)tetrahydrofuran-2-ol
  • Step 2 7-((3S,4R,5R)-3,4-bis(benzyloxy)-5-((benzyloxy)methyl)tetrahydrofuran-2- yl)imidazo[2,1-f][1,2,4]triazin-4-amine
  • Step 3 (3R,4S,5R)-2-(4-aminoimidazo[2,1-f][1,2,4]triazin-7-yl)-5-(hydroxymethyl)- tetrahydrofuran-3,4-diol
  • Step 4 (6aR,8S,9S,9aS)-8-(4-aminoimidazo[2,1-f][1,2,4]triazin-7-yl)-2,2,4,4- tetraisopropyltetrahydro-6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-9-ol
  • Step 5 O-((6aR,8S,9S,9aR)-8-(4-aminoimidazo[2,1-f][1,2,4]triazin-7-yl)-2,2,4,4- tetraisopropyltetrahydro-6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-9-yl) 1H-imidazole-1- carbothioate
  • Step 6 7-((6aR,8R,9aS)-2,2,4,4-tetraisopropyltetrahydro-6H-furo[3,2- f][1,3,5,2,4]trioxadisilocin-8-yl)imidazo[2,1-f][1,2,4]triazin-4-amine
  • Step 7 N-benzoyl-N-(7-((6aR,8R,9aS)-2,2,4,4-tetraisopropyltetrahydro-6H- furo[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl)imidazo[2,1-f][1,2,4]triazin-4-yl)benzamide
  • Step 8 N-(7-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2- yl)imidazo[2,1-f][1,2,4]triazin-4-yl)benzamide
  • Step 9 N-(7-((2R,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4- hydroxytetrahydrofuran-2-yl)imidazo[2,1-f][1,2,4]triazin-4-yl)benzamide
  • Step 1 (2R,3S,4R,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-fluoro- 2-(2-isobutyramido-6-oxo-1,6-dihydro-9H-purin-9-yl)tetrahydrofuran-3-yl phenyl phosphonate
  • Step 2 (2R,3S,4R,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-fluoro- 2-(2-isobutyramido-6-oxo-1,6-dihydro-9H-purin-9-yl)tetrahydrofuran-3-yl phosphonate
  • Step 1 ((2R,3R,4S,5R)-5-(5-amino-7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5- d]pyrimidin-3-yl)-4-(benzoyloxy)-3-fluorotetrahydrofuran-2-yl)methyl benzoate
  • Step 2 ((2R,3R,4S,5R)-4-(benzoyloxy)-3-fluoro-5-(5-isobutyramido-7-oxo-6,7- dihydro-3H- [1,2,3]triazolo[4,5-d]pyrimidin-3-yl)tetrahydrofuran-2-yl)methyl benzoate
  • Step 3 N-(3-((2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)
  • Step 4 N-(3-((2R,3S,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4- fluoro-3-hydroxytetrahydrofuran-2-yl)-7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5- yl)isobutyramide
  • N-(3-((2R,3R,5S)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-3-hydroxy- tetrahydrofuran-2-yl)-7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)isobutyramide was prepared according to procedures analogous to those described for Preparation 18 using the appropriately substituted ribose in Step 1.
  • Step 1 (3R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrothiophen-3-yl 2,4- dimethoxybenzoate
  • Step 2 (3R,4S,5R)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-4- hydroxytetrahydrothiophen-3-yl 2,4-dimethoxybenzoate
  • Step 3 (3R,4S,5R)-4-((1H-imidazole-1-carbonothioyl)oxy)-5-(((tert- butyldiphenylsilyl)oxy)methyl)tetrahydrothiophen-3-yl 2,4-dimethoxybenzoate
  • Step 4 (3R,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)tetrahydrothiophen-3-yl 2,4- dimethoxybenzoate
  • Step 5 (1R,3R,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-1- oxidotetrahydrothiophen-3-yl 2,4-dimethoxybenzoate
  • Step 7 (3R,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-(6-chloro-2- isobutyramido-9H-purin-9-yl)tetrahydrothiophen-3-yl 2,4-dimethoxybenzoate
  • Step 8 (2R,3R,5S)-2-(6-chloro-2-isobutyramido-9H-purin-9-yl)-5-(hydroxymethyl)- tetrahydrothiophen-3-yl 2,4-dimethoxybenzoate
  • Step 9 2-amino-9-((2R,3R,5S)-3-hydroxy-5-(hydroxymethyl)tetrahydrothiophen-2- yl)-1,9-dihydro-6H-purin-6-one
  • Step 10 N-(9-((2R,3R,5S)-3-hydroxy-5-(hydroxymethyl)tetrahydrothiophen-2-yl)-6- oxo-6,9-dihydro-1H-purin-2-yl)isobutyramide
  • Step 11 N-(9-((2R,3R,5S)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-3- hydroxytetrahydrothiophen-2-yl)-6-oxo-6,9-dihydro-1H-purin-2-yl)isobutyramide
  • N-(9-((2R,3R,5S)-3-hydroxy-5-(hydroxymethyl)tetrahydrothiophen-2-yl)-6-oxo- 6,9-dihydro-1H-purin-2-yl)isobutyramide (510mg, 1.443mmol) was co-evaporated with Py (3 ⁇ 5mL) and then re-suspended in Py (7mL). To the suspension was added DMTrCl (538mg, 1.587mmol), and the mixture was stirred at RT for 2h.
  • Step 1 N-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5- yl)isobutyramide
  • Step 2 ((2R,3S,4R,5R)-4-(benzoyloxy)-3-fluoro-5-(5-isobutyramido-7-oxo-6,7- dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)tetrahydrothiophen-2-yl)methyl benzoate
  • Step 3 N-(3-((2R,3R,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)tetrahydro- thiophen-2-yl)-7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)isobutyramide
  • Step 4 N-(3-((2R,3R,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4- fluoro-3-hydroxytetrahydrothiophen-2-yl)-7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d] pyrimidin-5-yl)isobutyramide
  • Step 1 8-((2R,3R,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-3,4- dihydroxytetrahydrofuran-2-yl)imidazo[1,2-a]pyrimidin-5(8H)-one
  • Step 2 8-((2R,3R,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4- ((tert-butyldimethylsilyl)oxy)-3-hydroxytetrahydrofuran-2-yl)imidazo[1,2-a]pyrimidin-5(8H)-one
  • Step 3 8- ⁇ 5-O-[bis(4-methoxyphenyl)(phenyl)methyl]-3-O-[tert-butyl(dimethyl)silyl]- 2-O-[hydroxy(oxido)- ⁇ 5 -phosphanyl]- ⁇ -D-ribofuranosyl ⁇ imidazo[1,2-a]pyrimidin-5(8H)-one
  • Step 4 (2R,3R,4R,5R)-5-(((((((2R,3R,4R,5R)-5-(6-benzamido-9H-purin-9-yl)-4- ((tert-butyldimethylsilyl)oxy)-2-(hydroxymethyl)tetrahydrofuran-3-yl)oxy)(2-cyanoethoxy) phosphorothioyl)oxy)methyl)-4-((tert-butyldimethylsilyl)oxy)-2-(5-oxoimidazo[1,2-a]pyrimidin- 8(5H)-yl)tetrahydrofuran-3-yl hydrogen phosphonate
  • Step 5 N- ⁇ 9-[(5R,7R,8R,12aR,14R,15R,15aR,16R)-15,16-bis ⁇ [tert-butyl
  • Step 6 8-[(5R,7R,8R,12aR,14R,15R,15aR,16R)-14-(6-amino-9H-purin-9-yl)-15,16- bis ⁇ [tert-butyl(dimethyl)silyl]oxy ⁇ -2,10-dioxido-2,10-disulfanyloctahydro-12H-5,8- methanofuro[3,2-l][1,3,6,9,11,2,10]pentaoxadiphosphacyclotetradecin-7-yl]imidazo[1,2- a]pyrimidin-5(8H)-one
  • Step 7 8-[(2R,5R,7R,8R,10R,12aR,14R,15R,15aS,16R)-14-(6-amino-9H-purin-9- yl)-15,16-dihydroxy-2,10-dioxido-2,10-disulfanyloctahydro-12H-5,8-methanofuro[3,2-l]
  • Example 1 (Diastereomer 1) (fast eluted): LCMS (ES, m/z): 689 [M-H]-.
  • Example 2 (Diastereomer 2) (slow eluted): LCMS (ES, m/z): 689 [M-H]-.
  • Example 18 8-[(5R,7R,8R,12aR,14R,15aS,16R)-14-(7-amino-3H-[1,2,3] triazolo[4,5-b]pyridin-3-yl)-16-hydroxy-2,10-dioxido-2,10-disulfanyloctahydro-12H-5,8- methanofuro[3,2-l][1,3,6,9,11,2,10]pentaoxadiphosphacyclotetradecin-7-yl]imidazo[1,2- a]pyrimidin-5(8H)-one
  • Step 1 (2R,3R,4R,5R)-4-((tert-butyldimethylsilyl)oxy)-5-(hydroxymethyl)-2-(5- oxoimidazo[1,2-a]pyrimidin-8(5H)-yl)tetrahydrofuran-3-yl hydrogen phosphonate
  • Step 2 2-(4-(tert-butyl)phenoxy)-N-(3-((2R,4S,5R)-4-hydroxy-5- (hydroxymethyl)tetrahydrofuran-2-yl)-3H-[1,2,3]triazolo[4,5-b]pyridin-7-yl)acetamide
  • Step 3 N-(3-((2R,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4- hydroxytetrahydrofuran-2-yl)-3H-[1,2,3]triazolo[4,5-b]pyridin-7-yl)-2-(4-(tert- butyl)phenoxy)acetamide
  • Step 4 (2R,3S,5R)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-5-(7-(2-(4- (tert-butyl)phenoxy)acetamido)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)tetrahydrofuran-3-yl (2- cyanoethyl) diisopropylphosphoramidite
  • Step 5 (2R,3R,4R,5R)-5-((((((2R,3S,5R)-2-((bis(4-methoxyphenyl)(phenyl) methoxy)methyl)-5-(7-(2-(4-(tert-butyl)phenoxy)acetamido)-3H-[1,2,3]triazolo[4,5-b]pyridin-3- yl)tetrahydrofuran-3-yl)oxy)(2-cyanoethoxy)phosphanyl)oxy)methyl)-4-((tert-butyldimethylsilyl) oxy)-2-(5-oxoimidazo[1,2-a]pyrimidin-8(5H)-yl)tetrahydrofuran-3-yl hydrogen phosphonate
  • Step 6 (2R,3R,4R,5R)-5-((((((2R,3S,5R)-2-((bis(4-methoxyphenyl)(phenyl)methoxy) methyl)-5-(7-(2-(4-(tert-butyl)phenoxy)acetamido)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl) tetrahydrofuran-3-yl)oxy)(2-cyanoethoxy)phosphorothioyl)oxy)methyl)-4-((tert-butyldimethyl- silyl)oxy)-2-(5-oxoimidazo[1,2-a]pyrimidin-8(5H)-yl)tetrahydrofuran-3-yl hydrogen
  • Step 7 (2R,3R,4R,5R)-5-(((((((2R,3S,5R)-5-(7-(2-(4-(tert-butyl)phenoxy) acetamido)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-2-(hydroxymethyl)tetrahydrofuran-3- yl)oxy)(2-cyanoethoxy)phosphorothioyl)oxy)methyl)-4-((tert-butyldimethylsilyl)oxy)-2-(5- oxoimidazo[1,2-a]pyrimidin-8(5H)-yl)tetrahydrofuran-3-yl hydrogen phosphonate
  • Step 8 N- ⁇ 3-[(5R,7R,8R,12aR,14R,15aS,16R)-16- ⁇ [tert-butyl(dimethyl)silyl]oxy ⁇ - 2-(2-cyanoethoxy)-10-hydroxy-7-(5-oxoimidazo[1,2-a]pyrimidin-8(5H)-yl)-2-sulfidooctahydro- 12H-5,8-methanofuro[3,2-l][1,3,6,9,11,2,10]pentaoxadiphosphacyclotetradecin-14-yl]-3H- [1,2,3]triazolo[4,5-b]pyridin-7-yl ⁇ -2-(4-tert-butylphenoxy)acetamide
  • Step 9 N- ⁇ 3-[(5R,7R,8R,12aR,14R,15aS,16R)-16- ⁇ [tert-butyl(dimethyl)silyl]oxy ⁇ - 2-(2-cyanoethoxy)-10-oxido-7-(5-oxoimidazo[1,2-a]pyrimidin-8(5H)-yl)-10-sulfanyl-2- sulfidooctahydro-12H-5,8-methanofuro[3,2-l][1,3,6,9,11,2,10]pentaoxadiphosphacyclo- tetradecin-14-yl]-3H-[1,2,3]triazolo[4,5-b]pyridin-7-yl ⁇ -2-(4-tert-butylphenoxy)acetamide
  • Step 10 8-[(5R,7R,8R,12aR,14R,15aS,16R)-14-(7-amino-3H-[1,2,3]triazolo[4,5- b]pyridin-3-yl)-16- ⁇ [tert-butyl(dimethyl)silyl]oxy ⁇ -2,10-dioxido-2,10-disulfanyloctahydro-12H- 5,8-methanofuro[3,2-l][1,3,6,9,11,2,10]pentaoxadiphosphacyclotetradecin-7-yl]imidazo[1,2- a]pyrimidin-5(8H)-one
  • Step 11 8-[(5R,7R,8R,12aR,14R,15aS,16R)-14-(7-amino-3H-[1,2,3]triazolo[4,5- b]pyridin-3-yl)-16-hydroxy-2,10-dioxido-2,10-disulfanyloctahydro-12H-5,8-methanofuro[3,2- l][1,3,6,9,11,2,10]pentaoxadiphosphacyclotetradecin-7-yl]imidazo[1,2-a]pyrimidin-5(8H)-one
  • the mixture was stirred at 50°C for 16h. Then, the mixture was concentrated under reduced pressure, and acetone (1.1mL) was added. Ethoxytrimethylsilane (3.9mL, 25mmol) was added to the mixture. The crude product crystallized out, and the mixture was maintained at 0°C. After 30min, the crude product was collected by filtration, and it was washed with acetone.
  • Step 1 8- ⁇ 5-O-[bis(4-methoxyphenyl)(phenyl)methyl]-2-O-[tert-butyl(dimethyl) silyl]- ⁇ -D-ribofuranosyl ⁇ imidazo[1,2-a]pyrimidin-5(8H)-one and 8- ⁇ 5-O-[bis(4-methoxyphenyl) (phenyl)methyl]-3-O-[tert-butyl(dimethyl)silyl]- ⁇ -D-ribofuranosyl ⁇ imidazo[1,2-a]pyrimidin- 5(8H)-one
  • Step 2 8- ⁇ 5-O-[bis(4-methoxyphenyl)(phenyl)methyl]-2-O-[tert- butyl(dimethyl)silyl]-3-O-(1H-imidazol-1-ylcarbonothioyl)- ⁇ -D-ribofuranosyl ⁇ imidazo[1,2- a]pyrimidin-5(8H)-one
  • Step 3 8-((2R,3R,5S)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-3-((tert- butyldimethylsilyl)oxy)tetrahydrofuran-2-yl)imidazo[1,2-a]pyrimidin-5(8H)-one
  • Step 4 8-((2R,3R,5S)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-3- hydroxytetrahydrofuran-2-yl)imidazo[1,2-a]pyrimidin-5(8H)-one
  • Step 5 8- ⁇ 5-O-[bis(4-methoxyphenyl)(phenyl)methyl]-3-deoxy-2-O-[hydroxyl (oxido)- ⁇ 5 -phosphanyl]- ⁇ -D-erythro-pentofuranosyl ⁇ imidazo[1,2-a]pyrimidin-5(8H)-one
  • Step 6 (2R,3R,5S)-5-(((((((2R,3R,4S,5R)-5-(6-benzamido-9H-purin-9-yl)-4-fluoro-2- (hydroxymethyl)tetrahydrofuran-3-yl)oxy)(2-cyanoethoxy)phosphorothioyl)oxy)methyl)-2-(5- oxoimidazo[1,2-a]pyrimidin-8(5H)-yl)tetrahydrofuran-3-yl hydrogen phosphonate
  • Step 7 N- ⁇ 9-[(5S,7R,8R,12aR,14R,15S,15aR)-2-(2-cyanoethoxy)-15-fluoro-10- oxido-7-(5-oxoimidazo[1,2-a]pyrimidin-8(5H)-yl)-10-sulfanyl-2-sulfidooctahydro-12H-5,8- methanofuro[3,2-l][1,3,6,9,11,2,10]pentaoxadiphosphacyclotetradecin-14-yl]-9H-purin-6- yl ⁇ benzamide
  • Step 8 8-[(2R,5S,7R,8R,10R,12aR,14R,15S,15aR)-14-(6-amino-9H-purin-9-yl)-15- fluoro-2,10-dioxido-2,10-disulfanyloctahydro-12H-5,8-methanofuro[3,2-l][1,3,6,9,11,2,10] pentaoxadiphosphacyclotetradecin-7-yl]imidazo[1,2-a]pyrimidin-5(8H)-one
  • Example 19 (diastereomer 1) (fast eluted): LCMS (ES, m/z): 675 [M-H]-.
  • Example 20 (diastereomer 2) (slow eluted): LCMS (ES, m/z): 675 [M-H]-.
  • Example 30 8,8'-[(5R,7R,8R,12aR,14R,15R,15aS,16R)-15,16-dihydroxy-2,10- dioxido-2,10-disulfanyloctahydro-12H-5,8-methanofuro[3,2-l][1,3,6,9,11,2,10]
  • Step 1 (2R,3R,4R,5R)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-((tert- butyldimethylsilyl)oxy)-5-(5-oxoimidazo[1,2-a]pyrimidin-8(5H)-yl)tetrahydrofuran-3-yl (2- cyanoethyl) diisopropylphosphoramidite
  • Step 2 (2R,3R,4R,5R)-5-((((((2R,3R,4R,5R)-2-((bis(4-methoxyphenyl)(phenyl) methoxy)methyl)-4-((tert-butyldimethylsilyl)oxy)-5-(5-oxoimidazo[1,2-a]pyrimidin-8(5H)- yl)tetrahydrofuran-3-yl)oxy)(2-cyanoethoxy)phosphanyl)oxy)methyl)-4-((tert-butyldimethylsilyl) oxy)-2-(5-oxoimidazo[1,2-a]pyrimidin-8(5H)-yl)tetrahydrofuran-3-yl hydrogen phosphonate
  • Step 3 (2R,3R,4R,5R)-5-((((((2R,3R,4R,5R)-2-((bis(4-methoxyphenyl)(phenyl) methoxy)methyl)-4-((tert-butyldimethylsilyl)oxy)-5-(5-oxoimidazo[1,2-a]pyrimidin-8(5H)- yl)tetrahydrofuran-3-yl)oxy)(2-cyanoethoxy)phosphorothioyl)oxy)methyl)-4-((tert- butyldimethylsilyl)oxy)-2-(5-oxoimidazo[1,2-a]pyrimidin-8(5H)-yl)tetrahydrofuran-3-yl hydrogen phosphonate
  • Step 4 (2R,3R,4R,5R)-4-((tert-butyldimethylsilyl)oxy)-5-((((((2R,3R,4R,5R)-4- ((tert-butyldimethylsilyl)oxy)-2-(hydroxymethyl)-5-(5-oxoimidazo[1,2-a]pyrimidin-8(5H)- yl)tetrahydrofuran-3-yl)oxy)(2-cyanoethoxy)phosphorothioyl)oxy)methyl)-2-(5-oxoimidazo[1,2- a]pyrimidin-8(5H)-yl)tetrahydrofuran-3-yl hydrogen phosphonate
  • Step 5 3- ⁇ [(5R,7R,8R,12aR,14R,15R,15aR,16R)-15,16-bis ⁇ [tert-butyl(dimethyl) silyl]oxy ⁇ -10-hydroxy-7,14-bis(5-oxoimidazo[1,2-a]pyrimidin-8(5H)-yl)-2-sulfidooctahydro- 12H-5,8-methanofuro[3,2-l][1,3,6,9,11,2,10]pentaoxadiphosphacyclotetradecin-2- yl]oxy ⁇ propanenitrile
  • Step 6 3- ⁇ [(5R,7R,8R,12aR,14R,15R,15aR,16R)-15,16-bis ⁇ [tert- butyl(dimethyl)silyl]oxy ⁇ -10-oxido-7,14-bis(5-oxoimidazo[1,2-a]pyrimidin-8(5H)-yl)-10- sulfanyl-2-sulfidooctahydro-12H-5,8-methanofuro[3,2-l][1,3,6,9,11,2,10]
  • Step 7 8,8'-[(5R,7R,8R,12aR,14R,15R,15aR,16R)-15,16-bis ⁇ [tert-butyl(dimethyl) silyl]oxy ⁇ -2,10-dioxido-2,10-disulfanyloctahydro-12H-5,8-methanofuro[3,2-l][1,3,6,9,11,2,10] pentaoxadiphosphacyclotetradecine-7,14-diyl]bisimidazo[1,2-a]pyrimidin-5(8H)-one
  • Step 8 8,8'-[(5R,7R,8R,12aR,14R,15R,15aS,16R)-15,16-dihydroxy-2,10-dioxido- 2,10-disulfanyloctahydro-12H-5,8-methanofuro[3,2-l][1,3,6,9,11,2,10]
  • Example 31 as shown in Table 3 below, were prepared according to procedures analogous to those outlined in Example 30 above using the appropriate monomers, described as Preparations or as obtained from commercial sources, in the coupling step.
  • Examples 32 and 33 1-[(5R,7R,8S,12aR,14R,15R,15aS,16R)-7-(2-amino-6-oxo- 1,6-dihydro-9H-purin-9-yl)-16-fluoro-15-hydroxy-2,10-dioxido-2,10-disulfanyl-octahydro- 12H-5,8-methanofuro[3,2-l][1,3,6,9,11,2,10]pentaoxadiphosphacyclotetradecin-14-yl]-1H- imidazo[2,1-b]purin-4(5H)-one (Diastereomer 1) and 1-[(5R,7R,8S,12aR,14R,15R,15aS, 16R)-7-(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)-16-fluoro-15-hydroxy-2,10-dioxido-
  • Step 1 (2R,3R,4S,5R)-2-(4-(benzyloxy)-1H-imidazo[2,1-b]purin-1-yl)-5-((bis(4- methoxyphenyl)(phenyl)methoxy)methyl)tetrahydrofuran-3,4-diol
  • Step 2 1-((2R,3R,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-3,4- dihydroxytetrahydrofuran-2-yl)-1H-imidazo[2,1-b]purin-4(5H)-one
  • Step 3 1-((2R,3R,4R,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4- hydroxy-3-((triisopropylsilyl)oxy)tetrahydrofuran-2-yl)-1H-imidazo[2,1-b]purin-4(5H)-one
  • Step 4 (2R,3R,4R,5R)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-5-(4-oxo- 4,5-dihydro-1H-imidazo[2,1-b]purin-1-yl)-4-((triisopropylsilyl)oxy)tetrahydrofuran-3-yl phenyl phosphonate
  • Step 5 (2R,3R,4R,5R)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-5-(4-oxo- 4,5-dihydro-1H-imidazo[2,1-b]purin-1-yl)-4-((triisopropylsilyl)oxy)tetrahydrofuran-3-yl hydrogen phosphonate
  • Step 6 (2R,3R,4R,5R)-2-(hydroxymethyl)-5-(4-oxo-4,5-dihydro-1H-imidazo[2,1- b]purin-1-yl)-4-((triisopropylsilyl)oxy)tetrahydrofuran-3-yl hydrogen phosphonate
  • Step 7 (2R,3R,4R,5R)-2-((((2-cyanoethoxy)(((2R,3S,4R,5R)-4-fluoro-5- (hydroxymethyl)-2-(2-isobutyramido-6-oxo-1,6-dihydro-9H-purin-9-yl)tetrahydrofuran-3- yl)oxy)phosphanyl)oxy)methyl)-5-(4-oxo-4,5-dihydro-1H-imidazo[2,1-b]purin-1-yl)-4- ((triisopropylsilyl)oxy)tetrahydrofuran-3-yl hydrogen phosphonate
  • Step 8 (2R,3R,4R,5R)-2-((((2-cyanoethoxy)(((2R,3S,4R,5R)-4-fluoro-5- (hydroxymethyl)-2-(2-isobutyramido-6-oxo-1,6-dihydro-9H-purin-9-yl)tetrahydrofuran-3-yl) oxy)phosphorothioyl)oxy)methyl)-5-(4-oxo-4,5-dihydro-1H-imidazo[2,1-b]purin-1-yl)-4- ((triisopropylsilyl)oxy)tetrahydrofuran-3-yl hydrogen phosphonate

Abstract

A class of polycyclic compounds of general formula (I), wherein Base1, Base2, Y, Za, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2, R2a, R3, R4, R4a, R5, R6, R6a, R7, R7a, R8, R8a, and R9 are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds.

Description

TITLE OF THE APPLICATION
CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS FIELD OF THE INVENTION
[0001] The present disclosure relates to cyclic di-nucleotide compounds and derivatives thereof that may be useful as STING (Stimulator of Interferon Genes) agonists that activate the STING pathway. The present disclosure also relates to processes for the synthesis and to uses of such cyclic di-nucleotide compounds. REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY
[0002] The sequence listing of the present application is submitted electronically via EFS- Web as an ASCII-formatted sequence listing, with a file name of
“24556_SEQLIST_14NOV2018”, a creation date of November 14, 2018, and a size of 25KB. This sequence listing submitted via EFS-Web is part of the specification and is herein incorporated by reference in its entirety. BACKGROUND OF THE INVENTION
[0003] The immune system has evolved to recognize and neutralize different types of threats in order to maintain the homeostasis of the host, and it is generally broken down into two arms: adaptive and innate. The adaptive immune system is specialized to recognize as foreign those antigens not naturally expressed in the host and to mount an anti-antigen response through the coordinated actions of many leukocyte subsets. The hallmark of adaptive immune responses is their ability to provide“memory” or long-lasting immunity against the encountered antigen. While this specific and long-lasting effect is critical to host health and survival, the adaptive immune response requires time to generate a full-blown response.
[0004] The innate immune system compensates for this time delay and is specialized to act quickly against different insults or danger signals. It provides the first line of defense against bacteria, viruses, parasites and other infectious threats, but it also responds strongly to certain danger signals associated with cellular or tissue damage. The innate immune system has no antigen specificity but does respond to a variety of effector mechanisms. Opsonization, phagocytosis, activation of the complement system, and production of soluble bioactive molecules such as cytokines or chemokines are all mechanisms by which the innate immune system mediates its response. By responding to these damage-associated molecular patterns (DAMPs) or pathogen-associated molecular patterns (PAMPs) described above, the innate immune system is able to provide broad protection against a wide range of threats to the host.
[0005] Free cytosolic DNA and RNA are among these PAMPs and DAMPs. It has recently been demonstrated that the main sensor for cytosolic DNA is cGAS (cyclic GMP-AMP synthase). Upon recognition of cytosolic DNA, cGAS catalyzes the generation of the cyclic- dinucleotide 2’3’-cGAMP, an atypical second messenger that strongly binds to the ER- transmembrane adaptor protein STING. A conformational change is undergone by cGAMP- bound STING, which translocates to a perinuclear compartment and induces the activation of critical transcription factors IRF-3 and NF-κB. This leads to a strong induction of type I interferons and production of pro-inflammatory cytokines such as IL-6, TNF-α and IFN-γ.
[0006] The importance of type I interferons and pro-inflammatory cytokines on various cells of the immune system has been very well established. In particular, these molecules strongly potentiate T-cell activation by enhancing the ability of dendritic cells and macrophages to uptake, process, present and cross-present antigens to T-cells. The T-cell stimulatory capacity of these antigen-presenting cells is augmented by the up-regulation of critical co-stimulatory molecules, such as CD80 or CD86. Finally, type I interferons can rapidly engage their cognate receptors and trigger the activation of interferon-responsive genes that can significantly contribute to adaptive immune cell activation.
[0007] From a therapeutic perspective, type I interferons are shown to have antiviral activities by directly inhibiting human hepatitis B virus and hepatitis C virus replication, and by stimulating immune responses to virally infected cells. Compounds that can induce type I interferon production are used in vaccines, where they act as adjuvants, enhancing specific immune responses to antigens and minimizing side effects by reducing dosage and broadening the immune response.
[0008] In addition, interferons, and compounds that can induce interferon production, have potential use in the treatment of human cancers. Such molecules are potentially useful as anti- cancer agents with multiple pathways of activity. Interferons can inhibit human tumor cell proliferation directly and may be synergistic with various approved chemotherapeutic agents. Type I interferons can significantly enhance anti-tumor immune responses by inducing activation of both the adaptive and innate immune cells. Finally, tumor invasiveness may be inhibited by interferons by modulating enzyme expression related to tissue remodeling. [0009] In view of the potential of type I interferons and type I interferon-inducing compounds as anti-viral and anti-cancer agents, there remains a need for new agents that can induce potent type I interferon production. With the growing body of data demonstrating that the cGAS-STING cytosolic DNA sensory pathway has a significant capacity to induce type I interferons, the development of STING activating agents is rapidly taking an important place in to day’s anti-tumor therapy landscape. SUMMARY OF THE INVENTION
[0010] The present disclosure relates to novel compounds of general formula (I). In particular, the present disclosure relates to compounds having the general structural formula (I):
Figure imgf000004_0001
or pharmaceutically acceptable salts, hydrates, solvates, or prodrugs thereof, as described herein. Embodiments of the disclosure include compounds of general formula (I), and pharmaceutically acceptable salts, hydrates, solvates, or prodrugs thereof, as well as synthesis and isolation of compounds of general formula (I), and pharmaceutically acceptable salts, hydrates, solvates, or prodrugs thereof. The compounds of general formula (I), and their pharmaceutically acceptable salts, hydrates, solvates, and/or prodrugs, may be useful as agents to induce immune responses, to induce STING-dependent type I interferon production, and/or to treat a cell proliferation disorders, such as cancers, in a subject. The compounds of general formula (I) could further be used in combination with other therapeutically effective agents, including but not limited to, other drugs useful for the treatment of cell proliferation disorders, such as cancers. The invention further relates to processes for preparing compounds of general formula (I), and pharmaceutical compositions that comprise compounds of general formula (I) and pharmaceutically acceptable salts thereof.
[0011] Other embodiments, aspects and features of the present invention are either further described in or will be apparent from the ensuing description, examples and appended claims. BRIEF DESCRIPTION OF THE DRAWINGS
[0012] Not Applicable DETAILED DESCRIPTION OF THE INVENTION
[0013] The present disclosure includes compounds of general formula (I), and
pharmaceutically acceptable salts, hydrates, solvates, or prodrugs thereof. These compounds and their pharmaceutically acceptable salts, hydrates, solvates, and/or prodrugs may be useful as agents to induce immune responses, to induce STING-dependent type I interferon production, and/or to treat a cell proliferation disorder.
[0014] Embodiments disclosed herein relate to compounds of general formula (I):
Figure imgf000005_0001
[0015] The present disclosure includes compounds of general formula (I), and
pharmaceutically acceptable salts, hydrates, solvates, or prodrugs thereof. These compounds and their pharmaceutically acceptable salts, hydrates, solvates, and/or prodrugs may be useful as agents to induce immune responses, to induce STING-dependent type I interferon production, and/or to treat a cell proliferation disorder.
[0016] Embodiments disclosed herein relate to compounds of general formula (I) or pharmaceutically acceptable salts, hydrates, solvates, or prodrugs thereof, wherein Base1 and
Base2 are each independently selected from the group consisting of , ,
Figure imgf000005_0002
Figure imgf000006_0001
Base1 and Base2 each may be independently substituted by 0-3 substituents R10, where each R10 is independently selected from the group consisting of F, Cl, I, Br, OH, SH, NH2, C1-3 alkyl, C3-6 cycloalkyl, O(C1-3 alkyl), O(C3-6 cycloalkyl), S(C1-3 alkyl), S(C3-6 cycloalkyl), NH(C1-3 alkyl), NH(C3-6 cycloalkyl), N(C1-3 alkyl)2, and N(C3-6 cycloalkyl)2; Y and Ya are each independently selected from the group consisting of -O-, -S-, -SO2-, -CH2-, and -CF2-; Xa and Xa1 are each independently selected from the group consisting of -O-, -S-, and -CH2-; Xb and Xb1 are each independently selected from the group consisting of -O-, -S-, and -CH2-; Xc and Xc1 are each independently selected from the group consisting of -SR9, -OR9, and -NR9R9; Xd and Xd1 are each independently selected from the group consisting of O and S; R1 and R1a are each independently selected from the group consisting of H, F, Cl, Br, I, OH, CN, N3, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, -O-C1-C6 alkyl, -O-C2-C6 alkenyl, and -O-C2-C6 alkynyl, where said R1 and R1a C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, -O-C1-C6 alkyl, -O-C2-C6 alkenyl, and -O-C2-C6 alkynyl are substituted by 0 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, CN, and N3; R2 and R2a are each independently selected from the group consisting of H, F, Cl, Br, I, OH, CN, N3, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, -O-C1-C6 alkyl, -O-C2-C6 alkenyl, and
-O-C2-C6 alkynyl, where said R2 and R2a C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, -O-C1-C6 alkyl, -O-C2-C6 alkenyl, and
-O-C2-C6 alkynyl are substituted by 0 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, CN, and N3; R3 is selected from the group consisting of H, F, Cl, Br, I, OH, CN, N3, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, -O-C1-C6 alkyl, -O-C2-C6 alkenyl, and -O-C2-C6 alkynyl, where said R3 C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, -O-C1-C6 alkyl, -O-C2-C6 alkenyl, and -O-C2-C6 alkynyl are substituted by 0 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, CN, and N3; R4 and R4a are each independently selected from the group consisting of H, F, Cl, Br, I, OH, CN, N3, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, -O-C1-C6 alkyl, -O-C2-C6 alkenyl, and -O-C2-C6 alkynyl, where said R4 and R4a C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, -O-C1-C6 alkyl, -O-C2-C6 alkenyl, and -O-C2-C6 alkynyl are substituted by 0 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, CN, and N3; R5 is selected from the group consisting of H, F, Cl, Br, I, OH, CN, N3, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, -O-C1-C6 alkyl, -O-C2-C6 alkenyl, and -O-C2-C6 alkynyl, where said R5 C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, -O-C1-C6 alkyl, -O-C2-C6 alkenyl, and -O-C2-C6 alkynyl are substituted by 0 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, CN, and N3; R6 and R6a are each independently selected from the group consisting of H, F, Cl, Br, I, OH, CN, N3, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, -O-C1-C6 alkyl, -O-C2-C6 alkenyl, and -O-C2-C6 alkynyl, where said R6 and R6a C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, -O-C1-C6 alkyl, -O-C2-C6 alkenyl, and -O-C2-C6 alkynyl are substituted by 0 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, CN, and N3; R7 and R7a are each independently selected from the group consisting of H, F, Cl, Br, I, OH, CN, N3, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, -O-C1-C6 alkyl, -O-C2-C6 alkenyl, and -O-C2-C6 alkynyl, where said R7 and R7a C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, -O-C1-C6 alkyl, -O-C2-C6 alkenyl, and -O-C2-C6 alkynyl are substituted by 0 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, CN, and N3; R8 and R8a are each independently selected from the group consisting of H, F, Cl, Br, I, OH, CN, N3, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, -O-C1-C6 alkyl, -O-C2-C6 alkenyl, and -O-C2-C6 alkynyl, where said R8 and R8a C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, -O-C1-C6 alkyl, -O-C2-C6 alkenyl, and -O-C2-C6 alkynyl are substituted by 0 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, CN, and N3; each R9 is independently selected from the group consisting of H, C1-C20 alkyl, and
Figure imgf000008_0001
Figure imgf000008_0002
where each R9 C1-C20 alkyl is optionally substituted by 0 to 3 substituents independently selected from the group consisting of OH, -O-C1-C20 alkyl,-S-C(O)C1-C6 alkyl, and C(O)OC1-C6 alkyl; optionally R1a and R3 are connected to form C1-C6 alkylene, C2-C6 alkenylene, -O-C1-C6 alkylene, or -O-C2-C6 alkenylene, such that where R1a and R3 are connected to form -O-C1-C6 alkylene, or -O-C2-C6 alkenylene, said O is bound at the R3 position; optionally R2a and R3 are connected to form C1-C6 alkylene, C2-C6 alkenylene, -O-C1-C6 alkylene, or -O-C2-C6 alkenylene, such that where R2a and R3 are connected to form -O-C1-C6 alkylene, or -O-C2-C6 alkenylene, said O is bound at the R3 position; optionally R3 and R6a are connected to form C1-C6 alkylene, C2-C6 alkenylene, -O-C1-C6 alkylene, or -O-C2-C6 alkenylene, such that where R3 and R6a are connected to form -O-C1-C6 alkylene, or -O-C2-C6 alkenylene, said O is bound at the R3 position; optionally R4 and R5 are connected to form C1-C6 alkylene, C2-C6 alkenylene, -O-C1-C6 alkylene, or -O-C2-C6 alkenylene, such that where R4 and R5 are connected to form -O-C1-C6 alkylene, or -O-C2-C6 alkenylene, said O is bound at the R5 position; optionally R5 and R6 are connected to form -O-C1-C6 alkylene, -O-C2-C6 alkenylene, or -O-C2-C6 alkynylene, such that where R5 and R6 are connected to form -O-C1-C6 alkylene, -O-C2-C6 alkenylene, or -O-C2-C6 alkynylene, said O is bound at the R5 position; optionally R7 and R8 are connected to form C1-C6 alkylene or C2-C6 alkenylene; and optionally R7a and R8a are connected to form C1-C6 alkylene or C2-C6 alkenylene.
[0017] In embodiments, at least one of Base1 and Base2 is each independently selected
from the group consisting of
Figure imgf000009_0001
Figure imgf000009_0002
[0018] In each embodiment described herein, variables Base1, Base2, Y, Ya, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2, R2a, R3, R4, R4a, R5, R6, R6a, R7, R7a, R8, R8a, and R9 of general formula (I), and the various aspects thereof, are each selected independently from each other.
[0019] In a first embodiment, Base1 and Base2 are each independently selected from the
group consisting of
Figure imgf000009_0003
Figure imgf000009_0004
Figure imgf000010_0001
where at least one of Base1 and Base2 is each independently
Figure imgf000010_0002
selected from the group consisting of
Figure imgf000011_0001
Figure imgf000011_0002
where Base1 and Base2 each may be independently substituted by 0-3 substituents R10, where each R10 is independently selected from the group consisting of F, Cl, I, Br, OH, SH, NH2, C1-3 alkyl, C3-6 cycloalkyl, O(C1-3 alkyl), O(C3-6 cycloalkyl), S(C1-3 alkyl), S(C3-6 cycloalkyl), NH(C1-3 alkyl), NH(C3-6 cycloalkyl), N(C1-3 alkyl)2, and N(C3-6 cycloalkyl)2. In particular
aspects, Base1 and Base2 are each independently selected from the group consisting of
Figure imgf000011_0003
Figure imgf000011_0004
Figure imgf000012_0001
Figure imgf000012_0002
where at least one of Base1 and Base2 is each
independently selected from the group consisting of
Figure imgf000012_0003
Figure imgf000012_0004
and where Base1 and Base2 each may be independently substituted by 0-3 substituents R10, where each R10 is independently selected from the group consisting of F, Cl, I, Br, OH, SH, NH2, C1-3 alkyl, C3-6 cycloalkyl, O(C1-3 alkyl), O(C3-6 cycloalkyl), S(C1-3 alkyl), S(C3-6 cycloalkyl), NH(C1-3 alkyl), NH(C3-6 cycloalkyl), N(C1-3 alkyl)2, and N(C3-6 cycloalkyl)2. In even more particular aspects, Base1 and Base2 are each independently selected from the group consisting of
Figure imgf000012_0005
O
Figure imgf000013_0001
, , , , , ,
where at least one of Base1 and Base2 is each independently
Figure imgf000013_0002
selected from the group consisting of
Figure imgf000013_0003
and where
Figure imgf000013_0004
Base1 and Base2 each may be independently substituted by 0-3 substituents R10, where each R10 is independently selected from the group consisting of F, Cl, I, Br, OH, SH, NH2, C1-3 alkyl, C3-6 cycloalkyl, O(C1-3 alkyl), O(C3-6 cycloalkyl), S(C1-3 alkyl), S(C3-6 cycloalkyl), NH(C1-3 alkyl), NH(C3-6 cycloalkyl), N(C1-3 alkyl)2, and N(C3-6 cycloalkyl)2. In even more particular aspects,
Base1 and Base2 are each independently selected from the group consisting of
NH NH NH
Figure imgf000013_0006
Figure imgf000014_0001
where at least one of Base1 and Base2 is each
independently selected from the group consisting of
Figure imgf000014_0002
Figure imgf000014_0003
and where Base1 and Base2 each may be independently substituted by 0-3 substituents R10, where each R10 is independently selected from the group consisting of F, Cl, I, Br, OH, SH, NH2, C1-3 alkyl, C3-6 cycloalkyl, O(C1-3 alkyl), O(C3-6 cycloalkyl), S(C1-3 alkyl), S(C3-6 cycloalkyl), NH(C1-3 alkyl), NH(C3-6 cycloalkyl), N(C1-3 alkyl)2, and N(C3-6 cycloalkyl)2. In still further instances of this embodiment, Base1 and Base2 are each independently selected from the group
consisting of
Figure imgf000014_0004
Figure imgf000014_0005
Figure imgf000014_0006
where at least one of Base1 and Base2 is each independently selected from the group consisting of
and
Figure imgf000014_0007
Figure imgf000015_0001
and where Base1 and Base2 each may be independently substituted by 0-3 substituents R10, where each R10 is independently selected from the group consisting of F, Cl, I, Br, OH, SH, NH2, C1-3 alkyl, C3-6 cycloalkyl, O(C1-3 alkyl), O(C3-6 cycloalkyl), S(C1-3 alkyl), S(C3-6 cycloalkyl), NH(C1-3 alkyl), NH(C3-6 cycloalkyl), N(C1-3 alkyl)2, and N(C3-6 cycloalkyl)2. In even more particular instances of this embodiment, Base1 is selected from the group
consisting of
Figure imgf000015_0002
Figure imgf000015_0003
, , , ; Base2 is selected from the group
consisting of
Figure imgf000015_0004
Figure imgf000015_0005
where at least one of
Base1 and Base2 is each independently selected from the group consisting of
Figure imgf000015_0006
Figure imgf000015_0007
and where Base1 and Base2 each may be independently substituted by 0-3 substituents R10, where each R10 is independently selected from the group consisting of F, Cl, I, Br, OH, SH, NH2, C1-3 alkyl, C3-6 cycloalkyl, O(C1-3 alkyl), O(C3-6 cycloalkyl), S(C1-3 alkyl), S(C3-6 cycloalkyl), NH(C1-3 alkyl), NH(C3-6 cycloalkyl), N(C1-3 alkyl)2, and N(C3-6 cycloalkyl)2. In this embodiment, all other groups are as provided in the general formula (I) above.
[0020] In a second embodiment, Y and Ya are each independently selected from the group consisting of -O- and -S-. In this embodiment, all other groups are as provided in the general formula (I) above or in the first embodiment described above.
[0021] In a third embodiment, Xa and Xa1 are each independently selected from the group consisting of -O- and -S-. In this embodiment, all other groups are as provided in the general formula (I) above or in the first through second embodiments described above.
[0022] In a fourth embodiment, Xb and Xb1 are each independently selected from the group consisting of -O- and -S-. In this embodiment, all other groups are as provided in the general formula (I) above or in the first through third embodiments described above.
[0023] In a fifth embodiment, Xc and Xc1 are each independently selected from the group consisting of -OR9, -SR9, and -NR9R9, where each R9 is independently selected from the group
consisting of H, C1-C20 alkyl,
Figure imgf000016_0001
where each R9 C1-C20 alkyl is optionally substituted by 0 to 3 substituents independently selected from the group consisting of -OH, -O-C1-C20 alkyl,-S-C(O)C1-C6 alkyl, and -C(O)OC1-C6 alkyl. In particular aspects, Xc and Xc1 are each independently selected from the group consisting of -OH,
Figure imgf000016_0002
Figure imgf000017_0001
In more particular aspects, Xc and Xc1 are each independently selected from the group consisting of -OH and -SH. In all aspects of this embodiment, all other groups are as provided in the general formula (I) above or in the first through fourth embodiment described above.
[0024] In a sixth embodiment, Xd and Xd1 are each independently selected from the group consisting of O and S. In this embodiment, all other groups are as provided in the general formula (I) above or in the first through fifth embodiments described above.
[0025] In a seventh embodiment, R1 and R1a are each H. In this embodiment, all other groups are as provided in the general formula (I) above or in the first through sixth embodiments described above.
[0026] In an eighth embodiment, R2 and R2a are each independently selected from the group consisting of H, F, Cl, I, Br, OH, CN, N3, C1-C6 alkyl, and C1-C6 haloalkyl, where said R2 and R2a C1-C6 alkyl or C1-C6 haloalkyl are substituted by 0 to 3 substituents selected from the group consisting of OH, CN, and N3. In particular aspects, R2 and R2a are each independently selected from the group consisting of H, F, Cl, I, Br, OH, CN, N3, -CF3, -CH3, -CH2OH, and -CH2CH3. In more particular aspects, R2 and R2a are each independently selected from the group consisting of H, F, Cl, OH, CN, N3, and -CH3. In even more particular aspects, R2 and R2a are each independently selected from the group consisting of H, F, and OH. In all aspects of this embodiment, all other groups are as provided in the general formula (I) above or in the first through seventh embodiments described above.
[0027] In a ninth embodiment, R3 is selected from the group consisting H, F, Cl, I, Br, OH, CN, N3, C1-C6 alkyl, and C1-C6 haloalkyl, where said R3 C1-C6 alkyl or C1-C6 haloalkyl are substituted by 0 to 3 substituents selected from the group consisting of OH, CN, and N3. In particular aspects, R3 is selected from the group consisting of H, F, Cl, I, Br, OH, CN, N3, -CF3, -CH3, -CH2OH, and -CH2CH3. In more particular aspects, R3 is selected from the group consisting of H, F, Cl, OH, CN, N3, and -CH3. In even more particular aspects, R3 is selected from the group consisting of H, F, and OH. In all aspects of this embodiment, all other groups are as provided in the general formula (I) above or in the first through eighth embodiments described above. [0028] In a tenth embodiment, R4 and R4a are each independently selected from the group consisting of H, F, Cl, I, Br, CN, OH, N3, C1-C6 alkyl, and C1-C6 haloalkyl, where said R4 and R4a C1-C6 alkyl or C1-C6 haloalkyl are substituted by 0 to 3 substituents selected from the group consisting of OH, CN, and N3. In particular aspects, R4 and R4a are each independently selected from the group consisting of H, F, Cl, I, Br, OH, CN, N3, -CF3, -CH3, -CH2OH, and -CH2CH3. In more particular aspects, R4 and R4a are each independently selected from the group consisting of H, F, Cl, OH, CN, N3, and -CH3. In even more particular aspects, R4 and R4a are each independently selected from the group consisting of H, F, and OH. In all aspects of this embodiment, all other groups are as provided in the general formula (I) above or in the first through ninth embodiments described above.
[0029] In an eleventh embodiment, R5 is selected from the group consisting of H, F, Cl, I, Br, OH, CN, N3, C1-C6 alkyl, and C1-C6 haloalkyl, where said R5 C1-C6 alkyl or C1-C6 haloalkyl are substituted by 0 to 3 substituents selected from the group consisting of OH, CN, and N3. In particular aspects, R5 is selected from the group consisting of H, F, Cl, I, Br, OH, CN, N3, -CF3, -CH3, -CH2OH, and -CH2CH3. In more particular aspects, R5 is selected from the group consisting of H, F, Cl, OH, CN, N3, and CH3. In even more particular aspects, R5 is selected from the group consisting of H, F, and OH. In all aspects, all other groups are as provided in the general formula (I) above or in the first through tenth embodiments described above.
[0030] In a twelfth embodiment, R6 and R6a are each independently selected from the group consisting of H, F, Cl, I, Br, OH, CN, N3, C1-C6 alkyl, C2-C6 alkenyl, and C2-C6 alkynyl, where said R6 and R6a C1-C6 alkyl, C2-C6 alkenyl, and C2-C6 alkynyl are substituted by 0 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, CN, and N3. In particular aspects, R6 and R6a are each independently selected from the group consisting of H, F, Cl, I, Br, OH, CN, N3, -CF3, -CH3, -CH2OH, CH2CH3, -CH=CH2, -C≡CH, and -C≡C-CH. In more particular aspects, R6 and R6a are each independently selected from the group consisting of H, F, CN, N3, -CH3, -CH=CH2, and -C≡CH. In even more particular aspects, R6 and R6a are each H. In all aspects of this embodiment, all other groups are as provided in the general formula (I) above or in the first through eleventh embodiments described above.
[0031] In a thirteenth embodiment, R7 and R7a are each independently selected from the group consisting of H, C1-C6 alkyl, and C1-C6 haloalkyl, where said R7 and R7a C1-C6 alkyl or C1-C6 haloalkyl are substituted by 0 to 3 substituents selected from the group consisting of OH, CN, and N3. In particular aspects, R7 and R7a are each independently selected from the group consisting of H, -CF3, -CH3, and -CH2CH3. In more particular aspects, R7 and R7a are each H. In all aspects of this embodiment, all other groups are as provided in the general formula (I) above or in the first through twelfth embodiments described above.
[0032] In a fourteenth embodiment, R8 and R8a are each independently selected from the group consisting of H, C1-C6 alkyl, and C1-C6 haloalkyl, where said R8 and R8a C1-C6 alkyl or C1-C6 haloalkyl are substituted by 0 to 3 substituents selected from the group consisting of OH, CN, and N3. In particular aspects, R8 and R8a are each independently selected from the group consisting of H, -CF3, -CH3, and -CH2CH3. In more particular aspects, R8 and R8a are each H. In all aspects of this embodiment, all other groups are as provided in the general formula (I) above or in the first through thirteenth embodiments described above.
[0033] In a fifteenth embodiment, R1a and R3 are connected to form C1-C6 alkylene, C2-C6 alkenylene, -O-C1-C6 alkylene, or -O-C2-C6 alkenylene, such that where R1a and R3 are connected to form -O-C1-C6 alkylene or -O-C2-C6 alkenylene, said O is bound at the R3 position. In this embodiment, all other groups are as provided in the general formula (I) above or in the first through fourteenth embodiments described above.
[0034] In a sixteenth embodiment, R2a and R3 are connected to form C1-C6 alkylene, C2-C6 alkenylene, -O-C1-C6 alkylene, or -O-C2-C6 alkenylene, such that where R2a and R3 are connected to form -O-C1-C6 alkylene or -O-C2-C6 alkenylene, said O is bound at the R3 position. In this embodiment, all other groups are as provided in the general formula (I) above or in the first through fourteenth embodiments described above.
[0035] In a seventeenth embodiment, R3 and R6a are connected to form C2-C6 alkylene, C2-C6 alkenylene, -O-C1-C6 alkylene, or -O-C2-C6 alkenylene,, such that where R3 and R6a are connected to form -O-C1-C6 alkylene or -O-C2-C6 alkenylene, said O is bound at the R3 position. In this embodiment, all other groups are as provided in the general formula (I) above or in the first through fourteenth embodiments described above.
[0036] In an eighteenth embodiment, R4 and R5 are connected to form C1-C6 alkylene, C2-C6 alkenylene, -O-C1-C6 alkylene, or -O-C2-C6 alkenylene, such that where R4 and R5 are connected to form -O-C1-C6 alkylene or -O-C2-C6 alkenylene, said O is bound at the R5 position. In this embodiment, all other groups are as provided in the general formula (I) above or in the first through fourteenth embodiments described above.
[0037] In a nineteenth embodiment, R5 and R6 are connected to form C1-C6 alkylene, C2-C6 alkenylene, -O-C1-C6 alkylene, or -O-C2-C6 alkenylene, such that where R5 and R6 are connected to form -O-C1-C6 alkylene or -O-C2-C6 alkenylene, said O is bound at the R5 position. In this embodiment, all other groups are as provided in the general formula (I) above or in the first through fourteenth embodiments described above.
[0038] In a twentieth embodiment, R7 and R8 are connected to form C1-C6 alkylene or C2-C6 alkenylene. In this embodiment, all other groups are as provided in the general formula (I) above or in the first through fourteenth embodiments described above.
[0039] In a twenty-first embodiment, R7a and R8a are connected to form C1-C6 alkylene or C2-C6 alkenylene. In this embodiment, all other groups are as provided in the general formula (I) above or in the first through fourteenth embodiments described above.
[0040] In a twenty-second embodiment, Base1 and Base2 are each independently selected
from the group consisting of
Figure imgf000020_0001
Figure imgf000020_0002
Figure imgf000021_0001
where at least one of Base1 and Base2 is each
independently selected from the group consisting of
Figure imgf000021_0002
Figure imgf000021_0003
and where Base1 and Base2 each may be independently substituted by 0-3 substituents R10, where each R10 is independently selected from the group consisting of F, Cl, I, Br, OH, SH, NH2, C1-3 alkyl, C3-6 cycloalkyl, O(C1-3 alkyl), O(C3-6 cycloalkyl), S(C1-3 alkyl), S(C3-6 cycloalkyl), NH(C1-3 alkyl), NH(C3-6 cycloalkyl), N(C1-3 alkyl)2, and N(C3-6 cycloalkyl)2; Y and Ya are each independently selected from the group consisting of -O- and -S-; Xa and Xa1 are each -O-; Xb and Xb1 are each -O-; Xc and Xc1 are each independently selected from the group consisting of -OH and -SH; Xd and Xd1 are each independently selected from the group consisting of O and S; R1 and R1a are each H; R2 and R2a are each independently selected from the group consisting of H, F, Cl, OH, CN, N3, and -CH3; R3 is selected from the group consisting of H, F, Cl, OH, CN, N3, and -CH3; R4 and R4a are each independently selected from the group consisting of H, F, Cl, OH, CN, N3, and -CH3; R5 is selected from the group consisting of H, F, Cl, OH, CN, N3, and -CH3; R6 and R6a are each independently selected from the group consisting of H, F, CN, N3, -CH3, -CH=CH2, and -C≡CH; R7 and R7a are each H; R8 and R8a are each H; optionally R3 and R6a are connected to form -O-C1-C6 alkylene or -O-C2-C6 alkenylene, such that where R3 and R6a are connected to form -O-C1-C6 alkylene or -O-C2-C6 alkenylene, said O is bound at the R3 position; and optionally R5 and R6 are connected to form C1-C6 alkylene, C2-C6 alkenylene, -O-C1-C6 alkylene, or -O-C2-C6 alkenylene, such that where R5 and R6 are connected to form -O-C1-C6 alkylene or -O-C2-C6 alkenylene, said O is bound at the R5 position. In this embodiment, all other groups are as provided in the general formula (I) above or in the first through fourteenth embodiments described above. [0041] In a twenty-third embodiment, Base1 and Base2 are each independently selected
from the group consisting of
Figure imgf000022_0001
Figure imgf000022_0002
where at least one of Base1 and Base2 is each independently selected from the group consisting
Figure imgf000022_0003
Figure imgf000022_0004
and where Base1 and Base2 each may be independently substituted by 0-3 substituents R10, where each R10 is independently selected from the group consisting of F, Cl, I, Br, OH, SH, NH2, C1-3 alkyl, C3-6 cycloalkyl, O(C1-3 alkyl), O(C3-6 cycloalkyl), S(C1-3 alkyl), S(C3-6 cycloalkyl), NH(C1-3 alkyl), NH(C3-6 cycloalkyl), N(C1-3 alkyl)2, and N(C3-6 cycloalkyl)2; Y and Ya are each independently selected from the group consisting of -O- and -S-; Xa and Xa1 are each -O-; Xb and Xb1 are each -O-; Xc and Xc1 are each independently selected from the group consisting of -SH and -OH; Xd and Xd1 are each independently selected from the group consisting of O and S; R1 and R1a are each H; R2 is H; R2a is selected from the group consisting of H, F, and OH; R3 is selected from the group consisting of H, F, and OH; R4 is selected from the group consisting of H, F, and OH; R4a is H; R5 is selected from the group consisting of H, F, and OH; R6 and R6a are each H; R7 and R7a are each H; and R8 and R8a are each H; and optionally R3 and R6a are connected to form -O-C1-C6 alkylene, such that where R3 and R6a are connected to form -O-C1-C6 alkylene, said O is bound at the R3 position. In this embodiment, all other groups are as provided in the general formula (I) above or in the first through fourteenth embodiments described above.
[0042] In a twenty-fourth embodiment, Base1 and Base2 are each independently selected
O
from the group consisting of
Figure imgf000023_0001
Figure imgf000024_0001
Figure imgf000024_0002
wherein at least one of Base1 and Base2 is each independently
selected from the group consisting of
Figure imgf000024_0003
Figure imgf000024_0004
and Base1 and Base2 each may be independently substituted by 0-3 substituents R10, where each R10 is independently selected from the group consisting of F, Cl, I, Br, OH, SH, NH2, C1-3 alkyl, C3-6 cycloalkyl, O(C1-3 alkyl), O(C3-6 cycloalkyl), S(C1-3 alkyl), S(C3-6 cycloalkyl), NH(C1-3 alkyl), NH(C3-6 cycloalkyl), N(C1-3 alkyl)2, and N(C3-6 cycloalkyl)2; Y and Ya are each independently selected from the group consisting of -O- and -S-; Xa and Xa1 are each independently selected from the group consisting of -O- and -S-; Xb and Xb1 are each independently selected from the group consisting of -O- and -S-; Xc and Xc1 are each independently selected from the group consisting of -SR9, -OR9, and NR9R9; Xd and Xd1 are each independently selected from the group consisting of O and S; R1 and R1a are each H; R2 and R2a are each independently selected from the group consisting of H, F, Cl, Br, I, OH, CN, N3, C1-C6 alkyl, and C1-C6 haloalkyl, where said R2 and R2a C1-C6 alkyl or C1-C6 haloalkyl are substituted by 0 to 3 substituents selected from the group consisting of OH, CN, and N3; R3 is selected from the group consisting of H, F, Cl, Br, I, OH, CN, N3, C1-C6 alkyl, and C1-C6 haloalkyl, where said R3 C1-C6 alkyl or C1-C6 haloalkyl are substituted by 0 to 3 substituents selected from the group consisting of OH, CN, and N3; R4 and R4a are each independently selected from the group consisting of H, F, Cl, I, Br, CN, OH, N3, C1-C6 alkyl, and C1-C6 haloalkyl, where said R4 and R4a C1-C6 alkyl or C1-C6 haloalkyl are substituted by 0 to 3 substituents selected from the group consisting of OH, CN, and N3; R5 is selected from the group consisting of H, F, Cl, Br, I, OH, N3, C1-C6 alkyl, and C1-C6 haloalkyl, where said R5 C1-C6 alkyl or C1-C6 haloalkyl are substituted by 0 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, CN, and N3; R6 and R6a are each independently selected from the group consisting of H, F, Cl, I, Br, OH, CN, N3, C1-C6 alkyl, C2-C6 alkenyl, and C2-C6 alkynyl, where said R6 and R6a C1-C6 alkyl, C2-C6 alkenyl, and C2-C6 alkynyl are substituted by 0 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, CN, and N3; R7 and R7a are each independently selected from the group consisting of H, C1-C6 alkyl, and C1-C6 haloalkyl, where said R7 and R7a C1-C6 alkyl or C1-C6 haloalkyl are substituted by 0 to 3 substituents selected from the group consisting of OH, CN, and N3; R8 and R8a are each independently selected from the group consisting of H, C1-C6 alkyl, and C1-C6 haloalkyl, where said R8 and R8a C1-C6 alkyl or C1-C6 haloalkyl are substituted by 0 to 3 substituents selected from the group consisting of OH, CN, and N3; each R9 is independently selected from the group
consisting of H, C1-C6 alkyl,
Figure imgf000025_0001
where each R9 C1-C6 alkyl is optionally substituted by 1 to 2 substituents independently selected from the group consisting of OH, -O-C1-C20 alkyl,-S-C(O)C1-C6 alkyl, and -C(O)OC1-C6 alkyl; optionally R3 and R6a are connected to form C2-C6 alkylene, C2-C6 alkenylene,-O-C1-C6 alkylene, or -O-C2- C6 alkenylene, such that where R3 and R6a are connected to form -O-C1-C6 alkylene or -O-C2-C6 alkenylene, said O is bound at the R3 position; and optionally R5 and R6 are connected to form C1-C6 alkylene, C2-C6 alkenylene, -O-C1-C6 alkylene, or -O-C2-C6 alkenylene, such that where R5 and R6 are connected to form -O-C1-C6 alkylene or -O-C2-C6 alkenylene, said O is bound at the R5 position. In this embodiment, all other groups are as provided in the general formula (I) above or in the first through fourteenth embodiments described above.
[0043] In a twenty-fifth embodiment, Base1 and Base2 are each independently selected
from the group consisting of
Figure imgf000025_0002
Figure imgf000026_0001
Figure imgf000027_0001
wherein at least one of Base1 and Base2 is each independently
selected from the group consisting of
Figure imgf000027_0002
Figure imgf000027_0003
and Base1 and Base2 each may be independently substituted by 0-3 substituents R10, where each R10 is independently selected from the group consisting of F, Cl, I, Br, OH, SH, NH2, C1-3 alkyl, C3-6 cycloalkyl, O(C1-3 alkyl), O(C3-6 cycloalkyl), S(C1-3 alkyl), S(C3-6 cycloalkyl), NH(C1-3 alkyl), NH(C3-6 cycloalkyl), N(C1-3 alkyl)2, and N(C3-6 cycloalkyl)2; Y and Ya are each independently selected from the group consisting of -O- and -S-; Xa and Xa1 are each independently selected from the group consisting of -O- and -S-; Xb and Xb1 are each independently selected from the group consisting of -O- and -S-; Xc and Xc1 are each independently selected from the group consisting of -OH, -SH,
Figure imgf000027_0004
Figure imgf000027_0005
Figure imgf000028_0001
Xd and Xd1 are each independently selected from the group consisting of O and S; R1 and R1a are each H; R2 and R2a are each independently selected from the group consisting of H, F, Cl, I, Br, OH, CN, N3, -CF3, -CH3, -CH2OH, and -CH2CH3; R3 is selected from the group consisting of H, F, Cl, I, Br, OH, CN, N3, -CF3, -CH3, -CH2OH, and -CH2CH3; R4 and R4a are each independently selected from the group consisting of H, F, Cl, I, Br, OH, CN, N3, -CF3, -CH3, -CH2OH, and -CH2CH3; R5 is selected from the group consisting of H, F, Cl, I, Br, OH, CN, N3, -CF3, -CH3, -CH2OH, and -CH2CH3; R6 and R6a are each independently selected from the group consisting of H, F, Cl, I, Br, OH, CN, N3, -CF3, -CH3, -CH2OH, -CH2CH3, -CH=CH2, -C≡CH, and -C≡C-CH; R7 and R7a are each independently selected from the group consisting of H, -CF3, -CH3, and -CH2CH3; R8 and R8a are each independently selected from the group consisting of H, -CF3, -CH3, and -CH2CH3;
optionally R3 and R6a are connected to C2-C6 alkylene, C2-C6 alkenylene, -O-C1-C6 alkylene, or -O-C2-C6 alkenylene, such that where R3 and R6a are connected to form -O-C1-C6 alkylene or -O-C2-C6 alkenylene, said O is bound at the R3 position; and optionally R5 and R6 are connected to form C1-C6 alkylene, C2-C6 alkenylene, -O-C1-C6 alkylene, or -O-C2-C6 alkenylene, such that where R5 and R6 are connected to form -O-C1-C6 alkylene or -O-C2-C6 alkenylene, said O is bound at the R5 position. In this embodiment, all other groups are as provided in the general formula (I) above or in the first through fourteenth embodiments described above.
[0044] In a twenty-sixth embodiment, Base1 and Base2 are each independently selected
from the group consisting of
Figure imgf000028_0002
Figure imgf000028_0003
Figure imgf000029_0001
Figure imgf000029_0002
wherein at least one of Base1
and Base2 is each independently selected from the group consisting of
Figure imgf000029_0003
Figure imgf000029_0004
Figure imgf000029_0005
and Base1 and Base2 each may be independently substituted by 0 to 3 substituents R10, where each R10 is independently selected from the group consisting of F, Cl, I, Br, OH, SH, NH2, C1-3 alkyl, C3-6 cycloalkyl, O(C1-3 alkyl), O(C3-6 cycloalkyl), S(C1-3 alkyl), S(C3-6 cycloalkyl), NH(C1-3 alkyl), NH(C3-6 cycloalkyl), N(C1-3 alkyl)2, and N(C3-6 cycloalkyl)2; Y and Ya are each independently selected from the group consisting of -O- and -S-; Xa and Xa1 are each -O-; Xb and Xb1 are each -O-; Xc and Xc1 are each independently selected from the group consisting of -OH and -SH; Xd and Xd1 are each independently selected from the group consisting of O and S; R1 and R1a are each H; R2 and R2a are each independently selected from the group consisting of H, F, Cl, OH, CN, N3, and -CH3; R3 is selected from the group consisting of H, F, Cl, OH, CN, N3, and -CH3; R4 and R4a are each independently selected from the group consisting of H, F, Cl, OH, CN, N3, and -CH3; R5 is selected from the group consisting of H, F, Cl, OH, CN, N3, and -CH3; R6 and R6a are each independently selected from the group consisting of H, F, CN, N3, -CH3, -CH=CH2, and -C≡CH; R7 and R7a are each H; R8 and R8a are each H; optionally R3 and R6a are connected to form -O-C1-C6 alkylene or -O-C2-C6 alkenylene, such that O is bound at the R3 position; and optionally R5 and R6 are connected to form C1-C6 alkylene, C2-C6 alkenylene, -O-C1-C6 alkylene, or -O-C2-C6 alkenylene, such that where R5 and R6 are connected to form -O-C1-C6 alkylene or -O-C2-C6 alkenylene, said O is bound at the R5 position. In this embodiment, all other groups are as provided in the general formula (I) above or in the first through fourteenth embodiments described above.
[0045] In a twenty-seventh embodiment, Base1 and Base2 are each independently selected
from the group consisting of
Figure imgf000030_0001
Figure imgf000030_0002
Figure imgf000031_0001
wherein at least one of Base1 and Base2 is each
independently selected from the group consisting of
Figure imgf000031_0002
Figure imgf000031_0003
and Base1 and Base2 each may be independently substituted by 0-3 substituents R10, where each R10 is independently selected from the group consisting of F, Cl, I, Br, OH, SH, NH2, C1-3 alkyl, C3-6 cycloalkyl, O(C1-3 alkyl), O(C3-6 cycloalkyl), S(C1-3 alkyl), S(C3-6 cycloalkyl), NH(C1-3 alkyl), NH(C3-6 cycloalkyl), N(C1-3 alkyl)2, and N(C3-6 cycloalkyl)2; Y and Ya are each independently selected from the group consisting of -O- and -S-; Xa and Xa1 are each -O-; Xb and Xb1 are each -O-; Xc and Xc1 are each independently selected from the group consisting of -OH and -SH; Xd and Xd1 are each independently selected from the group consisting of O and S; R1 and R1a are each H; R2 and R2a are each independently selected from the group consisting of H, F, Cl, OH, CN, N3, and -CH3; R3 is selected from the group consisting of H, F, Cl, OH, CN, N3, and -CH3; R4 and R4a are each independently selected from the group consisting of H, F, Cl, OH, CN, N3, and CH3; R5 is selected from the group consisting of H, F, Cl, OH, CN, N3, and -CH3; R6 and R6a are each independently selected from the group consisting of H, F, CN, N3, -CH3, -CH=CH2, and -C≡CH; R7 and R7a are each H; R8 and R8a are each H; optionally R3 and R6a are connected to form -O-C1-C6 alkylene or -O-C2-C6 alkenylene, such that where R3 and R6a are connected to form -O-C1-C6 alkylene or -O-C2-C6 alkenylene, said O is bound at the R3 position; and optionally R5 and R6 are connected to form C1-C6 alkylene, C2-C6 alkenylene, -O-C1-C6 alkylene, or -O-C2-C6 alkenylene, such that where R5 and R6 are connected to form -O-C1-C6 alkylene or -O-C2-C6 alkenylene, said O is bound at the R5 position. In this embodiment, all other groups are as provided in the general formula (I) above or in the first through fourteenth embodiments described above. [0046] In a twenty-eighth embodiment, Base1 and Base2 are each independently selected
from the group consisting of
Figure imgf000032_0001
Figure imgf000032_0002
wherein at least one of Base1 and Base2 is each independently selected from the group consisting
of
Figure imgf000032_0003
Figure imgf000032_0004
and Base1 and Base2 each may be independently substituted by 0-3 substituents R10, where each R10 is independently selected from the group consisting of F, Cl, I, Br, OH, SH, NH2, C1-3 alkyl, C3-6 cycloalkyl, O(C1-3 alkyl), O(C3-6 cycloalkyl), S(C1-3 alkyl), S(C3-6 cycloalkyl), NH(C1-3 alkyl), NH(C3-6 cycloalkyl), N(C1-3 alkyl)2, and N(C3-6 cycloalkyl)2; Y and Ya are each independently selected from the group consisting of -O- and -S-; Xa and Xa1 are each -O-; Xb and Xb1 are each -O-; Xc and Xc1 are each independently selected from the group consisting of -SH and -OH; Xd and Xd1 are each independently selected from the group consisting of O and S; R1 and R1a are each H; R2 and R2a are each independently selected from the group consisting of H, F, and OH; R3 is selected from the group consisting of H, F, and OH; R4 and R4a are each independently selected from the group consisting of H, F, and OH; R5 is selected from the group consisting of H, F, and OH; R6 and R6a are each H; R7 and R7a are each H; R8 and R8a are each H; and optionally R3 and R6a are connected to form -O-C1-C6 alkylene or -O-C2-C6 alkenylene, such that where R3 and R6a are connected to form -O-C1-C6 alkylene or -O-C2-C6 alkenylene, said O is bound at the R3 position. In this embodiment, all other groups are as provided in the general formula (I) above or in the first through fourteenth embodiments described above.
[0047] In a twenty-ninth embodiment, Base1 and Base2 are each independently selected
from the group consisting of
Figure imgf000033_0001
Figure imgf000033_0002
wherein at least one of Base1 and Base2 is each independently selected from the group consisting
Figure imgf000033_0003
Figure imgf000033_0004
and Base1 and Base2 each may be independently substituted by 0 to 3 substituents R10, where each R10 is independently selected from the group consisting of F, Cl, I, Br, OH, SH, NH2, C1-3 alkyl, C3-6 cycloalkyl, O(C1-3 alkyl), O(C3-6 cycloalkyl), S(C1-3 alkyl), S(C3-6 cycloalkyl), NH(C1-3 alkyl), NH(C3-6 cycloalkyl), N(C1-3 alkyl)2, and N(C3-6 cycloalkyl)2; Y and Ya are each independently selected from the group consisting of -O- and -S-; Xa and Xa1 are each -O-; Xb and Xb1 are each -O-; Xc and Xc1 are each independently selected from the group consisting of -SH and -OH; Xd and Xd1 are each independently selected from the group consisting of O and S; R1 and R1a are each H; R2 is H; R2a is selected from the group consisting of H, F, and OH; R3 is selected from the group consisting of H, F, and OH; R4 is selected from the group consisting of H, F, and OH; R4a is H; R5 is selected from the group consisting of H, F, and OH; R6 and R6a are each H; R7 and R7a are each H; R8 and R8a are each H; and optionally R3 and R6a are connected to form -O-C1-C6 alkylene, such that where R3 and R6a are connected to form -O-C1-C6 alkylene, said O is bound at the R3 position. In this embodiment, all other groups are as provided in the general formula (I) above or in the first through fourteenth embodiments described above.
[0048] In a thirtieth embodiment, Base1 and Base2 are each independently selected from
the group consisting of
Figure imgf000034_0001
Figure imgf000034_0002
wherein at least one of Base1 and Base2 is each independently selected from the group consisting
Figure imgf000034_0003
Figure imgf000034_0004
and Base1 and Base2 each may be independently substituted by 0-3 substituents R10, where each R10 is independently selected from the group consisting of F, Cl, I, Br, OH, SH, NH2, C1-3 alkyl, C3-6 cycloalkyl, O(C1-3 alkyl), O(C3-6 cycloalkyl), S(C1-3 alkyl), S(C3-6 cycloalkyl), NH(C1-3 alkyl), NH(C3-6 cycloalkyl), N(C1-3 alkyl)2, and N(C3-6 cycloalkyl)2; Y and Ya are each independently selected from the group consisting of -O- and -S-; Xa and Xa1 are each -O-; Xb and Xb1 are each -O-; Xc and Xc1 are each independently selected from the group consisting of -SH and -OH; Xd and Xd1 are each independently selected from the group consisting of O and S; R1 and R1a are each H; R2 is H; R2a is selected from the group consisting of H, F, and OH; R3 is selected from the group consisting of H, F, and OH; R4 is selected from the group consisting of H, F, and OH; R4a is H; R5 is selected from the group consisting of H, F, and OH; R6 and R6a are each H; R7 and R7a are each H; and R8 and R8a are each H. In this embodiment, all other groups are as provided in the general formula (I) above or in the first through fourteenth embodiments described above.
[0049] In a thirty-first embodiment, Base1 is selected from the group consisting of
Figure imgf000035_0001
Figure imgf000035_0002
Base2 is selected from the group consisting of
Figure imgf000035_0003
Figure imgf000035_0004
where at least one of Base1 and Base2
is each independently selected from the group consisting of
Figure imgf000035_0005
Figure imgf000035_0006
and where Base1 and Base2 each may be independently substituted by 0-3 substituents R10, where each R10 is independently selected from the group consisting of F, Cl, I, Br, OH, SH, NH2, C1-3 alkyl, C3-6 cycloalkyl, O(C1-3 alkyl), O(C3-6 cycloalkyl), S(C1-3 alkyl), S(C3-6 cycloalkyl), NH(C1-3 alkyl), NH(C3-6 cycloalkyl), N(C1-3 alkyl)2, and N(C3-6 cycloalkyl)2; Y and Ya are each independently selected from the group consisting of -O- and -S-; Xa and Xa1 are each -O-; Xb and Xb1 are each -O-; Xc and Xc1 are each independently selected from the group consisting of -SH and -OH; Xd and Xd1 are each independently selected from the group consisting of O and S; R1 and R1a are each H; R2 is H; R2a is selected from the group consisting of H, F, and OH; R4 is selected from the group consisting of H, F, and OH; R4a is H; R5 is selected from the group consisting of H, F, and OH; R6 is H; R7 and R7a are each H; and R8 and R8a are each H; and optionally R3 and R6a are connected to form -O-C1-C6 alkylene, such that where R3 and R6a are connected to form -O-C1-C6 alkylene, said O is bound at the R3 position. In this embodiment, all other groups are as provided in the general formula (I) above or in the first through fourteenth embodiments described above.
[0050] A thirty-second embodiment relates to a compound selected from the group
consisting of
Figure imgf000036_0001
Figure imgf000036_0002
Figure imgf000037_0001
Figure imgf000038_0001
Figure imgf000039_0001
and
Figure imgf000040_0001
pharmaceutically acceptable salts thereof.
[0051] A thirty-third embodiment relates to a pharmaceutical composition, said
pharmaceutical composition comprising (a) a compound according to any one of general formula (I) above or the first through thirty-second embodiments above or a pharmaceutically acceptable salt thereof; and (b) a pharmaceutically acceptable carrier.
[0052] A thirty-fourth embodiment relates to methods of inducing an immune response in a subject, comprising administering a therapeutically effective amount of a compound according to any one of general formula (I) above or the first through thirty-second embodiments above or a pharmaceutically acceptable salt thereof to the subject.
[0053] A thirty-fifth embodiment relates to methods of inducing an immune response in a subject, comprising administering a therapeutically effective amount of a composition according to the thirty-third embodiment above to the subject.
[0054] A thirty-sixth embodiment relates to methods of inducing STING-dependent type I interferon production in a subject, comprising administering a therapeutically effective amount of a compound according to any one of general formula (I) above or the first through thirty- second embodiments above or a pharmaceutically acceptable salt thereof to the subject.
[0055] A thirty-seventh embodiment relates to methods of inducing STING-dependent type I interferon production in a subject, comprising administering a therapeutically effective amount of a composition according to the thirty-third embodiment above to the subject.
[0056] A thirty-eighth embodiment relates to methods of inducing STING-dependent cytokine production in a subject, comprising administering a therapeutically effective amount of a compound according to any one of general formula (I) above or the first through thirty-second embodiments above or a pharmaceutically acceptable salt thereof to the subject.
[0057] A thirty-ninth embodiment relates to methods of inducing a STING-dependent cytokine production in a subject, comprising administering a therapeutically effective amount of a composition according to the thirty-third embodiment above to the subject. [0058] A fortieth embodiment relates to a compound selected from the exemplary species depicted in Examples 1 through 54 shown below.
[0059] A forty-first embodiment relates to a pharmaceutical composition, said
pharmaceutical composition comprising (a) a compound according to the fortieth embodiment above or a pharmaceutically acceptable salt thereof; and (b) a pharmaceutically acceptable carrier.
[0060] A forty-second embodiment relates to methods of inducing an immune response in a subject, comprising administering a therapeutically effective amount of a compound according to the fortieth embodiment above or a pharmaceutically acceptable salt thereof to the subject.
[0061] A forty-third embodiment relates to methods of inducing an immune response in a subject, comprising administering a therapeutically effective amount of a composition according to the forty-first embodiment above to the subject.
[0062] A forty-fourth embodiment relates to methods of inducing STING-dependent type I interferon production in a subject, comprising administering a therapeutically effective amount of a compound according to the fortieth embodiment above or a pharmaceutically acceptable salt thereof to the subject.
[0063] A forty-fifth embodiment relates to methods of inducing STING-dependent type I interferon production in a subject, comprising administering a therapeutically effective amount of a composition according to the forty-first embodiment above to the subject.
[0064] A forty-sixth embodiment relates to methods of inducing STING-dependent cytokine production in a subject, comprising administering a therapeutically effective amount of a compound according to the fortieth embodiment above or a pharmaceutically acceptable salt thereof to the subject.
[0065] A forty-seventh embodiment relates to methods of inducing STING-dependent cytokine production in a subject, comprising administering a therapeutically effective amount of a composition according to the forty-first embodiment above to the subject.
[0066] Other embodiments of the present disclosure include the following:
(a) A pharmaceutical composition comprising an effective amount of a compound of general formula (I), or a pharmaceutically acceptable salt thereof, and a
pharmaceutically acceptable carrier.
(b) The pharmaceutical composition of (a), further comprising an active agent selected from the group consisting of STING agonist compounds, anti-viral compounds, antigens, adjuvants, CTLA-4 and PD-1 pathway antagonists and other immunomodulatory agents, lipids, liposomes, peptides, anti-cancer and chemotherapeutic agents.
(c) A pharmaceutical combination that is (i) a compound of general formula (I), or a pharmaceutically acceptable salt thereof, and (ii) an active agent selected from the group consisting of STING agonist compounds, anti-viral compounds, antigens, adjuvants, CTLA-4 and PD-1 pathway antagonists and other immunomodulatory agents, lipids, liposomes, peptides, anti-cancer and chemotherapeutic agents; wherein the compound of general formula (I), or pharmaceutically acceptable salt thereof, and the active agent are each employed in an amount that renders the combination effective for inducing an immune response in a patient.
(d) A method of inducing an immune response in a patient, which comprises administering to the subject a therapeutically effective amount of a compound of general formula (I), or a pharmaceutically acceptable salt thereof.
(e) A method of inducing an immune response in a patient, which comprises administering to the subject a therapeutically effective amount of a composition of (a), a composition of (b), or a combination of (c).
(f) A method of inducing STING-dependent type I interferon production in a patient, which comprises administering to the subject a therapeutically effective amount of a compound of general formula (I), or a pharmaceutically acceptable salt thereof.
(g) A method of inducing STING-dependent type I interferon production in a patient, which comprises administering to the subject a therapeutically effective amount of a composition of (a), a composition of (b), or a combination of (c).
(h) A method of inducing STING-dependent cytokine production in a patient, which comprises administering to the subject a therapeutically effective amount of a compound of general formula (I), or a pharmaceutically acceptable salt thereof.
(i) A method of inducing STING-dependent cytokine production in a patient, which comprises administering to the subject a therapeutically effective amount of a composition of (a), a composition of (b), or a combination of (c).
(j) A method of treating a cell proliferation disorder in a subject, said method comprising administering a therapeutically effective amount of a compound of general formula (I), or a pharmaceutically acceptable salt thereof to the subject;
(k) The method of (j), wherein the cell proliferation disorder is cancer. (l) A method of treating a cell proliferation disorder in a subject, said method comprising administering a therapeutically effective amount of a composition of (a), a composition of (b), or a combination of (c) to the subject.
[0067] The present disclosure also includes a compound of the present disclosure for use (i) in, (ii) as a medicament for, or (iii) in the preparation of a medicament for: (a) inducing an immune response in a patient, or (b) inducing STING-dependent cytokine production in a patient. In these uses, the compounds of the present disclosure can optionally be employed in combination with one or more active agents selected from STING agonist compounds, anti-viral compounds, antigens, adjuvants, CTLA-4 and PD-1 pathway antagonists and other
immunomodulatory agents, lipids, liposomes, peptides, anti-cancer agents, and chemotherapeutic agents.
[0068] Additional embodiments of the disclosure include the pharmaceutical compositions, combinations and methods set forth in (a) through (l) above and the uses set forth in the preceding paragraph, wherein the compound of the present disclosure employed therein is a compound of one of the embodiments, aspects, instances, occurrences, or features of the compounds described above. In all of these embodiments, the compound may optionally be used in the form of a pharmaceutically acceptable salt, as appropriate.
[0069] In the embodiments of the compound provided above, it is to be understood that each embodiment may be combined with one or more other embodiments, to the extent that such a combination provides a stable compound and is consistent with the description of the embodiments. It is further to be understood that the embodiments of compositions and methods provided as (a) through (l) above are understood to include all embodiments of the compounds, including such embodiments as result from combinations of embodiments.
[0070] The term“subject” (alternatively“patient”) as used herein refers to a mammal that has been the object of treatment, observation, or experiment. The mammal may be male or female. The mammal may be one or more selected from the group consisting of humans, bovine (e.g., cows), porcine (e.g., pigs), ovine (e.g., sheep), capra (e.g., goats), equine (e.g., horses), canine (e.g., domestic dogs), feline (e.g., house cats), Lagomorpha (rabbits), rodents (e.g., rats or mice), Procyon lotor (e.g., raccoons). In particular embodiments, the subject is human.
[0071] As used herein, the term“immune response” relates to any one or more of the following: specific immune response, non-specific immune response, both specific and non- specific response, innate response, primary immune response, adaptive immunity, secondary immune response, memory immune response, immune cell activation, immune cell proliferation, immune cell differentiation, and cytokine expression. In certain embodiments, a compound of general formula (I), or a pharmaceutically acceptable salt of the foregoing, is administered in conjunction with one or more additional therapeutic agents including anti-viral compounds, vaccines intended to stimulate an immune response to one or more predetermined antigens, adjuvants, CTLA-4 and PD-1 pathway antagonists and other immunomodulatory agents, lipids, liposomes, peptides, anti-cancer agents, and chemotherapeutic agents, etc. In certain
embodiments, a compound of general formula (I), or a pharmaceutically acceptable salt of the foregoing, is administered in conjunction with one or more additional compositions including anti-viral compounds, vaccines intended to stimulate an immune response to one or more predetermined antigens, adjuvants, CTLA-4 and PD-1 pathway antagonists and other immunomodulatory agents, lipids, liposomes, peptides, anti-cancer agents, and chemotherapeutic agents, etc. [0072] Compounds
[0073] The term“alkyl” refers to a monovalent straight or branched chain, saturated aliphatic hydrocarbon radical having a number of carbon atoms in the specified range. Thus, for example,“C1-6 alkyl” (or“C1-C6 alkyl”) refers to any of the hexyl alkyl and pentyl alkyl isomers as well as n-, iso-, sec- and tert-butyl, n- and iso-propyl, ethyl, and methyl. As another example, “C1-4 alkyl” refers to n-, iso-, sec- and tert-butyl, n- and isopropyl, ethyl, and methyl.
[0074] As used herein, the term“alkylene” refers to a bivalent straight chain, saturated aliphatic hydrocarbon radical having a number of carbon atoms in the specified range.
[0075] As used herein, the term“alkenyl” refers to a monovalent straight or branched chain, unsaturated aliphatic hydrocarbon radical having a number of carbon atoms in the specified range and including one or more double bond.
[0076] As used herein, the term“alkenylene” refers to a bivalent straight chain, unsaturated aliphatic hydrocarbon radical having a number of carbon atoms in the specified range and including one or more double bond.
[0077] As used herein, the term“alkynyl” refers to a monovalent straight or branched chain, unsaturated aliphatic hydrocarbon radical having a number of carbon atoms in the specified range and including one or more triple bond. [0078] As used herein, the term“alkynylene” refers to a bivalent straight chain, unsaturated aliphatic hydrocarbon radical having a number of carbon atoms in the specified range and including one or more triple bond. The term“halogen” (or“halo”) refers to fluorine, chlorine, bromine, and iodine (alternatively referred to as fluoro, chloro, bromo, and iodo or F, Cl, Br, and I).
[0079] The term“haloalkyl” refers to an alkyl group as defined above in which one or more of the hydrogen atoms have been replaced with a halogen. Thus, for example,“C1-6 haloalkyl” (or“C1-C6 haloalkyl”) refers to a C1 to C6 linear or branched alkyl group as defined above with one or more halogen substituents. The term“fluoroalkyl” has an analogous meaning except the halogen substituents are restricted to fluoro. Suitable fluoroalkyls include the series (CH2)0-4CF3 (i.e., trifluoromethyl, 2,2,2-trifluoroethyl, 3,3,3-trifluoro-n-propyl, etc.).
[0080] As used herein, the term“haloalkenyl” refers to an alkenyl group as defined above in which one or more of the hydrogen atoms have been replaced with a halogen.
[0081] As used herein, the term“haloalkynyl” refers to an alkynyl group as defined above in which one or more of the hydrogen atoms have been replaced with a halogen.
[0082] As used herein, the term“alkoxy” as used herein, alone or in combination, includes an alkyl group connected to the oxy connecting atom. The term“alkoxy” also includes alkyl ether groups, where the term“alkyl” is defined above, and“ether” means two alkyl groups with an oxygen atom between them. Examples of suitable alkoxy groups include methoxy, ethoxy, n- propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy, methoxymethane (also referred to as “dimethyl ether”), and methoxyethane (also referred to as“ethyl methyl ether”).
[0083] As used herein, the term“cycloalkyl” refers to a saturated hydrocarbon containing one ring having a specified number of carbon atoms. Examples of cycloalkyl include
cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
[0084] As used herein, the term“heterocycle”,“heterocyclyl”, or“heterocyclic”, as used herein, represents a stable 3- to 6-membered monocyclic that is either saturated or unsaturated, and that consists of carbon atoms and from one to two heteroatoms selected from the group consisting of N, O, and S. The heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure. The term includes heteroaryl moieties. Examples of such heterocyclic elements include, but are not limited to, azepinyl, benzimidazolyl, benzisoxazolyl, benzofurazanyl, benzopyranyl, benzothiopyranyl, benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, cinnolinyl, dihydrobenzofuryl, dihydrobenzothienyl, dihydrobenzothiopyranyl, dihydrobenzothiopyranyl sulfone, 1,3-dioxolanyl, furyl, imidazolidinyl, imidazolinyl, imidazolyl, indolinyl, indolyl, isochromanyl, isoindolinyl, isoquinolinyl, isothiazolidinyl, isothiazolyl, isothiazolidinyl, morpholinyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, 2-oxopiperazinyl, 2-oxopiperdinyl, 2-oxopyrrolidinyl, piperidyl, piperazinyl, pyridyl, pyrazinyl, pyrazolidinyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrrolidinyl, pyrrolyl, quinazolinyl, quinolinyl, quinoxalinyl, tetrahydrofuryl,
tetrahydroisoquinolinyl, tetrahydroquinolinyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiazolyl, thiazolinyl, thienofuryl, thienothienyl, triazolyl, and thienyl.
[0085] As used herein, the term“spirocycle” or“spirocyclic ring” refers to a pendant cyclic group formed by substituents on a single atom.
[0086] The term“compound” refers to the compound and, in certain embodiments, to the extent they are stable, any hydrate or solvate thereof. A hydrate is the compound complexed with water, and a solvate is the compound complexed with a solvent, which may be an organic solvent or an inorganic solvent.
[0087] A“stable” compound is a compound that can be prepared and isolated and whose structure and properties remain or can be caused to remain essentially unchanged for a period of time sufficient to allow use of the compound for the purposes described herein (e.g., therapeutic administration to a subject). The compounds of the present invention are limited to stable compounds embraced by general formula (I), or pharmaceutically acceptable salts thereof.
[0088] Unless expressly stated to the contrary, all ranges cited herein are inclusive; i.e., the range includes the values for the upper and lower limits of the range as well as all values in between. As an example, temperature ranges, percentages, ranges of equivalents, and the like described herein include the upper and lower limits of the range and any value in the continuum there between. Numerical values provided herein, and the use of the term“about”, may include variations of ± 1%, ± 2%, ±3%, ± 4%, ± 5%, ± 10%, ± 15%, and ± 20% and their numerical equivalents. As used herein, the term“one or more” item includes a single item selected from the list as well as mixtures of two or more items selected from the list.
[0089] In the compounds of general formula (I), and pharmaceutically acceptable salts of the foregoing, the atoms may exhibit their natural isotopic abundances, or one or more of the atoms may be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominantly found in nature. The present disclosure is meant to include all suitable isotopic variations of the compounds of general formula (I), and pharmaceutically acceptable salts of the foregoing. For example, different isotopic forms of hydrogen (H) include protium (1H), deuterium (2H), and tritium (3H). Protium is the predominant hydrogen isotope found in nature. Enriching for deuterium may afford certain therapeutic advantages, such as increasing in vivo half-life or reducing dosage requirements, or may provide a compound useful as a standard for
characterization of biological samples. Isotopically-enriched compounds within general formula (I), and the pharmaceutically acceptable salts of the foregoing, can be prepared without undue experimentation by conventional techniques well known to those skilled in the art or by processes analogous to those described in the Schemes and Examples herein using appropriate isotopically-enriched reagents and/or intermediates.
[0090] In particular embodiments of the compounds of general formula (I), and/or pharmaceutically acceptable salts of the foregoing, the compounds are isotopically enriched with deuterium. In aspects of these embodiments, one or more of Base1, Base2, Y, Ya, Xa, Xa1, Xb, Xb1, R1, R1a, R2, R2a, R3, R4, R4a, R5, R6, R6a, R7, R7a, R8, R8a, and R9 may include deuterium.
[0091] As shown in the general structural formulas and the structures of specific compounds as provided herein, a straight line at a chiral center includes both (R) and (S) stereoisomers and mixtures thereof.
[0092] Recitation or depiction of a specific compound in the claims (i.e., a species) without a specific stereoconfiguration designation, or with such a designation for less than all chiral centers, is intended to encompass, for such undesignated chiral centers, the racemate, racemic mixtures, each individual enantiomer, a diastereoisomeric mixture and each individual diastereomer of the compound where such forms are possible due to the presence of one or more asymmetric centers.
[0093] The invention includes all possible enantiomers and diastereomers and mixtures of two or more stereoisomers, for example mixtures of enantiomers and/or diastereomers, in all ratios. Thus, enantiomers are a subject of the invention in enantiomerically pure form, both as levorotatory and as dextrorotatory antipodes, in the form of racemates and in the form of mixtures of the two enantiomers in all ratios. In the case of a cis/trans isomerism, the invention includes both the cis form and the trans form, as well as mixtures of these forms in all ratios. The preparation of individual stereoisomers can be carried out, if desired, by separation of a mixture by customary methods, for example by chromatography or crystallization, by the use of stereochemically uniform starting materials for the synthesis or by stereoselective synthesis. Optionally a derivatization can be carried out before a separation of stereoisomers. The separation of a mixture of stereoisomers can be carried out at an intermediate step during the synthesis of a compound of general formula (I), or a pharmaceutically acceptable salt of the foregoing, or it can be done on a final racemic product. Absolute stereochemistry may be determined by X-ray crystallography of crystalline products or crystalline intermediates that are derivatized, if necessary, with a reagent containing a stereogenic center of known configuration. Unless a particular isomer, salt, solvate (including hydrates) or solvated salt of such racemate, enantiomer, or diastereomer is indicated, the present invention includes all such isomers, as well as salts, solvates (including hydrates), and solvated salts of such racemates, enantiomers, diastereomers, and mixtures thereof.
[0094] Those skilled in the art will recognize that chiral compounds, and in particular sugars, can be drawn in a number of different ways that are equivalent. Those skilled in the art will further recognize that the identity and regiochemical position of the substituents on ribose can vary widely and that the same prinicples of steroechemical equivalence apply regardless of substituent. Non-limiting examples of such equivalence include those exemplified below.
Figure imgf000048_0001
[0095] Salts
[0096] As indicated above, the compounds of the present invention can be employed in the form of pharmaceutically acceptable salts. Those skilled in the art will recognize those instances in which the compounds of the invention may form salts. Examples of such compounds are described herein by reference to possible salts. Such reference is for illustration only.
Pharmaceutically acceptable salts can be used with compounds for treating patients. Non- pharmaceutical salts may, however, be useful in the preparation of intermediate compounds. [0097] The term“pharmaceutically acceptable salt” refers to a salt (including an inner salt such as a zwitterion) that possesses effectiveness similar to the parent compound and that is not biologically or otherwise undesirable (e.g., is neither toxic nor otherwise deleterious to the recipient thereof). Thus, an embodiment of the invention provides pharmaceutically acceptable salts of the compounds of the invention. The term“salt(s)”, as employed herein, denotes any of the following: acidic salts formed with inorganic and/or organic acids, as well as basic salts formed with inorganic and/or organic bases. Salts of compounds of the invention may be formed by methods known to those of ordinary skill in the art, for example, by reacting a compound of the invention with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in aqueous medium followed by lyophilization.
[0098] Exemplary acid addition salts include acetates, ascorbates, benzoates,
benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, fumarates, hydrochlorides, hydrobromides, hydroiodides, lactates, maleates, methanesulfonates (“mesylates”), naphthalenesulfonates, nitrates, oxalates, phosphates, propionates, salicylates, succinates, sulfates, tartarates, thiocyanates, toluenesulfonates (also known as tosylates) and the like. Suitable salts include acid addition salts that may, for example, be formed by mixing a solution of a compound with a solution of a pharmaceutically acceptable acid such as
hydrochloric acid, sulfuric acid, acetic acid, trifluoroacetic acid, or benzoic acid. Additionally, acids that are generally considered suitable for the formation of pharmaceutically useful salts from basic pharmaceutical compounds are discussed, for example, by P. Stahl et al, Camille G. (eds.), Handbook of Pharmaceutical Salts. Properties, Selection and Use. (2002) Zurich: Wiley- VCH; S. Berge et al, Journal of Pharmaceutical Sciences (1977) 66(1) 1-19; P. Gould,
International J. of Pharmaceutics (1986) 33201-217; Anderson et al, The Practice of Medicinal Chemistry (1996), Academic Press, New York; and in The Orange Book (Food & Drug
Administration, Washington, D.C. on their website). These disclosures are incorporated herein by reference thereto.
[0099] Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (for example, organic amines) such as dicyclohexylamine, t-butyl amine, choline, and salts with amino acids such as arginine, lysine and the like. Basic nitrogen- containing groups may be quarternized with agents such as lower alkyl halides (e.g., methyl, ethyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g., dimethyl, diethyl, and dibutyl sulfates), long chain halides (e.g., decyl, lauryl, and stearyl chlorides, bromides and iodides), aralkyl halides (e.g., benzyl and phenethyl bromides), and others. Compounds carrying an acidic moiety can be mixed with suitable pharmaceutically acceptable salts to provide, for example, alkali metal salts (e.g., sodium or potassium salts), alkaline earth metal salts (e.g., calcium or magnesium salts), and salts formed with suitable organic ligands such as quaternary ammonium salts. Also, in the case of an acid (such as -COOH) or alcohol group being present, pharmaceutically acceptable esters can be employed to modify the solubility or hydrolysis characteristics of the compound.
[0100] All such acid salts and base salts are intended to be pharmaceutically acceptable salts within the scope of the invention and all acid and base salts are considered equivalent to the free forms of the corresponding compounds for purposes of the invention.
[0101] In addition, when a compound of the invention contains both a basic moiety, such as, but not limited to an aliphatic primary, secondary, tertiary or cyclic amine, an aromatic or heteroaryl amine, pyridine or imidazole, and an acidic moiety, such as, but not limited to tetrazole or carboxylic acid, zwitterions (“inner salts”) may be formed and are included within the terms“salt(s)” as used herein. It is understood that certain compounds of the invention may exist in zwitterionic form, having both anionic and cationic centers within the same compound and a net neutral charge. Such zwitterions are included within the invention. [0102] Methods of Preparing Compounds
[0103] Several methods for preparing the compounds of general formula (I), and pharmaceutically acceptable salts of the foregoing, are described in the following Schemes and Examples. Starting materials and intermediates are purchased from commercial sources, made from known procedures, or are otherwise illustrated. In some cases the order of carrying out the steps of the reaction schemes may be varied to facilitate the reaction or to avoid unwanted reaction products.
[0104] In the following Methods and Schemes, PG1 or PG2 represents a protecting group for an amino group in a nucleobase, which may be a phenyl carbonyl group including benzoyl group, an alkyl carbonyl group including isobutyl carbonyl group and 2-(4-(tert-butyl)phenoxy) acetyl group or a formamidine group including N,N-dimethyl-formamidine. All other variables have the same meaning as provided above. [0105] Method 1
[0106] One method for the preparation of examples of Formula (I) of the instant invention is detailed in Scheme 1. This procedure was adequately modified from the previously reported procedure for cyclic dinucleotide synthesis (Barbara L. Gaffney et al., One-Flask Syntheses of c- di-GMP and the [Rp,Rp] and [Rp,Sp] Thiophosphate Analogues, 12 ORG. LETT.3269-3271 (2010)). The sequence starts with modified ribo-nucleoside with DMTr ether at 5’-O position and a nucleobase of which amino group was appropriately protected as described above if necessary. It was treated with diphenyl phosphite and then, aqueous trimethylamine to introduce an H-phosphonate group. Then, DMTr ether was removed under acidic condition. The resulting 5’-hydroxyl group was reacted with 3’-phosphoramidites of fully protected second modified ribo-nucleoside to give a linear dimer compound. It was immediately treated with (E)-N,N- dimethyl-N'-(3-thioxo-3H-1,2,4-dithiazol-5-yl)formimidamide or tert-butyl hydroperoxide. Then, the 5’-hydroxyl group of the second ribo-nucleoside was deprotected with dichloroacetic acid. Using diphenyl chlorophosphate as a coupling reagent, the H-phosphonate at 2’-O of the first ribo-nucleoside was reacted with 5’-OH of the second ribo-nucleoside to give a cyclic product. It was immediately sulfurized with 3H-1,2-benzodithiol-3-one. Treatment with ammonium hydroxide, t-butylamine, or methylamine plus fluoride anion in case silyl protection was used provided the desired cyclic dinucleotide 1G.
SCHEME 1
Figure imgf000052_0001
[0107] Method 2
[0108] One method for the preparation of examples of Formula (I) of the instant invention is detailed in Scheme 2. The sequence starts with a cyclic dinucleotide with 6-amino moiety in a nucleobase prepared from a sequence similar to Scheme 1. It was treated with adenosine monophosphate deaminase in an appropriate aqueous buffer solution to give cyclic dinucleotide 2B with 6-oxo moiety in the nucleobase. SCHEME 2
Figure imgf000053_0001
[0109] Methods of Use
[0110] Compounds described herein having therapeutic applications, such as the compounds of general formula (I), the compounds of the Examples 1 through 54, and pharmaceutically acceptable salts of the foregoing, may be administered to a patient for the purpose of inducing an immune response, inducing STING-dependent cytokine production and/or inducing anti-tumor activity. The term“administration” and variants thereof (e.g., “administering” a compound) means providing the compound to the individual in need of treatment. When a compound is provided in combination with one or more additional active agents (e.g., antiviral agents useful for treating HCV infection or anti-tumor agents for treating cancers),“administration” and its variants are each understood to include concurrent and sequential provision of the compound or salt and other agents. [0111] The compounds disclosed herein may be STING agonists. These compounds are potentially useful in treating diseases or disorders including, but not limited to, cell proliferation disorders. Cell-proliferation disorders include, but are not limited to, cancers, benign
papillomatosis, gestational trophoblastic diseases, and benign neoplastic diseases, such as skin papilloma (warts) and genital papilloma.
[0112] In specific embodiments, the disease or disorder to be treated is a cell proliferation disorder. In certain embodiments, the cell proliferation disorder is cancer. In particular embodiments, the cancer is selected from brain and spinal cancers, cancers of the head and neck, leukemia and cancers of the blood, skin cancers, cancers of the reproductive system, cancers of the gastrointestinal system, liver and bile duct cancers, kidney and bladder cancers, bone cancers, lung cancers, malignant mesothelioma, sarcomas, lymphomas, glandular cancers, thyroid cancers, heart tumors, germ cell tumors, malignant neuroendocrine (carcinoid) tumors, midline tract cancers, and cancers of unknown primary (i.e., cancers in which a metastasized cancer is found but the original cancer site is not known). In particular embodiments, the cancer is present in an adult patient; in additional embodiments, the cancer is present in a pediatric patient. In particular embodiments, the cancer is AIDS-related.
[0113] In specific embodiments, the cancer is selected from brain and spinal cancers. In particular embodiments, the cancer is selected from the group consisting of anaplastic
astrocytomas, glioblastomas, astrocytomas, and estheosioneuroblastomas (also known as olfactory blastomas). In particular embodiments, the brain cancer is selected from the group consisting of astrocytic tumor (e.g., pilocytic astrocytoma, subependymal giant-cell astrocytoma, diffuse astrocytoma, pleomorphic xanthoastrocytoma, anaplastic astrocytoma, astrocytoma, giant cell glioblastoma, glioblastoma, secondary glioblastoma, primary adult glioblastoma, and primary pediatric glioblastoma), oligodendroglial tumor (e.g., oligodendroglioma, and anaplastic oligodendroglioma), oligoastrocytic tumor (e.g., oligoastrocytoma, and anaplastic
oligoastrocytoma), ependymoma (e.g., myxopapillary ependymoma, and anaplastic
ependymoma); medulloblastoma, primitive neuroectodermal tumor, schwannoma, meningioma, atypical meningioma, anaplastic meningioma, pituitary adenoma, brain stem glioma, cerebellar astrocytoma, cerebral astorcytoma/malignant glioma, visual pathway and hypothalmic glioma, and primary central nervous system lymphoma. In specific instances of these embodiments, the brain cancer is selected from the group consisting of glioma, glioblastoma multiforme, paraganglioma, and suprantentorial primordial neuroectodermal tumors (sPNET). [0114] In specific embodiments, the cancer is selected from cancers of the head and neck, including nasopharyngeal cancers, nasal cavity and paranasal sinus cancers, hypopharyngeal cancers, oral cavity cancers (e.g., squamous cell carcinomas, lymphomas, and sarcomas), lip cancers, oropharyngeal cancers, salivary gland tumors, cancers of the larynx (e.g., laryngeal squamous cell carcinomas, rhabdomyosarcomas), and cancers of the eye or ocular cancers. In particular embodiments, the ocular cancer is selected from the group consisting of intraocular melanoma and retinoblastoma.
[0115] In specific embodiments, the cancer is selected from leukemia and cancers of the blood. In particular embodiments, the cancer is selected from the group consisting of myeloproliferative neoplasms, myelodysplastic syndromes, myelodysplastic/myeloproliferative neoplasms, acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelogenous leukemia (CML), myeloproliferative neoplasm (MPN), post-MPN AML, post- MDS AML, del(5q)-associated high risk MDS or AML, blast-phase chronic myelogenous leukemia, angioimmunoblastic lymphoma, acute lymphoblastic leukemia, Langerans cell histiocytosis, hairy cell leukemia, and plasma cell neoplasms including plasmacytomas and multiple myelomas. Leukemias referenced herein may be acute or chronic.
[0116] In specific embodiments, the cancer is selected from skin cancers. In particular embodiments, the skin cancer is selected from the group consisting of melanoma, squamous cell cancers, and basal cell cancers.
[0117] In specific embodiments, the cancer is selected from cancers of the reproductive system. In particular embodiments, the cancer is selected from the group consisting of breast cancers, cervical cancers, vaginal cancers, ovarian cancers, prostate cancers, penile cancers, and testicular cancers. In specific instances of these embodiments, the cancer is a breast cancer selected from the group consisting of ductal carcinomas and phyllodes tumors. In specific instances of these embodiments, the breast cancer may be male breast cancer or female breast cancer. In specific instances of these embodiments, the cancer is a cervical cancer selected from the group consisting of squamous cell carcinomas and adenocarcinomas. In specific instances of these embodiments, the cancer is an ovarian cancer selected from the group consisting of epithelial cancers.
[0118] In specific embodiments, the cancer is selected from cancers of the gastrointestinal system. In particular embodiments, the cancer is selected from the group consisting of esophageal cancers, gastric cancers (also known as stomach cancers), gastrointestinal carcinoid tumors, pancreatic cancers, gallbladder cancers, colorectal cancers, and anal cancer. In instances of these embodiments, the cancer is selected from the group consisting of esophageal squamous cell carcinomas, esophageal adenocarcinomas, gastric adenocarcinomas, gastrointestinal carcinoid tumors, gastrointestinal stromal tumors, gastric lymphomas, gastrointestinal lymphomas, solid pseudopapillary tumors of the pancreas, pancreatoblastoma, islet cell tumors, pancreatic carcinomas including acinar cell carcinomas and ductal adenocarcinomas, gallbladder adenocarcinomas, colorectal adenocarcinomas, and anal squamous cell carcinomas.
[0119] In specific embodiments, the cancer is selected from liver and bile duct cancers. In particular embodiments, the cancer is liver cancer (also known as hepatocellular carcinoma). In particular embodiments, the cancer is bile duct cancer (also known as cholangiocarcinoma); in instances of these embodiments, the bile duct cancer is selected from the group consisting of intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma.
[0120] In specific embodiments, the cancer is selected from kidney and bladder cancers. In particular embodiments, the cancer is a kidney cancer selected from the group consisting of renal cell cancer, Wilms tumors, and transitional cell cancers. In particular embodiments, the cancer is a bladder cancer selected from the group consisting of urethelial carcinoma (a transitional cell carcinoma), squamous cell carcinomas, and adenocarcinomas.
[0121] In specific embodiments, the cancer is selected from bone cancers. In particular embodiments, the bone cancer is selected from the group consisting of osteosarcoma, malignant fibrous histiocytoma of bone, Ewing sarcoma, chordoma (cancer of the bone along the spine).
[0122] In specific embodiments, the cancer is selected from lung cancers. In particular embodiments, the lung cancer is selected from the group consisting of non-small cell lung cancer, small cell lung cancers, bronchial tumors, and pleuropulmonary blastomas.
[0123] In specific embodiments, the cancer is selected from malignant mesothelioma. In particular embodiments, the cancer is selected from the group consisting of epithelial
mesothelioma and sarcomatoids.
[0124] In specific embodiments, the cancer is selected from sarcomas. In particular embodiments, the sarcoma is selected from the group consisting of central chondrosarcoma, central and periosteal chondroma, fibrosarcoma, clear cell sarcoma of tendon sheaths, and Kaposi's sarcoma.
[0125] In specific embodiments, the cancer is selected from lymphomas. In particular embodiments, the cancer is selected from the group consisting of Hodgkin lymphoma (e.g., Reed-Sternberg cells), non-Hodgkin lymphoma (e.g., diffuse large B-cell lymphoma, follicular lymphoma, mycosis fungoides, Sezary syndrome, primary central nervous system lymphoma), cutaneous T-cell lymphomas, primary central nervous system lymphomas. In specific embodiments, the cancer is selected from glandular cancers. In particular embodiments, the cancer is selected from the group consisting of adrenocortical cancer (also known as
adrenocortical carcinoma or adrenal cortical carcinoma), pheochromocytomas, paragangliomas, pituitary tumors, thymoma, and thymic carcinomas.
[0126] In specific embodiments, the cancer is selected from thyroid cancers. In particular embodiments, the thyroid cancer is selected from the group consisting of medullary thyroid carcinomas, papillary thyroid carcinomas, and follicular thyroid carcinomas.
[0127] In specific embodiments, the cancer is selected from germ cell tumors. In particular embodiments, the cancer is selected from the group consisting of malignant extracranial germ cell tumors and malignant extragonadal germ cell tumors. In specific instances of these embodiments, the malignant extragonadal germ cell tumors are selected from the group consisting of nonseminomas and seminomas.
[0128] In specific embodiments, the cancer is selected from heart tumors. In particular embodiments, the heart tumor is selected from the group consisting of malignant teratoma, lymphoma, rhabdomyosacroma, angiosarcoma, chondrosarcoma, infantile fibrosarcoma, and synovial sarcoma.
[0129] In specific embodiments, the cell-proliferation disorder is selected from benign papillomatosis, benign neoplastic diseases and gestational trophoblastic diseases. In particular embodiments, the benign neoplastic disease is selected from skin papilloma (warts) and genital papilloma. In particular embodiments, the gestational trophoblastic disease is selected from the group consisting of hydatidiform moles, and gestational trophoblastic neoplasia (e.g., invasive moles, choriocarcinomas, placental-site trophoblastic tumors, and epithelioid trophoblastic tumors).
[0130] As used herein, the terms“treatment” and“treating” refer to all processes in which there may be a slowing, interrupting, arresting, controlling, or stopping of the progression of a disease or disorder described herein. The terms do not necessarily indicate a total elimination of all disease or disorder symptoms. [0131] The terms“administration of” and or“administering” a compound should be understood to include providing a compound described herein, or a pharmaceutically acceptable salt thereof, and compositions of the foregoing to a subject.
[0132] The amount of a compound administered to a subject is an amount sufficient to induce an immune response and/or to induce STING-dependent type I interferon production in the subject. In an embodiment, the amount of a compound can be an“effective amount” or “therapeutically effective amount,” such that the subject compound is administered in an amount that will elicit, respectively, a biological or medical (i.e., intended to treat) response of a tissue, system, animal, or human that is being sought by a researcher, veterinarian, medical doctor, or other clinician. An effective amount does not necessarily include considerations of toxicity and safety related to the administration of a compound.
[0133] An effective amount of a compound will vary with the particular compound chosen (e.g., considering the potency, efficacy, and/or half-life of the compound); the route of administration chosen; the condition being treated; the severity of the condition being treated; the age, size, weight, and physical condition of the subject being treated; the medical history of the subject being treated; the duration of the treatment; the nature of a concurrent therapy; the desired therapeutic effect; and like factors and can be routinely determined by the skilled artisan.
[0134] The compounds disclosed herein may be administered by any suitable route including oral and parenteral administration. Parenteral administration is typically by injection or infusion and includes intravenous, intramuscular, intratumoral, and subcutaneous injection or infusion.
[0135] The compounds disclosed herein may be administered once or according to a dosing regimen where a number of doses are administered at varying intervals of time for a given period of time. For example, doses may be administered one, two, three, or four times per day. Doses may be administered until the desired therapeutic effect is achieved or indefinitely to maintain the desired therapeutic effect. Suitable dosing regimens for a compound disclosed herein depend on the pharmacokinetic properties of that compound, such as absorption, distribution and half-life, which can be determined by a skilled artisan. In addition, suitable dosing regimens, including the duration such regimens are administered, for a compound disclosed herein depend on the disease or condition being treated, the severity of the disease or condition, the age and physical condition of the subject being treated, the medical history of the subject being treated, the nature of concurrent therapy, the desired therapeutic effect, and like factors within the knowledge and expertise of the skilled artisan. It will be further understood by such skilled artisans that suitable dosing regimens may require adjustment given an individual subject's response to the dosing regimen or over time as the individual subject needs change. Typical daily dosages may vary depending upon the particular route of administration chosen.
[0136] One embodiment of the present disclosure provides for a method of treating a cell proliferation disorder comprising administration of a therapeutically effective amount of a compound of general formula (I), or a pharmaceutically acceptable salt of the foregoing, to a subject in need of treatment thereof. In embodiments, the disease or disorder to be treated is a cell proliferation disorder. In aspects of these embodiments, the cell proliferation disorder is cancer. In further aspects of these embodiments, the cancer is selected from brain and spinal cancers, cancers of the head and neck, leukemia and cancers of the blood, skin cancers, cancers of the reproductive system, cancers of the gastrointestinal system, liver and bile duct cancers, kidney and bladder cancers, bone cancers, lung cancers, malignant mesothelioma, sarcomas, lymphomas, glandular cancers, thyroid cancers, heart tumors, germ cell tumors, malignant neuroendocrine (carcinoid) tumors, midline tract cancers, and cancers of unknown primary.
[0137] In one embodiment, disclosed herein is the use of a compound of general formula (I), or a pharmaceutically acceptable salt of the foregoing, in a therapy. The compound may be useful in a method of inducing an immune response and/or inducing STING-dependent type I interferon production in a subject, such as a mammal in need of such inhibition, comprising administering an effective amount of the compound to the subject.
[0138] In one embodiment, disclosed herein is a pharmaceutical composition comprising at least one compound of general formula (I), or at least one pharmaceutically acceptable salt of the foregoing, for use in potential treatment to induce an immune response and/or to induce STING- dependent type I interferon production.
[0139] One embodiment disclosed herein is the use of a compound of general formula (I), or a pharmaceutically acceptable salt of the foregoing, in the manufacture of a medicament to induce an immune response and/or to induce STING-dependent type I interferon production. In embodiments, the disease or disorder to be treated is a cell proliferation disorder. In aspects of these embodiments, the cell proliferation disorder is cancer. In further aspects of these embodiments, the cancer is selected from brain and spinal cancers, cancers of the head and neck, leukemia and cancers of the blood, skin cancers, cancers of the reproductive system, cancers of the gastrointestinal system, liver and bile duct cancers, kidney and bladder cancers, bone cancers, lung cancers, malignant mesothelioma, sarcomas, lymphomas, glandular cancers, thyroid cancers, heart tumors, germ cell tumors, malignant neuroendocrine (carcinoid) tumors, midline tract cancers, and cancers of unknown primary. [0140] Compositions
[0141] The term“composition” as used herein is intended to encompass a dosage form comprising a specified compound in a specified amount, as well as any dosage form that results, directly or indirectly, from combination of a specified compound in a specified amount. Such term is intended to encompass a dosage form comprising a compound of general formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug of the foregoing, and one or more pharmaceutically acceptable carriers or excipients. In embodiments, the dosage form comprises compounds of general structural formula (I), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and one or more pharmaceutically acceptable carriers or excipients. In specific embodiments, the dosage form comprises compounds of general structural formula (I), or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or excipients. Accordingly, the compositions of the present disclosure encompass any composition made by admixing a compound of the present disclosure and one or more pharmaceutically acceptable carrier or excipients. By“pharmaceutically acceptable”, it is meant the carriers or excipients are compatible with the compound disclosed herein and with other ingredients of the composition.
[0142] For the purpose of inducing an immune response and/or inducing STING- dependent type I interferon production, the compounds of general formula (I), or
pharmaceutically acceptable salts of the foregoing, can be administered by means that produces contact of the active agent with the agent’s site of action. The compounds can be administered by conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in a combination of therapeutic agents. The compounds can be
administered alone, but typically are administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.
[0143] In one embodiment, disclosed herein is a composition comprising a compound of general formula (I), or a pharmaceutically acceptable salt of the foregoing, and one or more pharmaceutically acceptable carriers or excipients. The composition may be prepared and packaged in bulk form in which a therapeutically effective amount of a compound of the disclosure can be extracted and then given to a subject, such as with powders or syrups.
Alternatively, the composition may be prepared and packaged in unit dosage form in which each physically discrete unit contains a therapeutically effective amount of a compound of general formula (I), or a pharmaceutically acceptable salt of the foregoing.
[0144] The compounds disclosed herein and a pharmaceutically acceptable carrier or excipient(s) will typically be formulated into a dosage form adapted for administration to a subject by a desired route of administration. For example, dosage forms include those adapted for (1) oral administration, such as tablets, capsules, caplets, pills, troches, powders, syrups, elixirs, suspensions, solutions, emulsions, sachets, and cachets; and (2) parenteral administration, such as sterile solutions, suspensions, and powders for reconstitution. Suitable pharmaceutically acceptable carriers or excipients will vary depending upon the particular dosage form chosen. In addition, suitable pharmaceutically acceptable carriers or excipients may be chosen for a particular function that they may serve in the composition. For example, certain
pharmaceutically acceptable carriers or excipients may be chosen for their ability to facilitate the production of uniform dosage forms. Certain pharmaceutically acceptable carriers or excipients may be chosen for their ability to facilitate the production of stable dosage forms. Certain pharmaceutically acceptable carriers or excipients may be chosen for their ability to facilitate the carrying or transporting of a compound disclosed herein, once administered to the subject, from one organ or portion of the body to another organ or another portion of the body. Certain pharmaceutically acceptable carriers or excipients may be chosen for their ability to enhance patient compliance.
[0145] Suitable pharmaceutically acceptable excipients include the following types of excipients: diluents, lubricants, binders, disintegrants, fillers, glidants, granulating agents, coating agents, wetting agents, solvents, co-solvents, suspending agents, emulsifiers, sweeteners, flavoring agents, flavor masking agents, coloring agents, anti-caking agents, hemectants, chelating agents, plasticizers, viscosity increasing agents, antioxidants, preservatives, stabilizers, surfactants, and buffering agents.
[0146] A skilled artisan possesses the knowledge and skill in the art to select suitable pharmaceutically acceptable carriers and excipients in appropriate amounts for the use in the compositions of the disclosure. In addition, there are a number of resources available to the skilled artisan, which describe pharmaceutically acceptable carriers and excipients and may be useful in selecting suitable pharmaceutically acceptable carriers and excipients. Examples include REMINGTON'S PHARMACEUTICAL SCIENCES (Mack Publishing Company), THE
HANDBOOK OF PHARMACEUTICAL ADDITIVES (Gower Publishing Limited), and THE HANDBOOK OF PHARMACEUTICAL EXCIPIENTS (the American Pharmaceutical Association and the
Pharmaceutical Press).
[0147] The compositions of the disclosure are prepared using techniques and methods known to those skilled in the art. Some methods commonly used in the art are described in REMINGTON'S PHARMACEUTICAL SCIENCES (Mack Publishing Company).
[0148] In one embodiment, the disclosure is directed to a solid oral dosage form such as a tablet or capsule comprising a therapeutically effective amount of a compound of general formula (I), or a pharmaceutically acceptable salt of the foregoing, and a diluent or filler.
Suitable diluents and fillers include lactose, sucrose, dextrose, mannitol, sorbitol, starch (e.g., corn starch, potato starch, and pre-gelatinized starch), cellulose and its derivatives, (e.g., microcrystalline cellulose), calcium sulfate, and dibasic calcium phosphate. The solid oral dosage form may further comprise a binder. Suitable binders include starch (e.g., corn starch, potato starch, and pre-gelatinized starch) gelatin, acacia, sodium alginate, alginic acid, tragacanth, guar gum, povidone, and cellulose and its derivatives (e.g., microcrystalline cellulose). The solid oral dosage form may further comprise a disintegrant. Suitable disintegrants include crospovidone, sodium starch glycolate, croscarmelose, alginic acid, and sodium carboxymethyl cellulose. The solid oral dosage form may further comprise a lubricant. Suitable lubricants include stearic acid, magnesium stearate, calcium stearate, and talc.
[0149] Where appropriate, dosage unit formulations for oral administration can be microencapsulated. The composition can also be prepared to prolong or sustain the release as, for example, by coating or embedding particulate material in polymers, wax, or the like.
[0150] The compounds disclosed herein may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyrancopolymer, polyhydroxypropylmethacrylamidephenol, polyhydroxyethylaspartamidephenol, or
polyethyleneoxidepolylysine substituted with palmitoyl residues. Furthermore, the compounds of the disclosure may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example polylactic acid, polepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanacrylates, and cross- linked or amphipathic block copolymers of hydrogels. [0151] In one embodiment, the disclosure is directed to a liquid oral dosage form. Oral liquids such as solutions, syrups, and elixirs can be prepared in dosage unit form so that a given quantity contains a predetermined amount of a compound or a pharmaceutically acceptable salt thereof disclosed herein. Syrups can be prepared by dissolving the compound of the disclosure in a suitably flavored aqueous solution; elixirs are prepared through the use of a non-toxic alcoholic vehicle. Suspensions can be formulated by dispersing a compound disclosed herein in a non- toxic vehicle. Solubilizers and emulsifiers such as ethoxylated isostearyl alcohols and polyoxy ethylene sorbitol ethers, preservatives, flavor additives such as peppermint oil, or other natural sweeteners or saccharin or other artificial sweeteners and the like can also be added.
[0152] In one embodiment, the disclosure is directed to compositions for parenteral administration. Compositions adapted for parenteral administration include aqueous and non- aqueous sterile injection solutions that may contain anti-oxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions that may include suspending agents and thickening agents. The compositions may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules, and tablets. [0153] Combinations
[0154] The compounds of general formula (I), and/or pharmaceutically acceptable salts of the foregoing, may be administered in combination with one or more additional active agents. In embodiments, one or more compounds of general formula (I), or one or more pharmaceutically acceptable salts of the foregoing, and the one or more additional active agents may be co- administered. The additional active agent(s) may be administered in a single dosage form with the compound of general formula (I), or pharmaceutically acceptable salt of the foregoing, or the additional active agent(s) may be administered in separate dosage form(s) from the dosage form containing the compound of general formula (I), or pharmaceutically acceptable salt of the foregoing. The additional active agent(s) may be one or more agents selected from the group consisting of STING agonist compounds, anti-viral compounds, antigens, adjuvants, anti-cancer agents, CTLA-4, LAG-3, and PD-1 pathway antagonists, lipids, liposomes, peptides, cytotoxic agents, chemotherapeutic agents, immunomodulatory cell lines, checkpoint inhibitors, vascular endothelial growth factor (VEGF) receptor inhibitors, topoisomerase II inhibitors, smoothen inhibitors, alkylating agents, anti-tumor antibiotics, anti-metabolites, retinoids, and
immunomodulatory agents including but not limited to anti-cancer vaccines. It will be understood the descriptions of the above additional active agents may be overlapping. It will also be understood that the treatment combinations are subject to optimization, and it is understood that the best combination to use of the compounds of general formula (I), or pharmaceutically acceptable salts of the foregoing, and one or more additional active agents will be determined based on the individual patient needs.
[0155] A compound disclosed herein may be used in combination with one or more other active agents, including but not limited to, other anti-cancer agents that are used in the prevention, treatment, control, amelioration, or reduction of risk of a particular disease or condition (e.g., cell proliferation disorders). In one embodiment, a compound disclosed herein is combined with one or more other anti-cancer agents for use in the prevention, treatment, control amelioration, or reduction of risk of a particular disease or condition for which the compounds disclosed herein are useful. Such other active agents may be administered, by a route and in an amount commonly used therefor, contemporaneously or sequentially with a compound of the present disclosure.
[0156] When a compound disclosed herein is used contemporaneously with one or more other active agents, a composition containing such other active agents in addition to the compound disclosed herein is contemplated. Accordingly, the compositions of the present disclosure include those that also contain one or more other active ingredients, in addition to a compound disclosed herein. A compound disclosed herein may be administered either simultaneously with, or before or after, one or more other active agent(s). A compound disclosed herein may be administered separately, by the same or different route of administration, or together in the same pharmaceutical composition as the other agent(s).
[0157] Products provided as combinations may include a composition comprising a compound of general formula (I), or a pharmaceutically acceptable salt of the foregoing, and one or more other active agent(s) together in the same pharmaceutical composition, or may include a composition comprising a compound of general formula (I), or a pharmaceutically acceptable salt of the foregoing, and a composition comprising one or more other active agent(s) in separate form, e.g. in the form of a kit or in any form designed to enable separate administration either concurrently or on separate dosing schedules.
[0158] The weight ratio of a compound of general formula (I), or a pharmaceutically acceptable salt of the foregoing, to a second active agent may be varied and will depend upon the therapeutically effective dose of each agent. Generally, a therapeutically effective dose of each will be used. Combinations of a compound disclosed herein and other active agents will generally also be within the aforementioned range, but in each case, a therapeutically effective dose of each active agent should be used. In such combinations, the compound disclosed herein and other active agents may be administered separately or in conjunction. In addition, the administration of one element may be prior to, concurrent to, or subsequent to the administration of other agent(s).
[0159] In one embodiment, this disclosure provides a composition comprising a compound of general formula (I), or a pharmaceutically acceptable salt thereof, and at least one other active agent as a combined preparation for simultaneous, separate or sequential use in therapy. In one embodiment, the therapy is the treatment of a cell proliferation disorder, such as cancer.
[0160] In one embodiment, the disclosure provides a kit comprising two or more separate pharmaceutical compositions, at least one of which contains a compound of general formula (I), or a pharmaceutically acceptable salt of the foregoing. In one embodiment, the kit comprises means for separately retaining said compositions, such as a container, divided bottle, or divided foil packet. An example of such a kit is a blister pack, as typically used for the packaging of tablets, capsules, and the like.
[0161] A kit of this disclosure may be used for administration of different dosage forms, for example, oral and parenteral, for administration of the separate compositions at different dosage intervals, or for titration of the separate compositions against one another. To assist with compliance, a kit of the disclosure typically comprises directions for administration.
[0162] Disclosed herein is a use of a compound of general formula (I), or a
pharmaceutically acceptable salt of the foregoing, for treating a cell proliferation disorder, where the medicament is prepared for administration with another active agent. The disclosure also provides the use of another active agent for treating a cell proliferation disorder, where the medicament is administered with a compound of general formula (I), or a pharmaceutically acceptable salt of the foregoing. [0163] The disclosure also provides the use of a compound of general formula (I), or a pharmaceutically acceptable salt of the foregoing, for treating a cell proliferation disorder, where the patient has previously (e.g., within 24 hours) been treated with another active agent. The disclosure also provides the use of another active agent for treating a cell proliferation disorder, where the patient has previously (e.g., within 24 hours) been treated with a compound of general formula (I), or a pharmaceutically acceptable salt of the foregoing. The second agent may be administered a week, several weeks, a month, or several months after the administration of a compound disclosed herein.
[0164] STING agonist compounds that may be used in combination with the compounds of general formula (I), or pharmaceutically acceptable salts of the foregoing, disclosed herein include but are not limited to cyclic di-nucleotide compounds.
[0165] Anti-viral compounds that may be used in combination with the compounds of general formula (I), or pharmaceutically acceptable salts of the foregoing, disclosed herein include hepatitis B virus (HBV) inhibitors, hepatitis C virus (HCV) protease inhibitors, HCV polymerase inhibitors, HCV NS4A inhibitors, HCV NS5A inhibitors, HCV NS5b inhibitors, and human immunodeficiency virus (HIV) inhibitors.
[0166] Antigens and adjuvants that may be used in combination with the compounds of general formula (I), or the pharmaceutically acceptable salts of the foregoing, include B7 costimulatory molecule, interleukin-2, interferon-y, GM-CSF, CTLA-4 antagonists, OX-40/0X- 40 ligand, CD40/CD40 ligand, sargramostim, levamisol, vaccinia virus, Bacille Calmette-Guerin (BCG), liposomes, alum, Freund's complete or incomplete adjuvant, detoxified endotoxins, mineral oils, surface active substances such as lipolecithin, pluronic polyols, polyanions, peptides, and oil or hydrocarbon emulsions. Adjuvants, such as aluminum hydroxide or aluminum phosphate, can be added to increase the ability of the vaccine to trigger, enhance, or prolong an immune response. Additional materials, such as cytokines, chemokines, and bacterial nucleic acid sequences, like CpG, a toll-like receptor (TLR) 9 agonist as well as additional agonists for TLR 2, TLR 4, TLR 5, TLR 7, TLR 8, TLR9, including lipoprotein, LPS, monophosphoryllipid A, lipoteichoic acid, imiquimod, resiquimod, and in addition retinoic acid- inducible gene I (RIG-I) agonists such as poly I:C, used separately or in combination with the described compositions are also potential adjuvants.
[0167] CLTA-4 and PD-1 pathways are important negative regulators of immune response. Activated T-cells up-regulate CTLA-4, which binds on antigen-presenting cells and inhibits T- cell stimulation, IL-2 gene expression, and T-cell proliferation; these anti-tumor effects have been observed in mouse models of colon carcinoma, metastatic prostate cancer, and metastatic melanoma. PD-1 binds to active T-cells and suppresses T-cell activation; PD-1 antagonists have demonstrated anti-tumor effects as well. CTLA-4 and PD-1 pathway antagonists that may be used in combination with the compounds of general formula (Ia), the compounds of general formula (Ib), the compounds of general formula (I), or the pharmaceutically acceptable salts of the foregoing, disclosed herein, include ipilimumab, tremelimumab, nivolumab, pembrolizumab, CT-011, AMP-224, and MDX-1106.
[0168] “PD-1 antagonist” or“PD-1 pathway antagonist” means any chemical compound or biological molecule that blocks binding of PD-L1 expressed on a cancer cell to PD-1 expressed on an immune cell (T-cell, B-cell, or NKT-cell) and preferably also blocks binding of PD-L2 expressed on a cancer cell to the immune-cell expressed PD-1. Alternative names or synonyms for PD-1 and its ligands include: PDCD1, PD1, CD279, and SLEB2 for PD-1; PDCD1L1, PDL1, B7H1, B7-4, CD274, and B7-H for PD-L1; and PDCD1L2, PDL2, B7-DC, Btdc, and CD273 for PD-L2. In any of the treatment method, medicaments and uses of the present disclosure in which a human individual is being treated, the PD-1 antagonist blocks binding of human PD-L1 to human PD-1, and preferably blocks binding of both human PD-L1 and PD-L2 to human PD-1. Human PD-1 amino acid sequences can be found in NCBI Locus No.: NP_005009. Human PD- L1 and PD-L2 amino acid sequences can be found in NCBI Locus No.: NP_054862 and
NP_079515, respectively.
[0169] PD-1 antagonists useful in any of the treatment method, medicaments and uses of the present disclosure include a monoclonal antibody (mAb), or antigen binding fragment thereof, which specifically binds to PD-1 or PD-L1, and preferably specifically binds to human PD-1 or human PD-L1. The mAb may be a human antibody, a humanized antibody, or a chimeric antibody and may include a human constant region. In some embodiments, the human constant region is selected from the group consisting of IgG1, IgG2, IgG3, and IgG4 constant regions, and in preferred embodiments, the human constant region is an IgG1 or IgG4 constant region. In some embodiments, the antigen binding fragment is selected from the group consisting of Fab, Fab'-SH, F(ab')2, scFv, and Fv fragments.
[0170] Examples of mAbs that bind to human PD-1, and useful in the treatment method, medicaments and uses of the present disclosure, are described in U.S. Patent Nos. US7488802, US7521051, US8008449, US8354509, and US8168757, PCT International Patent Application Publication Nos. WO2004/004771, WO2004/072286, and WO2004/056875, and U.S. Patent Application Publication No. US2011/0271358.
[0171] Examples of mAbs that bind to human PD-L1, and useful in the treatment method, medicaments and uses of the present disclosure, are described in PCT International Patent Application Nos. WO2013/019906 and WO2010/077634 A1 and in U.S. Patent No. US8383796. Specific anti-human PD-L1 mAbs useful as the PD-1 antagonist in the treatment method, medicaments and uses of the present disclosure include MPDL3280A, BMS-936559,
MEDI4736, MSB0010718C, and an antibody that comprises the heavy chain and light chain variable regions of SEQ ID NO:24 and SEQ ID NO:21, respectively, of WO2013/019906.
[0172] Other PD-1 antagonists useful in any of the treatment method, medicaments, and uses of the present disclosure include an immune-adhesion that specifically binds to PD-1 or PD- L1, and preferably specifically binds to human PD-1 or human PD-L1, e.g., a fusion protein containing the extracellular or PD-1 binding portion of PD-L1 or PD-L2 fused to a constant region such as an Fc region of an immunoglobulin molecule. Examples of immune-adhesion molecules that specifically bind to PD-1 are described in PCT International Patent Application Publication Nos. WO2010/027827 and WO2011/066342. Specific fusion proteins useful as the PD-1 antagonist in the treatment method, medicaments, and uses of the present disclosure include AMP-224 (also known as B7-DCIg), which is a PD-L2-FC fusion protein and binds to human PD-1.
[0173] Examples of cytotoxic agents that may be used in combination with the compounds of general formula (I) or pharmaceutically acceptable salts thereof, include, but are not limited to, arsenic trioxide (sold under the tradename TRISENOX®), asparaginase (also known as L- asparaginase, and Erwinia L-asparaginase, sold under the tradenames ELSPAR® and
KIDROLASE®).
[0174] Chemotherapeutic agents that may be used in combination with the compounds of general formula (I), or pharmaceutically acceptable salts of the foregoing, disclosed herein include abiraterone acetate, altretamine, anhydrovinblastine, auristatin, bexarotene, bicalutamide, BMS 184476, 2,3,4,5,6-pentafluoro-N-(3-fluoro-4-methoxyphenyl)benzene sulfonamide, bleomycin, N,N-dimethyl-L-valyl-L-valyl-N-methyl-L-valyl-L-prolyl- 1-Lproline-t-butylamide, cachectin, cemadotin, chlorambucil, cyclophosphamide, 3',4'-didehydro-4'deoxy-8'-norvin- caleukoblastine, docetaxol, doxetaxel, cyclophosphamide, carboplatin, carmustine, cisplatin, cryptophycin, cyclophosphamide, cytarabine, dacarbazine (DTIC), dactinomycin, daunorubicin, decitabine dolastatin, doxorubicin (adriamycin), etoposide, 5-fluorouracil, finasteride, flutamide, hydroxyurea and hydroxyurea andtaxanes, ifosfamide, liarozole, lonidamine, lomustine (CCNU), MDV3100, mechlorethamine (nitrogen mustard), melphalan, mivobulin isethionate, rhizoxin, sertenef, streptozocin, mitomycin, methotrexate, taxanes, nilutamide, nivolumab, onapristone, paclitaxel, pembrolizumab, prednimustine, procarbazine, RPR109881, stramustine phosphate, tamoxifen, tasonermin, taxol, tretinoin, vinblastine, vincristine, vindesine sulfate, and vinflunine.
[0175] Examples of vascular endothelial growth factor (VEGF) receptor inhibitors include, but are not limited to, bevacizumab (sold under the trademark AVASTIN by Genentech/Roche), axitinib (described in PCT International Patent Publication No. WO01/002369), Brivanib Alaninate ((S)-((R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1- f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate, also known as BMS-582664), motesanib (N-(2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-[(4-pyridinylmethyl)amino]-3- pyridinecarboxamide. and described in PCT International Patent Application Publication No. WO02/068470), pasireotide (also known as SO 230, and described in PCT International Patent Publication No. WO02/010192), and sorafenib (sold under the tradename NEXAVAR).
[0176] Examples of topoisomerase II inhibitors, include but are not limited to, etoposide (also known as VP-16 and Etoposide phosphate, sold under the tradenames TOPOSAR,
VEPESID, and ETOPOPHOS), and teniposide (also known as VM-26, sold under the tradename VUMON).
[0177] Examples of alkylating agents, include but are not limited to, 5-azacytidine (sold under the trade name VIDAZA), decitabine (sold under the trade name of DECOGEN), temozolomide (sold under the trade names TEMODAR and TEMODAL by Schering- Plough/Merck), dactinomycin (also known as actinomycin-D and sold under the tradename COSMEGEN), melphalan (also known as L-PAM, L-sarcolysin, and phenylalanine mustard, sold under the tradename ALKERAN), altretamine (also known as hexamethylmelamine (HMM), sold under the tradename HEXALEN), carmustine (sold under the tradename BCNU), bendamustine (sold under the tradename TREANDA), busulfan (sold under the tradenames BUSULFEX® and MYLERAN®), carboplatin (sold under the tradename PARAPLATIN®), lomustine (also known as CCNU, sold under the tradename CEENU®), cisplatin (also known as CDDP, sold under the tradenames PLATINOL® and PLATINOL®-AQ), chlorambucil (sold under the tradename LEUKERAN®), cyclophosphamide (sold under the tradenames CYTOXAN® and NEOSAR®), dacarbazine (also known as DTIC, DIC and imidazole carboxamide, sold under the tradename DTIC-DOME®), altretamine (also known as hexamethylmelamine (HMM) sold under the tradename HEXALEN®), ifosfamide (sold under the tradename IFEX®), procarbazine (sold under the tradename MATULANE®), mechlorethamine (also known as nitrogen mustard, mustine and mechloroethamine hydrochloride, sold under the tradename MUSTARGEN®), streptozocin (sold under the tradename ZANOSAR®), thiotepa (also known as thiophosphoamide, TESPA and TSPA, and sold under the tradename THIOPLEX®.
[0178] Examples of anti-tumor antibiotics include, but are not limited to, doxorubicin (sold under the tradenames ADRIAMYCIN® and RUBEX®), bleomycin (sold under the tradename LENOXANE®), daunorubicin (also known as dauorubicin hydrochloride, daunomycin, and rubidomycin hydrochloride, sold under the tradename CERUBIDINE®), daunorubicin liposomal (daunorubicin citrate liposome, sold under the tradename DAUNOXOME®), mitoxantrone (also known as DHAD, sold under the tradename NOVANTRONE®), epirubicin (sold under the tradename ELLENCE™), idarubicin (sold under the tradenames IDAMYCIN®, IDAMYCIN PFS®), and mitomycin C (sold under the tradename MUTAMYCIN®).
[0179] Examples of anti-metabolites include, but are not limited to, claribine (2- chlorodeoxyadenosine, sold under the tradename LEUSTATIN®), 5-fluorouracil (sold under the tradename ADRUCIL®), 6-thioguanine (sold under the tradename PURINETHOL®), pemetrexed (sold under the tradename ALIMTA®), cytarabine (also known as arabinosylcytosine (Ara-C), sold under the tradename CYTOSAR-U®), cytarabine liposomal (also known as Liposomal Ara-C, sold under the tradename DEPOCYT™), decitabine (sold under the tradename DACOGEN®), hydroxyurea and (sold under the tradenames HYDREA®, DROXIA™ and MYLOCEL™), fludarabine (sold under the tradename FLUDARA®), floxuridine (sold under the tradename FUDR®), cladribine (also known as 2-chlorodeoxyadenosine (2-CdA) sold under the tradename LEUSTATIN™), methotrexate (also known as amethopterin, methotrexate sodium (MTX), sold under the tradenames RHEUMATREX® and TREXALL™), and pentostatin (sold under the tradename NIPENT®).
[0180] Examples of retinoids include, but are not limited to, alitretinoin (sold under the tradename PANRETIN®), tretinoin (all-trans retinoic acid, also known as ATRA, sold under the tradename VESANOID®), Isotretinoin (13-c/s-retinoic acid, sold under the tradenames
ACCUTANE®, AMNESTEEM®, CLARAVIS®, CLARUS®, DECUTAN®, ISOTANE®, IZOTECH®,
ORATANE®, ISOTRET®, and SOTRET®), and bexarotene (sold under the tradename TARGRETIN®). [0181] Activity: STING Biochemical [3H]cGAMP Competition Assay
[0182] The individual compounds described in the Examples herein are defined as STING agonists by (i) binding to the STING protein as evidenced by a reduction in binding of tritiated cGAMP ligand to the STING protein by at least 20% at 20uM (concentration of compound being tested) in a STING Biochemical [3H]cGAMP Competition Assay and (ii) demonstrating interferon production with a 6% or greater induction of IFN-β secretion at 30uM in the THP1 cell assay (where induction caused by cGAMP at 30uM was set at 100%).
[0183] The ability of compounds to bind STING is quantified by the ability to compete with tritiated cGAMP ligand for human STING receptor membrane using a radioactive filter- binding assay. The binding assay employs STING receptor obtained from Hi-Five cell membranes overexpressing full-length HAQ STING prepared in-house and tritiated cGAMP ligand also purified in-house.
[0184] The following experimental procedures detail the preparation of specific examples of the instant disclosure. The compounds of the examples are drawn in their neutral forms in the procedures and tables below. In some cases, the compounds were isolated as salts depending on the method used for their final purification and/or intrinsic molecular properties. The examples are for illustrative purposes only and are not intended to limit the scope of the instant disclosure in any way. [0185] ABBREVIATIONS
ABz 6-N-benzoyladenine
AcOH Acetic acid
AIBN Azobisisobutyronitrile, 2,2’-azobis(2-methylpropionitrile) AMPDA Adenosine monophosphate deaminase
atm Atmosphere, a unit of pressure defined as 101325Pa (1.01325 bar) BCl3 Boron trichloride
BF3-OEt2, BF3-Et2O Boron trifluoride diethyl etherate
BrCH2CHO Bromoacetaldehyde
BSA Trimethylsilyl N-(trimethylsilyl)acetimidate
Bz Benzoyl
BzCl Benzoyl chloride
CD3OD Deuterium-enriched methyl alcohol, deuterium-enriched methanol Ci Curie, a non-standard unit of radioactivity; 1Ci=3.7×1010Bq, where
Bq is Becquerel, the SI unit of radioactivity, equivalent to 1 disintegration per second (dps)
ClCH2CHO Chloroacetaldehyde
d Doublet
D2O Deuterium-enriched water
DCA Dichloroacetic acid
DCE Dichloroethane
DCM, CH2Cl2 Dichloromethane
ddd Doublet of doublet of doublet
ddt Doublet of doublet of triplet
DDTT (E)-N,N-dimethyl-N'-(3-thioxo-3H-1,2,4-dithiazol-5- yl)formimidamide, N’-(3-thioxo-3H-1,2,4-dithiazol-5-yl)-N,N- dimethylmethanimidamide
DEAD Diethyl azodicarboxylate
DIEA N-ethyl-N-isopropylpropan-2-amine
DIEA HCl N-ethyl-N-isopropylpropan-2-amine hydrochloride
DiPEA N,N-Diisopropylethylamine
DiPEA-HCl 2-chloro-N,N-diisopropylethylamine hydrochloride
DMA N,N-dimethylacetamide
DMAP Dimethylaminopyridine
DMF N,N-dimethylformamide
DMF-DMA N,N-Dimethylformamide dimethyl acetal
DMOCP 2-chloro-5,5-dimethyl-1,3,2-dioxaphosphineane 2-oxide
DMTr 4,4’-dimethoxytrityl
DMTrCl 4,4'-(chloro(phenyl)methylene)bis(methoxybenzene),
4,4’-dimethoxytrityl chloride
dq Doublet of quartet
EC50 half maximal effective concentration, concentration of a drug, antibody or toxicant that induces a response halfway between the baseline and maximum after a specified exposure time
eq Equivalents ES Electron spray
Et2O Diethyl ether
EtOAc Ethyl acetate
EtOH Ethyl alcohol, ethanol
g Gram
h Hour
H2 Hydrogen (gas)
HEPES 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid, a zwitterionic organic chemical buffering agent
hept Heptet
Hex Hexanes
HPLC High performance liquid chromatography
Hz Hertz
i-PrMgCl Isopropylmagnesium chloride
i-PrMgCl-LiCl Isopropylmagnesium chloride– lithium chloride i-PrOH Isopropanol, isopropyl alcohol
K2CO3 Potassium carbonate
LCMS Liquid chromatography–mass spectroscopy
m Multiplet
M Molar, moles per liter
m/e Mass/charge
mCi Millicurie
Me Methyl
MeCN, ACN Acetonitrile
MeCOOH, CH3COOH Acetic acid
MeMgBr, CH3MgBr Methylmagnesium bromide
MeNH2, CH3NH2 Methylamine
MeOH, CH3OH Methyl alcohol, methanol
MgCl2 Magnesium chloride
MgSO4 Magnesium sulfate
MOI Multiplicity of infection
MPLC Medium pressue liquid chromatography MTBE Methyl t-butyl ether, methyl tertiary butyl ether Na2CO3 Sodium carbonate
Na2SO4 Sodium sulfate
NaH Sodium hydride
NaHCO3 Sodium bicarbonate
NaHSO3 Sodium bisulfite
NaOMe Sodium methoxide
nBu3SnH Tri-n-butyltin hydride, tributyl stannane NH4HCO3 Ammonium bicarbonate
NH4OAc Ammonium acetate
NMP N-methyl-2-pyrrolidone
P2O5 Phosphorus pentoxide
Pd(OH)2/C Palladium hydroxide on carbon
Pd/C Palladium on charcoal
PPh3 Triphenylphosphine
Py Pyridine
q Quartet
RPM, rpm Revolutions per minute
RT, rt Room temperature, approximately 25°C s Singlet
sat Saturated
SnCl4 Tin(IV) chloride
t Triplet
TBAF, Bu4NF, Tetra-n-butylammonium fluoride
(CH3CH2CH2CH2)4NF
TBDPSCl tert-Butylchlorodiphenylsilane
TBS t-Butyldimethylsilyl
TBSCl t-Butyldimethylsilyl chloride
t-BuNH2 tert-Butylamine
t-BuO2H tert-Butyl peroxide
TEA, Et3N Triethylamine
TEA·3HF, Et3N·3HF Triethylamine trihydrofluoride TEA·HF Triethylamine hydrofluoride
TEAA Triethylammonium acetate
TES, Et3SiH Triethylsilane
TFA Trifluoroacetic acid
TFA·Py Pyridine 2,2,2-trifluoroacetate
THF Tetrahydrofuran
TIPSOTf Triisopropylsilyl trifluoromethanesulfonate
TLC Thin layer chromatography
TMA Trimethylamine
TMSCl Trimethylsilyl chloride
(TMS)3SiH Tris(trimethylsilyl)silane
TR Retention time
TrisCl Tris(hydroxymethyl)aminomethane hydrochloride
v/v Volume/volume
λem Emission wavelength
λex Excitation wavelength [0186] PREPARATIONS
[0187] The following experimental procedures detail the preparation of specific examples of the instant disclosure. The compounds of the examples are drawn in their neutral forms in the procedures and tables below. In some cases, the compounds were isolated as salts depending on the method used for their final purification and/or intrinsic molecular properties. The examples are for illustrative purposes only and are not intended to limit the scope of the instant disclosure in any way. [0188] Preparation 1: 8-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl)imidazo[1,2-a]pyrimidin-5(8H)-one
Figure imgf000075_0001
[0189] Step 1: (3aR,4R,12R,12aR)-2,2,2-triphenyl-3a,4,12,12a-tetrahydro-5H,8H-2l5- 4,12-epoxy[1,3,2]dioxaphospholo[4,5-e]pyrimido[2,1-b][1,3]oxazocin-8-one
Figure imgf000076_0001
[0190] To a stirred solution of uridine (50g, 205mmol) in THF (500mL) was added PPh3 (161g, 614mmol). DEAD (107g, 614mmol) was added to the mixture dropwise. The reaction mixture was left to stir for 12h and filtered. The product was recrystallized from DMF (2L) at 80°C.1H-NMR (400MHz, DMSO-d6): δ 8.05 (br d, J=7.5Hz, 1H), 7.67-7.51 (m, 2H), 7.47-7.17 (m, 15H), 5.96-5.85 (m, 2H), 4.84 (br dd, J=6.6, 13.2Hz, 1H), 4.73 (s, 1H), 4.60-4.46 (m, 2H), 4.16 (br d, J=12.7Hz, 1H).
[0191] Step 2: (6R,7R,8S,9R)-7,8-dihydroxy-7,8,9,10-tetrahydro-2H,6H-6,9- epoxypyrimido[2,1-b][1,3]oxazocin-2-one
Figure imgf000076_0002
[0192] A mixture of (3aR,4R,12R,12aR)-2,2,2-triphenyl-3a,4,12,12a-tetrahydro-5H,8H- 2l5-4,12-epoxy[1,3,2]dioxaphospholo[4,5-e]pyrimido[2,1-b][1,3]oxazocin-8-one (50g,
103mmol) in THF (500mL) and H2O (500mL) was heated to 60°C for 12h. The mixture was cooled to RT and concentrated. To the residue was added acetone (200mL). The mixture was allowed to stir for 10min, filtered, and washed with acetone. The filter cake was dried in vacuo to give the product.1H-NMR (400MHz, DMSO-d6): δ 8.02 (br d, J=7.0Hz, 1H), 5.93 (br d, J=7.0Hz, 1H), 5.58 (s, 1H), 5.42 (br s, 2H), 4.57-4.43 (m, 2H), 4.43-4.26 (m, 2H), 4.10 (br d, J=12.7Hz, 1H).
[0193] Step 3: 2-amino-1-(β-D-ribofuranosyl)pyrimidin-4(1H)-one
Figure imgf000076_0003
[0194] A mixture of (6R,7R,8S,9R)-7,8-dihydroxy-7,8,9,10-tetrahydro-2H,6H-6,9- epoxypyrimido[2,1-b][1,3]oxazocin-2-one (5.0g, 22mmol) in sat NH3 in MeOH (60mL) in autoclave was heated to 60°C for 12h. The mixture was cooled to RT and concentrated to give the product. LCMS (ES, m/z): 244 [M+H]+.1H-NMR (400MHz, DMSO-d6): δ 7.62 (br d, J=7.1Hz, 1H), 6.95 (br s, 2H), 5.58 (br d, J=7.5Hz, 1H), 5.54-5.37 (m, 2H), 5.37-5.16 (m, 2H), 4.12 (br s, 2H), 4.04-3.89 (m, 2H), 3.60 (br s, 2H), 3.17 (br s, 3H).
[0195] Step 4: 8-(β-D-ribofuranosyl)-8,8a-dihydroimidazo[1,2-a]pyrimidin-5(1H)-one
Figure imgf000077_0001
[0196] To a stirred solution of 2-amino-1-(β-D-ribofuranosyl)pyrimidin-4(1H)-one (8.0g, 33mmol) in DMF (80mL) were added K2CO3 (13.6g, 99mmol) and BrCH2CHO (32g,
260mmol). The reaction mixture was heated to 40°C for 4h, cooled to RT, and filtered. The filtrate was purified by reverse phase chromatography eluted with 1-25% ACN in aq NH4OH (0.05% v/v) to give the product. LCMS (ES, m/z): 268 [M+H]+.1H-NMR (400MHz, DMSO-d6): δ 8.19 (br d, J=7.5Hz, 1H), 7.65 (br s, 1H), 7.26 (br s, 1H), 6.10 (br s, 1H), 6.02 (br d, J=7.5Hz, 1H), 4.59 (br s, 1H), 4.27 (br d, J=15.9Hz, 2H), 3.99-3.90 (m, 1H), 3.88-3.79 (m, 1H). [0197] Preparation 2: (2R,3R,4R,5R)-5-(hydroxymethyl)-2-(8-oxoimidazo[1,2- b]pyridazin-5(8H)-yl)-4-((triisopropylsilyl)oxy)tetrahydrofuran-3-yl hydrogen phosphonate
Figure imgf000077_0002
[0198] Step 1: 6-chloropyridazin-3-amine
Figure imgf000077_0003
[0199] A mixture of 3,6-dichloropyridazine (100g, 671mmol) and NH4OH (47g, 50%, 671mmol) was heated to 120°C for 16h, cooled to RT, and filtered to give the product.1H-NMR (400MHz, DMSO-d6): δ 7.35 (s, 1H), 6.84 (s, 1H), 6.63 (s, 2H).
[0200] Step 2: 4-bromo-6-chloropyridazin-3-amine
Figure imgf000077_0004
[0201] To a stirred solution of 6-chloropyridazin-3-amine (179g, 1.38mol) in MeOH (2L) was added NaHCO3 (232g, 2.76mol). Br2 (265g, 1.66mol) was added to the mixture dropwise. The reaction mixture was left to stir at RT for 16h and concentrated to give the crude product. The residue was used in the next step without further purification.
[0202] Step 3: 8-bromo-6-chloroimidazo[1,2-b]pyridazine
Figure imgf000078_0001
[0203] To the crude 4-bromo-6-chloropyridazin-3-amine (120g, 576mmol) was added EtOH (1.2L). ClCH2CHO (600g, 7.65mol) was added to the mixture over 30min. The reaction mixture was heated to 90°C for 3h, cooled to RT, and concentrated. The residue was purified by silica gel column chromatography eluted with 9-50% EtOAc in petroleum ether to give the product.1H-NMR (400MHz, DMSO-d6): δ 8.01 (s, 1H), 7.68 (brs, 1H), 6.03 (s, 1H).
[0204] Step 4: 6-chloroimidazo[1,2-b]pyridazin-8(5H)-one
Figure imgf000078_0002
[0205] To 8-bromo-6-chloroimidazo[1,2-b]pyridazine (70g, 301mmol) were added H2O (700mL) and NaOH (26g, 647mmol). The reaction mixture was heated to 100°C for 16h, cooled to RT, and neutralized to pH 6-7 with HCl. The product was collected by filtration.
[0206] Step 5: imidazo[1,2-b]pyridazin-8(5H)-one
Figure imgf000078_0003
[0207] A flask containing 6-chloroimidazo[1,2-b]pyridazin-8(5H)-one (36g, 212mmol) and Pd/C (13g) in MeOH was degassed and purged with H2 for three times. The reaction mixture was left to stir under H2 (50psi) at 40°C for 16h, cooled to RT, and filtered. The filtrate was concentrated to give the product.1H-NMR (400MHz, DMSO-d6): δ 8.60 (d, 1H), 8.57 (d, 1H), 8.23 (d, 1H), 7.17 (d, 1H).
[0208] Step 6: 5-[2,3,5-tris-O-(phenylcarbonyl)-β-D-ribofuranosyl]imidazo[1,2- b]pyridazin-8(5H)-one
Figure imgf000078_0004
[0209] A mixture of imidazo[1,2-b]pyridazin-8(5H)-one (18g, 133mmol) and N,O- bis(trimethylsilyl)acetamide (108g, 532mmol) in MeCN (200mL) was heated to 70°C for 1h and cooled to RT. To the mixture were added 1-O-acetyl-2,3,5-tri-O-benzoyl-D-ribofuranose (45g, 89mmol), CH3CN (200mL), and SnCl4 (45.7g, 175mmol). The mixture was heated to 70°C for 3h, cooled to RT, and concentrated. The residue was purified by silica gel column
chromatography eluted with 9-100% of EtOAc in petroleum ether to give the product. LCMS (ES, m/z): 580 [M+H]+.1H-NMR (400MHz, DMSO-d6): δ 8.26 (s, 1H), 8.18 (s, 1H), 8.01-8.03 (d, J=8Hz, 3H), 7.92-7.94 (d, J=8Hz, 2H), 7.84–7.85 (d, J=4Hz, 2H), 7.74 (s, 1H), 7.60-7.65 (m, 3H), 7.40-7.52 (m, 2H), 6.01-6.07 (m, 3H), 4.81-4.88 (m, 3H).
[0210] Step 7: 5-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2- yl)imidazo[1,2-b]pyridazin-8(5H)-one
Figure imgf000079_0001
[0211] (2R,3R,4R,5R)-2-((benzoyloxy)methyl)-5-(8-oxoimidazo[1,2-b]pyridazin-5(8H)- yl)tetrahydrofuran-3,4-diyl dibenzoate (3.9g, 5.38mmol) was dissolved in a solution of MeNH2 in EtOH (30%, 60mL), and the resulting solution was stirred at RT for 6h. Then, the mixture was concentrated under reduced pressure, and the residue was purified by reverse phase (C18) chromatography eluted with 0 to 95% ACN in aq NH4HCO3 (0.04%) to give the product. LCMS (ES, m/z): 268.3 [M+H]+.1H-NMR (400MHz, DMSO-d6): δ 8.29 (d, J=2.3Hz, 1H), 8.21 (d, J=2.3Hz, 1H), 8.02 (d, J=6.4Hz, 1H), 7.14 (d, J=4.9Hz, 1H), 6.05 (d, J=6.4Hz, 1H), 5.61 (d, J=5.4Hz, 1H), 5.20 (t, J=5.1Hz, 1H), 5.15 (d, J=5.0Hz, 1H), 4.23 (q, J=5.0Hz, 1H), 4.11 (q, J=4.8Hz, 1H), 3.96 (q, J=3.6Hz, 1H), 3.73-3.68 (m, 1H), 3.63-3.58 (m, 1H).
[0212] Step 8: 5-((2R,3R,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-3,4- dihydroxytetrahydrofuran-2-yl)imidazo[1,2-b]pyridazin-8(5H)-one
Figure imgf000079_0002
[0213] To a solution of 5-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)
tetrahydrofuran-2-yl)imidazo[1,2-b]pyridazin-8(5H)-one (800mg, 2.99mmol) in Py (11mL) at 0°C was added 4,4'-(chloro(phenyl)methylene)bis (methoxybenzene) (0.112g, 3.29mmol). The mixture was stirred at RT for 2h. Then, the mixture was concentrated, and the residue was dissolved in CH2Cl2 (50mL). The solution was washed with sat aq NaHCO3 (10mL), dried (Na2SO4) and concentrated. It was purified by silica gel column chromatography eluted with 0- 10% MeOH in DCM (containing 1% Et3N) to give the product. LCMS (ES, m/z): 568.2 [M-H]-. 1H-NMR (400MHz, DMSO-d6): δ 8.17 (d, J=2.2Hz, 1H), 8.04 (d, J=6.4Hz, 1H), 7.99 (d, J=2.3Hz, 1H), 7.43-7.35 (m, 2H), 7.33-7.21 (m, 7H), 7.18 (d, J=4.0Hz, 1H), 6.93-6.84 (m, 4H), 6.08 (d, J=6.4Hz, 1H), 5.73 (d, J=5.3Hz, 1H), 5.20 (d, J=5.9Hz, 1H), 4.27 (q, J=4.9Hz, 1H), 4.16 (q, J=5.5Hz, 1H), 4.07 (dd, J=5.2, 3.5Hz, 1H), 3.73 (s, 6H), 3.26-3.24 (m, 2H).
[0214] Step 9: 5-((2R,3R,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-3- hydroxy-4-((triisopropylsilyl)oxy)tetrahydrofuran-2-yl)imidazo[1,2-b]pyridazin-8(5H)-one and 5-((2R,3R,4R,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxy-3- ((triisopropylsilyl)oxy)tetrahydrofuran-2-yl)imidazo[1,2-b]pyridazin-8(5H)-one
Figure imgf000080_0001
[0215] To a solution of 5-((2R,3R,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy) methyl)-3,4-dihydroxytetrahydrofuran-2-yl)imidazo[1,2-b]pyridazin-8(5H)-one (1.00g,
1.76mmol) in THF (17mL) was added (2S,4R)-2-methoxy-3-[(1S)-2-methyl-1-(1-methyl-1H- imidazol-2-yl)propyl]-4-(propan-2-yl)-1,3-oxazolidine (42mg, 0.15mmol), N-ethyl-N- isopropylpropan-2-aminium chloride (6.8mg, 0.053mmol), and N-ethyl-N-isopropylpropan-2- amine (682mg, 5.28mmol). The resulting mixture was stirred at RT for 5min and then, cooled to 0°C. To the reaction was added TIPSOTf (1.62g, 5.28mmol) over 2min. It was stirred at RT for 4h. Then, EtOAc (100mL) and H2O (50mL) were added. Layers were separated, and the aq layer was extracted with EtOAc (3×100mL). The combined organic layer was dried (Na2SO4), and concentrated to give a mixture containing the products. The crude was used for the next step without purification. LCMS (ES, m/z): 724.3 [M-H]-.
[0216] Step 10: (2R,3R,4R,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-2-(8- oxoimidazo[1,2-b]pyridazin-5(8H)-yl)-4-((triisopropylsilyl)oxy)tetrahydrofuran-3-yl hydrogen phosphonate
Figure imgf000080_0002
[0217] To a solution of the crude from Step 9 (3.5g, ~1.7mmol) in pyridine (9mL) at 0°C under Ar was added diphenyl phosphonate (2.06g, 8.80mmol) over 0.5min. The resulting mixture was warmed to RT for 20min. To the reaction mixture cooled at 0°C was added TEA (1.8mL) in H2O (1.8mL) dropwise over 0.5min. It was warmed to RT for 30min. The mixture was concentrated and then, co-evaporated with toluene (3×20mL) to give a crude. It was partitioned between CH2Cl2 (300mL) and aq NaHCO3 (5%, 80mL). The organic layer was washed with aq NaHCO3 (2×80mL), dried (Na2SO4) and concentrated. The residue was purified by reverse phase (C18) chromatography eluted with 35 to 55% ACN in aq NH4HCO3 (10mM) to give the product. LCMS (ES, m/z): 788.3 [M-H]-.1H-NMR (400MHz, DMSO-d6): δ 8.25 (d, J=2.2Hz, 1H), 8.09–8.00 (m, 1H), 7.98 (d, J=2.3Hz, 1H), 7.49-7.35 (m, 3H), 7.34-7.21 (m, 8H), 6.89 (d, J=8.6Hz, 4H), 6.16–6.06 (m, 1H), 4.71-4.54 (m, 2H), 4.48-4.29 (m, 1H), 3.75 (d, J=2.5Hz, 6H), 3.72-3.64 (m, 1H), 3.36 (d, J=14.6Hz, 5H), 3.00 (q, J=7.3Hz, 2H), 1.34-1.19 (m, 5H), 1.03-0.87 (m, 12H), 0.81 (d, J=6.7Hz, 8H).31P-NMR: (162MHz, DMSO-d6) δ 0.80 (s).
[0218] Step 11: (2R,3R,4R,5R)-5-(hydroxymethyl)-2-(8-oxoimidazo[1,2-b]pyridazin- 5(8H)-yl)-4-((triisopropylsilyl)oxy)tetrahydrofuran-3-yl hydrogen phosphonate
Figure imgf000081_0001
[0219] To a stirred solution of (2R,3R,4R,5R)-5-((bis(4-methoxyphenyl)(phenyl) methoxy)methyl)-2-(8-oxoimidazo[1,2-b]pyridazin-5(8H)-yl)-4-((triisopropylsilyl)oxy) tetrahydrofuran-3-yl hydrogen phosphonate (0.38g, 0.47mmol) in CH2Cl2 (6mL) was added H2O (85mg, 4.7mmol), and DCA in CH2Cl2 (6%, 6.0mL, 4.2mmol). The mixture was stirred at RT for 15min, and then Et3SiH (10mL) was added. After 40min, Py (0.66mL) was added to the reaction at 0°C, and the mixture was stirred for 5min. The reaction was concentrated to provide (2R,3R,4R,5R)-5-(hydroxymethyl)-2-(8-oxoimidazo[1,2-b]pyridazin-5(8H)-yl)-4-((triisopropyl- silyl)oxy)tetrahydrofuran-3-yl hydrogen phosphonate. LCMS (ES, m/z): 488.2 [M+H]+. [0220] Preparation 3: (2R,3S,4R,5R)-5-(6-benzamido-9H-purin-9-yl)-2-((bis(4- methoxyphenyl)(phenyl)methoxy)methyl)-4-((triisopropylsilyl)oxy)tetrahydrothiophen-3-yl (2-cyanoethyl) diisopropylphosphoramidite
Figure imgf000082_0001
[0221] Step 1: ((3aS,4R,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2-dimethyltetrahydrothieno [3,4-d][1,3]dioxol-4-yl)methanol
Figure imgf000082_0002
[0222] To a tube was added ((3aS,4R,6R,6aR)-6-(6-chloro-9H-purin-9-yl)-2,2- dimethyltetrahydrothieno[3,4-d][1,3]dioxol-4-yl)methanol (3.80g, 11.1mmol) in NH3 in i-PrOH (2.0M, 200mL). The tube was sealed, and the reaction was stirred at 90°C for 16h. The mixture was concentrated. The residue was purified by a silica gel column, eluted with 0-20% MeOH in DCM to give the product. LCMS (ES, m/z): 324.1 [M+H]+.1H-NMR (400MHz, DMSO-d6): δ 8.41 (s, 1H), 8.18 (s, 1H), 7.32 (s, 2H), 6.08 (d, J=2.5Hz, 1H), 5.43-5.29 (m, 2H), 5.05 (dd, J=5.5, 1.5Hz, 1H), 3.73-3.55 (m, 3H), 1.54 (s, 3H), 1.31 (s, 3H).
[0223] Step 2: N-(9-((3aR,4R,6R,6aS)-6-(hydroxymethyl)-2,2-dimethyltetrahydrothieno [3,4-d][1,3]dioxol-4-yl)-9H-purin-6-yl)benzamide
Figure imgf000082_0003
[0224] To a solution of ((3aS,4R,6R,6aR)-6-(6-amino-9H-purin-9-yl)-2,2- dimethyltetrahydrothieno[3,4-d][1,3]dioxol-4-yl)methanol (2.60g, 8.04mmol) in Py (30mL) at 0°C was added TMSCl (8.7g, 80mmol) dropwise. The mixture was warmed to RT and continued to stir for 2h. Then, BzCl (1.70g, 12.1mmol) was added, and the resulting mixture was stirred at RT for 2h. NH4OH (28%, 2mL) was added to the mixture, and it was stirred for 2h. Then, the reaction was concentrated under reduced pressure, and the residue was purified by a silica gel column chromatography eluted with 0-20% MeOH in DCM to give the product. LCMS (ES, m/z): 428.1 [M+H]+.1H-NMR (400MHz, DMSO-d6): δ 11.22 (s, 1H), 8.79 (s, 1H), 8.76 (s, 1H), 8.10-8.02 (m, 2H), 7.80-7.70 (m, 1H), 7.71-7.50 (m, 3H), 6.21 (d, J=2.2Hz, 1H), 5.46 (dd, J=5.5, 2.3Hz, 1H), 5.42-5.30 (m, 1H), 5.08 (dd, J=5.5, 1.4Hz, 1H), 3.74-3.58 (m, 2H), 1.57 (s, 3H), 1.33 (s, 3H).
[0225] Step 3: N-(9-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrothiophen- 2-yl)-9H-purin-6-yl)benzamide
Figure imgf000083_0001
[0226] To a solution N-(9-((3aR,4R,6R,6aS)-6-(hydroxymethyl)-2,2-dimethyltetra- hydrothieno[3,4-d][1,3]dioxol-4-yl)-9H-purin-6-yl)benzamide (2.7g, 6.3mmol) in H2O (75mL) at 0°C was added TFA (75mL). The solution was stirred at RT for 30min. The mixture was concentrated and the, co-evaporated with toluene (4×100mL). The residue was purified by a silica gel column eluted with 0-20% MeOH in DCM to give the product. LCMS (ES, m/z): 388.2 [M+H]+.1H-NMR (400MHz, DMSO-d6): δ 11.16 (br, s, 1H), 8.78 (s, 1H), 8.72 (s, 1H), 8.07- 7.97 (m, 2H), 7.68-7.46 (m, 3H), 5.97 (d, J=6.8Hz, 1H), 4.71 (dd, J=6.8, 3.4Hz, 1H), 4.21 (t, J=3.4Hz, 1H), 3.80 (dd, J=11.3, 6.9Hz, 1H), 3.62 (dd, J=11.4, 5.8Hz, 1H), 3.41-3.26 (m, 1H).
[0227] Step 4: N-(9-((2R,3R,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-3,4- dihydroxytetrahydrothiophen-2-yl)-9H-purin-6-yl)benzamide
Figure imgf000083_0002
[0228] To a solution of N-(9-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)
tetrahydrothiophen-2-yl)-9H-purin-6-yl)benzamide (2g, 5.16mmol) in pyridine (5mL) at 0°C was added 4,4'-(chloro(phenyl)methylene)bis(methoxybenzene) (1.92g, 5.68mmol). The solution was stirred at RT for 3h. Then, MeOH (3mL) was added, and it was concentrated. The residue was purified by a silica gel column chromatography eluted with 0-20% MeOH in DCM to give the product. LCMS (ES, m/z): 690.2 [M+H]+.1H-NMR (400MHz, DMSO-d6): δ 11.23 (br, s, 1H), 8.64 (s, 1H), 8.58 (s, 1H), 8.09-8.02 (m, 2H), 7.71-7.61 (m, 1H), 7.61-7.52 (m, 2H), 7.51- 7.38 (m, 2H), 7.38-7.22 (m, 7H), 6.97-6.82 (m, 4H), 5.99 (d, J=5.9Hz, 1H), 5.73 (d, J=5.6Hz, 1H), 5.43 (d, J=5.0Hz, 1H), 4.70 (q, J=4.9Hz, 1H), 4.28 (q, J=3.7Hz, 1H), 3.76-3.75 (m, 7H), 3.59-3.36 (m, 2H). [0229] Step 5: N-(9-((2R,3R,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4- hydroxy-3-((triisopropylsilyl)oxy)tetrahydrothiophen-2-yl)-9H-purin-6-yl)benzamide
Figure imgf000084_0001
[0230] N-(9-((2R,3R,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-3,4- dihydroxytetrahydrothiophen-2-yl)-9H-purin-6-yl)benzamide (1.23g, 1.78mmol), (2R,4S)-4- isopropyl-2-methoxy-3-((R)-2-methyl-1-(1-methyl-1H-imidazol-2-yl)propyl)oxazolidine (0.753g, 2.67mmol), and N-ethyl-N-isopropylpropan-2-aminium chloride (8.9mg, 0.053mmol) were co-evaporated with THF (3×10mL) and then re-dissolved in THF (80mL) under Ar. To the mixture at 0°C was added N-ethyl-N-isopropylpropan-2-amine (0.691g, 5.35mmol). It was stirred at RT for 5min, and then TIPSOTf (1.64g, 5.35mmol) was added dropwise. The mixture was stirred at RT for 16h. Then, the solution was diluted with EtOAc (50mL) and washed with Na2CO3 (3×50mL). The organic layer was dried (MgSO4) and concentrated to give a crude containing the product. The residue was used for the next reaction step without further purification. LCMS (ES, m/z): 846.3 [M+H]+.
[0231] Step 6: (2R,3S,4R,5R)-5-(6-benzamido-9H-purin-9-yl)-2-((bis(4- methoxyphenyl)(phenyl)methoxy)methyl)-4-((triisopropylsilyl)oxy)tetrahydrothiophen-3-yl (2- cyanoethyl) diisopropylphosphoramidite
Figure imgf000084_0002
[0232] To a stirred solution of 3-((bis(diisopropylamino)phosphino)oxy)propanenitrile (1.43g, 4.76mmol) in MeCN (15mL) under Ar was added pyridin-1-ium 2,2,2-trifluoroacetate (688mg, 3.57mmol) and a solution of the crude from Step 5 (~2.0g, 2.4mmol) in MeCN (15mL) over 2min. It was stirred at RT for 1h. Then, it was concentrated, and the residue was dissolved in EtOAc (100mL). The solution was washed with aq NaHCO3 (1%, 2×100mL), H2O (100mL) and brine (100mL), dried (Na2SO4), and purified by reverse phase (C18) chromatography eluted with 40 to 100% ACN in H2O to give the product. LCMS (ES, m/z): 1046.5 [M+H]+.1H-NMR (400MHz, DMSO-d6): δ 11.17 (s, 1H), 8.60 (d, J=1.5Hz, 1H), 8.50-8.43 (m, 1H), 8.09-7.99 (m, 2H), 7.72-7.62 (m, 1H), 7.57-7.54 (m, 2H), 7.47-7.44 (m, 2H), 7.40-7.23 (m, 7H), 6.95-6.92 (m, 4H), 6.05-5.97 (m, 1H), 5.30-5.26 (m, 1H), 4.71-4.67 (m, 1H), 3.94-3.82 (m, 2H), 3.76 (d, J=1.5Hz, 6H), 3.70 (t, J=3.6Hz, 1H), 3.61-3.58 (m, 1H), 3.50-3.38 (m, 1H), 2.77-2.67 (m, 2H), 2.53-2.49 (m, 2H), 1.18 (dt, J=18.4, 6.9Hz, 12H), 0.94-0.72 (m, 21H).31P-NMR (162MHz, DMSO-d6): δ 149.66, 149.23. [0233] Preparation 4: (2R,3S,5R)-5-(7-amino-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-2- (hydroxymethyl)tetrahydrofuran-3-ol
Figure imgf000085_0001
[0234] The title compound was prepared according to published procedure (Nucleoside & Nucleotides 1992, 11, 1059-1076). [0235] Preparation 5: 1-((3S,4R,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy) methyl)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)-1,5-dihydro-4H-imidazo[4,5-c]pyridin-4- one
Figure imgf000085_0002
[0236] Step 1: ((2R,3S,4S)-4-acetoxy-3-fluoro-5-(4-oxo-4,5-dihydro-1H-imidazo[4,5- c]pyridin-1-yl)tetrahydrofuran-2-yl)methyl benzoate
Figure imgf000085_0003
[0237] To a suspension of 4-(benzyloxy)-1H-imidazo[4,5-c]pyridine (0.795g, 3.53mmol) and (3S,4S,5R)-5-((benzoyloxy)methyl)-4-fluorotetrahydrofuran-2,3-diyl diacetate (1.00g, 2.94mmol) in MeCN (20mL) and DCE (10mL) at 0°C under Ar was added 3,4,6,7,8,9,10- octahydropyrimido[1,2-a]azepine (1.34g, 8.82mmol). The resulting mixture was stirred at 0°C for 30min. Then, TIPSOTf (3.92g, 17.7mmol) was added to the solution, and it was stirred at 0°C for 30min. Then, the solution was heated to 80°C for 16h. Then, the reaction mixture was cooled to 0°C, and sat aq NaHCO3 (10mL) and H2O (30mL) were added. Layers were separated, and the aq layer was extracted with EtOAc (3×50mL). The combined organic layers were washed with brine (100mL), dried (Na2SO4), and concentrated. The residue was purified by silica gel column chromatography, eluted with 1 to 10% MeOH in DCM to afford the product. LCMS (ES, m/z): 416.3 [M+H]+.
[0238] Step 2: 1-((3S,4R,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)- 1,5-dihydro-4H-imidazo[4,5-c]pyridin-4-one
Figure imgf000086_0001
[0239] To a stirred solution of ((2R,3S,4S)-4-acetoxy-3-fluoro-5-(4-oxo-4,5-dihydro-1H- imidazo[4,5-c]pyridin-1-yl)tetrahydrofuran-2-yl)methyl benzoate (2.5g, 5.3mmol) in MeOH (10mL) was added NaOMe (3.47g, 21.2mmol). The mixture was stirred at RT for 1h. Then, it was neutralized by addition of CH3COOH. The solution was concentrated under reduced pressure, and the residue was purified by reverse phase (AQ-C18) chromatography eluted with 0 to 30% ACN in aq NH4HCO3 (5mM) to give the product. LCMS (ES, m/z): 270.0 [M+H]+.1H- NMR (400MHz, DMSO-d6): δ 11.31 (s, 1H), 8.06 (s, 1H), 7.23 (d, J=7.1Hz, 1H), 6.62 (d, J=7.1Hz, 1H), 6.37 (d, J=2.9Hz, 1H), 5.85 (d, J=2.8Hz, 1H), 5.22–4.98 (m, 2H), 4.54 (d, J=17.7Hz, 1H), 4.28 (dtd, J=29.6, 6.0, 3.1Hz, 1H), 3.93-3.62 (m, 2H).
[0240] Step 3: 1-((3S,4R,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-fluoro- 3-hydroxytetrahydrofuran-2-yl)-1,5-dihydro-4H-imidazo[4,5-c]pyridin-4-one
Figure imgf000086_0002
[0241] To a solution of 1-((3S,4R,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)
tetrahydrofuran-2-yl)-1,5-dihydro-4H-imidazo[4,5-c]pyridin-4-one (340mg, 1.26mmol) in Py (0.5mL) was added 4,4'-(chloro(phenyl)methylene)bis(methoxybenzene) (0.43g, 1.1mmol). The solution was stirred at RT for 4h. Then, the mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography eluted with 1 to 10% MeOH in DCM (0.5% Et3N) to afford the product. LCMS (ES, m/z): 572.3 [M+H]+.1H-NMR
(400MHz, DMSO-d6): δ δ 11.32 (d, J=5.9Hz, 1H), 7.95 (s, 1H), 7.41 (d, J=7.8Hz, 2H), 7.37– 7.15 (m, 8H), 6.86 (dd, J=10.5, 8.6Hz, 4H), 6.60 (d, J=7.1Hz, 1H), 6.50–6.36 (m, 1H), 5.92 (d, J=2.6Hz, 1H), 5.77 (s, 1H), 5.27-5.06 (m, 1H), 4.65–4.42 (m, 2H), 3.73 (d, J=2.6Hz, 6H), 3.30- 3.24 (m, 1H). [0242] Preparation 6: 1-((2R,3R,5S)-5-((bis(4-methoxyphenyl)(phenyl)methoxy) methyl)-3-hydroxytetrahydrofuran-2-yl)-1,5-dihydro-4H-imidazo[4,5-c]pyridin-4-one
Figure imgf000087_0001
[0243] Step 1: ((2S,4R,5R)-4-acetoxy-5-(4-(benzyloxy)-1H-imidazo[4,5-c]pyridin-1- yl)tetrahydrofuran-2-yl)methyl 4-methylbenzoate and ((2S,4R,5R)-4-acetoxy-5-(4-oxo-4,5- dihydro-1H-imidazo[4,5-c]pyridin-1-yl)tetrahydrofuran-2-yl)methyl 4-methylbenzoate
Figure imgf000087_0002
[0244] A mixture of (3R,5S)-5-(((4-methylbenzoyl)oxy)methyl)tetrahydrofuran-2,3-diyl diacetate (2.69g, 8.00mmol) and 4-(benzyloxy)-1H-imidazo[4,5-c]pyridine (1.98g, 8.80mmol) was co-evaporated with MeCN (5×15mL) and then, re-dissolved in MeCN (64mL) under Ar. To the mixture was added 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine (1.32mL, 8.80mmol) and TIPSOTf (3.05mL, 16.8mmol). It was stirred at 80°C for 1h. Then, it was cooled to RT, and sat aq NaHCO3 (40mL) and H2O (150mL) were added. Layers were separated, and the aq layer was extracted with EtOAc (3×100mL). The combined organic phase was washed with brine (300mL), dried (Na2SO4) and concentrated. The residue was purified by silica gel column chromatography eluted with 0-10% MeOH in DCM to give ((2S,4R,5R)-4-acetoxy-5-(4- (benzyloxy)-1H-imidazo[4,5-c]pyridin-1-yl)tetrahydrofuran-2-yl)methyl 4-methylbenzoate. LCMS (ES, m/z): 502.2 [M+H]+.1H NMR (300MHz, DMSO-d6): δ 8.41 (s, 1H), 7.88-7.75 (m, 3H), 7.56-7.45 (m, 2H), 7.42–7.28 (m, 6H), 6.26 (d, J=1.7Hz, 1H), 5.59-5.47 (m, 3H), 4.76-4.41 (m, 3H), 2.62–2.54 (m, 1H), 2.41–2.22 (m, 4H), 2.12 (s, 3H). Later fractions gave ((2S,4R,5R)- 4-acetoxy-5-(4-oxo-4,5-dihydro-1H-imidazo[4,5-c]pyridin-1-yl)tetrahydrofuran-2-yl)methyl 4- methylbenzoate: LCMS (ES, m/z): 412.1 [M+H]+.1H NMR (300MHz, DMSO-d6): δ 11.23 (s, 1H), 8.20 (s, 1H), 7.81 (d, J=8.0Hz, 2H), 7.33 (d, J=7.9Hz, 2H), 7.12 (t, J=6.4Hz, 1H), 6.65 (d, J=7.1Hz, 1H), 6.16 (d, J=1.5Hz, 1H), 5.45 (d, J=5.8Hz, 1H), 4.75–4.39 (m, 3H), 2.39 (s, 3H), 2.33–2.22 (m, 2H), 2.11 (s, 3H). [0245] Step 2: ((2S,4R,5R)-4-acetoxy-5-(4-oxo-4,5-dihydro-1H-imidazo[4,5-c]pyridin-1- yl)tetrahydrofuran-2-yl)methyl 4-methylbenzoate
Figure imgf000088_0001
[0246] To a solution of ((2S,4R,5R)-4-acetoxy-5-(4-(benzyloxy)-1H-imidazo[4,5- c]pyridin-1-yl)tetrahydrofuran-2-yl)methyl 4-methylbenzoate (1.86g, 3.70mmol) in MeOH (40mL) was added Pd/C (10%, 0.80g). It was hydrogenated (1atm) at RT for 5h. Then, the mixture was filtered, and the filtrate was concentrated. The residue was purified by silica gel column chromatography eluted with 0-10% MeOH in DCM to give the product.
[0247] Step 3: 1-((2R,3R,5S)-3-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,5- dihydro-4H-imidazo[4,5-c]pyridin-4-one
Figure imgf000088_0002
[0248] To a solution of ((2S,4R,5R)-4-acetoxy-5-(4-oxo-4,5-dihydro-1H-imidazo[4,5- c]pyridin-1-yl)tetrahydrofuran-2-yl)methyl 4-methylbenzoate (1.60g, 3.88mmol) in MeOH (60mL) was added MeONa (0.52g, 9.7mmol). It was stirred at RT for 5h. Then, it was neutralized with diluted aq HCl. The resulting mixture was concentrated under reduced pressure, and the residue was purified by reverse phase (C18) chromatography eluted with 0 to 95% ACN in aq NH4HCO3 (5mM) to give the product. LCMS (ES, m/z): 251.9 [M+H]+.1H-NMR
(300MHz, DMSO-d6): δ 8.25 (s, 1H), 7.15 (d, J=7.1Hz, 1H), 6.65 (d, J=7.1Hz, 1H), 5.72 (d, J=2.1Hz, 1H), 4.35-4.28 (m, 2H), 3.67 (dd, J=12.1, 3.2Hz, 1H), 3.50 (dd, J=12.0, 3.8Hz, 1H), 2.16–2.07 (m, 1H), 1.88-1.81 (m, 1H).
[0249] Step 4: 1-((2R,3R,5S)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-3- hydroxytetrahydrofuran-2-yl)-1,5-dihydro-4H-imidazo[4,5-c]pyridin-4-one
Figure imgf000088_0003
[0250] To a solution of 1-((2R,3R,5S)-3-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)- 1,5-dihydro-4H-imidazo[4,5-c]pyridin-4-one (0.90g, 3.6mmol) in pyridine (23mL) was added 4,4'-(chloro(phenyl)methylene)bis(methoxybenzene) (1.21g, 3.58mmol). The resulting mixture was stirred at rt for 2h. Then, MeOH (8mL) was added, and the mixture was concentrated under reduced pressure. The residue was purified by reverse phase (C18) chromatography eluted with 0 to 95% ACN in aq NH4HCO3 (5mM) to give the product. LCMS (ES, m/z): 554.2 [M+H]+.1H- NMR (300MHz, DMSO-d6): δ 11.35-10.99 (m, 1H), 8.10 (s, 1H), 7.33-7.11 (m, 11H), 6.86-6.77 (m, 4H), 6.69 (d, J=7.0Hz, 1H), 5.81 (d, J=1.8Hz, 1H), 5.76 (d, J=3.8Hz, 1H), 3.72 (s, 6H), 3.23- 3.02 (m, 2H), 2.27-2.17 (m, 1H), 1.98-1.91 (m, 1H). [0251] Preparation 7: 3-((2R,3R,4S,5R)-3,4-dihydroxy-5- (hydroxymethyl)tetrahydrofuran-2-yl)-3,5-dihydro-9H-imidazo[1,2-a]purine-6,9(7H)-dione
Figure imgf000089_0001
[0252] Step 1: N-(9-((2R,3R,4R,5R)-3,4-bis((tert-butyldimethylsilyl)oxy)-5-(((tert- butyldimethylsilyl)oxy)methyl)tetrahydrofuran-2-yl)-6-oxo-6,9-dihydro-1H-purin-2-yl)-2- chloroacetamide
Figure imgf000089_0002
[0253] To a solution of 2-amino-9-((2R,3R,4R,5R)-3,4-bis((tert-butyldimethylsilyl)oxy)-5- (((tert-butyldimethylsilyl)oxy)methyl)tetrahydrofuran-2-yl)-1,9-dihydro-6H-purin-6-one (19.0g, 30.4mmol) in DCM (190mL) at 0°C under Ar was added 2-chloroacetyl chloride (4.11g, 36.4mmol) and Py (5.8g, 73mmol). The mixture was stirred at 0°C for 2h. Then, the volatile components were removed under reduced pressure, and the residue was co-evaporated with toluene (3×50mL) to give the crude product. LCMS (ES, m/z): 702.3 [M+H]+.
[0254] Step 2: 3-((2R,3R,4R,5R)-3,4-bis((tert-butyldimethylsilyl)oxy)-5-(((tert- butyldimethylsilyl)oxy)methyl)tetrahydrofuran-2-yl)-3,5-dihydro-9H-imidazo[1,2-a]purine- 6,9(7H)-dione
Figure imgf000089_0003
[0255] To a solution of the crude from Step 1 in DMF (350mL) at 0°C under Ar was added sodium hydride (60%, 2.2g, 91mmol), and the mixture was stirred at RT for 2h. Then, the reaction was quenched with AcOH (25mL). After 30min, the reaction mixture was concentrated under reduced pressure. To the residue was added DCM (80mL) and H2O (40mL). Layers were separated, and the aq layer was extracted with DCM (4×80mL). The combined organic solution was washed with brine (50mL), dried (Na2SO4), and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluted with 0-10% MeOH in DCM to give the product. LCMS (ES, m/z): 666.3 [M+H]+.1H-NMR: (400MHz, DMSO-d6): δ 8.16 (s, 1H), 5.81 (d, J=6.6Hz, 1H), 4.62 (m, J=6.6, 4.4Hz, 1H), 4.51 (d, J=9.7Hz, 2H), 4.22 (m, J=4.5, 1.9Hz, 1H), 4.05-3.98 (m, 1H), 3.89 (m, J=11.3, 5.6Hz, 1H), 3.74 (dd, J=11.3, 3.7Hz, 1H), 3.33 (s, 2H), 2.51 (m, J=1.8Hz, 15H), 0.92 (d, J=1.9Hz, 21H), 0.17–0.06 (m, 14H).
[0256] Step 3: 3-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)- 3,5-dihydro-9H-imidazo[1,2-a]purine-6,9(7H)-dione
Figure imgf000090_0001
[0257] To a solution of 3-((2R,3R,4R,5R)-3,4-bis((tert-butyldimethylsilyl)oxy)-5-(((tert- butyldimethylsilyl)oxy)methyl)tetrahydrofuran-2-yl)-3,5-dihydro-9H-imidazo[1,2-a]purine- 6,9(7H)-dione (8.80g, 13.2mmol) in THF (88mL) was added Et3N·3HF (1.66g, 21.1mmol), and the mixture was stirred at RT for 24h. Then, it was concentrated, and the residue was purified by silica gel column chromatography using 0-20% MeOH in DCM to give the product. LCMS (ES, m/z): 324.0 [M+H]+.1H NMR (400MHz, DMSO-d6): δ 8.09 (s, 1H), 5.76 (d, J=5.9Hz, 1H), 4.45 (t, J=5.5Hz, 1H), 4.32 (s, 2H), 4.11 (t, J=4.2Hz, 1H), 3.92 (m, J=3.8Hz, 1H), 3.64 (dd, J=12.0, 4.0Hz, 1H), 3.54 (dd, J=12.0, 4.0Hz, 1H). [0258] Preparation 8: 3-((2R,3R,4S,5R)-3,4-dihydroxy-5- (hydroxymethyl)tetrahydrofuran-2-yl)-3,5-dihydro-9H-imidazo[1,2-a]purin-9-one
Figure imgf000090_0002
[0259] Step 1: 2-amino-1-(2,2-diethoxyethyl)-9-((2R,3R,4S,5R)-3,4-dihydroxy-5- (hydroxymethyl)tetrahydrofuran-2-yl)-1,9-dihydro-6H-purin-6-one
Figure imgf000090_0003
[0260] To a suspension of guanosine (15.0g, 53.0mmol) in DMF (150mL) was added K2CO3 (11.0g, 79.0mmol), and it was heated at 90°C. After 15min, 2-bromo-1,1-diethoxyethane (12.3mL, 79.0mmol) was added over 10min. The reaction was heated at 90°C for 72h. Then, additional K2CO3 (7.32g, 52.7mmol) and 2-bromo-1,1-diethoxyethane (8.22mL, 52.7mmol) were added. After 48h, the reaction mixture was filtered through a layer of CELITE, and the filtrate was concentrated. The residue was purified by silica column chromatography eluted with 0 to 5.2% MeOH in DCM to give the product. LCMS (ES, m/z): 400.2 [M+H]+.1H-NMR (400MHz, DMSO-d6): δ 7.97 (s, 1H), 6.85 (br s, 2H), 5.70 (d, J=6.1Hz, 1H), 5.40 (d, J=6.0Hz, 1H), 5.13 (d, J=4.6Hz, 1H), 5.01 (t, J=5.5Hz, 1H), 4.72 (t, J=5.3Hz, 1H), 4.41 (q, J=5.8Hz, 1H), 4.13-4.01 (m, 3H), 3.86 (q, J=4.0Hz, 1H), 3.74-3.56 (m, 3H), 3.56-3.40 (m, 3H), 1.07 (td, J=7.0, 1.9Hz, 6H).
[0261] Step 2: 3-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)- 3,5-dihydro-9H-imidazo[1,2-a]purin-9-one
Figure imgf000091_0001
[0262] 2-amino-1-(2,2-diethoxyethyl)-9-((2R,3R,4S,5R)-3,4-dihydroxy-5- (hydroxymethyl)tetrahydrofuran-2-yl)-1,9-dihydro-6H-purin-6-one (2.4g, 3.6mmol) was dissolved in aq HCl (1N, 24mL, 24mmol), and the mixture was stirred at RT for 24h. Then, it was neutralized with concentrated NH4OH and concentrated. The crude was washed with cold H2O and purified by reverse phase (C18) chromatography eluted with 0 to 95% ACN in aq NH4HCO3 (5mM) to give the product. LCMS (ES, m/z): 308.1 [M+H]+.1H-NMR (300MHz, DMSO-d6): δ 12.49 (s, 1H), 8.17 (s, 1H), 7.64 (t, J=2.2Hz, 1H), 7.45 (t, J=2.5Hz, 1H), 5.84 (d, J=5.7Hz, 1H), 5.44 (d, J=6.0Hz, 1H), 5.18 (d, J=4.8Hz, 1H), 5.07 (t, J=5.5Hz, 1H), 4.49 (q, J=5.5Hz, 1H), 4.14 (q, J=4.2Hz, 1H), 3.93 (q, J=3.9Hz, 1H), 3.67 (dt, J=11.8, 4.2Hz, 1H), 3.62- 3.51 (m, 1H). [0263] Preparation 9: (2R,3R,4S,5R)-2-(4-(benzyloxy)-1H-imidazo[2,1-b]purin-1-yl)- 5-(hydroxymethyl)tetrahydrofuran-3,4-diol
Figure imgf000091_0002
[0264] The title compound was prepared according to published procedure (J. Org. Chem. 1987, 52, 2374-2378). [0265] Preparation 10: (2R,3S,4R,5R)-5-((bis(4- methoxyphenyl)(phenyl)methoxy)methyl)-4-fluoro-2-(2-isobutyramido-6-oxo-1,6-dihydro- 9H-purin-9-yl)tetrahydrofuran-3-yl (2-cyanoethyl) diisopropylphosphoramidite
Figure imgf000092_0001
[0266] Step 1: N-(9-((2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)tetrahydrofuran- 2-yl)-6-oxo-6,9-dihydro-1H-purin-2-yl)isobutyramide
Figure imgf000092_0002
[0267] To a suspension of 2-amino-9-((2R,3S,4S,5R)-4-fluoro-3-hydroxy-5- (hydroxymethyl)tetrahydrofuran-2-yl)-1,9-dihydro-6H-purin-6-one (CARBOSYNTH catalog # ND10826, 1.50g, 5.26mmol) in Py (30mL) at 0-5°C was added TMSCl (2.86g, 26.3mmol), and the mixture was stirred at RT for 30min. Then, isobutyric anhydride (2.50g, 15.8mmol) was added dropwise, and it was stirred for an additional for 2h. Then, MeOH (5.3mL) was added. After 5min, NH4OH (10.5mL) was added dropwise and stirring was continued for 30min. The reaction mixture was concentrated under reduced pressure, and MeOH (2mL) in CH2Cl2 (18mL) was added to the residue. Solids were filtered off, and the filtrate was concentrated and purified by flash column chromatography with 2-10% MeOH in CH2Cl2 to give the product. LCMS (ES, m/z): 356.1 [M+H]+.1H-NMR: (400MHz, DMSO-d6): δ 12.11 (s, 1H), 11.68 (s, 1H), 8.28 (s, 1H), 5.98 (d, J=6.1Hz, 1H), 5.85 (d, J=8.0Hz, 1H), 5.24 (t, J=5.4Hz, 1H), 5.14 (d, J=4.1Hz, 0.5H), 5.01 (d, J=4.2Hz, 0.5H), 4.87-4.69 (m, 1H), 4.26 (t, J=4.4Hz, 0.5H), 4.19 (t, J=4.4Hz, 0.5H), 3.61 (t, J=4.9Hz, 2H), 2.77 (hept, J=6.8Hz, 1H), 1.13 (d, J=6.7Hz, 6H).19F-NMR:
(376MHz, DMSO-d6): δ -197.5 (s).
[0268] Step 2: N-(9-((2R,3S,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4- fluoro-3-hydroxytetrahydrofuran-2-yl)-6-oxo-6,9-dihydro-1H-purin-2-yl)isobutyramide
Figure imgf000093_0001
[0269] N-(9-((2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)- 6-oxo-6,9-dihydro-1H-purin-2-yl)isobutyramide (1.30g, 3.66mmol) was co-evaporated with Py (3×10mL) and re-dissolved in Py (26mL). To the solution at 0°C-5°C was added DMTrCl (1.36g, 4.02mmol). It was stirred at RT for 3h and then concentrated. CH2Cl2 (40mL, with 1% Et3N) was added, and it was washed with sat aq NaHCO3 (15mL), H2O (10mL) and brine (10mL). The organic solution was dried (Na2SO4), concentrated and purified by silica gel column chromatography using 0-10% MeOH in CH2Cl2 (1% Et3N) to give the product. LCMS (ES, m/z): 656.2 [M-H]-.1H-NMR: (400MHz, DMSO-d6): δ 12.10 (s, 1H), 11.61 (s, 1H), 8.14 (s, 1H), 7.40-7.31 (m, 2H), 7.31-7.19 (m, 7H), 6.89-6.78 (m, 4H), 6.08 (d, J=6.1Hz, 1H), 5.87 (d, J=7.3Hz, 1H), 5.23 (dd, J=4.1, 1.8Hz, 0.5H), 5.10 (d, J=4.4Hz, 0.5H), 4.96 (dq, J=22.4, 5.9Hz, 1H), 4.30 (dt, J=26.1, 4.6Hz, 1H), 3.74 (d, J=1.1Hz, 6H), 3.39 (dd, J=10.6, 5.7Hz, 1H), 3.22 (dd, J=10.6, 3.8Hz, 1H), 2.76 (p, J=6.8Hz, 1H), 1.13 (d, J=6.8Hz, 6H).19F-NMR: (376MHz, DMSO- d6): δ -198.1 (s, 1F).
[0270] Step 3: (2R,3S,4R,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-fluoro- 2-(2-isobutyramido-6-oxo-1,6-dihydro-9H-purin-9-yl)tetrahydrofuran-3-yl (2-cyanoethyl) diisopropylphosphoramidite
Figure imgf000093_0002
[0271] To a solution of N-(9-((2R,3S,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy) methyl)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)-6-oxo-6,9-dihydro-1H-purin-2- yl)isobutyramide (2.10g, 3.19mmol) in MeCN (30mL) at 0°C under Ar was added pyridin-1-ium 2,2,2-trifluoroacetate (0.678g, 3.51mmol) and 3-((bis(diisopropylamino)phosphino)oxy)- propanenitrile (1.16g, 3.83mmol) in MeCN (2mL) over 5min. The resulting mixture was stirred at RT for 5h. Then, TEA in CH2Cl2 (2%, 300mL) and H2O (100mL) was added. Layers were separated, and the organic layer was washed with H2O (3×100mL) and brine (2×100mL). The organic layer was dried (Na2SO4), concentrated, and purified by flash column chromatography eluted with 10% DCM in EtOAc/Hex (2/3) to give the product. LCMS (ES, m/z): 858.3 [M+H]+. 1H-NMR: (400MHz, DMSO-d6): δ 12.07 (s, 1H), 11.55 (s, 1H), 8.08 (d, J=4.2Hz, 1H), 7.44-7.08 (m, 9H), 6.83 (ddd, J=8.9, 6.2, 2.1Hz, 4H), 5.99 (t, J=6.8Hz, 1H), 5.42-5.03 (m, 2H), 4.48-4.22 (m, 1H), 3.71 (s, 7H), 3.59-3.35 (m, 3H), 3.28-3.24 (m, 3H), 2.83-2.61 (m, 2H), 1.09 (s, 12H), 1.03 (d, J=6.8Hz, 3H), 0.74 (d, J=6.7Hz, 3H).19F-NMR: (376MHz, DMSO-d6): δ -195.8 (s), -197.1 (s).31P-NMR: (162MHz, DMSO-d6): δ 151.55 (d), 151.35 (d). [0272] Preparation 11: (2R,3S,4R,5R)-4-fluoro-5-(hydroxymethyl)-2-(9-oxo-5,9- dihydro-3H-imidazo[1,2-a]purin-3-yl)tetrahydrofuran-3-yl hydrogen phosphonate
Figure imgf000094_0001
[0273] Step 1: 2-amino-1-(2,2-diethoxyethyl)-9-((2R,3S,4S,5R)-4-fluoro-3-hydroxy-5- (hydroxymethyl)tetrahydrofuran-2-yl)-1,9-dihydro-6H-purin-6-one
Figure imgf000094_0002
[0274] To a stirred suspension of 2-amino-9-((2R,3S,4S,5R)-4-fluoro-3-hydroxy-5- (hydroxymethyl)tetrahydrofuran-2-yl)-1,9-dihydro-6H-purin-6-one (2.36g, 8.19mmol) in DMF (50mL) was added K2CO3 (2.29g, 16.6mmol) and 2-bromo-1,1-diethoxyethane (3.26g,
16.6mmol). It was stirred at 90°C for 3 days. Then, additional K2CO3 (0.572g, 4.14mmol) and 2- bromo-1,1-diethoxyethane (0.815g, 4.14mmol) were added. After 48h, the reaction mixture was then filtered through a pad of CELITE. The filtrate was concentrated, and the residue was purified by reverse phase (C18) chromatography eluted with 0 to 95% ACN in aq NH4HCO3 (5mM) to give the product. LCMS (ES, m/z): 402.3 [M+H]+.1H-NMR (400MHz, DMSO-d6): δ 7.99 (s, 1H), 6.89 (s, 2H), 5.91 (d, J=6.4Hz, 1H), 5.76 (d, J=8.1Hz, 1H), 5.21 (t, J=5.5Hz, 1H), 5.11 (d, J=4.1Hz, 0.5H), 4.98 (d, J=4.2Hz, 0.5H), 4.84-4.68 (m, 2H), 4.23 (t, J=4.4Hz, 0.5H), 4.16 (t, J=4.4Hz, 0.5H), 4.07 (d, J=5.9Hz, 2H), 3.69 (dq, J=9.7, 7.0Hz, 2H), 3.60 (t, J=5.0Hz, 2H), 3.50 (dtd, J=9.4, 7.4, 6.5Hz, 2H), 1.09 (td, J=7.1, 1.7Hz, 6H).
[0275] Step 2: 3-((2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2- yl)-3,5-dihydro-9H-imidazo[1,2-a]purin-9-one
Figure imgf000095_0001
[0276] 2-amino-1-(2,2-diethoxyethyl)-9-((2R,3S,4S,5R)-4-fluoro-3-hydroxy-5- (hydroxymethyl)tetrahydrofuran-2-yl)-1,9-dihydro-6H-purin-6-one (1.10g, 2.74mmol) was dissolved in aq HCl (27.4mL, 54.8mmol), and it was stirred for 24h. Then, the solution was neutralized with concentrated NH4OH and concentrated. The residue was purified by reverse phase (C18) chromatography eluted with 0 to 95% ACN in aq NH4HCO3 (5mM) to give the product. LCMS (ES, m/z): 310.2 [M+H]+.1H-NMR (300MHz, DMSO-d6): δ 8.13 (s, 1H), 7.60 (d, J=2.6Hz, 1H), 7.41 (d, J=2.6Hz, 1H), 5.86 (dd, J=12.3, 7.3Hz, 2H), 5.25 (t, J=5.6Hz, 1H), 5.13 (d, J=4.2Hz, 0.5H), 4.95 (d, J= 4.3Hz, 0.5H), 4.25 (t, J=4.5Hz, 0.5H), 4.16 (s, 0.5H), 3.60 (t, J=5.0Hz, 2H).
[0277] Step 3: 3-((2R,3S,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4- fluoro-3-hydroxytetrahydrofuran-2-yl)-5-(bis(4-methoxyphenyl)(phenyl)methyl)-3,5-dihydro-9H- imidazo[1,2-a]purin-9-one
Figure imgf000095_0002
[0278] To a solution of 3-((2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl)-3,5-dihydro-9H-imidazo[1,2-a]purin-9-one (600mg, 1.94mmol) in Py (12mL) and DMSO (24mL) was added a solution of 4,4'-(chloro(phenyl)methylene)bis
(methoxybenzene) (1.64g, 4.85mmol) in Py (6mL) over 30min. It was stirred at RT for 4h. Then, the reaction mixture was concentrated under reduced pressure, and the residue was purified by reverse phase (C18) chromatography eluted with 0 to 95% ACN in aq NH4HCO3 (5mM) to give the product. LCMS (ES, m/z): 914.3 [M+H]+.1H-NMR (400MHz, DMSO-d6): δ 7.97 (s, 1H), 7.70 (d, J=2.9Hz, 1H), 7.34-7.08 (m, 19H), 6.83 (ddt, J=8.7, 6.9, 2.9Hz, 8H), 5.63 (d, J=4.9Hz, 1H), 5.45 (d, J=4.3Hz, 1H), 4.44 (t, J=5.1Hz, 1H), 4.32 (dd, J=9.4, 4.6Hz, 1H), 4.09-3.97 (m, 1H), 3.71 (d, J=7.3Hz, 6H), 3.65 (s, 6H), 3.03 (d, J=5.7Hz, 2H).
[0279] Step 4: (2R,3S,4R,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-2-(5- (bis(4-methoxyphenyl)(phenyl)methyl)-9-oxo-5,9-dihydro-3H-imidazo[1,2-a]purin-3-yl)-4- fluorotetrahydrofuran-3-yl phenyl phosphonate
Figure imgf000096_0001
[0280] To a solution of 3-((2R,3S,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy) methyl)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)-5-(bis(4-methoxyphenyl)(phenyl)methyl)-3,5- dihydro-9H-imidazo[1,2-a]purin-9-one (0.65g, 0.71mmol) in Py (3mL) under Ar was added diphenyl phosphonate (1.16g, 4.98mmol), and it was stirred at RT for 20min. The reaction mixture was used for the next step without purification. LCMS (ES, m/z): 1054.4 [M+H]+.
[0281] Step 5: (2R,3S,4R,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-2-(5- (bis(4-methoxyphenyl)(phenyl)methyl)-9-oxo-5,9-dihydro-3H-imidazo[1,2-a]purin-3-yl)-4- fluorotetrahydrofuran-3-yl hydrogen phosphonate
Figure imgf000096_0002
[0282] To the reaction mixture from Step 4 at 0°C was added H2O (3.0mL, 0.17mol) and TEA (3.0mL, 33mmol). The mixture was stirred at RT for 20min. Then, it was concentrated and purified by reverse phase (C18) chromatography eluted with 0 to 95% ACN in aq NH4HCO3 (5mM) to give the product. LCMS (ES, m/z): 978.3 [M+H]+.31P NMR (162MHz, DMSO): δ -0.07 (s).
[0283] Step 6: (2R,3S,4R,5R)-4-fluoro-5-(hydroxymethyl)-2-(9-oxo-5,9-dihydro-3H- imidazo[1,2-a]purin-3-yl)tetrahydrofuran-3-yl hydrogen phosphonate
Figure imgf000096_0003
[0284] To the solution of (2R,3S,4R,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy) methyl)-2-(5-(bis(4-methoxyphenyl)(phenyl)methyl)-9-oxo-5,9-dihydro-3H-imidazo[1,2- a]purin-3-yl)-4-fluorotetrahydrofuran-3-yl hydrogen phosphonate (0.60g, 0.60mmol) in DCM (17mL) were added DCA in DCM (17.4mL, 10.8mmol) and H2O (0.20mL, 11mmol). It was stirred at rt for 20min and then Et3SiH (34.0mL, 212mmol) was added. The solution was stirred at rt for 60min. Py (6.4mL, 80mmol) was added, and the solution was stirred for 10min. The mixture was concentrated and co-evaporated with MeCN (3×15mL) to give the crude product, which was used for next step without purification. LCMS (ES, m/z): 374.0 [M+H]+. [0285] Preparation 12: (2R,3S,5R)-5-(4-amino-1H-pyrrolo[2,3-b]pyridin-1-yl)-2- (hydroxymethyl)tetrahydrofuran-3-ol
Figure imgf000097_0001
[0286] The title compound was prepared according to published procedure (Heterocycles 1989, 29, 795-805). [0287] Preparation 13: (2R,3R,4S,5R)-5-(7-benzamido-3H-[1,2,3]triazolo[4,5- d]pyrimidin-3-yl)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4- fluorotetrahydrofuran-3-yl (2-cyanoethyl) diisopropylphosphoramidite
Figure imgf000097_0002
[0288] Step 1: (2R,3R,4S,5R)-5-(7-amino-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-2- ((benzoyloxy)methyl)-4-fluorotetrahydrofuran-3-yl benzoate
Figure imgf000097_0003
[0289] To a mixture of 3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-amine (2.36g, 17.4mmol) in NMP (50mL) was added NaH (60%, 0.744g, 18.6 mmol). The mixture was vigorously stirred, and after 1h, generation of bubbles had completely ceased. The mixture was added to
((2R,3R,4S,5R)-3-(benzoyloxy)-5-bromo-4-fluorotetrahydrofuran-2-yl)methyl benzoate (neat, 5.25g, 12.4mmol) in one portion. It was stirred for 18h. LCMS showed several peaks with the desired mass (m/e=479). EtOAc (70mL) and H2O (70mL) were added to the reaction. Layers were separated, and the organic layer was washed with half saturated brine (3x10mL) and brine (1x10mL), dried (MgSO4), and concentrated. The crude was purified via silica column eluting with 0 to 50% EtOAc in Hex to give the product. LCMS (ES, m/z): 479.3 [M+H]+.1H-NMR (500MHz, DMSO-d6): δ 8.62 (s, 1H), 8.34 (s, 1H), 8.28 (s, 1H), 8.10-8.04 (m, 2H), 7.97-7.90 (m, 2H), 7.77-7.69 (m, 1H), 7.67-7.55 (m, 3H), 7.49-7.42 (m, 2H), 6.97 (dd, J=6.5, 3.1Hz, 1H), 6.49 (dt, J=17.6, 6.9Hz, 1H), 6.16 (dt, J=56, 6.6Hz, 1H), 4.76-4.62 (m, 3H).
[0290] Step 2: (2R,3R,4S,5R)-5-(7-amino-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-4- fluoro-2-(hydroxymethyl)tetrahydrofuran-3-ol
Figure imgf000098_0001
[0291] To a solution of (2R,3R,4S,5R)-5-(7-amino-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3- yl)-2-((benzoyloxy)methyl)-4-fluorotetrahydrofuran-3-yl benzoate (2.00g, 4.18mmol) in Py (10mL) at was added NH3 in MeOH (7N, 20mL, 140mmol). It was stirred for 48h. LCMS showed completion of the reaction (m/e=271). It was concentrated and purified by silica column chromatography eluting with 10% MeOH in CH2Cl2 to give the desired product. LCMS (ES, m/z): 271.1 [M+H]+.1H-NMR (500MHz, DMSO-d6): δ 8.54 (s, 1H), 8.33 (s, 1H), 8.22 (s, 1H), 6.73 (dd, J=6.5, 2.6Hz, 1H), 6.00 (d, J=5.4Hz, 1H), 5.51 (ddd, J=53, 7.2, 6.5Hz, 1H), 4.93 (t, J=5.8Hz, 1H), 4.86-4.74 (m, 1H), 3.91-3.83 (m, 1H), 3.77-3.61 (m, 2H).
[0292] Step 3: N-(3-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran- 2-yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl)benzamide
Figure imgf000098_0002
[0293] To a solution of (2R,3R,4S,5R)-5-(7-amino-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3- yl)-4-fluoro-2-(hydroxymethyl)tetrahydrofuran-3-ol (1.34g, 4.96mmol) in Py (30mL) at 0°C was added TMSCl (1.46mL, 11.4mmol). It was warmed to RT and stirred for 1h. Then, it was re- cooled to 0°C, and BzCl (0.921mL, 7.93mmol) was added dropwise. The reaction was slowly warmed to RT over 2h. LCMS showed completion of reaction (m/e=375, 479). H2O (3mL) was added. It was cooled to 0°C, and NH3 in MeOH (7N, 2.8mL, 20mmol) was added. After 1h, the reaction mixture was concentrated. It was purified by silica column chromatography eluting with 0 to 10% MeOH in CH2Cl2 to give the product. LCMS (ES, m/z): 375.2 [M+H]+.1H-NMR (500MHz, DMSO-d6): δ 11.95 (s, 1H), 8.98 (s, 1H), 8.10 (d, J=7.6Hz, 2H), 7.73-7.66 (m, 1H), 7.59 (t, J=7.7Hz, 2H), 6.91 (d, J=6.2Hz, 1H), 6.06 (d, J=5.6Hz, 1H), 5.59 (t, J=53, 6.8Hz, 1H), 4.90 (t, J=5.8Hz, 1H), 4.82 (dq, J=19.8, 7.0Hz, 1H), 3.92 (td, J=7.6, 2.9Hz, 1H), 3.75 (ddd, J=12.1, 5.6, 3.0Hz, 1H), 3.66 (dt, J=12.0, 6.6Hz, 1H).
[0294] Step 4: N-(3-((2R,3S,4R,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-3- fluoro-4-hydroxytetrahydrofuran-2-yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl)benzamide
Figure imgf000099_0001
[0295] To a solution of N-(3-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)- tetrahydrofuran-2-yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl)benzamide (1.25g, 3.34mmol) in Py (15mL) at 0°C was added DMTrCl (1.58g, 4.68mmol). It was stirred at RT for 1h. LCMS showed a peak with the desired mass (m/e=677). It was partly concentrated (to 5mL), and EtOAc (20mL) and H2O (10mL) were added. The layers were separated, and the aq layer was extracted with EtOAc (2×10mL). The combined organics were washed with brine (5mL), dried (MgSO4), concentrated and purified by silica column chromatography eluting with 0 to 60% EtOAc in Hex to give the product. LCMS (ES, m/z): 675.5 [M-H]-.1H-NMR (500MHz, DMSO-d6): δ 8.13-8.07 (m, 2H), 7.69 (t, J=7.4Hz, 1H), 7.59 (t, J=7.6Hz, 2H), 7.35-7.29 (m, 2H), 7.23-7.10 (m, 6H), 6.97 (d, J=6.5Hz, 1H), 6.81-6.74 (m, 2H), 6.74-6.67 (m, 2H), 6.07 (d, J=5.7Hz, 1H), 5.62 (dt, J=53, 7.0Hz, 1H), 4.91-4.79 (m, 1H), 4.15-4.07 (m, 1H), 3.69 (s, 3H), 3.67 (s, 3H), 3.44 (dd, J=10.4, 8.0Hz, 1H), 3.21 (dd, J=10.3, 2.4Hz, 1H).
[0296] Step 5: (2R,3R,4S,5R)-5-(7-benzamido-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-2- ((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-fluorotetrahydrofuran-3-yl (2-cyanoethyl) diisopropylphosphoramidite
Figure imgf000099_0002
[0297] To a solution of 3-((bis(diisopropylamino)phosphino)oxy)propanenitrile (8.02g, 26.6mmol) in ACN (90mL) at RT was added pyridin-1-ium 2,2,2-trifluoroacetate (3.85g, 19.95mmol) and a solution of N-(3-((2R,3S,4R,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy) methyl)-3-fluoro-4-hydroxytetrahydrofuran-2-yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl) benzamide (9g, 13.30mmol) in ACN (90mL). The resulting mixture was stirred for 1h. Then, it was concentrated, and the residue was dissolved in CH2Cl2 (1000mL). It was washed with aq NaHCO3 (1%, 2×300mL), H2O (300mL) and brine (300mL), dried (Na2SO4), concentrated, and purified by reverse phase (C18) chromatography eluting with 0 to 95% ACN in H2O to give the product. LCMS (ES, m/z): 877.5 [M+H]+.1H-NMR: (400MHz, DMSO-d6): δ 12.01 (s, 1H), 8.92 (s, 1H), 8.11 (d, J=7.6Hz, 2H), 7.66 (dt, J=42.3, 7.5Hz, 3H), 7.32 (td J=7.2, 6.6, 2.9Hz, 2H), 7.22-7.00 (m, 9H), 6.83-6.63 (m, 4H), 5.86 (ddt, J=52.8, 17.6, 6.9Hz, 1H), 5.16 (td, J=17.7, 17.2, 8.8Hz, 1H), 3.78-3.63 (m, 7H), 3.59-3.35 (m, 5H), 2.74 (t, J=5.9Hz, 1H), 2.63 (t, J=5.9Hz, 1H), 1.23-0.99 (m, 10H), 0.91 (d, J=6.7Hz, 2H).31P-NMR: (162MHz, DMSO-d6): δ 150.26, 149.60 (2 s, 1P). [0298] Preparation 14: N-(7-((2R,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy) methyl)-4-hydroxytetrahydrofuran-2-yl)imidazo[2,1-f][1,2,4]triazin-4-yl)benzamide
Figure imgf000100_0001
[0299] Step 1: (3R,4R,5R)-2-(4-aminoimidazo[2,1-f][1,2,4]triazin-7-yl)-3,4- bis(benzyloxy)-5-((benzyloxy)methyl)tetrahydrofuran-2-ol
Figure imgf000100_0002
[0300] To a stirring mixture of 7-bromoimidazo[2,1-f][1,2,4]triazin-4-amine (41g, 0.19mol) in THF (0.50L) at 0°C was added MeMgBr (3.0M in THF, 66mL, 0.19mol) dropwise to maintain the internal temperature below 10°C. Bis(chlorodimethylsilyl)ethane (41g,
190mmol) was added in one portion. MeMgBr (3.0M in diethyl ether, 66mL, 0.19mol) was then added dropwise to maintain the internal temperature below 10°C. i-PrMgCl-LiCl (1.3M in THF, 0.16L, 0.21mol) was added while maintaining the internal temperature below 10°C. A mixture of (3R,4R,5R)-3,4-bis(benzyloxy)-5-((benzyloxy)methyl)dihydrofuran-2(3H)-one (160g, 0.38mol) in THF was added dropwise at 0°C, and the mixture was then allowed to warm to RT and was stirred for 12h. The mixture was diluted with sat aq NH4Cl (100mL) and extracted with EtOAc (3×1000mL). The combined organic layers were dried over Na2SO4 and concentrated under reduced pressure. The resulting residue was purified by column chromatography (column height: 2500mm, diameter: 1000mm, 25-75% EtOAc in Hex) to afford (3R,4R,5R)-2-(4-aminoimidazo [2,1-f][1,2,4]triazin-7-yl)-3,4-bis(benzyloxy)-5-((benzyloxy)methyl)-tetrahydrofuran-2-ol.
[0301] Step 2: 7-((3S,4R,5R)-3,4-bis(benzyloxy)-5-((benzyloxy)methyl)tetrahydrofuran-2- yl)imidazo[2,1-f][1,2,4]triazin-4-amine
Figure imgf000101_0001
[0302] To a stirring mixture of (3R,4R,5R)-2-(4-aminoimidazo[2,1-f][1,2,4]triazin-7-yl)- 3,4-bis(benzyloxy)-5-((benzyloxy)methyl)tetrahydrofuran-2-ol (64g, 0.12mmol) in DCM (1.3L) at 0°C was added TES (81g, 0.69mol), and then BF3-OEt2 (21g, 0.15mol). The mixture was then allowed to warm to 25°C, and the mixture was stirred for 1h. More BF3-OEt2 (57g, 0.40mol) was added, and the mixture was then heated to 35°C for 4h. Upon cooling to RT, the mixture was quenched with sat aq NaHCO3 (200mL) and then extracted with EtOAc (3×300mL). The combined organic layers were dried over Na2SO4 and concentrated under reduced pressure. The resulting residue was purified by column chromatography (15-75% EtOAc in Hex) to afford 7- ((3S,4R,5R)-3,4-bis(benzyloxy)-5-((benzyloxy)methyl)tetrahydrofuran-2-yl)imidazo[2,1- f][1,2,4]triazin-4-amine. MS (ES, m/z)=538 [M+H]+.
[0303] Step 3: (3R,4S,5R)-2-(4-aminoimidazo[2,1-f][1,2,4]triazin-7-yl)-5-(hydroxymethyl)- tetrahydrofuran-3,4-diol
Figure imgf000101_0002
[0304] To a stirring mixture of 7-((3S,4R,5R)-3,4-bis(benzyloxy)-5-((benzyloxy)methyl)- tetrahydrofuran-2-yl)imidazo[2,1-f][1,2,4]triazin-4-amine (12g, 22mmol) in DCM (850mL) at -78°C was added BCl3 (18g, 0.16mol) dropwise. Upon completion, the mixture was stirred at -78°C for 3h. After 3h, the mixture was quenched with MeOH (50mL) at -78°C, and the mixture was allowed to warm to 25°C. The mixture was concentrated under reduced pressure. The residue was purified by column chromatography (9-25% MeOH in DCM) to afford (3R,4S,5R)- 2-(4-aminoimidazo[2,1-f][1,2,4]triazin-7-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol.
[0305] Step 4: (6aR,8S,9S,9aS)-8-(4-aminoimidazo[2,1-f][1,2,4]triazin-7-yl)-2,2,4,4- tetraisopropyltetrahydro-6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-9-ol
Figure imgf000102_0001
[0306] To a stirred mixture of (2S,3R,4S,5R)-2-(4-aminoimidazo[2,1-f][1,2,4]triazin-7-yl)- 5-(hydroxymethyl)tetrahydrofuran-3,4-diol (4.0g, 15mmol) in Py (0.10L) was added 1,3- dichloro-1,1,3,3-tetraisopropyldisiloxane (5.8mL, 18mmol). After 3h, the mixture was diluted with toluene (50mL) and then concentrated. The resulting mixture was taken up in DCM and MeOH, and then silica gel (40g) was added. The mixture was concentrated, placed under vacuum for 1h and then purified by column chromatography (0-80% EtOAc in Hex) to afford (6aR,8S,9S,9aS)-8-(4-aminoimidazo[2,1-f][1,2,4]triazin-7-yl)-2,2,4,4-tetraisopropyltetrahydro- 6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-9-ol. MS (ES, m/z)=510 [M+H]+.
[0307] Step 5: O-((6aR,8S,9S,9aR)-8-(4-aminoimidazo[2,1-f][1,2,4]triazin-7-yl)-2,2,4,4- tetraisopropyltetrahydro-6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-9-yl) 1H-imidazole-1- carbothioate
Figure imgf000102_0002
[0308] To a mixture of (6aR,8S,9S,9aS)-8-(4-aminoimidazo[2,1-f][1,2,4]triazin-7-yl)- 2,2,4,4-tetraisopropyltetrahydro-6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-9-ol (6.45g, 12.7mmol) in MeCN (63.0mL) and Py (63.0mL) was added 1,1'-thiocarbonyldiimidazole (2.71g,
15.2mmol). After 90min, more 1,1'-thiocarbonyldiimidazole (2.71g, 15.2mmol) was added, and the mixture was stirred overnight. After stirring overnight, the mixture was concentrated and purified by column chromatography (0-100% EtOAc in Hex) to afford O-((6aR,8S,9S, 9aR)-8-(4- aminoimidazo[2,1-f][1,2,4]triazin-7-yl)-2,2,4,4-tetraisopropyltetrahydro-6H-furo[3,2- f][1,3,5,2,4]trioxadisilocin-9-yl) 1H-imidazole-1-carbothioate. MS (ES, m/z)=620 [M+H]+.
[0309] Step 6: 7-((6aR,8R,9aS)-2,2,4,4-tetraisopropyltetrahydro-6H-furo[3,2- f][1,3,5,2,4]trioxadisilocin-8-yl)imidazo[2,1-f][1,2,4]triazin-4-amine
Figure imgf000103_0001
[0310] To a mixture of O-((6aR,8S,9S,9aR)-8-(4-aminoimidazo[2,1-f][1,2,4]triazin-7-yl)- 2,2,4,4-tetraisopropyltetrahydro-6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-9-yl) (5.65g, 9.11mmol) in toluene (91.0mL) was added 2,2’-azobis(2-methylpropionitrile (0.300g, 1.82mmol) and (TMS)3SiH (4.22mL, 13.7mmol). The mixture was heated to 85°C for 30min. After 30min, the mixture was allowed to cool to RT, placed directly on the column, and purified (0-80% EtOAc in Hex) to afford 7-((6aR,8R,9aS)-2,2,4,4-tetraisopropyltetrahydro-6H-furo[3,2-f][1,3,5,2,4] trioxadisilocin-8-yl)imidazo[2,1-f][1,2,4]triazin-4-amine. MS (ES, m/z)=494 [M+H]+.
[0311] Step 7: N-benzoyl-N-(7-((6aR,8R,9aS)-2,2,4,4-tetraisopropyltetrahydro-6H- furo[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl)imidazo[2,1-f][1,2,4]triazin-4-yl)benzamide
Figure imgf000103_0002
[0312] To a mixture of 7-((6aR,8R,9aS)-2,2,4,4-tetraisopropyltetrahydro-6H-furo[3,2-f] [1,3,5,2,4]trioxadisilocin-8-yl)imidazo[2,1-f][1,2,4]triazin-4-amine (15.7g, 31.8mmol) in Py (64.0mL) was added BzCl (11.0mL, 95.0mmol), and the mixture was heated to 50°C for 45min. After 45min, the mixture was allowed to cool to RT. After cooling, a precipitate formed and was filtered off. The filtrate was diluted with DCM (50mL) and toluene (50mL). The mixture was concentrated to about 50mL. The mixture was filtered, and the solids were washed with DCM. The filtrate and washes were combined, loaded onto a column, and purified (0-50% EtOAc in Hex) to afford N-benzoyl-N-(7-((6aR,8R,9aS)-2,2,4,4-tetraisopropyltetrahydro-6H-furo[3,2-f] [1,3,5,2,4]trioxadisilocin-8-yl)imidazo[2,1-f][1,2,4]triazin-4-yl)benzamide. MS (ES, m/z)=702 [M+H]+.
[0313] Step 8: N-(7-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2- yl)imidazo[2,1-f][1,2,4]triazin-4-yl)benzamide
Figure imgf000104_0001
[0314] To a mixture of N-benzoyl-N-(7-((6aR,8R,9aS)-2,2,4,4-tetraisopropyltetrahydro-6H- furo[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl)imidazo[2,1-f][1,2,4]triazin-4-yl)benzamide (10g, 14mmol) in THF (0.14L) was added TBAF ((1.0M in THF, 29mL, 29mmol), and the mixture was stirred for 1h. After 1h, the mixture was concentrated and purified by column
chromatography to afford N-(7-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydro-furan-2- yl)imidazo[2,1-f][1,2,4]triazin-4-yl)benzamide. MS (ES, m/z)=356 [M+H]+.
[0315] Step 9: N-(7-((2R,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4- hydroxytetrahydrofuran-2-yl)imidazo[2,1-f][1,2,4]triazin-4-yl)benzamide
Figure imgf000104_0002
[0316] To a mixture of N-(7-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2- yl)imidazo[2,1-f][1,2,4]triazin-4-yl)benzamide (6.1g, 17mmol) in Py (86mL) at 0°C was added DMTrCl (5.8g, 17mmol), and the mixture was allowed to warm to RT overnight. After stirring overnight, the mixture was diluted with toluene and then concentrated under reduced pressure to afford the crude product residue. The crude product residue was purified by silica gel
chromatography (0-100% EtOAc in Hex) to afford N-(7-((2R,4S,5R)-5-((bis(4-methoxyphenyl) (phenyl)-methoxy)methyl)-4-hydroxytetrahydrofuran-2-yl)imidazo[2,1-f][1,2,4]triazin-4-yl) benzamide. MS (ES, m/z)=658 [M+H]+. [0317] Preparation 15: 4'-thioadenosine
Figure imgf000104_0003
[0318] The title compound was prepared according to published procedures (Journal of Medicinal Chemistry 2006, 49(5), 1624-1634). [0319] Preparation 16: triethylammonium 5'-O-[bis(4-methoxyphenyl)(phenyl) methyl]-3'-deoxy-3'-fluoro-2'-O-[hydroxy(oxido)-λ5-phosphanyl]-N-(2- methylpropanoyl)guanosine
Figure imgf000105_0001
[0320] Step 1: (2R,3S,4R,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-fluoro- 2-(2-isobutyramido-6-oxo-1,6-dihydro-9H-purin-9-yl)tetrahydrofuran-3-yl phenyl phosphonate
Figure imgf000105_0002
[0321] To a stirred solution of N-(9-((2R,3S,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl) methoxy) methyl)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)-6-oxo-6,9-dihydro-1H-purin-2- yl)isobutyramide (1g, 1.520mmol) in Py (7.6mL) under Ar was added diphenyl phosphonate (1.068g, 4.56mmol), and it was stirred at RT for 20min. The reaction mixture containing the product was used for the next reaction step without purification.
[0322] Step 2: (2R,3S,4R,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-fluoro- 2-(2-isobutyramido-6-oxo-1,6-dihydro-9H-purin-9-yl)tetrahydrofuran-3-yl phosphonate
Figure imgf000105_0003
[0323] To the reaction mixture from Step 1 was added H2O (1.5mL) and Et3N (1.5mL). The mixture was stirred at RT for 20min. Then, it was concentrated, and the residue was partitioned between CH2Cl2 (50mL) and aq NaHCO3 (5%, 20mL). Layers were separated. The organic layer was washed with aq NaHCO3 (5%, 2x20mL), dried (Na2SO4), concentrated and purified by silica gel column chromatography using 0 to 7% MeOH in CH2Cl2 (1% Et3N) to give the product. LCMS (ES, m/z): 722 [M+H]+.31P-NMR: (162MHz, CD3OD): δ 2.73 (s, 1P).
[0324] Preparation 17: triethylammonium 5'-O-[bis(4-methoxyphenyl)(phenyl) methyl]-3'-deoxy-3'-fluoro-2'-O-[hydroxy(oxido)-λ5-phosphanyl]-N-(2- methylpropanoyl)guanosine
Figure imgf000106_0001
[0325] To a flask was added N-(7-((2R,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl) methoxy)methyl)-4-hydroxytetrahydrofuran-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)benzamide (4g, 6.09mmol), DCM (71.7mL), and 4,5-dicyanoimidazole (2.158g, 18.27mmol), and the solution was cooled to 0°C.2-Cyanoethyl N,N,N',N'-tetraisopropylphosphorodiamidite (6.77mL, 21.32mmol) was added, and the mixture was stirred for 15min at 0°C, after which time the mixture was concentrated under reduced pressure and purified by silica gel chromatography using a gradient of 30-100% EtOAc in Hex to yield (2R,3S,5R)-5-(4-benzamido-7H-pyrrolo[2,3- d]pyrimidin-7-yl)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl) tetrahydrofuran-3-yl (2- cyanoethyl) diisopropylphosphoramidite. LCMS (ES, m/z): 857 [M+H]+. [0326] Preparation 18: N-(3-((2R,3S,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl) methoxy)methyl)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)-7-oxo-6,7-dihydro-3H- [1,2,3]triazolo[4,5-d]pyrimidin-5-yl)isobutyramide
Figure imgf000106_0002
[0327] Step 1: ((2R,3R,4S,5R)-5-(5-amino-7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5- d]pyrimidin-3-yl)-4-(benzoyloxy)-3-fluorotetrahydrofuran-2-yl)methyl benzoate
Figure imgf000106_0003
[0328] To a suspension of 8-azaguanine (5.14g, 33.8mmol) in anhydrous MeCN (100mL) at RT was added dropwise (E)-trimethylsilyl N-(trimethylsilyl)acetimidate (16.53mL, 67.6mmol) then the mixture was stirred at 70°C for 2h. The reaction was cooled to rt, and a solution of ((2R,3R,4S)-5-acetoxy-4-(benzoyloxy)-3-fluorotetrahydrofuran-2-yl)methyl benzoate (6.8g, 16.90mmol) in anhydrous MeCN (20mL) was added followed by dropwise addition of SnCl4 (67.6mL, 67.6mmol). The homogeneous solution was stirred at 70°C for 2h. The reaction was cooled to RT and concentrated. The residue was dissolved in EtOAc (1000mL) and neutralized by pouring into sat aq NaHCO3 (500mL). The organic layer was separated, and the aq layer was extracted with EtOAc (4x500mL). The organic layers were combined and washed with H2O (3×700 mL), brine, dried over anhydrous Na2SO4, filtered, and concentrated to afford title compound without further purification. LCMS (ES, m/z): 495.3 [M+H]+.
[0329] Step 2: ((2R,3R,4S,5R)-4-(benzoyloxy)-3-fluoro-5-(5-isobutyramido-7-oxo-6,7- dihydro-3H- [1,2,3]triazolo[4,5-d]pyrimidin-3-yl)tetrahydrofuran-2-yl)methyl benzoate
Figure imgf000107_0001
[0330] To a solution of ((2R,3R,4S,5R)-5-(5-amino-7-oxo-6,7-dihydro-3H-[1,2,3] triazolo[4,5-d]pyrimidin-3-yl)-4-(benzoyloxy)-3-fluorotetrahydrofuran-2-yl)methyl benzoate (8g, 16.18mmol) from Step 1 in anhydrous DMA (40mL) at RT was added dropwise isobutyric anhydride (4.02mL, 24.27mmol). The mixture was stirred at 140°C for 4h. The reaction was cooled and diluted with EtOAc (600mL), washed with sat aq NH4Cl (4×500mL), brine, dried over anhydrous Na2SO4, filtered and concentrated. The crude product was purified by MPLC (220g silica gel, eluting with a gradient of 100% Hex to 100% EtOAc) to afford ((2R,3R,4S,5R)- 4-(benzoyloxy)-3-fluoro-5-(5-isobutyramido-7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5- d]pyrimidin-3-yl)tetrahydrofuran-2-yl)methyl benzoate. LCMS (ES, m/z): 565.3 [M+H]+.
[0331] Step 3: N-(3-((2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)
tetrahydrofuran-2-yl)-7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)isobutyramide
Figure imgf000107_0002
[0332] To a solution of ((2R,3R,4S,5R)-4-(benzoyloxy)-3-fluoro-5-(5-isobutyramido-7- oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)tetrahydrofuran-2-yl)methyl benzoate (6g, 10.63mmol) in THF (20mL), MeOH (16mL), and H2O (4mL) at 0°C was added 5N aq NaOH (4.89mL, 24.45mmol) and stirred for 1h. The reaction was neutralized with formic acid (1.223mL, 31.9mmol). The solvent was removed, and the residue was purified by MPLC (120g, silica gel, eluting with a gradient of 100% CH2Cl2 to 20% MeOH/CH2Cl2) to afford N-(3- ((2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-7-oxo-6,7-dihydro- 3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)isobutyramide. LCMS (ES, m/z): 357.2 [M+H]+.
[0333] Step 4: N-(3-((2R,3S,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4- fluoro-3-hydroxytetrahydrofuran-2-yl)-7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5- yl)isobutyramide
Figure imgf000108_0001
[0334] To a solution of N-(3-((2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl)-7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)isobutyramide (3g, 8.42mmol) in anhydrous Py (40mL) at 0°C was added 4,4'-dimethoxytrityl chloride (3.42g, 10.10mmol). The ice bath was removed, and the reaction mixture was allowed to reach RT and was stirred for 2h. The mixture was diluted with EtOAc (400 mL), washed with sat aq NaHCO3 (100mL), H2O (3×100mL), brine, and dried over anhydrous Na2SO4, filtered, and concentrated. The crude product was purified by MPLC (120 g silica gel, eluting with a gradient of 100% DCM to 15% MeOH/DCM to afford N-(3-((2R,3S,4S,5R)-5-((bis(4-methoxyphenyl)
(phenyl)methoxy)methyl)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)-7-oxo-6,7-dihydro-3H- [1,2,3]triazolo[4,5-d]pyrimidin-5-yl)isobutyramide. LCMS (ES, m/z): 659.3 [M+H]+.
[0335] Preparation 19: N-(3-((2R,3S,4R,5R)-5-((bis(4-methoxyphenyl)(phenyl) methoxy)methyl)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)-7-oxo-6,7-dihydro-3H- [1,2,3]triazolo[4,5-d]pyrimidin-5-yl)isobutyramide
Figure imgf000108_0002
[0336] N-(3-((2R,3S,4R,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-fluoro- 3-hydroxytetrahydrofuran-2-yl)-7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl) isobutyramide was prepared according to procedures analogous to those described for
Preparation 18 using the appropriately substituted ribose in Step 1. LCMS (ES, m/z): 659.4
[M+H]+. [0337] Preparation 20: N-(3-((2R,3R,5S)-5-((bis(4-methoxyphenyl)(phenyl)methoxy) methyl)-3-hydroxytetrahydrofuran-2-yl)-7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d] pyrimidin-5-yl)isobutyramide
Figure imgf000109_0001
[0338] N-(3-((2R,3R,5S)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-3-hydroxy- tetrahydrofuran-2-yl)-7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)isobutyramide was prepared according to procedures analogous to those described for Preparation 18 using the appropriately substituted ribose in Step 1. LCMS (ES, m/z): 641.2 [M+H]+. [0339] Preparation 21: N-(9-((2R,3R,5S)-5-((bis(4-methoxyphenyl)(phenyl)methoxy) methyl)-3-hydroxytetrahydrothiophen-2-yl)-6-oxo-6,9-dihydro-1H-purin-2-yl)
isobutyramide
Figure imgf000109_0002
[0340] Step 1: (3R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrothiophen-3-yl 2,4- dimethoxybenzoate
Figure imgf000109_0003
[0341] To a solution of (6aR,9R,9aS)-2,2,4,4-tetraisopropyltetrahydro-6H-thieno[3,2- f][1,3,5,2,4]trioxadisilocin-9-yl 2,4-dimethoxybenzoate (60g, 108mmol) in THF (500mL) were added AcOH (13.59g, 226mmol) and TBAF in THF (1M, 226mL, 226mmol). After 1h, it was concentrated under reduced pressure and purified by silica gel column chromatography eluting with 0-20% EtOAc in CH2Cl2 to give the product. LCMS (ES, m/z): 315.1 [M+H]+.1H-NMR (400MHz, CDCl3) δ 7.87 (d, J=8.7Hz, 1H), 6.58-6.46 (m, 2H), 5.51 (dt, J=5.0, 3.7Hz, 1H), 4.31 (td, J=6.9, 3.7Hz, 1H), 3.88 (d, J=12.0Hz, 8H), 3.58 (dt, J=7.1, 4.7Hz, 1H), 3.26 (dd, J=12.2, 5.0Hz, 1H), 3.15-3.01 (m, 2H), 2.31 (s, 1H).
[0342] Step 2: (3R,4S,5R)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-4- hydroxytetrahydrothiophen-3-yl 2,4-dimethoxybenzoate
Figure imgf000110_0001
[0343] To a solution of (3R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrothiophen-3-yl 2,4-dimethoxybenzoate (33g, 105mmol) in Py (300mL) was added TBDPSCl (43.3g, 157mmol). It was stirred at RT for 4h. Then, H2O (300mL) was added. Layers were separated, and the aq layer was extracted with CH2Cl2 (3x300mL). The combined organic layer was washed with brine (300mL), dried (Na2SO4), concentrated, and purified by silica gel column chromatography eluting with 1 to 10% EtOAc in petroleum ether to give the product. LCMS (ES, m/z): 575.3 [M+Na]+.1H-NMR (400MHz, DMSO-d6) δ 7.83 (d, J=8.7Hz, 1H), 7.68 (t, J=5.5Hz, 5H), 7.54- 7.38 (m, 6H), 6.69-6.60 (m, 2H), 5.40 (d, J=5.6Hz, 1H), 5.35-5.29 (m, 1H), 4.12 (s, 1H), 4.05 (d, J=7.3Hz, 1H), 3.85 (d, J=7.2Hz, 6H), 3.78-3.66 (m, 1H), 3.55 (d, J=7.2Hz, 1H), 3.14 (dd, J=11.0, 5.0Hz, 1H), 2.86-2.77 (m, 1H), 1.03 (s, 9H).
[0344] Step 3: (3R,4S,5R)-4-((1H-imidazole-1-carbonothioyl)oxy)-5-(((tert- butyldiphenylsilyl)oxy)methyl)tetrahydrothiophen-3-yl 2,4-dimethoxybenzoate
Figure imgf000110_0002
[0345] To a solution of (3R,4S,5R)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-4- hydroxytetrahydrothiophen-3-yl 2,4-dimethoxybenzoate (48g, 87mmol) in DCE (500mL) was added di(1H-imidazol-1-yl)methanethione (20.12g, 113mmol). It was heated at 85°C under Ar for 1h. Then, it was concentrated and used in the next step without purification. LCMS (ES, m/z): 663.2 [M+H]+.
[0346] Step 4: (3R,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)tetrahydrothiophen-3-yl 2,4- dimethoxybenzoate
Figure imgf000110_0003
[0347] To a solution of (3R,4S,5R)-4-((1H-imidazole-1-carbonothioyl)oxy)-5-(((tert- butyldiphenylsilyl)oxy)methyl)tetrahydrothiophen-3-yl 2,4-dimethoxybenzoate (crude, 57.6g, 87mmol) in THF (40mL) and toluene (200mL) was added n-Bu3SnH (139g, 478mmol). It was heated at 95°C, and 2, 2'-(diazene-1,2-diyl)bis(2-methylpropanenitrile) (1.427g, 8.69mmol) in toluene (200mL) was added over 30min. After 1h, the resulting mixture was concentrated and purified by silica gel column chromatography eluting with 0 to 10% EtOAc in petroleum ether to give the product. LCMS (ES, m/z): 537.3 [M+H]+.1H-NMR (400MHz, CDCl3) δ 7.88 (d, J=8.6Hz, 1H), 7.77-7.67 (m, 4H), 7.50-7.36 (m, 6H), 6.58-6.48 (m, 2H), 5.70 (p, J=3.8Hz, 1H), 3.95-3.74 (m, 10H), 3.28 (dd, J=12.0, 4.6Hz, 1H), 3.10-3.02 (m, 1H), 2.49-2.39 (m, 1H), 1.92 (ddd, J=13.3, 8.6, 4.1Hz, 1H), 1.09 (s, 9H).
[0348] Step 5: (1R,3R,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-1- oxidotetrahydrothiophen-3-yl 2,4-dimethoxybenzoate
Figure imgf000111_0001
[0349] To a solution of Ti(OiPr)4 (23.29mL, 78mmol) in CH2Cl2 (130mL) under Ar was added diethyl (L)-tartrate (38.3mL, 224mmol) dropwise. After 10min, the mixture was cooled to -20°C, and then TBHP in decane (~5.5M, 27.1mL, 149mmol) was added dropwise. After 5min, a solution of (3R,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)tetrahydrothiophen-3-yl 2,4- dimethoxybenzoate (40g, 74.5mmol) in CH2Cl2 (130mL) was added to the reaction at -20°C. The resulting mixture was stirred at -20°C for 16h. It was quenched by the addition of ice water (300mL) and allowed to warm up to RT. The precipitate was filtered off and washed with EtOAc (3×300mL). The filtrate was washed with H2O (3×200mL). The aq layer was extracted with EtOAc (400mL). The combined organic layer was dried (Na2SO4), concentrated and purified by flash chromatography eluting with 0 to 70% EtOAc in petroleum ether to give the product (mixture of two isomers). LCMS (ES, m/z): 553.2 [M+H]+.1H-NMR (400MHz, DMSO-d6) δ 7.81 (d, J=8.7Hz, 1H), 7.75-7.61 (m, 4H), 7.54-7.39 (m, 6H), 6.67-6.56 (m, 2H), 5.66 (q, J=3.8Hz, 1H), 4.12 (dt, J=10.5, 4.4Hz, 1H), 3.92-3.79 (m, 8H), 3.58-3.42 (m, 1H), 3.20-3.09 (m, 1H), 2.97 (d, J=15.0Hz, 1H), 2.05 (ddd, J=14.5, 10.5, 4.3Hz, 1H), 1.02 (s, 9H).
[0350] Step 6: (3R,5S)-2-acetoxy-5-(((tert-butyldiphenylsilyl)oxy)methyl)
tetrahydrothiophen-3-yl 2,4-dimethoxybenzoate
Figure imgf000111_0002
[0351] A solution of (3R,5S)-2-acetoxy-5-(((tert-butyldiphenylsilyl)oxy)methyl)- tetrahydrothiophen-3-yl 2,4-dimethoxybenzoate (21g, 34.2mmol) in acetic anhydride (210mL) was heated at 110°C. After stirring of 3.5h, the reaction mixture was cooled to RT and concentrated. The residue was purified by silica gel column chromatography eluting with 0% to 20% EtOAc in petroleum ether to give the product. LCMS (ES, m/z): 535.3 [M-OAc]+.1H-NMR (400MHz, DMSO-d6) δ 7.76-7.61 (m, 5H), 7.46 (dq, J=7.6, 4.5, 3.7Hz, 6H), 6.68-6.58 (m, 2H), 6.22 (d, J=4.3Hz, 0.65H), 5.94 (s, 0.28H), 5.51-5.46 (m, 0.33H), 5.38 (ddd, J=11.1, 7.2, 4.3Hz, 0.65H), 3.96-3.61 (m, 9H), 2.40-2.21 (m, 2H), 2.03 (d, J=1.6Hz, 3H), 1.01 (s, 9H).
[0352] Step 7: (3R,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-(6-chloro-2- isobutyramido-9H-purin-9-yl)tetrahydrothiophen-3-yl 2,4-dimethoxybenzoate
Figure imgf000112_0001
[0353] To a solution of N-(6-chloro-9H-purin-2-yl)isobutyramide (10.27g, 42.9mmol) in toluene (600mL) at 0°C was added trimethylsilyl N-(trimethylsilyl)acetimidate (23.26g,
114mmol). It was heated at 80°C for 1h and was cooled to 0°C again. To the reaction was then added a solution of (3R, 5S)-2-acetoxy-5-(((tert-butyldiphenylsilyl)oxy)methyl)-tetrahydro- thiophen-3-yl 2,4-dimethoxybenzoate (17g, 28.6mmol) in toluene (600mL) and TMSOTf (19.06g, 86mmol). It was heated to 80°C and stirred under Ar for 12h. At that time, the reaction was cooled to RT, and sat aq NaHCO3 (400mL) was added. Layers were separated, and the aq layer was extracted with EtOAc (4×1000mL). The combined organic phase was dried (Na2SO4), concentrated and purified by silica gel column chromatography eluting with 10% to 40% EtOAc in petroleum ether to give the product (mixture of α and β isomers). LCMS (ES, m/z): 774.3 [M+H]+.1H-NMR (400MHz, CDCl3) δ 8.48 (s, 0.32H), 8.35 (s, 0.69H), 7.97-7.83 (m, 1.67H), 7.70 (dq, J=8.4, 1.5Hz, 4H), 7.54 (d, J=8.7Hz, 0.33H), 7.49-7.36 (m, 6H), 6.57-6.36 (m, 2.5H), 6.18 (d, J=2.4Hz, 0.7H), 5.87-5.80 (m, 0.35H), 5.73 (q, J=3.3Hz, 0.75H), 4.23-4.01 (m, 1.2H), 3.98-3.74 (m, 7.8H), 3.11 (s, 0.73H), 2.95 (s, 0.37H), 2.57-2.36 (m, 1.75H), 2.30-2.20 (m, 0.34H), 1.23 (d, J=6.8Hz, 2.19H), 1.19 (dd, J=6.8, 3.5Hz, 4.38H), 1.09 (d, J=1.7Hz, 9H).
[0354] Step 8: (2R,3R,5S)-2-(6-chloro-2-isobutyramido-9H-purin-9-yl)-5-(hydroxymethyl)- tetrahydrothiophen-3-yl 2,4-dimethoxybenzoate
Figure imgf000112_0002
[0355] To a solution of (3R,5S)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2-(6-chloro-2- isobutyramido-9H-purin-9-yl)tetrahydrothiophen-3-yl 2,4-dimethoxybenzoate (20g, 25.8mmol) in THF (135mL) was added TBAF in THF (1M, 31mL, 31mmol) dropwise. After 1h, the reaction mixture was concentrated and purified by column chromatography using 1% to 10% MeOH in CH2Cl2 as the eluent to give a mixture of two isomers. It was re-purified by reverse phase (C18) chromatography eluting with 10 to 45% ACN in aq NH4CO3 (5mM) to give the product. LCMS (ES, m/z): 536.2 [M+H]+.1H-NMR (400MHz, DMSO-d6) δ 10.80 (s, 1H), 8.83 (s, 1H), 7.72 (d, J=8.7Hz, 1H), 6.65-6.55 (m, 2H), 6.18 (d, J=2.5Hz, 1H), 5.80 (q, J=3.5Hz, 1H), 5.22 (t, J=5.1Hz, 1H), 3.93-3.67 (m, 9H), 2.85 (p, J=6.9Hz, 1H), 2.70 (ddd, J=13.4, 8.5, 4.5Hz, 1H), 2.36 (dt, J=14.1, 5.0Hz, 1H), 1.06 (dd, J=6.8, 3.3Hz, 6H).
[0356] Step 9: 2-amino-9-((2R,3R,5S)-3-hydroxy-5-(hydroxymethyl)tetrahydrothiophen-2- yl)-1,9-dihydro-6H-purin-6-one
Figure imgf000113_0001
[0357] To a solution of (2R,3R,5S)-2-(6-chloro-2-isobutyramido-9H-purin-9-yl)-5- (hydroxymethyl)tetrahydrothiophen-3-yl 2,4-dimethoxybenzoate (6.0g, 11.19mmol) in MeOH (300mL) were added 2-mercaptoethanol (3.50g, 44.8mmol) and NaOMe (10.08g,56 mmol, 30% in MeOH). It was heated at 60°C for 16h, cooled to rt, and concentrated HCl (4mL) was added. The resulting mixture was concentrated, and H2O (100mL) and EtOAc (100mL) were added. Layers were separated, and the aq layer was extracted with EtOAc (3x100mL). The aq layer was basified with NaHCO3 (solid) to ~pH 8 and stirred at RT for 1h. The precipitate was filtered and kept under reduced pressure to give the product. LCMS (ES, m/z): 284.1 [M+H]+.1H-NMR (400MHz, DMSO-d6) δ 10.57 (s, 1H), 7.98 (s, 1H), 6.46 (s, 2H), 5.57 (dd, J=10.9, 3.9Hz, 2H), 5.12 (t, J=5.4Hz, 1H), 4.48 (p, J=4.1Hz, 1H), 3.78-3.53 (m, 3H), 2.11-1.99 (m, 2H).
[0358] Step 10: N-(9-((2R,3R,5S)-3-hydroxy-5-(hydroxymethyl)tetrahydrothiophen-2-yl)-6- oxo-6,9-dihydro-1H-purin-2-yl)isobutyramide
Figure imgf000113_0002
[0359] 2-amino-9-((2R,3R,5S)-3-hydroxy-5-(hydroxymethyl)tetrahydrothiophen-2-yl)-1,9- dihydro-6H-purin-6-one (580mg, 2.047mmol) was co-evaporated with Py (3x20mL) and then re- dissolved in Py (20mL). The mixture was cooled to 0°C and then treated with TMSCl (1557mg, 14.33mmol). It was warmed to RT and stirred for 2h. Then, the reaction was cooled to 0°C, and isobutyric anhydride (486mg, 3.07mmol) was added dropwise. It was warmed to RT and stirred for 2h. The reaction was quenched by the addition of MeOH (5mL). After 5min, NH4OH (ca 29%, 10mL) was added. The mixture was stirred at RT for 30min. Then, it was concentrated and purified by column chromatography on silica gel eluting with 10% to 20% MeOH in CH2Cl2 to give the product. LCMS (ES, m/z): 354.1 [M+H]+.1H-NMR (300MHz, CD3OD) δ: 8.40 (s, 1H), 5.83-5.82 (m, 1H), 4.62-4.59 (m, 1H), 3.89-3.80 (m, 2H), 3.79-3.74 (m, 1H), 2.73-2.64 (m, 1H), 2.19-2.11(m, 2H), 1.20 (d, J=6.8Hz, 6H).
[0360] Step 11: N-(9-((2R,3R,5S)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-3- hydroxytetrahydrothiophen-2-yl)-6-oxo-6,9-dihydro-1H-purin-2-yl)isobutyramide
Figure imgf000114_0001
[0361] N-(9-((2R,3R,5S)-3-hydroxy-5-(hydroxymethyl)tetrahydrothiophen-2-yl)-6-oxo- 6,9-dihydro-1H-purin-2-yl)isobutyramide (510mg, 1.443mmol) was co-evaporated with Py (3×5mL) and then re-suspended in Py (7mL). To the suspension was added DMTrCl (538mg, 1.587mmol), and the mixture was stirred at RT for 2h. At that time, the mixture was concentrated under reduced pressure, and residue was purified by column chromatography on silica gel eluting with 1% to 4% MeOH in CH2Cl2 (containing 1% Et3N) to give the product. LCMS (ES, m/z): 656.0 [M+H]+.1H-NMR (400MHz, CD3OD) δ: 8.02 (s, 1H), 7.51- 7.43 (m, 2H), 7.40-7.17 (m, 7H), 6.91-6.82 (m, 4H), 5.85-5.84 (d, J=2.3Hz, 1H), 4.59-4.57 (m, 1H), 4.02-3.95 (m, 1H), 3.78(s, 6H), 3.52-3.34 (m, 3H), 2.72-2.68 (m, 1H), 1.95-191(m, 1H), 1.38 (d, J=6.8Hz, 6H). [0362] Preparation 22: N-(3-((2R,3R,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)- methoxy)methyl)-4-fluoro-3-hydroxytetrahydrothiophen-2-yl)-7-oxo-6,7-dihydro-3H- [1,2,3]triazolo[4,5-d]pyrimidin-5-yl)isobutyramide
Figure imgf000114_0002
[0363] Step 1: N-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5- yl)isobutyramide
Figure imgf000115_0001
[0364] To a suspension of 5-amino-3,6-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one (5.0g, 32.9mmol) in anhydrous DMF (60mL) was added isobutyric anhydride (12.5mL,
76.0mmol) dropwise. The reaction mixture was refluxed at 150°C for 1h. The reaction was quenched with MeOH (6.6mL, 164mmol) and concentrated in vacuo. The residue was taken up in DCM (50mL)/Hex (100mL) and was stirred at vigorously at RT for 15min. The product was collected by filtration. LCMS (ES, m/z): 223.2 [M+H]+.1H NMR (500MHz, DMSO-d6) δ 16.04 (s, 1H), 12.19 (s, 1H), 11.78 (s, 1H), 2.78 (hept, J=6.7Hz, 1H), 1.13 (d, J=6.8Hz, 6H).
[0365] Step 2: ((2R,3S,4R,5R)-4-(benzoyloxy)-3-fluoro-5-(5-isobutyramido-7-oxo-6,7- dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)tetrahydrothiophen-2-yl)methyl benzoate
Figure imgf000115_0002
[0366] To a mixture of ((2R,3S,4R)-5-acetoxy-4-(benzoyloxy)-3-fluorotetrahydro- thiophen-2-yl)methyl benzoate (1.5g, 3.6mmol) and N-(7-oxo-6,7-dihydro-3H-[1,2,3]triazolo [4,5-d]pyrimidin-5-yl)isobutyramide (0.96g, 4.3mmol) in nitromethane (20mL) was added BF3·Et2O (0.54mL, 4.3mmol), and the resulting mixture was heated at 100°C under microwave irradiation for 1h. The reaction mixture was cooled, diluted in 100mL of EtOAc and washed with sat aq. NaHCO3 (100mL) and brine (100mL). The organic portion was dried over Na2SO4 and concentrated in vacuo. The residue was purified by a silica gel column, eluting with 0-35% EtOAc/Hex. LCMS (ES, m/z): 581.4 [M+H]+.1H NMR (500MHz, Chloroform-d) δ 12.24 (s, 1H), 9.70 (s, 1H), 8.06-8.03 (m, 2H), 7.99-7.96 (m, 2H), 7.67-7.62 (m, 1H), 7.61-7.56 (m, 1H), 7.53-7.46 (m, 2H), 7.46-7.40 (m, 2H), 6.73 (d, J=6.7Hz, 1H), 6.55-6.45 (m, 1H), 5.76 (t, J=2.9Hz, 0.5H), 5.66 (t, J=2.9Hz, 0.5H), 5.55 (dd, J=11.5, 8.8Hz, 1H), 4.86 (ddd, J=11.5, 7.8, 1.0Hz, 1H), 4.23 (dtd, J=15.0, 8.4, 2.5Hz, 1H), 2.93 (hept, J=6.9Hz, 1H), 1.41-1.32 (m, 6H).
[0367] Step 3: N-(3-((2R,3R,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)tetrahydro- thiophen-2-yl)-7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)isobutyramide
Figure imgf000116_0001
[0368] To a solution of ((2R,3S,4R,5R)-4-(benzoyloxy)-3-fluoro-5-(5-isobutyramido-7- oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)tetrahydrothiophen-2-yl)methyl benzoate (4.5g, 7.8mmol) in THF (35mL)/MeOH (28mL)/H (7mL) at 0°C was added 2N NaOH (8.6mL, 17.2mmol). The reaction mixture was stirred at 0°C for 1h and then neutralized with AcOH (2.3mL, 39.0mmol). The product was collected by filtration and carried on to the next step without further purification. LCMS (ES, m/z): 373.3 [M+H]+.
[0369] Step 4: N-(3-((2R,3R,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4- fluoro-3-hydroxytetrahydrothiophen-2-yl)-7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d] pyrimidin-5-yl)isobutyramide
Figure imgf000116_0002
[0370] To a solution of N-(3-((2R,3R,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)- tetrahydrothiophen-2-yl)-7-oxo-6,7-dihydro-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl) isobutyramide (1.8g, 4.8mmol) in Py (30mL) at 0°C was added DMTrCl(1.8g, 5.3mmol). The reaction mixture was stirred at 0°C for 1h. The reaction was quenched with H2O (1mL), and the mixture was concentrated. The residue was diluted in 100mL of EtOAc and washed with sat aq. NaHCO3 (100mL) and brine (100mL). The separated organic layer was dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The residue was purified by a silica gel column, eluting with 0-100% EtOAc/Hex containing 0.1% Et3N to give product. LCMS (ES, m/z): 675.5 [M+H]+.1H NMR (500MHz, Chloroform-d) δ 12.13 (bs, 1H), 8.46 (bs, 1H), 7.54-7.48 (m, 2H), 7.38 (tt, J=6.8, 2.6Hz, 4H), 7.31-7.27 (m, 2H), 7.24-7.18 (m, 1H), 6.83 (dd, J=9.0, 1.0Hz, 4H), 6.16 (d, J=7.2Hz, 1H), 5.36 (m, 1H), 5.33-5.24 (m, 1H), 3.79-3.76 (m, 1H), 3.78 (s, 3H), 3.72 (d, J=1.8Hz, 1H), 3.70 (s, 3H), 3.43 (dd, J=10.2, 5.6Hz, 1H), 3.34 (dd, J=10.2, 5.4Hz, 1H), 2.14 (dt, J=13.7, 6.7Hz, 1H), 1.05 (d, J=6.9Hz, 3H), 1.00 (d, J=6.9Hz, 3H). [0371] Preparation 23: 7-(2-deoxy-β-D-erythro-pentofuranosyl)-5-fluoro-7H- pyrrolo[2,3-d]pyrimidin-4-amine
Figure imgf000117_0001
[0372] The title compound was prepared according to published procedures (Synthesis 2006 (12), 2005-2012). [0373] EXAMPLES [0374] Examples 1 and 2: 8-[(2R,5R,7R,8R,10R,12aR,14R,15R,15aS,16R)-14-(6-amino- 9H-purin-9-yl)-15,16-dihydroxy-2,10-dioxido-2,10-disulfanyloctahydro-12H-5,8- methanofuro[3,2-l][1,3,6,9,11,2,10]pentaoxadiphosphacyclotetradecin-7-yl]imidazo[1,2- a]pyrimidin-5(8H)-one (Diastereomer 1) and 8-[(2S,5R,7R,8R,10R,12aR,14R,15R,
15aS,16R)-14-(6-amino-9H-purin-9-yl)-15,16-dihydroxy-2,10-dioxido-2,10- disulfanyloctahydro-12H-5,8-methanofuro[3,2-l][1,3,6,9,11,2,10]pentaoxadiphospha- cyclotetradecin-7-yl]imidazo[1,2-a]pyrimidin-5(8H)-one (Diastereomer 2)
Figure imgf000117_0002
[0375] Step 1: 8-((2R,3R,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-3,4- dihydroxytetrahydrofuran-2-yl)imidazo[1,2-a]pyrimidin-5(8H)-one
Figure imgf000117_0003
[0376] To a solution of 8-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)
tetrahydrofuran-2-yl)imidazo[1,2-a]pyrimidin-5(8H)-one (1.70g, 6.36mmol) in Py (25mL) was added DMTrCl (2.37g, 7.00mmol). The resulting mixture was stirred at RT for 4h. It was concentrated, and EtOAc (100mL) and H2O (40mL) were added. Layers were separated, and the aq layer was extracted with EtOAc (2×50mL). The combined organics were washed with brine (50mL), dried (MgSO4), and purified by column chromatography eluted with 0 to 10% MeOH in CH2Cl2 (0.2% of Et3N) to give the product. LCMS (ES, m/z): 1137.5 [2M-H]-.1H-NMR
(300MHz, DMSO-d6): δ 8.15 (d, J=7.9Hz, 1H), 7.64 (s, 1H), 7.43-7.17 (m, 10H), 6.92-6.81 (m, 4H), 6.09 (d, J=3.2Hz, 1H), 5.63 (d, J=5.1Hz, 1H), 5.50 (d, J=7.8Hz, 1H), 5.20 (d, J=6.2Hz, 1H), 4.39-4.17 (m, 2H), 4.06 (dt, J=6.8, 3.5Hz, 1H), 3.72 (s, 6H), 3.38 -3.23 (m, 2H).
[0377] Step 2: 8-((2R,3R,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4- ((tert-butyldimethylsilyl)oxy)-3-hydroxytetrahydrofuran-2-yl)imidazo[1,2-a]pyrimidin-5(8H)-one
Figure imgf000118_0001
[0378] To a solution of 8-((2R,3R,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy) methyl)-3,4-dihydroxytetrahydrofuran-2-yl)imidazo[1,2-a]pyrimidin-5(8H)-one (5.0g, 8.8mmol), (2S,4R)-4-isopropyl-2-methoxy-3-((S)-2-methyl-1-(1-methyl-1H-imidazol-2-yl)propyl) oxazolidine (3.71g, 13.2mmol) and DIEA HCl (0.044g, 0.263mmol) in THF (90mL) at 0°C under Ar was added DIEA (3.40g, 26.3mmol) and TBSOTf (2.55g, 9.66mmol). The resulting mixture was stirred at RT for 1.5h. Then, it was concentrated, and the residue was partitioned between EtOAc (200mL) and H2O (100mL). The aq layer was extracted with EtOAc
(2×200mL), and the combined organic phase was dried (Na2SO4) and concentrated. The crude was purified by silica gel chromatography eluted with 0-40% EtOAc in Hex to give the product. LCMS (ES, m/z): 682.1 [M-H]-.1H-NMR (400MHz, DMSO-d6): δ 8.25 (d, J=7.9Hz, 1H), 7.67 (t, J=1.4Hz, 1H), 7.44-7.36 (m, 2H), 7.36-7.21 (m, 8H), 6.90 (dt, J=9.1, 1.2Hz, 4H), 6.09 (d, J=3.7Hz, 1H), 5.58 (dd, J=7.8, 1.0Hz, 1H), 5.50 (d, J=5.9Hz, 1H), 4.45 (q, J=4.9Hz, 1H), 4.34 (t, J=5.4Hz, 1H), 4.07 (dt, J=5.9, 4.1Hz, 1H), 3.75 (s, 6H), 3.47 (dd, J=10.9, 3.5Hz, 1H), 3.25 (dd, J=10.9, 4.3Hz, 1H), 0.80 (s, 9H), 0.05 (s, 3H), -0.00 (s, 3H).
a. Step 3: 8-{5-O-[bis(4-methoxyphenyl)(phenyl)methyl]-3-O-[tert-butyl(dimethyl)silyl]- 2-O-[hydroxy(oxido)-λ5-phosphanyl]-β-D-ribofuranosyl}imidazo[1,2-a]pyrimidin-5(8H)-one
Figure imgf000118_0002
[0379] A solution of 8-((2R,3R,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy) methyl)-4-((tert-butyldimethylsilyl)oxy)-3-hydroxytetrahydrofuran-2-yl)imidazo[1,2-a] pyrimidin-5(8H)-one (1.0g, 1.46mmol) in Py (10mL) was concentrated in vacuo. To the residue was added Py (9.3mL) followed by dropwise addition of diphenyl phosphite (0.84mL, 4.4mmol). The mixture was left to stir for 5h, treated with TEA (0.61mL, 4.4mmol) and H2O (0.61mL, 34mmol), and left to stir for 30min. The mixture was concentrated, and the residue was partitioned between DCM and 5% NaHCO3 solution. The organic layer was separated, washed with 5% NaHCO3 solution (2x), dried over Na2SO4, and purified by silica gel column
chromatography eluted with 0-18% of MeOH in DCM with 0.5% TEA to afford the product as the triethylammonium salt. LCMS (ES, m/z): 746 [M-H]-.1H-NMR (600MHz, DMSO-d6): δ 9.94 (s, 1H), 8.21 (d, J=7.8Hz, 1H), 7.66 (s, 1H), 7.4-6.78 (m, 15H), 6.19 (s, 1H), 5.69 (d, J=7.8Hz, 1H), 5.07 (brs, 1H), 4.54 (s, 1H), 3.98 (m, 1H), 3.72 (s, 6H), 3.38 (m, 1H), 3.15 (m, 1H), 0.79 (s, 9H), 0.07 (s, 3H), 0.02 (s, 3H).
[0380] Step 4: (2R,3R,4R,5R)-5-((((((2R,3R,4R,5R)-5-(6-benzamido-9H-purin-9-yl)-4- ((tert-butyldimethylsilyl)oxy)-2-(hydroxymethyl)tetrahydrofuran-3-yl)oxy)(2-cyanoethoxy) phosphorothioyl)oxy)methyl)-4-((tert-butyldimethylsilyl)oxy)-2-(5-oxoimidazo[1,2-a]pyrimidin- 8(5H)-yl)tetrahydrofuran-3-yl hydrogen phosphonate
Figure imgf000119_0001
[0381] A solution of (2R,3R,4R,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)- 4-((tert-butyldimethylsilyl)oxy)-2-(5-oxoimidazo[1,2-a]pyrimidin-8(5H)-yl)tetrahydrofuran-3-yl hydrogen phosphonate (0.64g, 0.67mmol) in MeCN (4.6 mL) was concentrated in vacuo.
Addition of MeCN (4.6 mL) followed by concentration was repeated twice. The residue was taken up in MeCN (4.6mL), cooled to 0°C, and treated with pyrrole (0.14mL, 2.02mmol) and TFA (0.16mL, 2.02mmol) over 1min. The reaction mixture was allowed to warm to RT (1.5h) and left to stir at RT for 0.5h. The mixture was cooled to 0°C and treated with Py (0.22mL, 2.7mmol).
[0382] A solution of (2R,3R,4R,5R)-5-(6-benzamido-9H-purin-9-yl)-2-((bis(4- methoxyphenyl)(phenyl)methoxy)methyl)-4-((tert-butyldimethylsilyl)oxy)tetrahydrofuran-3-yl (2-cyanoethyl) diisopropylphosphoramidite (0.886g, 0.896mmol) in ACN (4.6mL) in a separate flask was concentrated in vacuo. Addition of MeCN (4.6mL) followed by concentration was repeated twice. The residue was taken up in MeCN (1.6mL) and transferred to the H- phosphonate solution over 1min at 0°C. The mixture was left to stir at 0°C for 20min, treated with DDTT (0.166g, 0.809mmol), and left to stir at 0°C for 20min. The mixture was treated with 1-propanol (0.51mL, 6.7mmol), warmed to RT, and left to stir for 10min. TFA (0.519mL, 6.74mmol) was added to the reaction mixture; the mixture was left to stir for 1h and treated with pyridine (0.60mL, 7.4mmol). The mixture was concentrated to half the volume. The residue was added into rapidly stirring isopropyl acetate (46mL). The precipitate was filtered and dried under vacuum overnight to afford the crude products. LCMS (ES, m/z): 1060 [M-H]-.
[0383] Step 5: N-{9-[(5R,7R,8R,12aR,14R,15R,15aR,16R)-15,16-bis{[tert-butyl
(dimethyl)silyl]oxy}-2-(2-cyanoethoxy)-10-oxido-7-(5-oxoimidazo[1,2-a]pyrimidin-8(5H)-yl)-10- sulfanyl-2-sulfidooctahydro-12H-5,8-methanofuro[3,2-l][1,3,6,9,11,2,10]
pentaoxadiphosphacyclotetradecin-14-yl]-9H-purin-6-yl}benzamide
Figure imgf000120_0001
[0384] A solution of the crude (2R,3R,4R,5R)-5-((((((2R,3R,4R,5R)-5-(6-benzamido-9H- purin-9-yl)-4-((tert-butyldimethylsilyl)oxy)-2-(hydroxymethyl)tetrahydrofuran-3-yl)oxy)(2- cyanoethoxy)phosphorothioyl)oxy)methyl)-4-((tert-butyldimethylsilyl)oxy)-2-(5-oxoimidazo [1,2-a]pyrimidin-8(5H)-yl)tetrahydrofuran-3-yl hydrogen phosphonate in Py (4mL) was concentrated in vacuo. Addition of Py (4mL) followed by concentration was repeated once. The residue was taken up in Py (3.3mL).
[0385] Into a separate flask were added MeCN (32mL), Py (2.0mL), and diphenyl chlorophosphate (0.699mL, 3.37mmol). The solution was cooled to -20°C, and the solution of the hydrogen phosphonate in Py was added dropwise. The residue was rinsed with Py (0.6mL) and added to the reaction mixture. The mixture was left to stir at -23°C to -20°C for 20min.3H- 1,2-benzodithiol-3-one (0.136g, 0.809mmol) and H2O (0.243mL, 13.5mmol) were added, and the cooling bath was removed. After the mixture was warmed to RT, it was concentrated and purified by silica gel column chromatography eluted with 100% EtOAc, then 5-20% MeOH in DCM to give the products. LCMS (ES, m/z): 1074 [M-H]-.
[0386] Step 6: 8-[(5R,7R,8R,12aR,14R,15R,15aR,16R)-14-(6-amino-9H-purin-9-yl)-15,16- bis{[tert-butyl(dimethyl)silyl]oxy}-2,10-dioxido-2,10-disulfanyloctahydro-12H-5,8- methanofuro[3,2-l][1,3,6,9,11,2,10]pentaoxadiphosphacyclotetradecin-7-yl]imidazo[1,2- a]pyrimidin-5(8H)-one
Figure imgf000121_0001
[0387] To a stirred solution of N-{9-[(5R,7R,8R,12aR,14R,15R,15aR,16R)-15,16-bis {[tert- butyl(dimethyl)silyl]oxy}-2-(2-cyanoethoxy)-10-oxido-7-(5-oxoimidazo[1,2-a]pyrimidin-8(5H)- yl)-10-sulfanyl-2-sulfidooctahydro-12H-5,8-methanofuro[3,2-l][1,3,6,9,11,2,10]
pentaoxadiphosphacyclotetradecin-14-yl]-9H-purin-6-yl}benzamide (0.773g, 0.718mmol) in Py (8mL) were added H2O (2mL) and NH4OH (28%, 8mL). The mixture was left to stir for 5h, concentrated, and lyophilized to give the crude products. LCMS (ES, m/z): 917 [M-H]-.
[0388] Step 7: 8-[(2R,5R,7R,8R,10R,12aR,14R,15R,15aS,16R)-14-(6-amino-9H-purin-9- yl)-15,16-dihydroxy-2,10-dioxido-2,10-disulfanyloctahydro-12H-5,8-methanofuro[3,2-l]
[1,3,6,9,11,2,10]pentaoxadiphosphacyclotetradecin-7-yl]imidazo[1,2-a]pyrimidin-5(8H)-one (Diastereomer 1) and 8-[(2S,5R,7R,8R,10R,12aR,14R,15R,15aS,16R)-14-(6-amino-9H-purin-9- yl)-15,16-dihydroxy-2,10-dioxido-2,10-disulfanyloctahydro-12H-5,8-methanofuro[3,2-l]
[1,3,6,9,11,2,10]pentaoxadiphosphacyclotetradecin-7-yl]imidazo[1,2-a]pyrimidin-5(8H)-one (Diastereomer 2)
Figure imgf000121_0002
[0389] To a stirred solution of the crude 8-[(5R,7R,8R,12aR,14R,15R,15aR,16R)-14-(6- amino-9H-purin-9-yl)-15,16-bis{[tert-butyl(dimethyl)silyl]oxy}-2,10-dioxido-2,10- disulfanyloctahydro-12H-5,8-methanofuro[3,2-l][1,3,6,9,11,2,10]pentaoxadiphosphacyclo- tetradecin-7-yl]imidazo[1,2-a]pyrimidin-5(8H)-one (0.660g, 0.718mmol) in Py (1.5mL) were added TEA (2mL, 14.4mmol) and HF·TEA (0.1mL, 0.82mmol). The mixture was heated to 50°C for 6h, cooled to RT, diluted with H2O, lyophilized, and purified by reverse phase HPLC (eluted MeCN/H2O gradient with 100mM TEAA modifier, linear gradient) to afford two diastereomers of the title compounds.
[0390] Example 1 (Diastereomer 1) (fast eluted): LCMS (ES, m/z): 689 [M-H]-.1H-NMR (600MHz, D2O): δ 8.48 (d, J=7.9Hz, 1H), 8.26 (s, 1H), 8.18 (s, 1H), 7.67 (s, 1H), 7.28 (s, 1H), 6.50 (d, J=8.2Hz, 1H), 6.12 (s, 1H), 5.41 (d, J=7.9Hz, 1H), 5.09-5.06 (m, 2H), 5.00 (d, J=3.6Hz, 1H), 4.76 (m, 1H), 4.56-4.46 (m, 3H), 4.32–4.20 (m, 3H).
[0391] Example 2 (Diastereomer 2) (slow eluted): LCMS (ES, m/z): 689 [M-H]-.1H-NMR (600MHz, D2O): δ 8.30 (d, J=7.9Hz, 1H), 8.26 (s, 1H), 8.21 (s, 1H), 7.66 (s, 1H), 7.27 (s, 1H), 6.53 (d, J=8.2Hz, 1H), 6.13 (s, 1H), 5.56 (d, J=7.8Hz, 1H), 5.09 (td, J=8.7, 4.0Hz, 1H), 4.93- 4.89 (m, 2H), 4.80 (m, 1H), 4.56-4.53 (m, 2H), 4.42–4.37 (m, 2H), 4.29 (m, 1H), 4.16 (dd, J=11.9, 5.0Hz, 1H). [0392] Examples 3 through 9, as shown in Table 1 below, were prepared according to procedures analogous to those outlined in Examples 1 and 2 above using appropriate monomers, described as Preparations or as obtained from commercial sources, in the coupling step.
Table 1
Figure imgf000122_0001
Figure imgf000123_0001
- 122 -
Figure imgf000124_0001
Figure imgf000125_0001
[0393] Example 18: 8-[(5R,7R,8R,12aR,14R,15aS,16R)-14-(7-amino-3H-[1,2,3] triazolo[4,5-b]pyridin-3-yl)-16-hydroxy-2,10-dioxido-2,10-disulfanyloctahydro-12H-5,8- methanofuro[3,2-l][1,3,6,9,11,2,10]pentaoxadiphosphacyclotetradecin-7-yl]imidazo[1,2- a]pyrimidin-5(8H)-one
Figure imgf000126_0001
[0394] Step 1: (2R,3R,4R,5R)-4-((tert-butyldimethylsilyl)oxy)-5-(hydroxymethyl)-2-(5- oxoimidazo[1,2-a]pyrimidin-8(5H)-yl)tetrahydrofuran-3-yl hydrogen phosphonate
Figure imgf000126_0002
[0395] To a solution of (2R,3R,4R,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy) methyl)-4-((tert-butyldimethylsilyl)oxy)-2-(5-oxoimidazo[1,2-a]pyrimidin-8(5H)-yl) tetrahydrofuran-3-yl hydrogen phosphonate (0.76g, 0.9mmol) in CH2Cl2 (13mL) at RT was added H2O (0.16mL), and DCA in CH2Cl2 (6%, 13mL, 8.1mmol). The mixture was stirred for 30min, and then Et3SiH (16mL) was added. After 40min, Py (1.5mL) was added, and it was stirred for 10min. The solution was concentrated to give the crude product, which was used for the next reaction step without purification. LCMS (ES, m/z): 446.2 [M+H]+.
[0396] Step 2: 2-(4-(tert-butyl)phenoxy)-N-(3-((2R,4S,5R)-4-hydroxy-5- (hydroxymethyl)tetrahydrofuran-2-yl)-3H-[1,2,3]triazolo[4,5-b]pyridin-7-yl)acetamide
Figure imgf000126_0003
[0397] (2R,3S,5R)-5-(7-amino-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-2-(hydroxymethyl) tetrahydrofuran-3-ol (470mg, 1.87mmol) was co-evaporated with Py (3×5mL) and then re- suspended in Py (14mL). To the mixture under Ar at 0°C was added TMSCl (1.66mL,
13.1mmol), and it was stirred at RT for 2h. To the resulting mixture at 0°C was added 2-(4-(tert- butyl)phenoxy) acetyl chloride (0.576mL, 2.81mmol) over 1min. It was stirred at RT for 2h. Then, H2O (3.5mL) was added, and it was stirred for 20min. Then, NH4OH (7mL) was added, and it was stirred for 1h. It was concentrated and purified by preparative-TLC eluted with 3% MeOH in CH2Cl2 to give the product. LCMS (ES, m/z): 442.3 [M+H]+.1H-NMR (400MHz, DMSO-d6): δ 11.37 (s, 1H), 8.63 (d, J=5.4Hz, 1H), 8.21 (d, J=5.4Hz, 1H), 7.38-7.29 (m, 2H), 6.96-6.87 (m, 2H), 6.81 (t, J=6.4Hz, 1H), 5.42 (d, J=4.6Hz, 1H), 4.99 (s, 2H), 4.83 (t, J=5.8Hz, 1H), 4.66-4.55 (m, 1H), 3.96-3.92 (m, 1H), 3.60 (dt, J=11.1, 5.4Hz, 1H), 3.42 (dt, J=11.8, 6.0Hz, 1H), 3.18-3.10 (m, 1H), 2.51-2.45 (m, 1H), 1.26 (s, 9H).
[0398] Step 3: N-(3-((2R,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4- hydroxytetrahydrofuran-2-yl)-3H-[1,2,3]triazolo[4,5-b]pyridin-7-yl)-2-(4-(tert- butyl)phenoxy)acetamide
Figure imgf000127_0001
[0399] To a solution of 2-(4-(tert-butyl)phenoxy)-N-(3-((2R,4S,5R)-4-hydroxy-5- (hydroxymethyl) tetrahydrofuran-2-yl)-3H-[1,2,3]triazolo[4,5-b]pyridin-7-yl)acetamide (467mg, 1.06mmol) in Py (5mL) at 0°C under Ar was added 4,4'-(chloro(phenyl)methylene)bis
(methoxybenzene) (394mg, 1.16mmol), and the mixture was stirred at RT for 2h. Then, MeOH (3mL) was added, and the volatile components were removed under reduced pressure. The residue was purified by chromatography on silica gel eluted with 0-2.8% MeOH in CH2Cl2 to the product. LCMS (ES, m/z): 744.3 [M+H]+.1H-NMR (300MHz, DMSO-d6): δ 11.31 (s, 1H), 8.57 (d, J=5.4Hz, 1H), 8.18 (d, J=5.4Hz, 1H), 7.34–7.25 (m, 2H), 7.20 (dd, J=6.8, 3.0Hz, 2H), 7.11- 7.06 (m, 7H), 6.92-6.78 (m, 3H), 6.73-6.65 (m, 2H), 6.65-6.58 (m, 2H), 5.42 (d, J=4.9Hz, 1H), 4.94 (s, 2H), 4.72-4.58 (m, 1H), 4.03 (q, J=5.3Hz, 1H), 3.65 (s, 3H), 3.63 (s, 3H), 3.18-2.93 (m, 3H), 2.56-2.48 (m, 1H), 1.22 (s, 9H).
[0400] Step 4: (2R,3S,5R)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-5-(7-(2-(4- (tert-butyl)phenoxy)acetamido)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)tetrahydrofuran-3-yl (2- cyanoethyl) diisopropylphosphoramidite
Figure imgf000127_0002
[0401] To a solution of 3-((bis(diisopropylamino)phosphino)oxy)propanenitrile (477mg, 1.58 mol) in MeCN (8mL) at rt under Ar was added pyridin-1-ium 2,2,2-trifluoroacetate (229mg, 1.19mmol) and a solution of dry N-(3-((2R,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy) methyl)-4-hydroxytetrahydrofuran-2-yl)-3H-[1,2,3]triazolo[4,5-b]pyridin-7-yl)-2-(4-(tert- butyl)phenoxy)acetamide (589mg, 0.792mmol) in MeCN (3.75mL) over 2min. After 1h, the residue was dissolved in EtOAc (60mL). It was washed with aq NaHCO3 (1%, 2×40mL), H2O (40mL), and brine (40mL), dried (Na2SO4), concentrated and purified by reverse phase (C18) chromatography eluted with 0 to 95% ACN in H2O to give the product. LCMS (ES, m/z): 944.5 [M+H]+.1H-NMR (300MHz, DMSO-d6): δ 11.35 (s, 1H), 8.58 (dd, J=5.4, 1.4Hz, 1H), 8.18 (dd, J=5.4, 1.4Hz, 1H), 7.32-7.24 (m, 2H), 7.18 (dd, J=6.7, 3.0Hz, 2H), 7.14-7.00 (m, 7H), 6.91-6.80 (m, 3H), 6.72-6.57 (m, 4H), 5.03-4.89 (m, 3H), 4.17 (t, J=4.9Hz, 1H), 3.79-3.37 (m, 10H), 3.27– 3.06 (m, 2H), 2.97 (dd, J=10.4, 6.1Hz, 1H), 2.78-2.58 (m, 3H), 1.21 (s, 9H), 1.14-1.06 (m, 9H), 0.98 (d, J=6.7Hz, 3H).31P NMR (121MHz, DMSO-d6): δ 147.79, 147.14.
[0402] Step 5: (2R,3R,4R,5R)-5-((((((2R,3S,5R)-2-((bis(4-methoxyphenyl)(phenyl) methoxy)methyl)-5-(7-(2-(4-(tert-butyl)phenoxy)acetamido)-3H-[1,2,3]triazolo[4,5-b]pyridin-3- yl)tetrahydrofuran-3-yl)oxy)(2-cyanoethoxy)phosphanyl)oxy)methyl)-4-((tert-butyldimethylsilyl) oxy)-2-(5-oxoimidazo[1,2-a]pyrimidin-8(5H)-yl)tetrahydrofuran-3-yl hydrogen phosphonate
Figure imgf000128_0001
[0403] (2R,3R,4R,5R)-4-((tert-butyldimethylsilyl)oxy)-5-(hydroxymethyl)-2-(5- oxoimidazo[1,2a]-pyrimidin-8(5H)-yl)tetrahydrofuran-3-yl phosphonate (~290mg, 0.56mmol) was co-evaporated with MeCN (3×3mL) and then re-dissolved in MeCN (2.5mL). Activated 4Å molecular sieve (200mg) was added to the solution under Ar. (2R,3S,5R)-2-((bis(4-methoxy- phenyl)(phenyl)methoxy)methyl)-5-(7-(2-(4-(tert-butyl)phenoxy)acetamido)-3H[1,2,3]triazolo [4,5-b]pyridin-3-yl)tetrahydrofuran-3-yl(2-cyanoethyl)diisopropylphosphoramidite (480mg, 0.508mmol) was also co-evaporated with MeCN (3×3mL), and then re-dissolved in MeCN (2.5mL). Activated 4Å molecular sieve (200mg) was added to the solution under Ar. After 30min, it was added to the (2R,3R,4R,5R)-4-((tert-butyldimethylsilyl) oxy)-5-(hydroxymethyl)- 2-(5-oxoimidazo[1,2a]-pyrimidin-8(5H)-yl)tetrahydrofuran-3-yl phosphonate solution. The resulting mixture under Ar was stirred at RT for 30min. The reaction mixture was used for the next reaction step without purification. LCMS (ES, m/z): 1288.6 [M+H]+.
[0404] Step 6: (2R,3R,4R,5R)-5-((((((2R,3S,5R)-2-((bis(4-methoxyphenyl)(phenyl)methoxy) methyl)-5-(7-(2-(4-(tert-butyl)phenoxy)acetamido)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl) tetrahydrofuran-3-yl)oxy)(2-cyanoethoxy)phosphorothioyl)oxy)methyl)-4-((tert-butyldimethyl- silyl)oxy)-2-(5-oxoimidazo[1,2-a]pyrimidin-8(5H)-yl)tetrahydrofuran-3-yl hydrogen
phosphonate
Figure imgf000129_0001
[0405] To the reaction mixture from Step 5 at RT was added (E)-N,N-dimethyl-N'-(3- thioxo-3H-1,2,4-dithiazol-5-yl)formimidamide (0.115g, 0.560mmol), and the mixture was stirred for 1h. Then, it was filtered, and the filtrate was concentrated to give the crude product, which was used for the next step without purification. LCMS (ES, m/z): 1318.5 [M-H]-.
[0406] Step 7: (2R,3R,4R,5R)-5-((((((2R,3S,5R)-5-(7-(2-(4-(tert-butyl)phenoxy) acetamido)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-2-(hydroxymethyl)tetrahydrofuran-3- yl)oxy)(2-cyanoethoxy)phosphorothioyl)oxy)methyl)-4-((tert-butyldimethylsilyl)oxy)-2-(5- oxoimidazo[1,2-a]pyrimidin-8(5H)-yl)tetrahydrofuran-3-yl hydrogen phosphonate
Figure imgf000129_0002
[0407] To a solution of the crude from Step 6 in CH2Cl2 (5.6mL) at RT was added H2O (0.1mL) and DCA (6%, 7.3mL, 4.6mmol) in CH2Cl2. After 15min, TES (59mg, 0.51mmol) was added, and it was stirred for 40min. Then, Py (0.74mL, 9.2mmol) was added. After 5min, the mixture was concentrated, and the residue was purified by reverse phase (C18) chromatography eluted with 0 to 95% ACN in aq NH4HCO3 (5mM) to give the product. LCMS (ES, m/z): 1018.3 [M+H]+.31P NMR (121MHz, CD3OD): δ 66.89(s), 66.81 (s); 2.96 (s), 2.87 (s).
[0408] Step 8: N-{3-[(5R,7R,8R,12aR,14R,15aS,16R)-16-{[tert-butyl(dimethyl)silyl]oxy}- 2-(2-cyanoethoxy)-10-hydroxy-7-(5-oxoimidazo[1,2-a]pyrimidin-8(5H)-yl)-2-sulfidooctahydro- 12H-5,8-methanofuro[3,2-l][1,3,6,9,11,2,10]pentaoxadiphosphacyclotetradecin-14-yl]-3H- [1,2,3]triazolo[4,5-b]pyridin-7-yl}-2-(4-tert-butylphenoxy)acetamide
Figure imgf000130_0001
[0409] To a solution of (2R,3R,4R,5R)-5-((((((2R,3S,5R)-5-(7-(2-(4-(tert-butyl)phenoxy) acetamido)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-2-(hydroxymethyl)tetrahydrofuran-3-yl)oxy) (2-cyanoethoxy)phosphorothioyl)oxy)methyl)-4-((tert-butyldimethylsilyl)oxy)-2-(5-oxoimidazo [1,2-a]pyrimidin-8(5H)-yl)tetrahydrofuran-3-yl phosphonate (300mg, 0.290mmol) in DCM (29mL) and Py (29mL) at -40°C under Ar was added diphenyl phosphorochloridate (1.2mL, 5.80mmol) over 5min. It was stirred at -40°C for 20min. The reaction mixture was used for the next reaction step immediately without purification. LCMS (ES, m/z): 1000.1 [M+H]+.
[0410] Step 9: N-{3-[(5R,7R,8R,12aR,14R,15aS,16R)-16-{[tert-butyl(dimethyl)silyl]oxy}- 2-(2-cyanoethoxy)-10-oxido-7-(5-oxoimidazo[1,2-a]pyrimidin-8(5H)-yl)-10-sulfanyl-2- sulfidooctahydro-12H-5,8-methanofuro[3,2-l][1,3,6,9,11,2,10]pentaoxadiphosphacyclo- tetradecin-14-yl]-3H-[1,2,3]triazolo[4,5-b]pyridin-7-yl}-2-(4-tert-butylphenoxy)acetamide
Figure imgf000130_0002
[0411] To the reaction mixture from Step 8 at -40°C was added 3H-benzo[c][1,2]dithiol-3- one (0.073g, 0.44mmol) and H2O (0.3mL). It was stirred at RT for 40min, and the - mixture was concentrated under reduced pressure. The residue was purified by reverse phase (C18) chromatography eluted with 0 to 95% ACN in aq NH4HCO3 (5mM) to give the product. LCMS (ES, m/z): 1032.3 [M+H]+.1H-NMR (300MHz, CD3OD): δ 8.60-8.57 (m, 1H), 8.45 (d, J=8.0Hz, 0.5H), 8.29-8.27 (m, 1H), 8.16 (d, J=8.0Hz, 0.5H), 7.62-7.61 (m, 1H), 7.41-7.29 (m, 2H), 7.27- 7.13 (m, 1H), 7.09-6.90 (m, 3H), 6.56 (d, J=8.7Hz, 1H), 6.04 (dd, J=36.6, 7.9Hz, 1H), 5.76-5.74 (m, 1H), 5.17-5.13 (m, 1H), 4.82-4.79 (m, 2H), 4.68-4.63 (m, 1H), 4.60-4.11 (m, 5H), 3.97-3.70 (m, 2H), 3.00-2.94 (m, 3H), 1.27 (s, 9H), 0.97-0.96 (m, 9H), 0.28 (d, J=4.1Hz, 3H), 0.23 (d, J=2.3Hz, 3H).31P NMR (121MHz, CD3OD): δ 66.05-64.43 (m, 1P), 57.93-57.39 (m, 1P).
[0412] Step 10: 8-[(5R,7R,8R,12aR,14R,15aS,16R)-14-(7-amino-3H-[1,2,3]triazolo[4,5- b]pyridin-3-yl)-16-{[tert-butyl(dimethyl)silyl]oxy}-2,10-dioxido-2,10-disulfanyloctahydro-12H- 5,8-methanofuro[3,2-l][1,3,6,9,11,2,10]pentaoxadiphosphacyclotetradecin-7-yl]imidazo[1,2- a]pyrimidin-5(8H)-one
Figure imgf000131_0001
[0413] To a suspension of N-{3-[(5R,7R,8R,12aR,14R,15aS,16R)-16-{[tert-butyl
(dimethyl)silyl]oxy}-2-(2-cyanoethoxy)-10-oxido-7-(5-oxoimidazo[1,2-a]pyrimidin-8(5H)-yl)- 10-sulfanyl-2-sulfidooctahydro-12H-5,8-methanofuro[3,2-l][1,3,6,9,11,2,10]pentaoxadiphospha- cyclotetradecin-14-yl]-3H-[1,2,3]triazolo[4,5-b]pyridin-7-yl}-2-(4-tert-butylphenoxy)acetamide (118mg, 0.112mmol) in NH4OH (9.9mL, 64mmol) was added NH4OAc (1.0g, 13mmol). The resulting mixture was stirred at rt for 16h. Then, it was concentrated under reduced pressure, and the residue was purified by reverse phase (C18) chromatography eluted with 0 to 95% ACN in aq NH4HCO3 (5mM) to give the product. LCMS (ES, m/z): 789.2 [M+H]+.1H-NMR (400MHz, CD3OD): δ 8.98 (d, J=7.9Hz, 0.5H), 8.62 (dd, J=10.6, 7.9Hz, 0.5H), 8.09 (dd, J=5.6, 1.9Hz, 1H), 7.76-7.61 (m, 1H), 7.19 (d, J=1.7Hz, 1H), 6.89-6.81 (m, 1H), 6.67 (dd, J=8.6, 3.5Hz, 1H), 6.50 (dd, J=5.6, 1.3Hz, 1H), 6.22-6.02 (m, 1H), 5.59-5.41 (m, 1H), 5.30 (tdd, J=11.9, 8.4, 4.0Hz, 1H), 4.81-4.67 (m, 1.5H), 4.58-4.50 (m, 0.5H), 4.41-4.35 (m, 0.5H), 4.31-4.26 (m, 1.5H), 4.21-3.88 (m, 3H), 3.70-3.58 (m, 1H), 3.07–2.88 (m, 1H), 1.01 (s, 9H), 0.32 (d, J=5.5Hz, 3H), 0.26 (s, 3H). 31P NMR (162MHz, CD3OD): δ 57.05-56.52 (m).
[0414] Step 11: 8-[(5R,7R,8R,12aR,14R,15aS,16R)-14-(7-amino-3H-[1,2,3]triazolo[4,5- b]pyridin-3-yl)-16-hydroxy-2,10-dioxido-2,10-disulfanyloctahydro-12H-5,8-methanofuro[3,2- l][1,3,6,9,11,2,10]pentaoxadiphosphacyclotetradecin-7-yl]imidazo[1,2-a]pyrimidin-5(8H)-one
Figure imgf000132_0001
[0415] To a stirred suspension of 8-[(5R,7R,8R,12aR,14R,15aS,16R)-14-(7-amino-3H- [1,2,3]triazolo[4,5-b]pyridin-3-yl)-16-{[tert-butyl(dimethyl)silyl]oxy}-2,10-dioxido-2,10- disulfanyloctahydro-12H-5,8-methanofuro[3,2-l][1,3,6,9,11,2,10] pentaoxadiphospha- cyclotetradecin-7-yl]imidazo[1,2-a]pyrimidin-5(8H)-one (68mg, 0.083mmol) in Py (0.22mL) at RT was added TEA (1.15mL, 8.26mmol) and TEA·3HF (0.674mL, 4.13mmol). The mixture was stirred at 50°C for 16h. Then, the mixture was concentrated under reduced pressure, and acetone (1.1mL) was added. Ethoxytrimethylsilane (3.9mL, 25mmol) was added to the mixture. The crude product crystallized out, and the mixture was maintained at 0°C. After 30min, the crude product was collected by filtration, and it was washed with acetone. The crude product was purified by reverse phase (C18) chromatography eluted with 0 to 15% ACN in aq NH4HCO3 (30mM) over 55min (TR: 41.2 min) and then, prep-HPLC (XBridge Shield RP18 OBD Column, 19mm×250mm) eluted with 10 to 11% ACN in aq NH4HCO3 (10mM) over 11min to afford the product (TR: 8.33 min). LCMS (ES, m/z): 674.9 [M+H]+.1H-NMR (400MHz, D2O): δ 8.38 (d, J=7.9Hz, 1H), 8.03 (d, J=5.7Hz, 1H), 7.61 (d, J=1.9Hz, 1H), 7.22 (d, J=1.9Hz, 1H), 6.73 (t, J=6.3Hz, 1H), 6.53 (d, J=8.2Hz, 1H), 6.49 (d, J=5.7Hz, 1H), 6.17 (d, J=7.9Hz, 1H), 5.34 (dq, J=8.7, 4.0Hz, 1H), 5.02 (ddd, J=10.0, 8.2, 4.3Hz, 1H), 4.64 (d, J=4.2Hz, 1H), 4.52-4.34 (m, 3H), 4.19-4.09 (m, 1H), 3.99-3.80 (m, 2H), 3.44 (dt, J=14.4, 6.0Hz, 1H), 2.93 (ddd, J=14.5, 7.0, 4.3Hz, 1H).31P NMR (162MHz, D2O): δ 55.36 (s), 53.98 (s). [0416] Examples 19 and 20: 8-[(2R,5S,7R,8R,10R,12aR,14R,15S,15aR)-14-(6-amino- 9H-purin-9-yl)-15-fluoro-2,10-dioxido-2,10-disulfanyloctahydro-12H-5,8-methanofuro[3,2- l][1,3,6,9,11,2,10]pentaoxadiphosphacyclotetradecin-7-yl]imidazo[1,2-a]pyrimidin-5(8H)- one (Diastereomer 1) and 8-[(2S,5S,7R,8R,10R,12aR,14R,15S,15aR)-14-(6-amino-9H-purin- 9-yl)-15-fluoro-2,10-dioxido-2,10-disulfanyloctahydro-12H-5,8-methanofuro[3,2- l][1,3,6,9,11,2,10]pentaoxadiphosphacyclotetradecin-7-yl]imidazo[1,2-a]pyrimidin-5(8H)- one (Diastereomer 2
Figure imgf000133_0001
[0417] Step 1: 8-{5-O-[bis(4-methoxyphenyl)(phenyl)methyl]-2-O-[tert-butyl(dimethyl) silyl]-β-D-ribofuranosyl}imidazo[1,2-a]pyrimidin-5(8H)-one and 8-{5-O-[bis(4-methoxyphenyl) (phenyl)methyl]-3-O-[tert-butyl(dimethyl)silyl]-β-D-ribofuranosyl}imidazo[1,2-a]pyrimidin- 5(8H)-one
Figure imgf000133_0002
[0418] To a stirred solution of 8-{5-O-[bis(4-methoxyphenyl)(phenyl)methyl]-β-D- ribofuranosyl}imidazo[1,2-a]pyrimidin-5(8H)-one (1.64g, 2.88mmol) in DMF (6mL) were added imidazole (0.49g, 7.2mmol) and TBSCl (0.521g, 3.46mmol). The mixture was left to stir overnight. The mixture was concentrated, and purified by silica gel column chromatography eluting with 10-80% of EtOAc in Hex with 1% TEA to give the products. For 8-{5-O-[bis(4- methoxyphenyl)(phenyl)methyl]-2-O-[tert-butyl(dimethyl)silyl]-β-D-ribofuranosyl}imidazo[1,2- a]pyrimidin-5(8H)-one (fast eluting): LCMS (ES, m/z): 706 [M+Na]+.1H-NMR (600MHz, DMSO-d6): δ 8.19 (d, J=7.8Hz, 1H), 7.66 (s, 1H), 7.18–7.44 (m, 10H), 6.91 (d, J=8.5Hz, 4H), 6.10 (d, J=2.8Hz, 1H), 5.50 (d, J=7.8Hz, 1H), 5.26 (d, J=6.0Hz, 1H), 4.48 (brs, 1H), 4.22 (m, J=5.6Hz, 1H), 4.11 (brs, 1H), 3.74 (s, 6H), 3.31–3.42 (m, 2H), 0.81 (s, 9H), 0.02 (s, 3H), 0.01 (s, 3H). For 8-{5-O-[bis(4-methoxyphenyl)(phenyl)methyl]-3-O-[tert-butyl(dimethyl)silyl]-β-D- ribofuranosyl}imidazo[1,2-a]pyrimidin-5(8H)-one (slow eluting): LCMS (ES, m/z): 706
[M+Na]+.1H-NMR (600MHz, DMSO-d6): δ 8.25 (d, J=7.8Hz, 1H), 7.66 (s, 1H), 7.20-7.40 (m, 10H), 6.89 (d, J=7.5Hz, 4H), 6.08 (d, J=3.3Hz, 1H), 5.56 (d, J=7.8Hz, 1H), 5.52 (d, J=5.8Hz, 1H), 4.43 (m, J=4.8Hz, 1H), 4.33 (t, J=5.3Hz, 1H), 4.05 (m, 1H), 3.73 (s, 6H), 3.45 (dd, J=10.7, 2.8Hz, 1H), 3.22 (dd, J=10.7, 3.9Hz, 1H), 0.78 (s, 9H), 0.03 (s, 3H), -0.02 (s, 3H).
[0419] Step 2: 8-{5-O-[bis(4-methoxyphenyl)(phenyl)methyl]-2-O-[tert- butyl(dimethyl)silyl]-3-O-(1H-imidazol-1-ylcarbonothioyl)-β-D-ribofuranosyl}imidazo[1,2- a]pyrimidin-5(8H)-one
Figure imgf000134_0001
[0420] To a stirred solution of 8-{5-O-[bis(4-methoxyphenyl)(phenyl)methyl]-2-O-[tert- butyl(dimethyl)silyl]-β-D-ribofuranosyl}imidazo[1,2-a]pyrimidin-5(8H)-one (3.98g, 5.82mmol) in DCM (29mL) was added DMAP (71mg, 0.58mmol).1,1'-Thiocarbonyldiimidazole (1.245g, 6.98mmol) was added to the mixture in small portions. The mixture was left to stir overnight. The mixture was purified by silica gel column chromatography eluting with 10-80% EtOAc in Hex with 1% TEA to give the product. LCMS (ES, m/z): 816 [M+Na]+.1H-NMR (600MHz, DMSO-d6): δ 8.58 (s, 1H), 8.21 (d, J=7.9Hz, 1H), 7.88 (s, 1H), 7.69 (s, 1H), 7.13-7.46 (m, 10H), 6.87 (m, 4H), 6.21 (d, J=5.9Hz, 1H), 6.12 (m, 1H), 5.89 (d, J=7.8Hz, 1H), 5.32 (t, J=5.6Hz, 1H), 4.62 (d, J=3.8Hz, 1H), 3.72 (s, 6H), 3.43-3.52 (m, 2H), 0.60 (s, 9H), -0.15 (s, 3H), -0.34 (s, 3H).
[0421] Step 3: 8-((2R,3R,5S)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-3-((tert- butyldimethylsilyl)oxy)tetrahydrofuran-2-yl)imidazo[1,2-a]pyrimidin-5(8H)-one
Figure imgf000134_0002
[0422] To a stirred solution of 8-{5-O-[bis(4-methoxyphenyl)(phenyl)methyl]-2-O-[tert- butyl(dimethyl)silyl]-3-O-(1H-imidazol-1-ylcarbonothioyl)-β-D-ribofuranosyl}imidazo[1,2- a]pyrimidin-5(8H)-one (4.23g, 5.33mmol) in toluene (152mL) were added AIBN (1.05g, 6.39mmol) and nBu3SnH (2.82mL, 10.65mmol). The reaction mixture was heated to 95°C for 1h, cooled to RT, concentrated, and purified by silica gel column chromatography eluting with 5- 80% EtOAc in Hex with 1% TEA to give the product. LCMS (ES, m/z): 690 [M+Na]+.1H-NMR (600MHz, DMSO-d6): δ 8.19 (d, J=7.8Hz, 1H), 7.65 (s, 1H), 7.44-6.87 (m, 14H), 6.03 (s, 1H), 5.37 (d, J=7.8Hz, 1H), 4.65 (d, J=3.5Hz, 1H), 4.52 (brs, 1H), 3.74 (s, 6H), 3.40 (m, 2H), 2.21 (m, 1H), 1.87 (dd, J=13.0, 4.8Hz, 1H), 0.86 (s, 9H), 0.12 (s, 3H), 0.07 (s, 3H).
[0423] Step 4: 8-((2R,3R,5S)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-3- hydroxytetrahydrofuran-2-yl)imidazo[1,2-a]pyrimidin-5(8H)-one
Figure imgf000135_0001
[0424] To a stirred solution of 8-((2R,3R,5S)-5-((bis(4-methoxyphenyl)(phenyl) methoxy)methyl)-3-((tert-butyldimethylsilyl)oxy)tetrahydrofuran-2-yl)imidazo[1,2-a]pyrimidin- 5(8H)-one (2.54g, 3.80mmol) in THF (38mL) at 0°C was added TBAF (1.0M in THF, 7.61mL, 7.61mmol). The cooling bath was removed, and the mixture was left to stir at RT for 45min. The mixture was cooled to 0°C, diluted with EtOAc, and treated with sat NaHCO3 solution. The aq layer was extracted with EtOAc (3x). The combined organics were dried (Na2SO4), concentrated, and purified by silica gel column chromatography eluting with 5-70% EtOAc:EtOH (3:1) in Hex with 0.5% TEA to give the product. LCMS (ES, m/z): 576 [M+Na]+.1H-NMR (600MHz, DMSO-d6): δ 8.19 (d, J=7.8Hz, 1H), 7.66 (s, 1H), 7.43-6.85 (m, 14H), 6.06 (s, 1H), 5.78 (d, J=3.5Hz, 1H), 5.38 (d, J=7.7Hz, 1H), 4.55 (brs, 1H), 4.49 (s, 1H), 3.74 (s, 6H), 3.36 (m, 2H), 2.20 (m, 1H), 1.88 (dd, J=13.0, 4.8Hz, 1H).
[0425] Step 5: 8-{5-O-[bis(4-methoxyphenyl)(phenyl)methyl]-3-deoxy-2-O-[hydroxyl (oxido)-λ5-phosphanyl]-β-D-erythro-pentofuranosyl}imidazo[1,2-a]pyrimidin-5(8H)-one
Figure imgf000135_0002
[0426] A solution of 8-((2R,3R,5S)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-3- hydroxytetrahydrofuran-2-yl)imidazo[1,2-a]pyrimidin-5(8H)-one (546mg, 0.986mmol) in Py (5mL) was concentrated in vacuo. To the residue was added Py (6mL) followed by dropwise addition of diphenyl phosphite (567µL, 2.96mmol). The mixture was left to stir for 5h, treated with TEA (378µl, 2.71mmol) and H2O (374µl, 20.8mmol), left to stir for 45min and
concentrated. The residue was partitioned between DCM and sat NaHCO3 solution. The organic layer was washed with sat aq NaHCO3 (2x), dried over Na2SO4, and purified by silica gel column chromatography eluting with 0-18% of MeOH in DCM with 0.5% TEA to give the product. LCMS (ES, m/z): 616 [M-H]-.1H-NMR (500MHz, DMSO-d6): δ 9.85 (brs, 1H), 8.17 (d, J=7.8Hz, 1H), 7.65 (s, 1H), 7.42–6.81 (m, 14H), 6.14 (s, 1H), 5.47 (d, J=7.8Hz, 1H), 4.91 (m, 1H), 4.48 (m, 1H), 3.73 (s, 6H), 3.30 (m, 2H), 2.34 (m, 1H), 2.13 (dd, J=13.2, 5.2Hz, 1H). [0427] Step 6: (2R,3R,5S)-5-((((((2R,3R,4S,5R)-5-(6-benzamido-9H-purin-9-yl)-4-fluoro-2- (hydroxymethyl)tetrahydrofuran-3-yl)oxy)(2-cyanoethoxy)phosphorothioyl)oxy)methyl)-2-(5- oxoimidazo[1,2-a]pyrimidin-8(5H)-yl)tetrahydrofuran-3-yl hydrogen phosphonate
Figure imgf000136_0001
[0428] A solution of (2R,3R,5S)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-2-(5- oxoimidazo[1,2-a]pyrimidin-8(5H)-yl)tetrahydrofuran-3-yl hydrogen phosphonate (520mg, 0.723mmol) in MeCN (3mL) was concentrated in vacuo. Addition of MeCN (3mL) followed by concentration was repeated twice. The residue was taken up in MeCN (2.5mL), cooled to 0°C, and treated with pyrrole (152µl, 2.17mmol) and TFA (167µl, 2.17mmol) over 1min. The reaction mixture was allowed to warm to RT over 1.5h. Then, the mixture was cooled to 0°C and treated with pyridine (234µl, 2.89mmol).
[0429] A solution of (2R,3R,4S,5R)-5-(6-benzamido-9H-purin-9-yl)-2-((bis(4- methoxyphenyl)(phenyl)methoxy)methyl)-4-fluorotetrahydrofuran-3-yl (2-cyanoethyl) diisopropylphosphoramidite (0.842g, 0.962mmol) in ACN (4mL) was concentrated in vacuo. The residue was taken up in ACN (1.6mL) and transferred to the H-phosphonate solution at 0°C over 1min. The mixture was left to stir at 0°C for 20min, treated with (E)-N,N-dimethyl-N'-(3- thioxo-3H-1,2,4-dithiazol-5-yl)formimidamide (0.178g, 0.868mmol), and left to stir at 0°C for 20min. The mixture was treated with 1-propanol (0.543mL, 7.23mmol), warmed to RT, and left to stir for 10min. TFA (0.557mL, 7.23mmol) was added to the mixture, and the reaction mixture was left to stir for 2h and treated with Py (0.643mL, 7.95mmol). The mixture was concentrated to half the volume. The residue was added into rapidly stirring isopropyl acetate (50mL). The precipitate was collected by filtration and kept under high vacuum overnight to give the crude products. LCMS (ES, m/z): 818 [M-H]-.
[0430] Step 7: N-{9-[(5S,7R,8R,12aR,14R,15S,15aR)-2-(2-cyanoethoxy)-15-fluoro-10- oxido-7-(5-oxoimidazo[1,2-a]pyrimidin-8(5H)-yl)-10-sulfanyl-2-sulfidooctahydro-12H-5,8- methanofuro[3,2-l][1,3,6,9,11,2,10]pentaoxadiphosphacyclotetradecin-14-yl]-9H-purin-6- yl}benzamide
Figure imgf000137_0001
[0431] A solution of the crude (2R,3R,5S)-5-((((((2R,3R,4S,5R)-5-(6-benzamido-9H- purin-9-yl)-4-fluoro-2-(hydroxymethyl)tetrahydrofuran-3-yl)oxy)(2-cyanoethoxy)
phosphorothioyl)oxy)methyl)-2-(5-oxoimidazo[1,2-a]pyrimidin-8(5H)-yl)tetrahydrofuran-3-yl hydrogen phosphonate from the previous step in Py (4mL) was concentrated in vacuo. Addition of Py (4mL) followed by concentration was repeated once. The residue was taken up in Py (3.6mL). Into a separate flask were added MeCN (34mL), Py (2.2mL), and diphenyl
chlorophosphate (0.749mL, 3.62mmol). The solution was cooled to -20°C, and the solution of the hydrogen phosphonate in Py was added dropwise. The residue was rinsed with Py (0.7mL) and added to the reaction mixture. The mixture was left to stir at -23°C to -20°C for 20min.3H- 1,2-benzodithiol-3-one (0.146g, 0.868mmol) and H2O (0.26mL, 14.5mmol) were added, and the cooling bath was removed. After the mixture was warmed to RT, it was concentrated and purified by silica gel column chromatography eluting with 100% EtOAc, then 5-20% MeOH in DCM to give the products. LCMS (ES, m/z): 832 [M-H]-.
[0432] Step 8: 8-[(2R,5S,7R,8R,10R,12aR,14R,15S,15aR)-14-(6-amino-9H-purin-9-yl)-15- fluoro-2,10-dioxido-2,10-disulfanyloctahydro-12H-5,8-methanofuro[3,2-l][1,3,6,9,11,2,10] pentaoxadiphosphacyclotetradecin-7-yl]imidazo[1,2-a]pyrimidin-5(8H)-one
(Diastereomers 1-2)
Figure imgf000137_0002
[0433] To a stirred solution of N-{9-[(5S,7R,8R,12aR,14R,15S,15aR)-2-(2-cyanoethoxy)- 15-fluoro-10-oxido-7-(5-oxoimidazo[1,2-a]pyrimidin-8(5H)-yl)-10-sulfanyl-2-sulfidooctahydro- 12H-5,8-methanofuro[3,2-l][1,3,6,9,11,2,10]pentaoxadiphosphacyclotetradecin-14-yl]-9H-purin- 6-yl}benzamide (599mg, 0.718mmol) in Py (8mL) were added H2O (2mL) and NH4OH (28%, 8mL). The mixture was left to stir for 5h, concentrated, lyophilized, and purified by reverse phase HPLC (eluting MeCN/H2O gradient with 100mM TEAA modifier, linear gradient) to afford the title compounds.
[0434] Example 19 (diastereomer 1) (fast eluted): LCMS (ES, m/z): 675 [M-H]-.1H-NMR (600MHz, D2O): δ 8.48 (d, J=7.9Hz, 1H), 8.31 (brs, 1H), 8.24 (s, 1H), 7.66 (s, 1H), 7.28 (s, 1H), 6.54 (dd, J=19.1, 3.0Hz, 1H), 6.37 (d, J=6.4Hz, 1H), 6.01 (d, J=7.9Hz, 1H), 5.71 (d, J=49.8Hz, 1H), 5.21-5.12 (m, 2H), 4.70 (d, J=7.7Hz, 1H), 4.54 (m, 1H), 4.32-4.16 (m, 4H), 2.72 (m, 1H), 2.56 (m, 1H).
[0435] Example 20 (diastereomer 2) (slow eluted): LCMS (ES, m/z): 675 [M-H]-.1H-NMR (600MHz, D2O): δ 8.30 (s, 1H), 8.22 (s, 1H), 8.16 (d, J=7.8Hz, 1H), 7.65 (s, 1H), 7.26 (s, 1H), 6.54 (dd, J=16.2, 3.4Hz, 1H), 6.33 (d, J=4.6Hz, 1H), 5.93 (d, J=7.8Hz, 1H), 5.62 (d, J=50.3Hz, 1H), 5.09 (m, 2H), 4.66 (brs, 1H), 4.50 (t, J=11.3Hz, 1H), 4.41 (brs, 1H), 4.29 (m, 1H), 4.23 (m, 1H), 4.14 (m, 1H), 2.76 (m, 1H), 2.42 (m, 1H). [0436] Examples 21 through 28, as shown in Table 2 below, were prepared according to procedures analogous to those outlined in Examples 19 and 20 above using the appropriate monomers, described as Preparations or as obtained from commercial sources, in the coupling step.
Table 2
Figure imgf000138_0001
- 137 -
Figure imgf000139_0001
Figure imgf000140_0002
[0437] Examples 29: 9-[(2R,5S,7R,8R,10R,12aR,14R,15S,15aR)-15-fluoro-2,10- dioxido-7-(5-oxoimidazo[1,2-a]pyrimidin-8(5H)-yl)-2,10-disulfanyloctahydro-12H-5,8- methanofuro[3,2-l][1,3,6,9,11,2,10]pentaoxadiphosphacyclotetradecin-14-yl]-1,9-dihydro- 6H-purin-6-one
Figure imgf000140_0001
[0438] To 8-[(2R,5S,7R,8R,10R,12aR,14R,15S,15aR)-14-(6-amino-9H-purin-9-yl)-15- fluoro-2,10-dioxido-2,10-disulfanyloctahydro-12H-5,8-methanofuro[3,2-l][1,3,6,9,11,2,10] pentaoxadiphosphacyclotetradecin-7-yl]imidazo[1,2-a]pyrimidin-5(8H)-one triethylammonium salt (16mg, 18µmol) were added sodium phosphate buffer (pH 6.8, 50mM, 1.5mL) and AMPDA (20mg). The reaction mixture was left to stir overnight, filtered, and purified by reverse phase HPLC (eluting MeCN/H2O gradient with 100mM TEAA modifier, linear gradient) to afford the product. LCMS (ES, m/z): 676 [M-H]-.1H NMR (600MHz, D2O): δ 8.20 (m, 1H), 8.16 (d, J=7.9Hz, 1H), 8.14 (s, 1H), 7.63 (s, 1H), 7.25 (s, 1H), 6.51 (dd, J=18.9, 3.4Hz, 1H), 6.32 (d, J=4.4Hz, 1H), 6.03 (d, J=7.8Hz, 1H), 5.58 (d, J=50.2Hz, 1H), 5.11-5.03 (m, 2H), 4.65 (brs, 1H), 4.53 (t, J=11.2Hz, 1H), 4.39 (brs, 1H), 4.27 (m, 1H), 4.21-4.10 (m, 2H), 2.78 (dt, J=13.6, 7.0Hz, 1H), 2.35 (m, 1H). [0439] Example 30: 8,8'-[(5R,7R,8R,12aR,14R,15R,15aS,16R)-15,16-dihydroxy-2,10- dioxido-2,10-disulfanyloctahydro-12H-5,8-methanofuro[3,2-l][1,3,6,9,11,2,10]
pentaoxadiphosphacyclo-tetradecine-7,14-diyl]bisimidazo[1,2-a]pyrimidin-5(8H)-one
Figure imgf000141_0001
[0440] Step 1: (2R,3R,4R,5R)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-((tert- butyldimethylsilyl)oxy)-5-(5-oxoimidazo[1,2-a]pyrimidin-8(5H)-yl)tetrahydrofuran-3-yl (2- cyanoethyl) diisopropylphosphoramidite
Figure imgf000141_0002
[0441] To a stirred solution of dry 3-((bis(diisopropylamino)phosphino)oxy) propanenitrile (643mg, 2.14mmol) in MeCN (4mL) under Ar was added pyridin-1-ium 2,2,2-trifluoroacetate (309mg, 1.60mmol) and 8-((2R,3R,4R,5R)-5-((bis(4-methoxyphenyl)(phenyl) methoxy)methyl)- 3-((tert-butyldimethylsilyl)oxy)-4-hydroxytetrahydrofuran-2-yl)imidazo[1,2-a]pyrimidin-5(8H)- one (730 mg, 1.07 mmol) in MeCN (4mL). The resulting mixture was stirred at RT for 1h, then concentrated. The residue was dissolved in EtOAc (100mL), washed with aq NaHCO3 (1%, 2×50mL), H2O (50mL) and brine (50mL), dried (Na2SO4) and purified by reverse phase (C18) chromatography eluted with 60 to 95% ACN in aq NH4HCO3 (5mM) to give the product. LCMS (ES, m/z): 884.1 [M+H]+.1H NMR (300MHz, DMSO-d6): δ 8.14 (dd, J=7.9, 5.1Hz, 1H), 7.65- 7.60 (m, 1H), 7.40-7.35 (m, 2H), 7.33-7.21 (m, 7H), 7.18-7.15(m, 1H), 6.99-6.77 (m, 4H), 6.13- 5.93 (m, 1H), 5.58 (dd, J=12.2, 7.9Hz, 1H), 4.76 (dt, J=29.9, 4.6Hz, 1H), 4.39-4.15 (m, 2H), 3.74-3.69 (m, 7H), 3.66-3.31 (m, 5H), 2.73 (t, J=5.9Hz, 1H), 2.55 (t, J=5.9Hz, 1H), 1.15-0.92 (m, 12H), 0.73 (d, J=5.2Hz, 9H), 0.06~-0.34 (m, 6H).31P NMR: (121MHz, DMSO-d6) δ 148.94(s), 148.68(s).
[0442] Step 2: (2R,3R,4R,5R)-5-((((((2R,3R,4R,5R)-2-((bis(4-methoxyphenyl)(phenyl) methoxy)methyl)-4-((tert-butyldimethylsilyl)oxy)-5-(5-oxoimidazo[1,2-a]pyrimidin-8(5H)- yl)tetrahydrofuran-3-yl)oxy)(2-cyanoethoxy)phosphanyl)oxy)methyl)-4-((tert-butyldimethylsilyl) oxy)-2-(5-oxoimidazo[1,2-a]pyrimidin-8(5H)-yl)tetrahydrofuran-3-yl hydrogen phosphonate
Figure imgf000142_0001
[0443] (2R,3R,4R,5R)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-((tert-butyl- dimethylsilyl)oxy)-5-(5-oxoimidazo[1,2-a]pyrimidin-8(5H)-yl)tetrahydrofuran-3-yl (2- cyanoethyl)diisopropylphosphoramidite (540mg, 0.611mmol) was co-evaporated with MeCN (3×6mL) and re-dissolved in MeCN (5mL). Activated 4Å molecular sieve (300mg) was added. (2R,3R,4R,5R)-4-((tert-butyldimethylsilyl)oxy)-5-(hydroxymethyl)-2-(5-oxoimidazo[1,2- a]pyrimidin-8(5H)-yl)tetrahydrofuran-3-yl hydrogen phosphonate (crude, ~0.71 mmol) was co- evaporated with MeCN (3×8mL) and re-dissolved in MeCN (4mL) under Ar. Activated 4Å molecular sieve (300mg) was added. To this mixture was added the mixture containing (2R,3R, 4R,5R)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-((tert-butyldimethylsilyl) oxy)-5- (5-oxoimidazo[1,2-a]pyrimidin-8(5H)-yl)tetrahydrofuran-3-yl (2-cyanoethyl)diisopropyl- phosphoramidite dropwise, and it was stirred for 30min. The reaction mixture was used for the next reaction step directly without purification. LCMS (ES, m/z): 1228.4 [M+H]+.
[0444] Step 3: (2R,3R,4R,5R)-5-((((((2R,3R,4R,5R)-2-((bis(4-methoxyphenyl)(phenyl) methoxy)methyl)-4-((tert-butyldimethylsilyl)oxy)-5-(5-oxoimidazo[1,2-a]pyrimidin-8(5H)- yl)tetrahydrofuran-3-yl)oxy)(2-cyanoethoxy)phosphorothioyl)oxy)methyl)-4-((tert- butyldimethylsilyl)oxy)-2-(5-oxoimidazo[1,2-a]pyrimidin-8(5H)-yl)tetrahydrofuran-3-yl hydrogen phosphonate
Figure imgf000142_0002
[0445] To the reaction mixture from Step 2 was added (E)-N,N-dimethyl-N'-(3-thioxo-3H- 1,2,4-dithiazol-5-yl)formimidamide (138mg, 0.672mmol), and the mixture was stirred at rt for 1h. Then, it was concentrated to give the crude product, which was used for the next reaction step directly without purification. LCMS (ES, m/z): 1258.5 [M-H]-. [0446] Step 4: (2R,3R,4R,5R)-4-((tert-butyldimethylsilyl)oxy)-5-((((((2R,3R,4R,5R)-4- ((tert-butyldimethylsilyl)oxy)-2-(hydroxymethyl)-5-(5-oxoimidazo[1,2-a]pyrimidin-8(5H)- yl)tetrahydrofuran-3-yl)oxy)(2-cyanoethoxy)phosphorothioyl)oxy)methyl)-2-(5-oxoimidazo[1,2- a]pyrimidin-8(5H)-yl)tetrahydrofuran-3-yl hydrogen phosphonate
Figure imgf000143_0001
[0447] To a solution of crude from Step 4 in DCM (9mL) was added H2O (0.11mL, 6.1mmol) and DCA (8.8mL, 5.58mmol). The mixture was stirred at RT for 30min and then, Et3SiH (20mL) was added. After 1h, Py (0.90mL, 11mmol) was added, and the mixture was stirred for 10min. It was concentrated, and the residue was purified by reverse phase (C18) chromatography eluted with 0 to 95% ACN in aq NH4HCO3 (5mM) to give the product. LCMS (ES, m/z): 958.3 [M+H]+.1H NMR (300MHz, CD3OD): δ 8.25-8.20 (m, 1H), 8.10-8.05 (m, 1H), 7.86-7.84 (m, 0.5H), 7.72-7.68 (m, 1H), 7.65-7.58 (m, 1H), 7.25-7.22 (m, 2H), 6.26-6.21 (m, 1H), 6.04-5.84 (m, 4H), 5.77-5.75 (m, 0.5H), 5.32-5.17 (m, 1H), 5.16-4.97 (m, 2H), 4.63-4.18 (m, 6H), 4.09-3.52 (m, 4H), 1.05-0.90 (m, 9H), 0.85-0.63 (m, 9H), 0.27-0.23 (m, 6H), -0.06 to -0.09 (m, 3H), -0.2 to -0.30 (m, 3H).31P-NMR: (121MHz, CD3OD) δ 67.88 (s), 67.65 (s); 3.23 (s), 3.12 (s).
[0448] Step 5: 3-{[(5R,7R,8R,12aR,14R,15R,15aR,16R)-15,16-bis{[tert-butyl(dimethyl) silyl]oxy}-10-hydroxy-7,14-bis(5-oxoimidazo[1,2-a]pyrimidin-8(5H)-yl)-2-sulfidooctahydro- 12H-5,8-methanofuro[3,2-l][1,3,6,9,11,2,10]pentaoxadiphosphacyclotetradecin-2- yl]oxy}propanenitrile
Figure imgf000143_0002
[0449] To Py (30mL) at -40°C under Ar was added diphenyl phosphorochloridate (1.65g, 6.15mmol) and a solution of (2R,3R,4R,5R)-4-((tert-butyldimethylsilyl)oxy)-5-((((((2R,3R,4R, 5R)-4-((tert-butyldimethylsilyl)oxy)-2-(hydroxymethyl)-5-(5-oxoimidazo[1,2-a]pyrimidin- 8(5H)-yl)tetrahydrofuran-3-yl)oxy)(2-cyanoethoxy)phosphorothioyl)oxy)methyl)-2-(5- oxoimidazo[1,2-a]pyrimidin-8(5H)-yl)tetrahydrofuran-3-yl hydrogen phosphonate (0.30g, 0.31mmol) in DCM (30mL) drop-wise over 5min. It was stirred at -40°C for 30min. The reaction mixture was used for the next reaction step immediately without purification. LCMS (ES, m/z): 940.3 [M+H]+.
[0450] Step 6: 3-{[(5R,7R,8R,12aR,14R,15R,15aR,16R)-15,16-bis{[tert- butyl(dimethyl)silyl]oxy}-10-oxido-7,14-bis(5-oxoimidazo[1,2-a]pyrimidin-8(5H)-yl)-10- sulfanyl-2-sulfidooctahydro-12H-5,8-methanofuro[3,2-l][1,3,6,9,11,2,10]
pentaoxadiphosphacyclotetradecin-2-yl]oxy}propanenitrile
Figure imgf000144_0001
[0451] To the mixture from Step 5 at -40°C was added 3H-benzo[c][1,2]dithiol-3-one (78mg, 0.46mmol). It was warmed to RT and stirred for 40min. The mixture was concentrated and purified by reverse phase (C18) chromatography eluted with 0 to 95% ACN in aq NH4HCO3 (5mM) to give the product. LCMS (ES, m/z): 972.3 [M+H]+.31P-NMR: (121MHz, CD3OD) δ 67.71-64.65 (m), 62.22-53.56 (m).
[0452] Step 7: 8,8'-[(5R,7R,8R,12aR,14R,15R,15aR,16R)-15,16-bis{[tert-butyl(dimethyl) silyl]oxy}-2,10-dioxido-2,10-disulfanyloctahydro-12H-5,8-methanofuro[3,2-l][1,3,6,9,11,2,10] pentaoxadiphosphacyclotetradecine-7,14-diyl]bisimidazo[1,2-a]pyrimidin-5(8H)-one
Figure imgf000144_0002
[0453] 3-{[(5R,7R,8R,12aR,14R,15R,15aR,16R)-15,16-bis{[tert-butyl(dimethyl)silyl] oxy}-10-oxido-7,14-bis(5-oxoimidazo[1,2-a]pyrimidin-8(5H)-yl)-10-sulfanyl-2-sulfidoocta- hydro-12H-5,8-methanofuro[3,2-l][1,3,6,9,11,2,10]pentaoxadiphosphacyclotetra-decin-2-yl] oxy}propanenitrile (0.25g, 0.21mmol) was dissolved in MeCN (5mL) and t-BuNH2 (10mL, 94mmol) was added. It was stirred at RT for 1h. Then, the solution was concentrated and the residue was purified by reverse phase (C18) chromatography eluted with 0 to 95% ACN in aq NH4HCO3 (5mM) over 55min to give the product (TR=43min). LCMS (ES, m/z): 919.3 [M+H]+. 1H NMR (400MHz, CD3OD): δ 8.87 (d, J=7.9Hz, 1H), 8.51 (d, J=7.8Hz, 1H), 7.63 (dd, J=16.2, 1.7Hz, 2H), 7.20 (dd, J=28.2, 1.7Hz, 2H), 6.66 (d, J=8.3Hz, 1H), 6.16 (d, J=3.2Hz, 1H), 5.81 (dd, J=15.7, 7.9Hz, 2H), 5.31-5.07 (m, 2H), 4.95-4.91 (m, 1H), 4.75-4.72 (m, 1H), 4.57-4.53 (m, 1H), 4.45-4.41 (m, 1H), 4.32-4.21 (m, 2H), 4.18-4.14 (m, 1H), 3.95-3.91 (m, 1H), 1.05-0.91(m, 18H), 0.34- 0.11 (m, 12H).31P-NMR: (162MHz, CD3OD) δ 57.80 (s), 57.12 (s).
[0454] Step 8: 8,8'-[(5R,7R,8R,12aR,14R,15R,15aS,16R)-15,16-dihydroxy-2,10-dioxido- 2,10-disulfanyloctahydro-12H-5,8-methanofuro[3,2-l][1,3,6,9,11,2,10]
pentaoxadiphosphacyclotetradecine-7,14-diyl]bisimidazo[1,2-a]pyrimidin-5(8H)-one
Figure imgf000145_0001
[0455] To a suspension of 8,8'-[(5R,7R,8R,12aR,14R,15R,15aR,16R)-15,16-bis{[tert- butyl(dimethyl)silyl]oxy}-2,10-dioxido-2,10-disulfanyloctahydro-12H-5,8-methanofuro[3,2- l][1,3,6,9,11,2,10]pentaoxadiphosphacyclotetradecine-7,14-diyl]bisimidazo[1,2-a]pyrimidin- 5(8H)-one (38mg, 0.040mmol) in Py (0.2mL) was added Et3N·3HF (0.64g, 4.0mmol) and TEA (0.83mL, 6.0mmol). The mixture was heated at 50°C for 3h. Then, it was concentrated, and acetone (0.6mL) and ethoxytrimethylsilane (3.7mL) were added. The mixture was stirred at 0°C for 30min, and the resulting solid was collected by filtration and purified by reverse phase (AQ C18) chromatography eluted with 0 to 95% ACN in aq NH4HCO3 (5mM) over 58min to give the product (TR=36min). LCMS (ES, m/z): 690.8 [M+H]+.1H NMR (400MHz, D2O): δ 8.30 (d, J=7.9Hz, 1H), 8.13 (d, J=7.9Hz, 1H), 7.70-7.49 (m, 2H), 7.37-7.14 (m, 2H), 6.47 (d, J=8.1Hz, 1H), 6.02 (s, 1H), 5.45 (d, J=7.8Hz, 1H), 5.25 (d, J=7.9Hz, 1H), 5.08-4.91 (m, 2H), 4.70-4.65 (m, 2H), 4.55-4.39 (m, 3H), 4.33-4.28 (m, 2H), 4.13-4.06 (m, 1H).31P-NMR: (162MHz, D2O) δ 55.16 (s), 52.14 (s). [0456] Example 31, as shown in Table 3 below, were prepared according to procedures analogous to those outlined in Example 30 above using the appropriate monomers, described as Preparations or as obtained from commercial sources, in the coupling step.
Table 3
Figure imgf000146_0003
[0457] Examples 32 and 33: 1-[(5R,7R,8S,12aR,14R,15R,15aS,16R)-7-(2-amino-6-oxo- 1,6-dihydro-9H-purin-9-yl)-16-fluoro-15-hydroxy-2,10-dioxido-2,10-disulfanyl-octahydro- 12H-5,8-methanofuro[3,2-l][1,3,6,9,11,2,10]pentaoxadiphosphacyclotetradecin-14-yl]-1H- imidazo[2,1-b]purin-4(5H)-one (Diastereomer 1) and 1-[(5R,7R,8S,12aR,14R,15R,15aS, 16R)-7-(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)-16-fluoro-15-hydroxy-2,10-dioxido- 2,10-disulfanyloctahydro-12H-5,8-methanofuro[3,2-l][1,3,6,9,11,2,10]pentaoxa- diphosphacyclotetradecin-14-yl]-1H-imidazo[2,1-b]purin-4(5H)-one (Diastereomer 2)
Figure imgf000146_0001
[0458] Step 1: (2R,3R,4S,5R)-2-(4-(benzyloxy)-1H-imidazo[2,1-b]purin-1-yl)-5-((bis(4- methoxyphenyl)(phenyl)methoxy)methyl)tetrahydrofuran-3,4-diol
Figure imgf000146_0002
[0459] To a stirred solution of (2R,3R,4S,5R)-2-(4-(benzyloxy)-1H-imidazo[2,1-b]purin-1- yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol (1.27g, 3.20mmol) in Py (25mL) under Ar were added N-ethyl-N-isopropylpropan-2-amine (1.06mL, 6.39mmol) and DMTrCl (1.62g,
4.79mmol). The resulting mixture was stirred at RT for 2h. Then, MeOH (2mL) was added. It was concentrated and purified by silica gel column chromatography eluted with 0 to 5.6% MeOH in DCM to give the product. LCMS (ES, m/z): 700.4 [M+H]+.1H-NMR (400MHz, DMSO-d6): δ 8.35 (s, 1H), 8.07 (d, J=1.7Hz, 1H), 7.58–7.48 (m, 3H), 7.45-7.33 (m, 3H), 7.14- 7.06 (m, 5H), 7.04-6.95 (m, 4H), 6.73-6.62 (m, 4H), 6.30 (d, J=2.0Hz, 1H), 5.98 (d, J=5.0Hz, 1H), 5.61-5.47 (m, 2H), 5.28 (d, J=7.2Hz, 1H), 4.90-4.81 (m, 1H), 4.39 (td, J=7.2, 4.5Hz, 1H), 4.19 (dt, J=7.0, 3.3Hz, 1H), 3.68,3.67 (2 s, 6H), 3.25 (dd, J=11.1, 2.3Hz, 1H), 2.95 (dd, J=10.8, 3.8Hz, 1H).
[0460] Step 2: 1-((2R,3R,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-3,4- dihydroxytetrahydrofuran-2-yl)-1H-imidazo[2,1-b]purin-4(5H)-one
Figure imgf000147_0001
[0461] To a solution of (2R,3R,4S,5R)-2-(4-(benzyloxy)-1H-imidazo[2,1-b]purin-1-yl)-5- ((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)tetrahydrofuran-3,4-diol (1.00g, 1.43mmol) in MeOH (20mL) and EtOAc (10mL) was added Pd(OH)2/C (0.22g). The mixture was charged with H2 (2atm) and stirred at 40°C for 30h. It was filtered, and the filtrate was concentrated. The crude was purified by reverse phase (AQ-C18) chromatography eluted with 0 to 95% ACN in aq NH4HCO3 (5mM) to give the product. LCMS (ES, m/z): 610.3 [M+H]+.1H-NMR (400MHz, DMSO-d6): δ 11.53 (br s, 1H), 8.22 (s, 1H), 7.79 (d, J=1.8Hz, 1H), 7.26–7.11 (m, 6H), 7.09-7.01 (m, 4H), 6.80-6.66 (m, 4H), 6.18 (d, J=2.0Hz, 1H), 5.99 (s, 1H), 5.29 (d, J=7.5Hz, 1H), 4.82 (d, J=4.5Hz, 1H), 4.38 (q, J=5.8, 5.3Hz, 1H), 4.18 (dt, J=6.8, 3.1Hz, 1H), 3.73 (s, 3H), 3.72 (s, 3H), 3.27 (dd, J=10.9, 2.5Hz, 1H), 2.96 (dd, J =10.9, 3.8Hz, 1H).
[0462] Step 3: 1-((2R,3R,4R,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4- hydroxy-3-((triisopropylsilyl)oxy)tetrahydrofuran-2-yl)-1H-imidazo[2,1-b]purin-4(5H)-one
Figure imgf000147_0002
[0463] To a solution of 1-((2R,3R,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy) methyl)-3,4-dihydroxytetrahydrofuran-2-yl)-1H-imidazo[2,1-b]purin-4(5H)-one (0.37g, 0.60mmol) in THF (6mL) were added (2R,4S)-4-isopropyl-2-methoxy-3-((R)-2-methyl-1-(1- methyl-1H-imidazol-2-yl)propyl)oxazolidine (0.068g, 0.240mmol), DiPEA·HCl (3.0mg, 0.018mmol), and DiPEA (0.491mL, 2.82mmol). The mixture was stirred at RT for 5min and then cooled to 0°C. To the mixture was added TIPSOTf (0.70mL, 2.6mmol) over 2min. It was stirred at RT for 2h. Then, the mixture was concentrated, and EtOAc (50 mL) and aq NaHCO3 (5%, 30mL) were added. Layers were separated, and the organic layer was washed with aq NaHCO3 (5%, 30mL), dried (Na2SO4) and concentrated. The crude product was used for next step directly. LCMS (ES, m/z): 766.3 [M+H]+.
[0464] Step 4: (2R,3R,4R,5R)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-5-(4-oxo- 4,5-dihydro-1H-imidazo[2,1-b]purin-1-yl)-4-((triisopropylsilyl)oxy)tetrahydrofuran-3-yl phenyl phosphonate
Figure imgf000148_0001
[0465] To a solution of crude from Step 3 in Py (4mL) under Ar was added diphenyl phosphonate (0.58mL, 3.0mmol), and the reaction was stirred at RT for 20min. It was used for the next reaction step without purification. LCMS (ES, m/z): 906.2 [M+H]+.
[0466] Step 5: (2R,3R,4R,5R)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-5-(4-oxo- 4,5-dihydro-1H-imidazo[2,1-b]purin-1-yl)-4-((triisopropylsilyl)oxy)tetrahydrofuran-3-yl hydrogen phosphonate
Figure imgf000148_0002
[0467] To the reaction mixture from Step 4 at 0°C was added H2O (2mL) and TEA (2mL). It was stirred at RT for 20min. Then, it was concentrated, and the residue was purified by reverse phase (AQ-C18) chromatography eluted with 0 to 95% ACN in aq NH4HCO3 (5mM) to give the product. LCMS (ES, m/z): 830.2 [M+H]+.1H-NMR (400MHz, DMSO-d6): δ 12.34 (br s, 1H), 7.99 (s, 1H), 7.69 (s, 1H), 7.34 (s, 0.5H), 7.20-7.12 (m, 6H), 7.06-7.02 (m, 4H), 6.75-6.71 (m, 4H), 6.14 (d, J=3.7Hz, 1H), 5.88 (s, 0.5H), 4.99 (s, 1H), 4.89-4.74 (m, 1H), 4.37 (d, J=5.7Hz, 1H), 3.70-3.69 (m, 6H), 3.30-3.28 (m, 1H), 3.06-3.02 (m, 1H), 1.10–0.84 (m, 21H).31P-NMR: (162MHz, DMSO-d6) δ 1.13 (s, 1P).
[0468] Step 6: (2R,3R,4R,5R)-2-(hydroxymethyl)-5-(4-oxo-4,5-dihydro-1H-imidazo[2,1- b]purin-1-yl)-4-((triisopropylsilyl)oxy)tetrahydrofuran-3-yl hydrogen phosphonate
Figure imgf000149_0001
[0469] To a solution of (2R,3R,4R,5R)-2-((bis(4-methoxyphenyl)(phenyl)methoxy) methyl)-5-(4-oxo-4,5-dihydro-1H-imidazo[2,1-b]purin-1-yl)-4-((triisopropylsilyl)oxy) tetrahydrofuran-3-yl hydrogen phosphonate (290mg, 0.342mmol) in DCM (5.1mL) at RT was added H2O (62mg, 3.4mmol) and DCA in DCM (5%, 5.1mL, 3.1mmol). It was stirred for 15min, and then Et3SiH (5mL) was added. After 1h, Py (0.2mL) was added, and the mixture was stirred for 5min. Then, it was concentrated, and the residue was used for the next reaction step without purification. LCMS (ES, m/z): 528.2 [M+H]+.
[0470] Step 7: (2R,3R,4R,5R)-2-((((2-cyanoethoxy)(((2R,3S,4R,5R)-4-fluoro-5- (hydroxymethyl)-2-(2-isobutyramido-6-oxo-1,6-dihydro-9H-purin-9-yl)tetrahydrofuran-3- yl)oxy)phosphanyl)oxy)methyl)-5-(4-oxo-4,5-dihydro-1H-imidazo[2,1-b]purin-1-yl)-4- ((triisopropylsilyl)oxy)tetrahydrofuran-3-yl hydrogen phosphonate
Figure imgf000149_0002
[0471] (2R,3S,4R,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-fluoro-2-(2- isobutyramido-6-oxo-1,6-dihydro-9H-purin-9-yl)tetrahydrofuran-3-yl (2-cyanoethyl)diisopropyl- phosphoramidite (0.32g, 0.38mmol) was co-evaporated with MeCN (3×3mL) and re-dissolved in MeCN (3mL). Activated 4Å molecular sieve (100mg) was added. (2R,3R,4R,5R)-2-(hydroxyl- methyl)-5-(4-oxo-4,5-dihydro-1H-imidazo[2,1-b]purin-1-yl)-4-((triisopropylsilyl)oxy) tetrahydrofuran-3-yl hydrogen phosphonate (crude, 0.89g, 0.34mmol) was co-evaporated with MeCN (3×5mL) and re-suspended in MeCN (8mL) under Ar. Activated 4Å molecular sieve (100mg) was added. After 30min, to the mixture was added the mixture containing (2R,3S,4R, 5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-fluoro-2-(2-isobutyramido-6-oxo-1,6- dihydro-9H-purin-9-yl)tetrahydrofuran-3-yl (2-cyanoethyl) diisopropylphosphoramidite, and it was stirred at RT for 15min. Then, the reaction mixture was used for the next reaction step without purification. LCMS (ES, m/z): 980.1 [M-H]-.
[0472] Step 8: (2R,3R,4R,5R)-2-((((2-cyanoethoxy)(((2R,3S,4R,5R)-4-fluoro-5- (hydroxymethyl)-2-(2-isobutyramido-6-oxo-1,6-dihydro-9H-purin-9-yl)tetrahydrofuran-3-yl) oxy)phosphorothioyl)oxy)methyl)-5-(4-oxo-4,5-dihydro-1H-imidazo[2,1-b]purin-1-yl)-4- ((triisopropylsilyl)oxy)tetrahydrofuran-3-yl hydrogen phosphonate
Figure imgf000150_0001
[0473] To the reaction mixture from Step 7 was added (E)-N,N-dimethyl-N'-(3-thioxo-3H- 1,2,4-dithiazol-5-yl)formimidamide (77mg, 0.38mmol), and the mixture was stirred at RT for 1h. It was concentrated, and the residue was purified by reverse phase (C18) chromatography eluted with 0 to 95% ACN in aq NH4HCO3 (5mM) to give the product. LCMS (ES, m/z): 1014.3
[M+H]+.1H-NMR (400MHz, CD3OD): δ 8.35 (d, J=8.6Hz, 1H), 8.23-8.06 (m, 1H), 7.86 (s, 0.5H), 7.76 (d, J=14.0Hz, 1H), 7.23 (d, J=17.0Hz, 1H), 6.44-6.11 (m, 2.5H), 5.59-5.55 (m, 1H), 5.50-5.26 (m, 1H), 4.71 (d, J=5.5Hz, 1H), 4.62-4.17 (m, 5H), 4.12-3.75 (m, 3H), 3.08-2.51 (m, 3H), 1.29–1.13 (m, 6H), 0.98-0.88 (m, 21H).31P-NMR: (162MHz, CD3OD) δ 67.45-66.89 (m); 3.97-3.90 (m).
[0474] Step 9: N-(9-{(5R,7R,8S,12aR,14R,15R,15aR,16R)-10-(2-cyanoethoxy)-16-fluoro- 2-hydroxy-14-(4-oxo-4,5-dihydro-1H-imidazo[2,1-b]purin-1-yl)-10-sulfido-15-[(tripropan-2- ylsilyl)oxy]octahydro-12H-5,8-methanofuro[3,2-l][1,3,6,9,11,2,10]pentaoxadiphosphacyclo- tetradecin-7-yl}-6-oxo-6,9-dihydro-1H-purin-2-yl)-2-methylpropanamide
Figure imgf000150_0002
[0475] To Py (3.5mL) and DCM (3.5mL) at -40°C under Ar was added diphenyl phosphorochloridate (0.285mL, 1.38mmol), and a solution of (2R,3R,4R,5R)-2-((((2- cyanoethoxy)(((2R,3S,4R,5R)-4-fluoro-5-(hydroxymethyl)-2-(2-isobutyramido-6-oxo-1,6- dihydro-9H-purin-9-yl)tetrahydrofuran-3-yl)oxy)phosphorothioyl)oxy)methyl)-5-(4-oxo-4,5- dihydro-1H-imidazo[2,1-b]purin-1-yl)-4-((triisopropylsilyl)oxy)tetrahydrofuran-3-yl hydrogen phosphonate (71mg, 0.069mmol) in Py (3.5mL) and DCM (3.5mL). It was stirred at -40°C for 30min. Then, the reaction mixture was used for the next step without purification. LCMS (ES, m/z): 996.4 [M+H]+.
[0476] Step 10: N-(9-{(5R,7R,8S,12aR,14R,15R,15aR,16R)-10-(2-cyanoethoxy)-16-fluoro- 2-oxido-14-(4-oxo-4,5-dihydro-1H-imidazo[2,1-b]purin-1-yl)-2-sulfanyl-10-sulfido-15- [(tripropan-2-ylsilyl)oxy]octahydro-12H-5,8-methanofuro[3,2-l][1,3,6,9,11,2,10]pentaoxa- diphosphacyclotetradecin-7-yl}-6-oxo-6,9-dihydro-1H-purin-2-yl)-2-methylpropanamide
Figure imgf000151_0001
[0477] To the reaction mixture from Step 9 at -40°C was added 3H-benzo[c][1,2]dithiol-3- one (17.4mg, 0.104mmol). The reaction was stirred at rt for 2h, and then MeOH (1mL) was added. It was concentrated and purified by reverse phase (AQ-C18) chromatography eluted with 0 to 95% ACN in aq NH4HCO3 (5mM) to give the product. LCMS (ES, m/z): 1028.4 [M+H]+. 1H-NMR (400MHz, CD3OD): δ 8.57-8.02 (m, 2H), 7.99-7.55 (m, 1H), 7.56-7.12 (m, 7H), 6.50- 6.08 (m, 2H), 5.65-4.95 (m, 6H), 4.72-4.18 (m, 5H), 4.13-3.56 (m, 3H), 2.95-2.65 (m, 3H), 1.45- 0.73 (m, 24H).31P-NMR: (162MHz, CD3OD) δ 67.53-63.91 (m), 58.62-55.15 (m).
[0478] Step 11: 1-{(5R,7R,8S,12aR,14R,15R,15aR,16R)-7-(2-amino-6-oxo-1,6-dihydro- 9H-purin-9-yl)-16-fluoro-2,10-dioxido-2,10-disulfanyl-15-[(tripropan-2-ylsilyl)oxy]octahydro- 12H-5,8-methanofuro[3,2-l][1,3,6,9,11,2,10]pentaoxadiphosphacyclotetradecin-14-yl}-1H- imidazo[2,1-b]purin-4(5H)-one
Figure imgf000151_0002
[0479] N-(9-{(5R,7R,8S,12aR,14R,15R,15aR,16R)-10-(2-cyanoethoxy)-16-fluoro-2- oxido-14-(4-oxo-4,5-dihydro-1H-imidazo[2,1-b]purin-1-yl)-2-sulfanyl-10-sulfido-15- [(tripropan-2-ylsilyl)oxy]octahydro-12H-5,8-methanofuro[3,2-l][1,3,6,9,11,2,10]pentaoxadi- phosphacyclotetradecin-7-yl}-6-oxo-6,9-dihydro-1H-purin-2-yl)-2-methylpropanamide (57mg, 0.055mmol) was dissolved in MeNH2 in EtOH (30%, 3.2mL, 22mmol), and it was stirred at RT for 3h. Then, it was concentrated, and the crude product was used for the next reaction step without purification. LCMS (ES, m/z): 905.3 [M+H]+.
[0480] Step 12: 1-[(5R,7R,8S,12aR,14R,15R,15aS,16R)-7-(2-amino-6-oxo-1,6-dihydro-9H- purin-9-yl)-16-fluoro-15-hydroxy-2,10-dioxido-2,10-disulfanyloctahydro-12H-5,8- methanofuro[3,2-l][1,3,6,9,11,2,10]pentaoxadiphosphacyclotetradecin-14-yl]-1H-imidazo[2,1- b]purin-4(5H)-one (Diastereomer 1-2)
Figure imgf000152_0001
[0481] To a solution of the crude from Step 11 in Py (0.12mL) under Ar were added TEA (0.76mL, 5.5mmol) and TEA·3HF (0.45mL, 2.7mmol). The mixture was stirred at 50°C for 15h. Then, it was cooled to RT, and acetone (5.5mL) and ethoxytrimethylsilane (2.6mL, 17mmol) were added. After stirring for 30min, precipitates formed, and the reaction mixture was purified by prep-HPLC (XBridge Shield RP18 OBD Column, 19mm×250mm) eluted with 5 to 15% ACN in aq NH4HCO3 (10mM) over 20min to provide two peaks (TR: 13.53 and 16.58min) with matching mass (LCMS (ES, m/z): 749.0 [M+H]+). Fractions at TR=13.53 were further purified by reverse phase chromatography (AQ-C18) eluted with 0 to 95% ACN in aq NH4HCO3 (5 mM) to give the product. Example 32 (diastereomer 1): LCMS (ES, m/z): 749.0 [M+H]+.1H-NMR: (400MHz, D2O): δ 8.12 (s, 1H), 7.86 (s, 1H), 7.61 (d, J=2.4Hz, 1H), 7.22 (d, J=2.3Hz, 1H), 6.35 (d, J=1.6Hz, 1H), 5.99 (d, J=8.6Hz, 1H), 5.88-5.72 (m, 1H), 5.46 (dd, J=53.5, 3.4Hz, 1H), 5.19 (td, J=8.6, 4.7Hz, 1H), 4.56-4.40 (m, 4H), 4.14-4.00 (m, 2H).31P-NMR: (162MHz, D2O): δ 55.37 (s), 52.33 (s). Fractions at TR=16.58 were further purified by reverse phase
chromatography (AQ-C18) eluted with 0 to 95% ACN in aq NH4HCO3 (5 mM) to give the product. Example 33 (diastereomer 2): LCMS (ES, m/z): 749.0 [M+H]+.1H-NMR: (400MHz, D2O): δ 8.26 (s, 1H), 7.89 (s, 1H), 7.65 (d, J=2.4Hz, 1H), 7.26 (d, J=2.4Hz, 1H), 6.33 (d, J=2.5Hz, 1H), 6.01 (d, J=8.5Hz, 1H), 5.93-5.72 (m, 1H), 5.44-5.20 (m, 2H), 4.81 (dd, J=4.7, 2.6Hz, 1H), 4.55-4.34 (m, 4H), 4.05 (t, J=12.7Hz, 2H).31P-NMR: (162MHz, D2O): δ 55.75 (s), 55.64 (s). [0482] Example 34: 8-[(5R,7R,8R,12aR,14R,15aS,16R)-14-(4-amino-1H-pyrrolo[2,3- b]pyridin-1-yl)-16-hydroxy-2,10-dioxido-2,10-disulfanyloctahydro-12H-5,8-methanofuro
[3,2-l][1,3,6,9,11,2,10]pentaoxadiphosphacyclotetradecin-7-yl]imidazo[1,2-a]pyrimidin- 5(8H)-one
Figure imgf000153_0001
[0483] Step 1: (Z)-N'-(1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)- 1H-pyrrolo[2,3-b]pyridin-4-yl)-N,N-dimethylformimidamide
Figure imgf000153_0002
[0484] To a solution of (2R,3S,5R)-5-(4-amino-1H-pyrrolo[2,3-b]pyridin-1-yl)-2- (hydroxymethyl)tetrahydrofuran-3-ol (0.14mg, 0.56mmol) in DMF (2mL) was added DMF- DMA (1.0g, 8.4mmol). The resulting mixture was stirred at 40°C for 12h. Then, it was concentrated and the residue was purified by column chromatography eluted with 0% to 10% MeOH in DCM to give the product. LCMS (ES, m/z): 305.2 [M+H]+.1H NMR (300MHz, DMSO-d6): δ 8.04-7.90 (m, 2H), 7.46 (d, J=3.7Hz, 1H), 6.59 (dd, J=7.4, 5.5Hz, 2H), 6.46 (d, J=3.6Hz, 1H), 5.27 -5.15 (m, 2H), 4.35-4.30 (m, 1H), 3.83-3.80 (m, 1H), 3.62 -3.41 (m, 2H), 3.03 (d, J=17.3Hz, 6H), 2.62-2.49 (m, 1H), 2.18-2.14 (m, 1H).
[0485] Step 2: (Z)-N'-(1-((2R,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4- hydroxytetrahydrofuran-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)-N,N-dimethylformimidamide
Figure imgf000153_0003
[0486] To a mixture of (Z)-N'-(1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)-N,N-dimethylformimidamide (100mg, 0.33mmol) in Py (1.8mL) was added DMTrCl (122mg, 0.361mmol). After stirring at RT for 2h, the mixture was concentrated, and the residue was purified by reverse phase chromatography (C18) eluted with 0 to 95% aq NH4HCO3 (5mM) in MeCN to give the product. LCMS (ES, m/z): 607.3 [M+H]+.1H NMR (300MHz, DMSO-d6): δ 8.03-7.92 (m, 2H), 7.41-7.12 (m, 9H), 6.85-6.80 (m, 4H), 6.72-6.54 (m, 2H), 6.46 (d, J=3.7Hz, 1H), 5.73 (s, 1H), 5.27 (d, J=4.4Hz, 1H), 4.33 (dt, J=6.7, 3.6Hz, 1H), 3.90 (q, J=4.4Hz, 1H), 3.72 (s, 6H), 3.18-3.15 (m, 2H), 3.06 (s, 3H), 3.00 (s, 3H), 2.51-2.48 (m, 1H), 2.26-2.13 (m, 1H).
[0487] Step 3: (2R,3S,5R)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-5-(4-(((Z)- (dimethylamino)methylene)amino)-1H-pyrrolo[2,3-b]pyridin-1-yl)tetrahydrofuran-3-yl (2- cyanoethyl) diisopropylphosphoramidite
Figure imgf000154_0001
[0488] To a stirred solution of 3-((bis(diisopropylamino)phosphino)oxy)propanenitrile (129mg, 0.429mmol) in MeCN (2mL) under Ar was added TFA·Py (62mg, 0.32mmol) and a solution of (Z)-N'-(1-((2R,4S,5R)-5-((bis(4-methoxyphenyl)(phenyl)methoxy) methyl)-4- hydroxytetrahydrofuran-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)-N,N-dimethylformimidamide in MeCN (4mL) over 2min. The resulting mixture was stirred at RT for 1h. Then, it was concentrated, and DCM (40mL) was added. The solution was washed with aq NaHCO3 (1%, 2×20mL), H2O (20mL), and brine (20mL), dried (Na2SO4), and concentrated. The residue was purified by reverse phase chromatography (C18) eluted with 0 to 95% aq NH4HCO3 (5mM) in MeCN to give the product. LCMS (ES, m/z): 807.5 [M+H]+.1H NMR (400MHz, DMSO-d6): δ 8.06-7.95 (m, 2H), 7.42-7.37 (m, 3H), 7.33-7.25 (m,7H), 6.85-6.81 (m, 4H), 6.72-6.59 (m, 2H), 6.51 (dd, J=3.7,1.5Hz, 1H), 4.65 (m, 1H), 4.06 (dq, J=21.5, 4.3Hz, 1H), 3.83-3.51 (m, 10H), 3.29-3.12 (m, 2H), 3.06 (d, J=24.2Hz, 6H), 2.75-2.70 (m, 3H), 2.50-2.40 (m, 1H), 1.20-1.13 (m, 9H), 1.06 (d, J=6.7Hz, 3H).31P NMR (162MHz, DMSO-d6): δ 147.54 (s), 146.94 (s).
[0489] Step 4: (2R,3R,4R,5R)-5-((((((2R,3S,5R)-2-((bis(4-methoxyphenyl)(phenyl) methoxy)methyl)-5-(4-(((Z)-(dimethylamino)methylene)amino)-1H-pyrrolo[2,3-b]pyridin-1- yl)tetrahydrofuran-3-yl)oxy)(2-cyanoethoxy)phosphanyl)oxy)methyl)-4-((tert-butyldimethylsilyl) oxy)-2-(5-oxoimidazo[1,2-a]pyrimidin-8(5H)-yl)tetrahydrofuran-3-yl hydrogen phosphonate
Figure imgf000155_0001
[0490] (2R,3R,4R,5R)-4-((tert-butyldimethylsilyl)oxy)-5-(hydroxymethyl)-2-(5- oxoimidazo[1,2-a]pyrimidin-8(5H)-yl)tetrahydrofuran-3-yl hydrogen phosphonate (crude, 0.24g, ~0.130mmol) was also co-evaporated with MeCN (3×3mL), and then re-dissolved in MeCN (1mL). Activated 4Å molecular sieve (100mg) was added to the solution under Ar. (2R,3S,5R)- 2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-5-(4-(((Z)-(dimethylamino)methylene) amino)-1H-pyrrolo[2,3-b]pyridin-1-yl)tetrahydrofuran-3-yl (2-cyanoethyl)diisopropyl- phosphoramidite (0.115g, 0.143mmol) was co-evaporated with MeCN (3×3mL) and re-dissolved in MeCN (1mL). Activated 4Å molecular sieve (100mg) was added to the solution under Ar. After 30min, it was added to the solution containing (2R,3R,4R,5R)-4-((tert-butyldimethylsilyl) oxy)-5-(hydroxymethyl)-2-(5-oxoimidazo[1,2-a]pyrimidin-8(5H)-yl)tetrahydrofuran-3-yl hydrogen phosphonate. The resulting mixture under Ar was stirred at RT for 30min. It was used for the next reaction step without purification. LCMS (ES, m/z): 1151.5 [M+H]+.
[0491] Step 5: (2R,3R,4R,5R)-5-((((((2R,3S,5R)-2-((bis(4-methoxyphenyl)(phenyl)methoxy) methyl)-5-(4-(((Z)-(dimethylamino)methylene)amino)-1H-pyrrolo[2,3-b]pyridin-1-yl) tetra- hydrofuran-3-yl)oxy)(2-cyanoethoxy)phosphorothioyl)oxy)methyl)-4-((tert-butyldimethylsilyl) oxy)-2-(5-oxoimidazo[1,2-a]pyrimidin-8(5H)-yl)tetrahydrofuran-3-yl hydrogen phosphonate
Figure imgf000155_0002
[0492] To the reaction mixture from Step 4 was added (E)-N,N-dimethyl-N'-(3-thioxo-3H- 1,2,4-dithiazol-5-yl)formimidamide (0.029g, 0.14mmol), and it was stirred at RT for 30min. Then, it was concentrated to give a crude containing the product, and it was used for the next reaction step without purification. LCMS (ES, m/z): 1183.5 [M+H]+.
[0493] Step 6: (2R,3R,4R,5R)-4-((tert-butyldimethylsilyl)oxy)-5-((((2-cyanoethoxy)(((2R, 3S,5R)-5-(4-(((Z)-(dimethylamino)methylene)amino)-1H-pyrrolo[2,3-b]pyridin-1-yl)-2- (hydroxymethyl)tetrahydrofuran-3-yl)oxy)phosphorothioyl)oxy)methyl)-2-(5-oxoimidazo[1,2- a]pyrimidin-8(5H)-yl)tetrahydrofuran-3-yl hydrogen phosphonate
Figure imgf000156_0001
[0494] To a solution of the crude from Step 5 in DCM (1.8mL) was added H2O (23mg, 1.3mmol) and DCA in DCM (6%, 1.87mL, 1.17mmol). The reaction was stirred at RT for 30min. Then, Et3SiH (2.0mL) was added to the reaction, and it was stirred for 1h. Then, Py (185mg, 2.34mmol) was added, and the resulting solution was concentrated. The residue was purified by reverse phase chromatography (C18) eluted with 0 to 95% aq NH4HCO3 (5mM) in MeCN to give the product. LCMS (ES, m/z): 881.3 [M+H]+.1H NMR (400MHz, CD3OD): δ 8.10-7.94 (m, 3H), 7.68-7.51 (m, 2H), 7.41-7.34 (m, 1H), 7.23-7.15 (m, 1H), 6.75-6.65 (m, 1H), 6.63-6.44 (m, 1.5H), 6.32-6.23 (m, 1H), 6.06-5.88 (m, 0.5H), 5.80-5.74 (m, 1H), 5.35-5.30 (m, 1H), 5.24-5.19 (m, 1H), 4.86-4.77 (m, 2H), 4.57-4.22 (m, 6H), 3.79-3.76 (m, 2H), 3.22-3.05 (m, 5H), 3.05-2.78 (m, 3H), 2.64-2.42 (m, 1H), 1.00 (d, J=6.8Hz, 9H), 0.33-0.17 (m, 6H).31P NMR (162MHz, CD3OD): δ 66.88 (s), 66.77 (s); 2.98 (s), 2.87 (s).
[0495] Step 7: N'-{1-[(5R,7R,8R,12aR,14R,15aS,16R)-16-{[tert-butyl(dimethyl)silyl] oxy}- 2-(2-cyanoethoxy)-10-hydroxy-7-(5-oxoimidazo[1,2-a]pyrimidin-8(5H)-yl)-2-sulfidooctahydro- 12H-5,8-methanofuro[3,2-l][1,3,6,9,11,2,10]pentaoxadiphosphacyclo-tetradecin-14-yl]-1H- pyrrolo[2,3-b]pyridin-4-yl}-N,N-dimethylimidoformamide
Figure imgf000156_0002
[0496] (2R,3R,4R,5R)-4-((tert-butyldimethylsilyl)oxy)-5-((((2-cyanoethoxy) (((2R,3S,5R)- 5-(4-(((Z)-(dimethylamino)methylene)amino)-1H-pyrrolo[2,3-b]pyridin-1-yl)-2-(hydroxyl- methyl)tetrahydrofuran-3-yl)oxy)phosphorothioyl)oxy)methyl)-2-(5-oxoimidazo[1,2-a] pyrimidin-8(5H)-yl)tetrahydrofuran-3-yl hydrogen phosphonate (40mg, 0.045mmol) was co- evaporated with Py (3×2mL) and then dissolved in DCM (5mL). To this solution at -40°C was added a solution of diphenyl phosphorochloridate (239mg, 0.891mmol) in Py (5mL) over 10min. The resulting mixture was stirred at -40°C for 20min. Then, it was used for the next reaction step directly. LCMS (ES, m/z): 863.3 [M+H]+.
[0497] Step 8: N'-{1-[(5R,7R,8R,12aR,14R,15aS,16R)-16-{[tert-butyl(dimethyl)silyl] oxy}- 2-(2-cyanoethoxy)-10-oxido-7-(5-oxoimidazo[1,2-a]pyrimidin-8(5H)-yl)-10-sulfanyl-2- sulfidooctahydro-12H-5,8-methanofuro[3,2-l][1,3,6,9,11,2,10]pentaoxadiphosphacyclotetra- decin-14-yl]-1H-pyrrolo[2,3-b]pyridin-4-yl}-N,N-dimethylimidoformamide
Figure imgf000157_0001
[0498] To the reaction mixture from Step 7 at -40°C was added 3H-benzo[c][1,2]dithiol-3- one (11mg, 0.068mmol) and H2O (0.05mL). After stirring at RT for 40min, the mixture was concentrated under reduced pressure. The residue was purified by reverse phase chromatography (C18) eluted with 0 to 95% aq NH4HCO3 (5mM) in MeCN to give the product. LCMS (ES, m/z): 895.3 [M+H]+.31P NMR (162MHz, CD3OD): δ 65.78-65.36 (m), 58.29-57.20 (m).
[0499] Step 9: 8-[(5R,7R,8R,12aR,14R,15aS,16R)-14-(4-amino-1H-pyrrolo[2,3-b]pyridin- 1-yl)-16-{[tert-butyl(dimethyl)silyl]oxy}-2,10-dioxido-2,10-disulfanyloctahydro-12H-5,8- methanofuro[3,2-l][1,3,6,9,11,2,10]pentaoxadiphosphacyclotetradecin-7-yl]imidazo[1,2- a]pyrimidin-5(8H)-one
Figure imgf000157_0002
[0500] N'-{1-[(5R,7R,8R,12aR,14R,15aS,16R)-16-{[tert-butyl(dimethyl)silyl]oxy}-2-(2- cyanoethoxy)-10-oxido-7-(5-oxoimidazo[1,2-a]pyrimidin-8(5H)-yl)-10-sulfanyl-2-sulfido- octahydro-12H-5,8-methanofuro[3,2-l][1,3,6,9,11,2,10] pentaoxadiphosphacyclo-tetradecin-14- yl]-1H-pyrrolo[2,3-b]pyridin-4-yl}-N,N-dimethylimidoformamide (20mg, 0.022mmol) and NH4OAc (1.0g, 13mmol) were dissolved in NH4OH (10mL, 260mmol), and the resulting mixture was stirred at rt for 3h. Then, it was concentrated, and the residue was purified by reverse phase chromatography (C18) eluted with 0 to 95% aq NH4HCO3 (5mM) in MeCN over 51min to give the product (TR=32.5min). LCMS (ES, m/z): 787.3 [M+H]+.
[0501] Step 10: 8-[(5R,7R,8R,12aR,14R,15aS,16R)-14-(4-amino-1H-pyrrolo[2,3- b]pyridin-1-yl)-16-hydroxy-2,10-dioxido-2,10-disulfanyloctahydro-12H-5,8-methanofuro[3,2- l][1,3,6,9,11,2,10]pentaoxadiphosphacyclotetradecin-7-yl]imidazo[1,2-a]pyrimidin-5(8H)-one
Figure imgf000158_0001
[0502] To a suspension of 8-[(5R,7R,8R,12aR,14R,15aS,16R)-14-(4-amino-1H- pyrrolo[2,3-b]pyridin-1-yl)-16-{[tert-butyl(dimethyl)silyl]oxy}-2,10-dioxido-2,10- disulfanyloctahydro-12H-5,8-methanofuro[3,2-l][1,3,6,9,11,2,10] pentaoxadiphosphacyclo- tetradecin-7-yl]imidazo[1,2-a]pyrimidin-5(8H)-one (10mg, ~0.012mmol) in Py (0.2mL) were added TEA (62mg, 0.61mmol) and TEA·3HF (49mg, 0.31mmol). The mixture was stirred at 50°C for 3h. Then, it was concentrated, and acetone (1.1mL) and ethoxytrimethylsilane (3.9mL, 25mmol) were added. After stirring for 30min, precipitates were formed. The precipitates were purified by reverse phase chromatography (C18) eluted with 0 to 95% aq NH4HCO3 (30mM) in MeCN to give the product. LCMS (ES, m/z): 672.9 [M+H]+.1H NMR (400MHz, D2O): δ 8.37 (d, J=7.9Hz, 1H), 7.86-7.83 (m, 1H), 7.65 (s, 1H), 7.32-7.28 (m, 2H), 6.67-6.63 (m, 1H), 6.56 (d, J=8.3Hz, 1H), 6.46-6.40 (m, 2H), 6.01 (d, J=7.9Hz, 1H), 5.19-4.99 (m, 2H), 4.88-4.82 (m, 2H), 4.53-4.48 (m, 1H), 4.41-4.28 (m, 2H), 4.19-4.02 (m, 1H), 3.97-3.73 (m, 1H), 2.96-2.73 (m, 2H). 31P NMR (162MHz, D2O): δ 55.28 (s), 53.94 (s). [0503] Example 35: 2-amino-9-[(5R,7R,8S,12aR,14R,15aS,16R)-16-fluoro-2,10- dioxido-14-(4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,10-disulfanyloctahydro- 12H-5,8-methanofuro[3,2-l][1,3,6,9,11,2,10]pentaoxadiphosphacyclotetradecin-7-yl]-1,9- dihydro-6H-purin-6-one (Diastereomer 1)
Figure imgf000159_0001
[0504] Step 1 : 3'-deoxy-3'-fluoro-2'-O-[hydroxy(oxido)-λ5-phosphanyl]-N-(2- methylpropanoyl)guanosine
Figure imgf000159_0002
[0505] To a stirred solution of triethylammonium 5'-O-[bis(4-methoxyphenyl)(phenyl) methyl]-3'-deoxy-3'-fluoro-2'-O-[hydroxy(oxido)-λ5-phosphanyl]-N-(2-methylpropanoyl) guanosine (1.35g, 1.50mmol) in DCM (22.5mL) were added H2O (0.27mL, 15mmol) and 2,2- DCA in DCM solution (0.6M, 22.5mL, 13.5mmol) at RT. The mixture was stirred at RT for 15min, treated with Et3SiH (5mL), and left to stir for 1.5h. Py (2.4mL, 30mmol) was added, and the mixture was stirred for 5min and concentrated under reduced pressure to give the crude product as the pyridinium salt. LCMS (ES, m/z): 420 [M+H]+.
[0506] Step 2 : (2R,3S,4R,5R)-5-((((((2R,3S,5R)-5-(4-benzamido-7H-pyrrolo[2,3- d]pyrimidin-7-yl)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)tetrahydrofuran-3-yl)oxy)(2- cyanoethoxy)phosphorothioyl)oxy)methyl)-4-fluoro-2-(2-isobutyramido-6-oxo-1,6-dihydro-9H- purin-9-yl)tetrahydrofuran-3-yl hydrogen phosphonate
Figure imgf000159_0003
[0507] A solution of 7-{5-O-[bis(4-methoxyphenyl)(phenyl)methyl]-3-O-[(2- cyanoethoxy)(dipropan-2-ylamino)phosphanyl]-2-deoxy-β-D-erythro-pentofuranosyl}-N- (phenylcarbonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (1.41g, 1.65mmol) in MeCN (5mL) was concentrated in vacuo. Addition of MeCN (5mL) followed by concentration was repeated twice. To the residue were added MeCN (5mL) and activated 4Å molecular sieves (100mg).
[0508] The crude pyridinium 3'-deoxy-3'-fluoro-2'-O-[hydroxy(oxido)-λ5-phosphanyl]-N- (2-methylpropanoyl)guanosine was dissolved in MeCN (5m) and concentrated in vacuo.
Addition of MeCN (5mL) followed by concentration was repeated twice. To the residue were added MeCN (5mL) and activated 4Å molecular sieves (100mg). After 30min, the
phosphoramidite solution was added to the H-phosphonate solution over 5min. The flask was rinsed with MeCN (1mL), and the solution was transferred to the H-phosphonate solution (2x). The resulting mixture was charged with Ar and stirred at RT for 10min, treated with DDTT (0.339g, 1.65mmol), and left to stir for 45min. The mixture was concentrated to give the product as the pyridinium salt. LCMS (ES, m/z): 1205 [M-H]-.
[0509] Step 3 : (2R,3S,4R,5R)-5-((((((2R,3S,5R)-5-(4-benzamido-7H-pyrrolo[2,3- d]pyrimidin-7-yl)-2-(hydroxymethyl)tetrahydrofuran-3-yl)oxy)(2-cyanoethoxy)phosphorothioyl) oxy)methyl)-4-fluoro-2-(2-isobutyramido-6-oxo-1,6-dihydro-9H-purin-9-yl)tetrahydrofuran-3-yl hydrogen phosphonate
Figure imgf000160_0001
[0510] The crude pyridinium (2R,3S,4R,5R)-5-((((((2R,3S,5R)-5-(4-benzamido-7H- pyrrolo[2,3-d]pyrimidin-7-yl)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)
tetrahydrofuran-3-yl)oxy)(2-cyanoethoxy)phosphorothioyl)oxy)methyl)-4-fluoro-2-(2- isobutyramido-6-oxo-1,6-dihydro-9H-purin-9-yl)tetrahydrofuran-3-yl hydrogen phosphonate was dissolved in DCM (22.5mL) was treated with H2O (0.27mL, 15mmol) and 2,2-DCA in DCM (0.6M, 22.5mL, 13.5mmol) at RT over 3min. The mixture was left to stir for 15min and cooled to 0°C. The mixture was treated with Hex (50mL) and left to stir for 30min. The supernatant was decanted, and DCM and Hex (30mL each) were added to the residue. The supernatant was decanted, and the residue was dried under vacuum and purified by reverse phase (C18) chromatography eluting with 0 to 95% MeCN in 5mM aq NH4HCO3 solution to give the product as the ammonium salt. LCMS (ES, m/z): 903 [M-H]-. [0511] Step 4 : N-{7-[(5R,7R,8S,12aR,14R,15aS,16R)-2-(2-cyanoethoxy)-16-fluoro-10- hydroxy-7-{2-[(2-methylpropanoyl)amino]-6-oxo-1,6-dihydro-9H-purin-9-yl}-2,10-disulfido- octahydro-12H-5,8-methanofuro[3,2-l][1,3,6,9,11,2,10] pentaoxadiphosphacyclotetradecin-14- yl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}benzamide
Figure imgf000161_0001
[0512] A solution of ammonium (2R,3S,4R,5R)-5-((((((2R,3S,5R)-5-(4-benzamido-7H- pyrrolo[2,3-d]pyrimidin-7-yl)-2-(hydroxymethyl)tetrahydrofuran-3-yl)oxy)(2-cyanoethoxy) phosphorothioyl)oxy)methyl)-4-fluoro-2-(2-isobutyramido-6-oxo-1,6-dihydro-9H-purin-9- yl)tetrahydrofuran-3-yl hydrogen phosphonate (850mg, 0.922mmol) in Py (10mL) was concentrated in vacuo. Addition of Py (10mL) followed by concentration was repeated twice. The residue was taken up in DCM (92mL) and Py (22mL).
[0513] To a stirred Py (70mL) in a separate flask was added diphenyl chlorophosphate (4954mg, 18.44mmol) under Ar at -40°C over 5min. To the solution was added hydrogen phosphonate solution dropwise at -40°C over 20min. The resulting mixture was stirred at -40°C for 20min and treated with 3H-1,2-benzodithiol-3-one (233mg, 1.38mmol) in one portion and H2O (332mg, 18.4mmol) at -40°C. After stirring at RT for 40min, the mixture was concentrated under reduced pressure. The residue was purified by reverse phase (C18) chromatography eluting with 0 to 95% MeCN in 5mM aq NH4HCO3 solution to give the product as the ammonium salt (800mg, 0.885mmol). LCMS (ES, m/z): 917 [M-H]-.
[0514] Step 5: 2-amino-9-[(5R,7R,8S,12aR,14R,15aS,16R)-14-(4-amino-7H-pyrrolo[2,3- d]pyrimidin-7-yl)-16-fluoro-2,10-dioxido-2,10-disulfanyloctahydro-12H-5,8-methanofuro[3,2- l][1,3,6,9,11,2,10]pentaoxadiphosphacyclotetradecin-7-yl]-1,9-dihydro-6H-purin-6-one
Figure imgf000161_0002
[0515] To ammonium N-{7-[(5R,7R,8S,12aR,14R,15aS,16R)-2-(2-cyanoethoxy)-16-fluoro- 10-hydroxy-7-{2-[(2-methylpropanoyl)amino]-6-oxo-1,6-dihydro-9H-purin-9-yl}-2,10- disulfidooctahydro-12H-5,8-methanofuro[3,2-l][1,3,6,9,11,2,10] pentaoxadiphosphacyclo- tetradecin-14-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}benzamide (800mg, 0.885mmol) was added MeNH2 in EtOH (30% w/w, 47mL), and the resulting solution was left to stir at RT for 8h and concentrated. The residue was taken up in acetone (30mL), left to stir overnight, filtered, and washed with acetone (5mLx2). The filter cake was dissolved in DMSO (8mL) and then filtered. The filtrate was purified by reverse phase (C18) chromatography eluting with 0 to 100% MeCN in 30mM aq NH4HCO3 solution to give the four phosphorus diastereomers as the diammonium salts. The second fastest eluting peak fractions were collected and lyophilized to give the product as the diammonium salt. LCMS (ES, m/z): 692 [M+H]+.1H-NMR: (400MHz, D2O): δ 8.28 (s, 1H), 8.03 (s, 1H), 7.17 (d, J=3.7Hz, 1H), 6.33-6.32 (m, 2H), 5.97 (d, J=8.5Hz, 1H), 5.48 (d, J=55.6Hz, 1H), 5.26-5.14 (m, 1H), 4.91-4.87 (m, 1H), 4.66-4.64 (m, 1H), 4.19-4.13 (m, 4H), 4.02-3.99 (m, 1H), 2.71-2.68 (m, 2H).31P-NMR: (162MHz, D2O): δ 54.14, 52.59.
[0516] Step 6: 2-amino-9-[(5R,7R,8S,12aR,14R,15aS,16R)-16-fluoro-2,10-dioxido-14-(4- oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,10-disulfanyloctahydro-12H-5,8- methanofuro[3,2-l][1,3,6,9,11,2,10]pentaoxadiphosphacyclotetradecin-7-yl]-1,9-dihydro-6H- purin-6-one
Figure imgf000162_0001
[0517] To diammonium 2-amino-9-[(5R,7R,8S,12aR,14R,15aS,16R)-14-(4-amino-7H- pyrrolo[2,3-d]pyrimidin-7-yl)-16-fluoro-2,10-dioxido-2,10-disulfanyloctahydro-12H-5,8- methanofuro[3,2-l][1,3,6,9,11,2,10]pentaoxadiphosphacyclotetradecin-7-yl]-1,9-dihydro-6H- purin-6-one (4.3mg, 6.1µmol) were added sodium phosphate buffer (pH 6.8, 50mM, 8mL) and AMPDA (200mg). The reaction mixture was left to stir for 11 days, filtered, and purified by reverse phase HPLC (eluting MeCN/H2O gradient with 100mM TEAA modifier, linear gradient) to afford the product (Diastereomer 1) as the triethylammonium salt. LCMS (ES, m/z): 691 [M- H]-.1H NMR (600MHz, D2O): δ 8.39 (s, 1H), 8.07 (s, 1H), 7.28 (d, J=3.3Hz, 1H), 6.62 (m, 2H), 6.11 (d, J=8.6Hz, 1H), 5.58 (dd, J=53.1, 2.4Hz, 1H), 5.45 (m, 1H), 5.21 (m, 1H), 4.41 (brs, 1H), 4.23-4.30 (m, 2H), 4.10 (m, 2H), 2.95-3.08 (m, 2H), 2.86 (m, 1H). [0518] Examples 36 through 51, as shown in Table 5 below, were prepared according to procedures analogous to those outlined in Example 35 above.
Table 5
Figure imgf000163_0001
Figure imgf000164_0001
Figure imgf000165_0001
Figure imgf000166_0001
[0519] Example 52: 2-amino-9-[(5R,7R,8S,12aR,14R,15aS,16R)-14-(4-amino-5-fluoro- 7H-pyrrolo[2,3-d]pyrimidin-7-yl)-16-fluoro-2,10-dioxido-2,10-disulfanyloctahydro-12H-5,8- methanofuro[3,2-l][1,3,6,9,11,2,10]pentaoxadiphosphacyclotetradecin-7-yl]-1,9-dihydro- 6H-purin-6-one
Figure imgf000167_0001
[0520] Step 1: N-{5-fluoro-7-[(6aR,8R,9aS)-2,2,4,4-tetra(propan-2-yl)tetrahydro-6H- furo[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}benzamide
Figure imgf000167_0002
[0521] BzCl (1.2mL, 10.3mmol) was added to a stirring solution of 5-fluoro-7- [(6aR,8R,9aS)-2,2,4,4-tetra(propan-2-yl)tetrahydro-6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-8- yl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine (3.3g, 6.5mmol) in Py (32mL) at 0°C. The reaction mixture was allowed to warm to RT and stir for 1h. MeOH (10mL) was added, and the reaction mixture was allowed to stir for 30min. The reaction mixture was concentrated in vacuo. The residue was purified by flash column chromatography on silica eluting with Hex, EtOAc, and EtOH to give the titled compound. LCMS (ES, m/z): 615 [M+H]+.
[0522] Step 2: 7-(2-deoxy-β-D-erythro-pentofuranosyl)-5-fluoro-N-(phenylcarbonyl)-7H- pyrrolo[2,3-d]pyrimidin-4-amine
Figure imgf000167_0003
[0523] To N-{5-fluoro-7-[(6aR,8R,9aS)-2,2,4,4-tetra(propan-2-yl)tetrahydro-6H-furo[3,2- f][1,3,5,2,4]trioxadisilocin-8-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}benzamide (2.8g, 4.60mmol) in THF (46mL) at RT was added TBAF (1M, 14mL, 14mmol). The reaction mixture was stirred overnight. The reaction mixture was concentrated in vacuo. The residue was purified by flash column chromatography on silica eluting with hexane, EtOAc, and EtOH to give the titled compound. LCMS (ES, m/z): 373 [M+H]+.
[0524] Step 3: 7-{5-O-[bis(4-methoxyphenyl)(phenyl)methyl]-2-deoxy-β-D-erythro- pentofuranosyl}-5-fluoro-N-(phenylcarbonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine
Figure imgf000168_0001
[0525] DMTrCl (1.33g, 3.93mmol) was added to 7-(2-deoxy-β-D-erythro-pentofuranosyl)- 5-fluoro-N-(phenylcarbonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (1.2g, 3.3mmol) in Py (12mL) at 0°C. The reaction mixture was allowed to warm to RT and stir overnight. Additional DMTrCl (1.33g, 3.93mmol) was added, and the reaction mixture was stirred for 4h. DMAP (0.040g, 0.33mmol) was added, and the reaction mixture was stirred for 2h. The reaction mixture was concentrated in vacuo. The residue was purified by flash column chromatography on silica eluting with MeOH and DCM with 1% TEA additive to give the title compound. LCMS (ES, m/z): 675 [M+H]+.
[0526] Step 4: 7-{5-O-[bis(4-methoxyphenyl)(phenyl)methyl]-3-O-[(2-cyanoethoxy) (dipropan-2-ylamino)phosphanyl]-2-deoxy-β-D-erythro-pentofuranosyl}-5-fluoro-N- (phenylcarbonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine
Figure imgf000168_0002
[0527] To 7-{5-O-[bis(4-methoxyphenyl)(phenyl)methyl]-2-deoxy-β-D-erythro- pentofuranosyl}-5-fluoro-N-(phenylcarbonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (1.5g, 2.2mmol) in DCM (22mL) was added 4,5-dicyanoimidazole (0.8g, 6.7mmol) followed by 2- cyanoethyl N,N,N’,N’-tetraisopropylphosphorodiamidite (2.1mL, 6.7mmol) at 0°C. The reaction mixture was stirred overnight. The reaction mixture was concentrated in vacuo. The product was purified by flash column chromatography on silica eluting with EtOAc and Hex with 1% TEA additive to the title compound. LCMS (ES, m/z): 875 [M+H]+.
[0528] Step 5: (2R,3S,4R,5R)-5-((((((2R,3S,5R)-5-(4-benzamido-5-fluoro-7H-pyrrolo [2,3- d]pyrimidin-7-yl)-2-(hydroxymethyl)tetrahydrofuran-3-yl)oxy)(2-cyanoethoxy)phosphorothioyl) oxy)methyl)-4-fluoro-2-(2-isobutyramido-6-oxo-1,6-dihydro-9H-purin-9-yl)tetrahydrofuran-3-yl hydrogen phosphonate
Figure imgf000169_0001
[0529] Pyrrole (0.277mL, 3.96mmol) was added to a stirring solution of 5'-O-[bis(4- methoxyphenyl)(phenyl)methyl]-3'-deoxy-3'-fluoro-2'-O-[hydroxy(oxido)-λ~5~-phosphanyl]-N- (2-methylpropanoyl)guanosine (1.2g, 1.3mmol) in MeCN (4.5mL) at 0°C followed by TFA (0.3mL, 4.0mmol). The reaction mixture was stirred at 0°C for 2h.7-{5-O-[bis(4-methoxy- phenyl)(phenyl)methyl]-3-O-[(2-cyanoethoxy)(dipropan-2-ylamino)phosphanyl]-2-deoxy-β-D- erythro-pentofuranosyl}-5-fluoro-N-(phenylcarbonyl)-7H-pyrrolo[2,3-d] pyrimidin-4-amine (1.2g, 1.3mmol) in MeCN (4.50mL) was added at 0°C. The reaction mixture was allowed to stir for 30min. (E)-N,N-dimethyl-N'-(3-thioxo-3H-1,2,4-dithiazol-5-yl) formimidamide (0.33g, 1.6mmol) was added at 0°C. The reaction mixture was allowed to stir for 30min.1-propanol (1mL, 13mmol) was added at 0°C, and the reaction mixture was allowed to stir for 10min and warmed to RT. TFA (1.0mL, 13mmol) was added, and the reaction mixture stirred at RT for 30min. Py (1.3mL, 16mmol) was added, and the reaction mixture was stirred for 20min. The reaction mixture was concentrated to half volume, diluted with isopropyl acetate (15mL), and left to stir overnight. The precipitate was isolated by filtration to give the title compound that was used in the next step without further purification.
[0530] Step 6: 2-amino-9-[(5R,7R,8S,12aR,14R,15aS,16R)-14-(4-amino-5-fluoro-7H- pyrrolo[2,3-d]pyrimidin-7-yl)-16-fluoro-2,10-dioxido-2,10-disulfanyloctahydro-12H-5,8- methanofuro[3,2-l][1,3,6,9,11,2,10]pentaoxadiphosphacyclotetradecin-7-yl]-1,9-dihydro-6H- purin-6-one
Figure imgf000169_0002
[0531] Diphenyl chlorophosphate (1.4mL, 6.6mmol) was added to degassed MeCN (60mL) and Py (5mL) at RT. A solution of the crude (2R,3S,4R,5R)-5-((((((2R,3S,5R)-5-(4- benzamido-5-fluoro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-(hydroxymethyl)tetrahydrofuran-3- yl)oxy)(2-cyanoethoxy)phosphorothioyl)oxy)methyl)-4-fluoro-2-(2-isobutyramido-6-oxo-1,6- dihydro-9H-purin-9-yl)tetrahydrofuran-3-yl hydrogen phosphonate in Py (8mL) was added dropwise while maintaining the internal temperature below -20°C. The reaction mixture was stirred for 30min.3H-1,2-Benzodithiol-3-one (0.3g, 1.6mmol) followed by H2O (0.5mL, 26mmol) were added, and the reaction mixture was allowed to warm to RT and stir for 30min. The reaction mixture was concentrated in vacuo and azeotroped with Py. The residue was dissolved in Py (8mL) and cooled to 0°C. MeNH2 (12.16mL, 98mmol, 33% v/v in EtOH) was added, and the reaction mixture was allowed to warm to RT and stir overnight. The reaction mixture was concentrated in vacuo, and purified by reverse phase HPLC (eluted MeCN/H2O gradient with 100mM TEAA modifier, linear gradient) to give the four phosphorus
diastereomers as triethylammonium salts. The slowest eluting peak fractions were collected and lyophilized to give the product as the triethylammonium salt. LCMS (ES, m/z): 708 [M-H]-.1H NMR (600MHz, D2O) δ 8.14 (s, 1H), 7.97 (s, 1H), 7.15 (s, 1H), 6.63 (m, 1H), 6.07 (d, J=8.5Hz, 1H), 5.77 (m, 1H), 5.53 (dd, J=53.3, 2.4Hz, 1H), 5.35 (m, 1H), 4.75 (m, 1H), 4.48 (m, 1H), 4.31–4.08 (m, 4H), 2.80 (m, 2H).
[0532] Step 7: 2-amino-9-[(5R,7R,8S,12aR,14R,15aS,16R)-16-fluoro-14-(5-fluoro-4-oxo- 3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,10-dioxido-2,10-disulfanyloctahydro-12H-5,8- methanofuro[3,2-l][1,3,6,9,11,2,10]pentaoxadiphosphacyclotetradecin-7-yl]-1,9-dihydro-6H- purin-6-one (Diastereomer 1)
Figure imgf000170_0001
[0533] To triethylammonium 2-amino-9-[(5R,7R,8S,12aR,14R,15aS,16R)-14-(4-amino-5- fluoro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-16-fluoro-2,10-dioxido-2,10-disulfanyloctahydro-12H- 5,8-methanofuro[3,2-l][1,3,6,9,11,2,10]pentaoxadiphosphacyclotetradecin-7-yl]-1,9-dihydro-6H- purin-6-one (4.6mg, 5.7µmol) were added sodium phosphate buffer (pH 6.8, 50mM, 8mL) and AMPDA (200mg). The reaction mixture was left to stir for 4 days, filtered, and purified by reverse phase HPLC (eluting MeCN/H2O gradient with 100mM TEAA modifier, linear gradient) to afford the product (Diastereomer 1) as the triethylammonium salt. LCMS (ES, m/z): 709 [M- H]-.1H NMR (600MHz, D2O) δ 8.02 (s, 1H), 7.99 (s, 1H), 7.04 (s, 1H), 6.66 (m, 1H), 6.07 (d, J=8.5Hz, 1H), 5.76 (m, 1H), 5.49 (d, J=55.8Hz, 1H), 5.34 (m, 1H), 4.74 (m, 1H), 4.47 (m, 1H), 4.31 (brs, 1H), 4.22–4.13 (m, 2H), 4.06 (m, 1H), 2.80 (m, 3H). [0534] Example 53, as shown in Table 6 below, was prepared according to procedures analogous to those outlined in Example 52 above.
Table 6
Figure imgf000171_0003
[0535] Example 54: 2-amino-9-[(5S,7R,8R,12aR,14R,15aS)-2-hydroxy-2,10-dioxido- 14-(4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-10-sulfanyloctahydro-12H-5,8- methanofuro[3,2-l][1,3,6,9,11,2,10]pentaoxadiphosphacyclotetradecin-7-yl]-1,9-dihydro- 6H-purin-6-one
Figure imgf000171_0001
[0536] Step 1: 3'-deoxy-2'-O-[hydroxy(oxido)-λ5-phosphanyl]-N-(2- methylpropanoyl)guanosine
Figure imgf000171_0002
[0537] To a stirred solution of triethylammonium 5'-O-[bis(4-methoxyphenyl)(phenyl) methyl]-3'-deoxy-2'-O-[hydroxy(oxido)-λ5-phosphanyl]-N-(2-methylpropanoyl)guanosine (1.28g, 1.59mmol) in DCM (24mL) were added H2O (0.287g, 15.9mmol) and DCA in DCM solution (0.6M, 23.85mL, 14.31mmol) at RT. The mixture was stirred at RT for 10min, treated with Et3SiH (32mL), and left to stir for 1h. Py (2.264g, 28.6mmol) was added, and the mixture was concentrated under reduced pressure to give the crude product as the pyridinium salt. LCMS (ES, m/z): 402 [M+H]+.
[0538] Step 2: (2R,3R,5S)-5-((((((2R,3S,5R)-5-(4-benzamido-7H-pyrrolo[2,3-d]pyrimidin- 7-yl)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)tetrahydrofuran-3-yl)oxy)(2- cyanoethoxy)phosphoryl)oxy)methyl)-2-(2-isobutyramido-6-oxo-1,6-dihydro-9H-purin-9- yl)tetrahydrofuran-3-yl hydrogen phosphonate
Figure imgf000172_0001
[0539] A solution of 7-{5-O-[bis(4-methoxyphenyl)(phenyl)methyl]-3-O-[(2- cyanoethoxy)(dipropan-2-ylamino)phosphanyl]-2-deoxy-β-D-erythro-pentofuranosyl}-N- (phenylcarbonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (1.43g, 1.67mmol) in MeCN (5mL) was concentrated in vacuo. Addition of MeCN (5mL) followed by concentration was repeated twice. To the residue were added MeCN (12mL) and activated 4Å molecular sieves (150mg).
[0540] The crude pyridinium 3'-deoxy-3'-fluoro-2'-O-[hydroxy(oxido)-λ5-phosphanyl]-N- (2-methylpropanoyl)guanosine was dissolved in MeCN (5m) and concentrated in vacuo.
Addition of MeCN (5mL) followed by concentration was repeated twice. To the residue were added MeCN (12mL) and activated 4Å molecular sieves (150mg). After 30min, the
phosphoramidite solution was added to the H-phosphonate solution. The flask was rinsed with MeCN (1mL), and the solution was transferred to the H-phosphonate solution (2x). The resulting mixture was charged with Ar and stirred at RT for 30min, treated with tBuO2H (5.5M in decane, 1.0mL, 5.5mmol) over 1min, and left to stir for 1h. The mixture was cooled to 0°C, treated with aq Na2S2O3 solution (18g in 3mL H2O) slowly. The mixture was left to stir at RT for 5min and concentrated to give the crude product as the pyridinium salt. LCMS (ES, m/z): 1171 [M-H]-. [0541] Step 3: (2R,3R,5S)-5-((((((2R,3S,5R)-5-(4-benzamido-7H-pyrrolo[2,3-d]pyrimidin- 7-yl)-2-(hydroxymethyl)tetrahydrofuran-3-yl)oxy)(2-cyanoethoxy)phosphoryl) oxy)methyl)-2-(2- isobutyramido-6-oxo-1,6-dihydro-9H-purin-9-yl)tetrahydrofuran-3-yl hydrogen phosphonate
Figure imgf000173_0001
[0542] The crude pyridinium (2R,3R,5S)-5-((((((2R,3S,5R)-5-(4-benzamido-7H-pyrrolo [2,3-d]pyrimidin-7-yl)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)tetrahydrofuran-3- yl)oxy)(2-cyanoethoxy)phosphoryl)oxy)methyl)-2-(2-isobutyramido-6-oxo-1,6-dihydro-9H- purin-9-yl)tetrahydrofuran-3-yl hydrogen phosphonate was dissolved in DCM (24mL) was treated with H2O (286mg, 15.9mmol) and DCA in DCM (0.6M, 23.9mL, 14.3mmol) at RT. The mixture was left to stir for 10min, treated with Et3SiH (20mL), left to stir for 1h, and treated with Py (2.26g, 28.6mmol). The mixture was concentrated and purified by reverse phase (C18) chromatography eluting with 0 to 95% MeCN in 5mM aq NH4HCO3 solution to give the product as the ammonium salt. LCMS (ES, m/z): 871 [M+H]+.
[0543] Step 4: N-{7-[(5S,7R,8R,12aR,14R,15aS)-2-(2-cyanoethoxy)-10-hydroxy-7-{2-[(2- methylpropanoyl)amino]-6-oxo-1,6-dihydro-9H-purin-9-yl}-2-oxido-10-sulfidooctahydro-12H- 5,8-methanofuro[3,2-l][1,3,6,9,11,2,10]pentaoxadiphosphacyclotetradecin-14-yl]-7H- pyrrolo[2,3-d]pyrimidin-4-yl}benzamide
Figure imgf000173_0002
[0544] A solution of ammonium (2R,3R,5S)-5-((((((2R,3S,5R)-5-(4-benzamido-7H- pyrrolo[2,3-d]pyrimidin-7-yl)-2-(hydroxymethyl)tetrahydrofuran-3-yl)oxy)(2-cyanoethoxy) phosphoryl)oxy)methyl)-2-(2-isobutyramido-6-oxo-1,6-dihydro-9H-purin-9-yl)tetrahydrofuran- 3-yl hydrogen phosphonate (803mg, 0.923mmol) in Py (5mL) was concentrated in vacuo. Addition of Py (5mL) followed by concentration was repeated twice. The residue was taken up in DCM (70mL) and Py (20mL).
[0545] To a stirred Py (72mL) and DCM (20mL) in a separate flask was added diphenyl chlorophosphate (4961mg, 18.47mmol) under Ar at -40°C. To the solution was added the hydrogen phosphonate solution dropwise at -40°C over 30min. The resulting mixture was left to stir at -40°C for 40min and treated with 3H-1,2-benzodithiol-3-one (255mg, 1.384mmol) in one portion and H2O (416mg, 23.1mmol) at -40°C. After stirring at RT for 1h, the mixture was concentrated under reduced pressure. The residue was purified by reverse phase (C18) chromatography eluting with 0 to 95% MeCN in 5mM aq NH4HCO3 solution to give the product as the ammonium salt. LCMS (ES, m/z): 885 [M+H]+.
[0546] Step 5: 2-amino-9-[(5S,7R,8R,12aR,14R,15aS)-14-(4-amino-7H-pyrrolo[2,3-d] pyrimidin-7-yl)-2-hydroxy-2,10-dioxido-10-sulfanyloctahydro-12H-5,8-methanofuro[3,2-l]
[1,3,6,9,11,2,10]pentaoxadiphosphacyclotetradecin-7-yl]-1,9-dihydro-6H-purin-6-one
Figure imgf000174_0001
[0547] To ammonium N-{7-[(5S,7R,8R,12aR,14R,15aS)-2-(2-cyanoethoxy)-10-hydroxy-7- {2-[(2-methylpropanoyl)amino]-6-oxo-1,6-dihydro-9H-purin-9-yl}-2-oxido-10- sulfidooctahydro-12H-5,8-methanofuro[3,2-l][1,3,6,9,11,2,10]pentaoxadiphospha- cyclotetradecin-14-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}benzamide (580mg, 0.656mmol) was added MeNH2 in EtOH (33% w/w, 38 mL), and the resulting solution was left to stir at RT for 3h and concentrated. The residue was purified by Prep-HPLC (Atlantis Prep T3 OBD Column) eluting with 4 to 13% MeCN in 10mM aq NH4HCO3 solution to give the two phosphorus diastereomers as the diammonium salts. The slower eluting peak fractions were collected and lyophilized to give the product as the diammonium salt. LCMS (ES, m/z): 658 [M+H]+.1H- NMR: (400MHz, D2O): δ 8.07 (s, 1H), 7.86 (s, 1H), 7.35 (d, J=3.8Hz, 1H), 6.52 (dd, J=6.8, 4.4Hz, 1H), 6.48 (d, J=3.7Hz, 1H), 5.78 (d, J=6.0Hz, 1H), 5.47-5.37 (m, 1H), 5.10-5.04 (m, 1H), 4.56-48 (m, 1H), 4.23-4.21 (m, 1H), 4.15-4.00 (m, 4H), 2.83-2.76 (m, 1H), 2.74-2.67 (m, 1H), 2.63-2.55 (m, 1H), 2.47-2.41 (m, 1H).31P-NMR: (162MHz, D2O): δ 53.18, -0.86. [0548] Step 6: 2-amino-9-[(5S,7R,8R,12aR,14R,15aS)-2-hydroxy-2,10-dioxido-14-(4-oxo- 3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-10-sulfanyloctahydro-12H-5,8-methanofuro [3,2- l][1,3,6,9,11,2,10]pentaoxadiphosphacyclotetradecin-7-yl]-1,9-dihydro-6H-purin-6-one
Figure imgf000175_0001
[0549] To diammonium 2-amino-9-[(5S,7R,8R,12aR,14R,15aS)-14-(4-amino-7H-pyrrolo [2,3-d]pyrimidin-7-yl)-2-hydroxy-2,10-dioxido-10-sulfanyloctahydro-12H-5,8-methanofuro[3,2- l][1,3,6,9,11,2,10]pentaoxadiphosphacyclotetradecin-7-yl]-1,9-dihydro-6H-purin-6-one (2.7mg, 4.0µmol) were added sodium phosphate buffer (pH 6.8, 50mM, 8mL) and AMPDA (200mg). The reaction mixture was left to stir for 11 days and filtered. The filtrate was treated with AMPDA (200mg) and left to stir for 2 weeks. The mixture was purified by reverse phase HPLC (eluting ACN/H2O gradient with 100mM TEAA modifier, linear gradient) to afford the product as the triethylammonium salt. LCMS (ES, m/z): 657 [M-H]-.1H NMR (500MHz, D2O): δ 8.07 (s, 1H), 7.98 (s, 1H), 7.35 (s, 1H), 6.68-6.61 (m, 2H), 5.92 (d, J=4.6Hz, 1H), 5.45 (m, 1H), 5.13 (brs, 1H), 4.62 (brs, 1H), 4.33 (s, 1H), 4.23-4.08 (m, 4H), 3.08–2.66 (m, 3H), 2.53 (m, 1H). [0550] BIOLOGICAL EVALUATION
[0551] The individual compounds described in the Examples herein are defined as STING agonists by (i) binding to the STING protein as evidenced by a reduction in binding of tritiated cGAMP ligand to the STING protein by at least 20% at 20uM (concentration of compound being tested) in a STING Biochemical [3H]cGAMP Competition Assay and (ii) demonstrating interferon production with a 6% or greater induction of IFN-β secretion at 30uM in the THP1 cell assay (where induction caused by cGAMP at 30uM was set at 100%).
[0552] [3H]-cGAMP Synthesis
[0553] 2.3mL of buffer solution containing 80mM TrisCl, 200mM MgCl2, and 20mM NaCl followed by 0.32mL of 10mM aq solution of GTP was added to a plastic 50mL AMICON tube. A solution of [3H]ATP (21Ci/mmol, 45mCi) in 0.5mL H2O was then added followed by 1mL of 1mg/mL solution of DNA (Herring testes activator DNA, Sigma, #D6898) and 53uL of 47mM solution of cGAS enzyme. Additional H2O was added to bring the total volume to 10mL. [0554] The reaction was stirred for 2h at 37°C and then added directly to an Amicon Ultra- 1510K centrifuge tube and spun for 1h at 4,000g. The collected solution was then purified on a semi-prep Mono Q column using the following mobile phases:
A: 0.05M TrisCl pH 8.5 adjusted with 1M NaOH
B: 0.05M TrisCl, 0.5M NaCl pH 8.5 adjusted with 1M NaOH
[0555] Gradient: 100% A for 5min followed by a linear gradient to 50:50 (A:B) over 25min, 3mL/min, 254nm.
[0556] The collected product fractions were pooled and adjusted to a total volume of 30mL with buffer A. A total yield of 15.5mCi of [3H]cGAMP was isolated at a radiochemical purity of 98.0% at a specific activity of 21.5Ci/mmol.
[0557] cGAS Enzyme
[0558] A recombinant DNA vector was chemically synthesized to express the truncated human cGAS enzyme (residues 161-522). To aid in expression and purification, the amino terminus contains a hexahistidine tag, SUMO tag and TEV cleavage site. The recombinant enzyme was overexpressed in ROSETTA™ 2(DE3) Single Competent Cells (Novagen). Affinity purification was carried out using HIS-Select HF Nickel Affinity Gel (Sigma) followed by size exclusion chromatography using a Hi-Load 26/60 SUPERDEX200 prep grade column (GE Healthcare). Fractions were pooled, concentrated, flash-frozen in liquid nitrogen and stored at -80°C until needed. [0559] Example 55: 3H-cGAMP filtration binding assay (HAQ STING)
[0560] The ability of compounds to bind STING is quantified by their ability to compete with tritiated cGAMP ligand for human STING receptor membrane using a radioactive filter- binding assay. The binding assay employs STING receptor obtained from Trichoplusia ni cell membranes (T.ni; Expression Systems, cat # 94-002F, www.expressionsystems.com) overexpressing full-length HAQ STING and tritiated cGAMP ligand.
[0561] The basic HAQ STING filtration assay protocol is as follows:
[0562] The compounds were serially titrated by the Hamilton STARPlus CORE in a 96- well plate (Greiner, #651201) using a 1:3 ten-point dose response format. After compound preparation, a 2.2ug/ml working concentration of STING membrane (SEQ. ID. No.1) was prepared by diluting concentrated membrane into assay buffer (1x PBS; Invitrogen
#SH30028.02) and douncing 7x using a manual tissue homogenizer (Wheaton, #357546).148uL of prepared membrane was then manually added to each well of a 96-well deep-well polypropylene plate (Fisher Scientific, #12-566-121). Following membrane addition, 2uL of either titrated test compound, DMSO control (Sigma #276855), or cold cGAMP control was added to the appropriate wells using a BIOMEK FX. Compound and membrane then preincubated for 60min at RT to allow compound binding to equilibrate. Following equilibration, 8nM of [3H] c-GAMP ligand was prepared by diluting into assay buffer, and 50uL of this working stock was then manually added to each well of the assay plate. Plates were then incubated at RT for 60min, and the contents of each assay plate were then filtered through a 96-well GF/B filter plate (PerkinElmer, #6005250) using a TOMTEC MACH III Cell Harvester equipped with 20mM HEPES buffer (Fisher Scientific, #BP299500). The filter plates were then dried at 55°C for 30min using a pressurized oven before 30uL of ULTIMA GOLD F scintillate was added to each well. Tritium levels for each reaction well were then measured using a PerkinElmer TopCount plate reader.
[0563] After normalization to controls, the percent activity for each compound
concentration was calculated by measuring the amount of remaining radioactivity. The plot of percent activity versus the log of compound concentration was fit with a 4-parameter dose response equation to calculate EC50 values.
[0564] The final reaction conditions were:
Figure imgf000177_0001
[0565] Compound concentrations tested were 20.000, 637.00, 2.200, 0.740, 0.247, 0.082, 0.027, 0.009, 0.003, and 0.001μM with 1.0% residual DMSO.
[0566] Full-Length STING (HAQ) Virus Generation
[0567] STING virus was generated using an insect cell baculovirus system. Spodoptera frugiperda Sf21 cells (Kempbio, Inc.) were diluted to 5e5 cells/ml in Sf-900II SFM media (LifeTechnologies #10902088) without antibiotics. The cell suspension was added to each well of a treated 6-well plate (2mL per well, 1e6 cells total), and the cells were allowed to adhere for at least 30min. Meanwhile, a 1mL co-transfection mix was assembled by combining 500ng of HAQ STING [STING(1-379)R71H,G230A,H232R,R293Q-GG-AviTag-GS-HRV3C- HIS8/pBAC1] DNA (Genewiz custom synthesis) with 1mL Sf-900II SFM media containing 10µL Cellfectin® II Reagent (Invitrogen #10362100) and 100ng viral backbone BestBac 2.0, v- cath/chiA Deleted Linearized Baculovirus DNA (Expression Systems #91-002). The transfection mixtures were allowed to incubate for 30min. After incubation, media was gently removed from the adhered cells in the 6-well plate, the 1mL transfection mixtures were added (1mL per well), and the plate was placed in a humidified incubator at 27°C. The following day, 1mL Sf-900II SFM media (no antibiotics) was added to each well of the 6-well plate. After media addition, the cells were allowed to incubate with DNA (SEQ. ID. No.2) at 27°C for 5-7 days to generate the P0 viral stock. To generate P1 viral stocks, 0.5mL of P0 viral supernatant was added to 50mL uninfected Sf21 cells (seeded the day prior to infection at a density of 5x105 cells/mL to allow for one overnight doubling) in Sf-900II SFM media containing 5µg/mL gentamicin (Invitrogen #15710072). The infected cells were then incubated at 27°C for 3 days while shaking at 110rpm (ATR Biotech Multitron Infors HT #AJ118). On day 3, P1 cultures were counted using a ViCell XR (Beckman Coulter Life Sciences #383556) to confirm infection had occurred (cell size≥3µm larger than uninfected cells and viability approximately 85-95%). Cultures were harvested in 50mL conical tubes and centrifuged at 2000xg for 10min at 4°C. The P1 viral supernatants were poured off into clean 50ml centrifuge tubes, and the remaining P1 cell pellets were used to generate Baculovirus Infected Insect Cells (BIICs). Cryopreservation media containing Sf-900II SFM media with 10% heat inactivated FBS, 10% DMSO (Sigma #D2650), and 5µg/ml gentamicin was prepared and sterilized through 0.22µM filter immediately prior to use. P1 cell pellets were resuspended to a density of 2e7 cells/ml and aliquoted into cryovials (1mL per vial). Cryovials were placed in MR. FROSTY™ cell freezers O/N at -80°C and transferred to liquid nitrogen for long term storage the following day. To generate P2 viral stock, 0.5mL of the P1 viral supernatant was added to 50mL uninfected Sf21 cells (seeded the day prior to infection at a density of 5x105 cells/mL to allow for one overnight doubling) in Sf-900II SFM media containing 5µg/mL gentamicin. These cells were incubated at 27°C for 3 days while shaking at 110rpm before harvesting P2 stock with centrifugation at 2000xg for 10min at 4°C. The P2 viral supernatants were poured off and discarded, while the P2 cell pellets were used to generate P2 BIICs following the same protocol described above. The baculovirus generation protocol has been validated to consistently produce P1/P2 BIICs with titers of 2e9 pfu/mL (2e7 cells/mLx100 pfu/cell).
[0568] Full-Length STING (HAQ) Expression [0569] To generate STING membranes, P1/P2 BIICs were amplified overnight by adding thawed BIICs to Sf21 cells seeded at a density of 1.0x106cells/mL. The volume of BIIC used to infect the culture was calculated using an assumed BIIC titer of 2e9 pfu/ml to achieve an MOI of 10 in the overnight amplification. After culturing overnight, the cells were counted on a ViCell XR to confirm infection had occurred (cell size≥3µm larger than uninfected cells and viability approximately 80-90%). The volume of infected Sf21 cells from the overnight amplification used to infect the large-scale expression of Trichoplusia ni (T.ni; Expression Systems, cat # 94-002F, www.expressionsystems.com) seeded at a density of 1.0x106 in cell media (ESF921 SFM containing 5µg/mL gentamicin) at MOI=2.0 was calculated based on (100 pfu/infected Sf21 cell). The cells were allowed to express for 48h at 27°C before harvesting the cell pellet, by centrifugation at 3,400xg for 10min at 4°C. T. ni cells were counted on a ViCell XR to confirm infection had occurred (cell size≥3µm larger than uninfected cells and viability approximately 80-90%) prior to harvest.
[0570] Full-Length STING (HAQ) Membrane Generation
[0571] Buffer stock reagents:
1) 1M HEPES pH 7.5, Teknova, Cat#H1035
2) 5M NaCl, Sigma Aldrich, Cat#S5150-1L
3) KCl, Sigma Aldrich, Cat#319309-500ML
4) Complete EDTA-free protease inhibitor tablets, Roche Diagnostics, Cat#11873580001 5) Benzonase, Universal Nuclease, Pierce, Cat#88702
[0572] Lysis buffer [25mM HEPES pH 7.5, 10mM MgCl2, 20mM KCl, (Benzonase 1:5000, Complete Protease Inhibitor tab/50mL)] was added to the pellet of cells expressing full- length STING (HAQ) prepared above at 5mL Lysis buffer per g of cell pellet. The pellet was resuspended and dounced twenty times using a Wheaton Dounce Homogenizer to disrupt the cell membrane. Homogenized lysate was then passed through the EMULSIFLEX-C5 microfluidizer at a pressure close to 5000PSI. The resuspended pellet was centrifuged at 36,000rpm (100,000xg) in a 45Ti rotor ultra-high speed centrifuge for 45min, 4°C. The supernatant was removed. The pellet then was resuspended in wash buffer [(25mM HEPES pH7.5, 1mM MgCl2, 20mM KCl, 1M NaCl (Complete Protease Inhibitor tab/50mL)] at a volume of 50mL pellet/centrifuge tube. The pellet/wash buffer mixture was then homogenized, using a glass homogenizer on ice (20 strokes), followed by centrifugation at 36,000rpm for 45min at 4°C. The supernatant was removed. The wash step was repeated once more. The resulting membrane was resuspended in 20mM HEPES pH 7.5, 500mM NaCl, 10% glycerol, EDTA-free Protease Inhibitors (1tablet/50mL). The protein concentration was measured by Bradford assay (Bio-Rad Protein Assay, Cat#500-0006), and protein enrichment was determined by SDS-PAGE and confirmed by Western blot. The resuspended membranes were stored at -80°C.
[0573] Full-Length HAQ STING [STING(1-379)R71H,G230A,H232R,R293Q-GG-AviTag- GS-HRV3C-HIS8]Amino Acid Sequence:
MPHSSLHPSIPCPRGHGAQKAALVLLSACLVTLWGLGEPPEHTLRYLVLHLASLQLGLL LNGVCSLAEELHHIHSRYRGSYWRTVRACLGCPLRRGALLLLSIYFYYSLPNAVGPPFT WMLALLGLSQALNILLGLKGLAPAEISAVCEKGNFNVAHGLAWSYYIGYLRLILPELQA RIRTYNQHYNNLLRGAVSQRLYILLPLDCGVPDNLSMADPNIRFLDKLPQQTADRAGIK DRVYSNSIYELLENGQRAGTCVLEYATPLQTLFAMSQYSQAGFSREDRLEQAKLFCQTL EDILADAPESQNNCRLIAYQEPADDSSFSLSQEVLRHLRQEEKEEVTVGSLKTSAVPSTST MSQEPELLISGMEKPLPLRTDFSGGGLNDIFEAQKIEWHEGSLEVLFQGPHHHHHHHH
(SEQ. ID. No.1)
[0574] Full-length HAQ [STING(1-379)R71H,G230A,H232R,R293Q-GG-AviTag-GS- HRV3C-HIS8/pBAC1] Plasmid DNA Sequence:
GGAACGGCTCCGCCCACTATTAATGAAATTAAAAATTCCAATTTTAAAAAACGCAGC AAGAGAAACATTTGTATGAAAGAATGCGTAGAAGGAAAGAAAAATGTCGTCGACAT GCTGAACAACAAGATTAATATGCCTCCGTGTATAAAAAAAATATTGAACGATTTGA AAGAAAACAATGTACCGCGCGGCGGTATGTACAGGAAGAGGTTTATACTAAACTGT TACATTGCAAACGTGGTTTCGTGTGCCAAGTGTGAAAACCGATGTTTAATCAAGGCT CTGACGCATTTCTACAACCACGACTCCAAGTGTGTGGGTGAAGTCATGCATCTTTTA ATCAAATCCCAAGATGTGTATAAACCACCAAACTGCCAAAAAATGAAAACTGTCGA CAAGCTCTGTCCGTTTGCTGGCAACTGCAAGGGTCTCAATCCTATTTGTAATTATTGA ATAATAAAACAATTATAAATGCTAAATTTGTTTTTTATTAACGATACAAACCAAACG CAACAAGAACATTTGTAGTATTATCTATAATTGAAAACGCGTAGTTATAATCGCTGA GGTAATATTTAAAATCATTTTCAAATGATTCACAGTTAATTTGCGACAATATAATTTT ATTTTCACATAAACTAGACGCCTTGTCGTCTTCTTCTTCGTATTCCTTCTCTTTTTCAT TTTTCTCTTCATAAAAATTAACATAGTTATTATCGTATCCATATATGTATCTATCGTA TAGAGTAAATTTTTTGTTGTCATAAATATATATGTCTTTTTTAATGGGGTGTATAGTA CCGCTGCGCATAGTTTTTCTGTAATTTACAACAGTGCTATTTTCTGGTAGTTCTTCGG AGTGTGTTGCTTTAATTATTAAATTTATATAATCAATGAATTTGGGATCGTCGGTTTT GTACAATATGTTGCCGGCATAGTACGCAGCTTCTTCTAGTTCAATTACACCATTTTTT AGCAGCACCGGATTAACATAACTTTCCAAAATGTTGTACGAACCGTTAAACAAAAA CAGTTCACCTCCCTTTTCTATACTATTGTCTGCGAGCAGTTGTTTGTTGTTAAAAATA ACAGCCATTGTAATGAGACGCACAAACTAATATCACAAACTGGAAATGTCTATCAA TATATAGTTGCTGATCAGATCTGATCATGGAGATAATTAAAATGATAACCATCTCGC AAATAAATAAGTATTTTACTGTTTTCGTAACAGTTTTGTAATAAAAAAACCTATAAA TATAGGATCCATGCCCCACTCCAGCCTGCATCCATCCATCCCGTGTCCCAGGGGTCA CGGGGCCCAGAAGGCAGCCTTGGTTCTGCTGAGTGCCTGCCTGGTGACCCTTTGGGG GCTAGGAGAGCCACCAGAGCACACTCTCCGGTACCTGGTGCTCCACCTAGCCTCCCT GCAGCTGGGACTGCTGTTAAACGGGGTCTGCAGCCTGGCTGAGGAGCTGCACCACA TCCACTCCAGGTACCGGGGCAGCTACTGGAGGACTGTGCGGGCCTGCCTGGGCTGC CCCCTCCGCCGTGGGGCCCTGTTGCTGCTGTCCATCTATTTCTACTACTCCCTCCCAA ATGCGGTCGGCCCGCCCTTCACTTGGATGCTTGCCCTCCTGGGCCTCTCGCAGGCAC TGAACATCCTCCTGGGCCTCAAGGGCCTGGCCCCAGCTGAGATCTCTGCAGTGTGTG AAAAAGGGAATTTCAACGTGGCCCATGGGCTGGCATGGTCATATTACATCGGATATC TGCGGCTGATCCTGCCAGAGCTCCAGGCCCGGATTCGAACTTACAATCAGCATTACA ACAACCTGCTACGGGGTGCAGTGAGCCAGCGGCTGTATATTCTCCTCCCATTGGACT GTGGGGTGCCTGATAACCTGAGTATGGCTGACCCCAACATTCGCTTCCTGGATAAAC TGCCCCAGCAGACCGCTGACCGTGCTGGCATCAAGGATCGGGTTTACAGCAACAGC ATCTATGAGCTTCTGGAGAACGGGCAGCGGGCGGGCACCTGTGTCCTGGAGTACGC CACCCCCTTGCAGACTTTGTTTGCCATGTCACAATACAGTCAAGCTGGCTTTAGCCG GGAGGATAGGCTTGAGCAGGCCAAACTCTTCTGCCAGACACTTGAGGACATCCTGG CAGATGCCCCTGAGTCTCAGAACAACTGCCGCCTCATTGCCTACCAGGAACCTGCAG ATGACAGCAGCTTCTCGCTGTCCCAGGAGGTTCTCCGGCACCTGCGGCAGGAGGAA AAGGAAGAGGTTACTGTGGGCAGCTTGAAGACCTCAGCGGTGCCCAGTACCTCCAC GATGTCCCAAGAGCCTGAGCTCCTCATCAGTGGAATGGAAAAGCCCCTCCCTCTCCG CACGGATTTCTCTGGCGGTGGCCTGAACGACATCTTCGAAGCCCAGAAAATCGAATG GCATGAAGGCAGCCTGGAAGTGCTGTTCCAGGGCCCACACCACCATCATCACCATC ACCATTAATGAGCGGCCGCACTCGAGCACCACCACCACCACCACTAACCTAGGTAG CTGAGCGCATGCAAGCTGATCCGGGTTATTAGTACATTTATTAAGCGCTAGATTCTG TGCGTTGTTGATTTACAGACAATTGTTGTACGTATTTTAATAATTCATTAAATTTATA ATCTTTAGGGTGGTATGTTAGAGCGAAAATCAAATGATTTTCAGCGTCTTTATATCT GAATTTAAATATTAAATCCTCAATAGATTTGTAAAATAGGTTTCGATTAGTTTCAAA CAAGGGTTGTTTTTCCGAACCGATGGCTGGACTATCTAATGGATTTTCGCTCAACGC CACAAAACTTGCCAAATCTTGTAGCAGCAATCTAGCTTTGTCGATATTCGTTTGTGTT TTGTTTTGTAATAAAGGTTCGACGTCGTTCAAAATATTATGCGCTTTTGTATTTCTTT CATCACTGTCGTTAGTGTACAATTGACTCGACGTAAACACGTTAAATAGAGCTTGGA CATATTTAACATCGGGCGTGTTAGCTTTATTAGGCCGATTATCGTCGTCGTCCCAACC CTCGTCGTTAGAAGTTGCTTCCGAAGACGATTTTGCCATAGCCACACGACGCCTATT AATTGTGTCGGCTAACACGTCCGCGATCAAATTTGTAGTTGAGCTTTTTGGAATTATT TCTGATTGCGGGCGTTTTTGGGCGGGTTTCAATCTAACTGTGCCCGATTTTAATTCAG ACAACACGTTAGAAAGCGATGGTGCAGGCGGTGGTAACATTTCAGACGGCAAATCT ACTAATGGCGGCGGTGGTGGAGCTGATGATAAATCTACCATCGGTGGAGGCGCAGG CGGGGCTGGCGGCGGAGGCGGAGGCGGAGGTGGTGGCGGTGATGCAGACGGCGGT TTAGGCTCAAATGTCTCTTTAGGCAACACAGTCGGCACCTCAACTATTGTACTGGTTT CGGGCGCCGTTTTTGGTTTGACCGGTCTGAGACGAGTGCGATTTTTTTCGTTTCTAAT AGCTTCCAACAATTGTTGTCTGTCGTCTAAAGGTGCAGCGGGTTGAGGTTCCGTCGG CATTGGTGGAGCGGGCGGCAATTCAGACATCGATGGTGGTGGTGGTGGTGGAGGCG CTGGAATGTTAGGCACGGGAGAAGGTGGTGGCGGCGGTGCCGCCGGTATAATTTGT TCTGGTTTAGTTTGTTCGCGCACGATTGTGGGCACCGGCGCAGGCGCCGCTGGCTGC ACAACGGAAGGTCGTCTGCTTCGAGGCAGCGCTTGGGGTGGTGGCAATTCAATATTA TAATTGGAATACAAATCGTAAAAATCTGCTATAAGCATTGTAATTTCGCTATCGTTT ACCGTGCCGATATTTAACAACCGCTCAATGTAAGCAATTGTATTGTAAAGAGATTGT CTCAAGCTCGGATCGATCCCGCACGCCGATAACAAGCCTTTTCATTTTTACTACAGC ATTGTAGTGGCGAGACACTTCGCTGTCGTCGAGGTTTAAACGCTTCCTCGCTCACTG ACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGG TAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAA GGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAG GCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAA ACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCT CTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAG CGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGC TCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCC GGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCA GCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTT GAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCT GCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAA CCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAA AAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACG AAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGA TCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTT GGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTAT TTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGG GCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTC CAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCT GCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGT AGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTG TCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGA GTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATC GTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCAT AATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAA CCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAA TACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAA CGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATG TAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTG GGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACG GAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGT TATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGG GTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGACGCGCCCTGTAGCGGCGCATTA AGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCT AGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCC GTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACC TCGACCCCAAAAAACTTGATTAGGGTGATGGTTCACGTAGTGGGCCATCGCCCTGAT AGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTT CCAAACTGGAACAACACTCAACCCTATCTCGGTCTATTCTTTTGATTTATAAGGGATT TTGCCGATTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCG AATTTTAACAAAATATTAACGTTTACAATTTCCCATTCGCCATTCAGGCTGCGCAACT GTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGCTATTACGCCA (SEQ. ID. No.2) [0575] Certain compounds of the disclosure were evaluated in HAQ STING in vitro binding assay as described above. Table 7 tabulates the biological data for these compounds as EC50 values.
Table 7: 3H-cGAMP filtration binding assay for HAQ STING
Figure imgf000184_0001
[0576] Example 56: 3H-cGAMP filtration binding assay (WT STING)
[0577] The ability of compounds to bind STING is quantified by their ability to compete with tritiated cGAMP ligand for human STING receptor membrane using a radioactive filter- binding assay. The binding assay employs STING receptor obtained from Trichoplusia ni cell membranes (T.ni; Expression Systems, cat #94-002F, www.expressionsystems.com)
overexpressing full-length WT STING and tritiated cGAMP ligand. [0578] The basic WT STING filtration assay protocol is as follows:
[0579] 16nM of [3H] c-GAMP ligand was prepared by diluting into assay buffer, and 50uL of this working stock was manually added to each well of the assay plate. After ligand addition, 2uL of either titrated test compound, DMSO control (Sigma #276855), or cold cGAMP control was added to the appropriate wells using a BIOMEK FX. The serially titrated compound was prepared on a Hamilton STARPlus CORE in a 96-well plate (Greiner, #651201) using a 1:3 ten- point dose response format. Following compound addition, a 2.2ug/ml working concentration of STING membrane (SEQ. ID. No.3) was prepared by diluting concentrated membrane into assay buffer (1x PBS; Invitrogen #SH30028.02) and douncing 7x using a manual tissue homogenizer (Wheaton, #357546).148uL of this prepared membrane was then manually added to each well of a 96-well deep-well polypropylene plate (Fisher Scientific, #12-566-121). Compound, ligand, and membrane then incubated for 60min at RT before the contents of each assay plate were filtered through a 96-well GF/B filter plate (PerkinElmer, #6005250) using a TOMTEC MACH III Cell Harvester equipped with 20mM HEPES buffer (Fisher Scientific, #BP299500). The filter plates were then dried at 55°C for 30min using a pressurized VWR oven before 30uL of ULTIMA GOLD F scintillate was added to each well. Tritium levels for each reaction well were then measured using a PerkinElmer TopCount plate reader.
[0580] After normalization to controls, the percent activity for each compound
concentration was calculated by measuring the amount of remaining radioactivity. The plot of percent activity versus the log of compound concentration was fit with a 4-parameter dose response equation to calculate EC50 values.
[0581] The final reaction conditions were:
Figure imgf000185_0001
[0582] Compound concentrations tested were 20.000, 637.00, 2.200, 0.740, 0.247, 0.082, 0.027, 0.009, 0.003, and 0.001μM with 1.0% residual DMSO.
[0583] Full-Length STING (WT) Virus Generation
[0584] STING virus was generated using an insect cell baculovirus system. Spodoptera frugiperda Sf21 cells (Kempbio, Inc.) were diluted to 5e5 cells/ml in Sf-900II SFM media (LifeTechnologies #10902088) without antibiotics. The cell suspension was added to each well of a treated 6-well plate (2mL per well, 1e6 cells total), and the cells were allowed to adhere for at least 30min. Meanwhile, a 1mL co-transfection mix was assembled by combining 500ng of WT STING[STING(1-379)H232R-gg-AviTag-gs-HRV3C-HIS8/pBAC1] (Genewiz custom synthesis) with 1mL Sf-900II SFM media containing 10µL CELLFECTIN® II Reagent (Invitrogen #10362100) and 100ng viral backbone BestBac 2.0, v-cath/chiA Deleted Linearized Baculovirus DNA (Expression Systems #91-002). The transfection mixtures were allowed to incubate for 30min. After incubation, media was gently removed from the adhered cells in the 6-well plate, the 1mL transfection mixtures were added (1mL per well), and the plate was placed in a humidified incubator at 27°C. The following day, 1mL Sf-900II SFM media (no antibiotics) was added to each well of the 6-well plate. After media addition, the cells were allowed to incubate with DNA [(SEQ. ID. No.4) and linearized viral backbone BestBac 2.0] at 27°C for 5-7 days to generate the P0 viral stock. To generate P1 viral stocks, 0.5mL of P0 viral supernatant was added to 50mL uninfected Sf21 cells (seeded the day prior to infection at a density of 5x105 cells/mL to allow for one overnight doubling) in Sf-900II SFM media containing 5µg/mL gentamicin (Invitrogen #15710072). The infected cells were then incubated at 27°C for 3 days while shaking at 110rpm (ATR Biotech Multitron Infors HT #AJ118). On day 3, P1 cultures were counted using a ViCell XR (Beckman Coulter Life Sciences #383556) to confirm infection had occurred (cell size≥3µm larger than uninfected cells and viability approximately 85-95%). Cultures were harvested in 50mL conical tubes and centrifuged at 2000xg for 10min at 4°C. The P1 viral supernatants were poured off into clean 50ml centrifuge tubes, and the remaining P1 cell pellets were used to generate Baculovirus Infected Insect Cells (BIICs). Cryopreservation media containing Sf-900II SFM media with 10% heat inactivated FBS, 10% DMSO (Sigma #D2650), and 5µg/ml gentamicin was prepared and sterilized through 0.22µM filter immediately prior to use. P1 cell pellets were resuspended to a density of 2e7 cells/ml and aliquoted into cryovials (1mL per vial). Cryovials were placed in MR. FROSTY™ cell freezers O/N at -80°C and transferred to liquid nitrogen for long term storage the following day. To generate P2 viral stock, 0.5mL of the P1 viral supernatant was added to 50mL uninfected Sf21 cells (seeded the day prior to infection at a density of 5x105 cells/mL to allow for one overnight doubling) in Sf-900II SFM media containing 5µg/mL gentamicin. These cells were incubated at 27°C for 3 days while shaking at 110rpm before harvesting P2 stock with centrifugation at 2000xg for 10min at 4°C. The P2 viral supernatants were poured off and discarded, while the P2 cell pellets were used to generate P2 BIICs following the same protocol described above. The baculovirus generation protocol has been validated to consistently produce P1/P2 BIICs with titers of 2e9 pfu/mL (2e7 cells/mLx100pfu/cell).
[0585] Full-Length STING (WT) Expression
[0586] To generate STING membranes, P1/P2 BIICs were amplified overnight by adding thawed BIICs to Sf21 cells seeded at a density of 1.0x106 cells/mL. The volume of BIIC used to infect the culture was calculated using an assumed BIIC titer of 2e9 pfu/ml to achieve an MOI of 10 in the overnight amplification. After culturing overnight, the cells were counted on a ViCell XR to confirm infection had occurred (cell size≥3µm larger than uninfected cells and viability approximately 80-90%). The volume of infected Sf21 cells from the overnight amplification used to infect the large-scale expression of Trichoplusia ni (T.ni; Expression Systems, cat # 94-002F, www.expressionsystems.com) seeded at a density of 1.0x106 in cell media (ESF921 SFM containing 5µg/mL gentamicin) at MOI=2.0 was calculated based on (100pfu/infected Sf21 cell). The cells were allowed to express for 48h at 27°C before harvesting the cell pellet, by
centrifugation at 3,400xg for 10min at 4°C. T. ni cells were counted on a ViCell XR to confirm infection had occurred (cell size≥3µm larger than uninfected cells and viability approximately 80-90%) prior to harvest.
[0587] Full-Length STING (WT) Membrane Generation
[0588] Buffer stock reagents:
1) 1 M HEPES pH 7.5, Teknova, Cat#H1035
2) 5 M NaCl, Sigma Aldrich, Cat#S5150-1L
3) KCl, Sigma Aldrich, Cat#319309-500ML
4) Complete EDTA-free protease inhibitor tablets, Roche Diagnostics, Cat#11873580001 5) Benzonase, Universal Nuclease, Pierce, Cat#88702
[0589] Lysis buffer [25mM HEPES pH 7.5, 10mM MgCl2, 20mM KCl, (Benzonase 1:5000, Complete Protease Inhibitor tab/50mL)] was added to the pellet of cells expressing full- length STING (WT) prepared above at 5mL Lysis buffer per g of cell pellet. The pellet was resuspended and dounced twenty times using a Wheaton Dounce Homogenizer to disrupt the cell membrane. Homogenized lysate was then passed through the emulsiflex-C5 microfluidizer at a pressure close to 5000PSI. The resuspended pellet was centrifuged at 36,000rpm (100,000xg) in a 45Ti rotor ultra-high speed centrifuge for 45min, 4°C. The supernatant was removed. The pellet then was resuspended in wash buffer [(25mM HEPES pH 7.5, 1mM MgCl2, 20mM KCl, 1M NaCl (Complete Protease Inhibitor tab/50mL)] at a volume of 50mL/pellet/centrifuge tube. The pellet/wash buffer mixture was then homogenized, using a glass homogenizer on ice (20 strokes), followed by centrifugation at 36,000rpm for 45min at 4°C. The supernatant was removed. The wash step was repeated once more. The resulting membrane was resuspended in 20mM HEPES pH 7.5, 500mM NaCl, 10% glycerol, EDTA-free Protease Inhibitors
(1tablet/50mL). The protein concentration was measured by Bradford assay (Bio-Rad Protein Assay, Cat#500-0006), and protein enrichment was determined by SDS-PAGE and confirmed by Western blot. The resuspended membranes were stored at -80°C.
[0590] Full-Length STING WT [STING(1-379)H232R-gg-AviTag-gs-HRV3C-HIS8] Amino Acid Sequence:
MPHSSLHPSIPCPRGHGAQKAALVLLSACLVTLWGLGEPPEHTLRYLVLHLASLQLGLL LNGVCSLAEELRHIHSRYRGSYWRTVRACLGCPLRRGALLLLSIYFYYSLPNAVGPPFT WMLALLGLSQALNILLGLKGLAPAEISAVCEKGNFNVAHGLAWSYYIGYLRLILPELQA RIRTYNQHYNNLLRGAVSQRLYILLPLDCGVPDNLSMADPNIRFLDKLPQQTGDRAGIK DRVYSNSIYELLENGQRAGTCVLEYATPLQTLFAMSQYSQAGFSREDRLEQAKLFCRTL EDILADAPESQNNCRLIAYQEPADDSSFSLSQEVLRHLRQEEKEEVTVGSLKTSAVPSTST MSQEPELLISGMEKPLPLRTDFSGGGLNDIFEAQKIEWHEGSLEVLFQGPHHHHHHHH
(SEQ. ID. No.3)
[0591] Full-length WT STING [STING(1-379)H232R-gg-AviTag-gs-HRV3C-HIS8/pBAC1] plasmid sequence:
GGAACGGCTCCGCCCACTATTAATGAAATTAAAAATTCCAATTTTAAAAAACGCAGC AAGAGAAACATTTGTATGAAAGAATGCGTAGAAGGAAAGAAAAATGTCGTCGACAT GCTGAACAACAAGATTAATATGCCTCCGTGTATAAAAAAAATATTGAACGATTTGA AAGAAAACAATGTACCGCGCGGCGGTATGTACAGGAAGAGGTTTATACTAAACTGT TACATTGCAAACGTGGTTTCGTGTGCCAAGTGTGAAAACCGATGTTTAATCAAGGCT CTGACGCATTTCTACAACCACGACTCCAAGTGTGTGGGTGAAGTCATGCATCTTTTA ATCAAATCCCAAGATGTGTATAAACCACCAAACTGCCAAAAAATGAAAACTGTCGA CAAGCTCTGTCCGTTTGCTGGCAACTGCAAGGGTCTCAATCCTATTTGTAATTATTGA ATAATAAAACAATTATAAATGTCAAATTTGTTTTTTATTAACGATACAAACCAAACG CAACAAGAACATTTGTAGTATTATCTATAATTGAAAACGCGTAGTTATAATCGCTGA GGTAATATTTAAAATCATTTTCAAATGATTCACAGTTAATTTGCGACAATATAATTTT ATTTTCACATAAACTAGACGCCTTGTCGTCTTCTTCTTCGTATTCCTTCTCTTTTTCAT TTTTCTCTTCATAAAAATTAACATAGTTATTATCGTATCCATATATGTATCTATCGTA TAGAGTAAATTTTTTGTTGTCATAAATATATATGTCTTTTTTAATGGGGTGTATAGTA CCGCTGCGCATAGTTTTTCTGTAATTTACAACAGTGCTATTTTCTGGTAGTTCTTCGG AGTGTGTTGCTTTAATTATTAAATTTATATAATCAATGAATTTGGGATCGTCGGTTTT GTACAATATGTTGCCGGCATAGTACGCAGCTTCTTCTAGTTCAATTACACCATTTTTT AGCAGCACCGGATTAACATAACTTTCCAAAATGTTGTACGAACCGTTAAACAAAAA CAGTTCACCTCCCTTTTCTATACTATTGTCTGCGAGCAGTTGTTTGTTGTTAAAAATA ACAGCCATTGTAATGAGACGCACAAACTAATATCACAAACTGGAAATGTCTATCAA TATATAGTTGCTGATCAGATCTGATCATGGAGATAATTAAAATGATAACCATCTCGC AAATAAATAAGTATTTTACTGTTTTCGTAACAGTTTTGTAATAAAAAAACCTATAAA TATAGGATCCATGCCCCACTCCAGCCTGCATCCATCCATCCCGTGTCCCAGGGGTCA CGGGGCCCAGAAGGCAGCCTTGGTTCTGCTGAGTGCCTGCCTGGTGACCCTTTGGGG GCTAGGAGAGCCACCAGAGCACACTCTCCGGTACCTGGTGCTCCACCTAGCCTCCCT GCAGCTGGGACTGCTGTTAAACGGGGTCTGCAGCCTGGCTGAGGAGCTGCGCCACA TCCACTCCAGGTACCGGGGCAGCTACTGGAGGACTGTGCGGGCCTGCCTGGGCTGC CCCCTCCGCCGTGGGGCCCTGTTGCTGCTGTCCATCTATTTCTACTACTCCCTCCCAA ATGCGGTCGGCCCGCCCTTCACTTGGATGCTTGCCCTCCTGGGCCTCTCGCAGGCAC TGAACATCCTCCTGGGCCTCAAGGGCCTGGCCCCAGCTGAGATCTCTGCAGTGTGTG AAAAAGGGAATTTCAACGTGGCCCATGGGCTGGCATGGTCATATTACATCGGATATC TGCGGCTGATCCTGCCAGAGCTCCAGGCCCGGATTCGAACTTACAATCAGCATTACA ACAACCTGCTACGGGGTGCAGTGAGCCAGCGGCTGTATATTCTCCTCCCATTGGACT GTGGGGTGCCTGATAACCTGAGTATGGCTGACCCCAACATTCGCTTCCTGGATAAAC TGCCCCAGCAGACCGGTGACCGTGCTGGCATCAAGGATCGGGTTTACAGCAACAGC ATCTATGAGCTTCTGGAGAACGGGCAGCGGGCGGGCACCTGTGTCCTGGAGTACGC CACCCCCTTGCAGACTTTGTTTGCCATGTCACAATACAGTCAAGCTGGCTTTAGCCG GGAGGATAGGCTTGAGCAGGCCAAACTCTTCTGCCGGACACTTGAGGACATCCTGG CAGATGCCCCTGAGTCTCAGAACAACTGCCGCCTCATTGCCTACCAGGAACCTGCAG ATGACAGCAGCTTCTCGCTGTCCCAGGAGGTTCTCCGGCACCTGCGGCAGGAGGAA AAGGAAGAGGTTACTGTGGGCAGCTTGAAGACCTCAGCGGTGCCCAGTACCTCCAC GATGTCCCAAGAGCCTGAGCTCCTCATCAGTGGAATGGAAAAGCCCCTCCCTCTCCG CACGGATTTCTCTGGCGGTGGCCTGAACGACATCTTCGAAGCCCAGAAAATCGAATG GCATGAAGGCAGCCTGGAAGTGCTGTTCCAGGGCCCACACCACCATCATCACCATC ACCATTAATGAGCGGCCGCACTCGAGCACCACCACCACCACCACTAACCTAGGTAG CTGAGCGCATGCAAGCTGATCCGGGTTATTAGTACATTTATTAAGCGCTAGATTCTG TGCGTTGTTGATTTACAGACAATTGTTGTACGTATTTTAATAATTCATTAAATTTATA ATCTTTAGGGTGGTATGTTAGAGCGAAAATCAAATGATTTTCAGCGTCTTTATATCT GAATTTAAATATTAAATCCTCAATAGATTTGTAAAATAGGTTTCGATTAGTTTCAAA CAAGGGTTGTTTTTCCGAACCGATGGCTGGACTATCTAATGGATTTTCGCTCAACGC CACAAAACTTGCCAAATCTTGTAGCAGCAATCTAGCTTTGTCGATATTCGTTTGTGTT TTGTTTTGTAATAAAGGTTCGACGTCGTTCAAAATATTATGCGCTTTTGTATTTCTTT CATCACTGTCGTTAGTGTACAATTGACTCGACGTAAACACGTTAAATAGAGCTTGGA CATATTTAACATCGGGCGTGTTAGCTTTATTAGGCCGATTATCGTCGTCGTCCCAACC CTCGTCGTTAGAAGTTGCTTCCGAAGACGATTTTGCCATAGCCACACGACGCCTATT AATTGTGTCGGCTAACACGTCCGCGATCAAATTTGTAGTTGAGCTTTTTGGAATTATT TCTGATTGCGGGCGTTTTTGGGCGGGTTTCAATCTAACTGTGCCCGATTTTAATTCAG ACAACACGTTAGAAAGCGATGGTGCAGGCGGTGGTAACATTTCAGACGGCAAATCT ACTAATGGCGGCGGTGGTGGAGCTGATGATAAATCTACCATCGGTGGAGGCGCAGG CGGGGCTGGCGGCGGAGGCGGAGGCGGAGGTGGTGGCGGTGATGCAGACGGCGGT TTAGGCTCAAATGTCTCTTTAGGCAACACAGTCGGCACCTCAACTATTGTACTGGTTT CGGGCGCCGTTTTTGGTTTGACCGGTCTGAGACGAGTGCGATTTTTTTCGTTTCTAAT AGCTTCCAACAATTGTTGTCTGTCGTCTAAAGGTGCAGCGGGTTGAGGTTCCGTCGG CATTGGTGGAGCGGGCGGCAATTCAGACATCGATGGTGGTGGTGGTGGTGGAGGCG CTGGAATGTTAGGCACGGGAGAAGGTGGTGGCGGCGGTGCCGCCGGTATAATTTGT TCTGGTTTAGTTTGTTCGCGCACGATTGTGGGCACCGGCGCAGGCGCCGCTGGCTGC ACAACGGAAGGTCGTCTGCTTCGAGGCAGCGCTTGGGGTGGTGGCAATTCAATATTA TAATTGGAATACAAATCGTAAAAATCTGCTATAAGCATTGTAATTTCGCTATCGTTT ACCGTGCCGATATTTAACAACCGCTCAATGTAAGCAATTGTATTGTAAAGAGATTGT CTCAAGCTCGGATCGATCCCGCACGCCGATAACAAGCCTTTTCATTTTTACTACAGC ATTGTAGTGGCGAGACACTTCGCTGTCGTCGAGGTTTAAACGCTTCCTCGCTCACTG ACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGG TAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAA GGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAG GCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAA ACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCT CTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAG CGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGC TCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCC GGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCA GCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTT GAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCT GCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAA CCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAA AAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACG AAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGA TCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTT GGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTAT TTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGG GCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTC CAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCT GCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGT AGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTG TCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGA GTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATC GTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCAT AATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAA CCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAA TACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAA CGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATG TAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTG GGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACG GAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGT TATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGG GTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGACGCGCCCTGTAGCGGCGCATTA AGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCT AGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCC GTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACC TCGACCCCAAAAAACTTGATTAGGGTGATGGTTCACGTAGTGGGCCATCGCCCTGAT AGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTT CCAAACTGGAACAACACTCAACCCTATCTCGGTCTATTCTTTTGATTTATAAGGGATT TTGCCGATTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCG AATTTTAACAAAATATTAACGTTTACAATTTCCCATTCGCCATTCAGGCTGCGCAACT GTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGCTATTACGCCA (SEQ. ID. No.4) [0592] Certain compounds of the disclosure were evaluated in WT STING in vitro binding assay as described above. The following table tabulates the biological data for these compounds as EC50 values.
Table 8: 3H-cGAMP filtration binding assay for WT STING
Figure imgf000192_0001
[0593] Example 57: IFN-β secretion in THP1 cell culture (5h)
[0594] The ability of compounds to stimulate the secretion of interferon-beta from THP1 cells was measured using a human IFN-β AlphaLISA kit (Perkin Elmer, Cat. No. AL265F). The basic protocol is as follows:
[0595] A Labcyte Echo 550 acoustic dispenser was used to transfer 120nL of compound dissolved in DMSO into the wells of an empty, sterile 384-well microplate, (Corning, Cat. No. 3712). THP1 cells (American Type Culture Collection, Cat. No. TIB202) previously frozen in Recovery Medium (Life Technologies, Cat. No.12648-010) were thawed and immediately diluted 10-fold into 37°C assay medium (RPMI 1640+L-Glutamine & phenol red, Life
Technologies, Cat. No.11875-085; 0.5% heat inactivated fetal bovine serum, Sigma Aldrich, Cat. No. F4135; 1mM Sodium Pyruvate, Life Technologies, Cat. No.11360-070; 1x non- essential amino acids; Life Technologies, Cat. No.11140-050). The cell viability and count was ascertained using a Beckman Coulter V-Cell XR cell counter. The cell suspension was centrifuged at 200xg for 5min at RT. Cells were resuspended to a density of 0.8x106/mL in 37°C assay medium. Subsequent liquid transfers were performed using either a Matrix electronic multichannel pipette or an Agilent Bravo Automated Liquid Handling Platform.
[0596] The assay was started by dispensing 40μL of the previously prepared cell suspension into the wells of the plate containing compounds. After 5h incubation at 37°C, 5% CO2 in a humidified atmosphere, the plate of cells and compounds was centrifuged at 200xg for 5min at RT. From each well, 5μL of supernatant was transferred into corresponding wells of a white 384-well plate (Perkin Elmer, Cat. No.6005620). To these supernatant-containing wells was added 10μL of 5x Anti-Analyte Acceptor beads (50μg/mL of AlphaLISA HiBlock Buffer) and incubated for 30min at RT while shaking on an orbital plate shaker. To each well was added 10μL of 5x Biotinylated Antibody Anti-analyte (5nM in AlphaLISA HiBlock Buffer) and incubated on an orbital plate shaker for 60min at RT or overnight at 4°C. To each well was added 25μL of 2x SA-Donor beads (80μg/mL in AlphaLISA HiBlock Buffer) and incubated for 30-45min at RT in the dark while shaking on an orbital plate shaker. The plate was then read on a Perkin Elmer Envision (λex=680nm, λem=570nm). The percent effect of the AlphaLISA signal at each compound concentration was calculated based on 30uM cGAMP positive controls and 0.3% DMSO negative controls. The plot of percent effect versus the log of compound concentration was fit with a 4-parameter concentration response equation to calculate EC50 values. The test compounds were tested at concentrations 30000, 10000, 3333, 1111, 370.4, 123.4, 41.2, 13.7, 4.6, and 1.5nM with 0.3% residual DMSO. The control compound, cGAMP was tested at concentrations 100000, 33333, 11111, 3704, 1235, 412, 137, 46, and 15nM with 0.3% residual DMSO.
[0597] Compounds of the disclosure were evaluated for IFN-β secretion in THP1 cell culture as described above. The following table tabulates the biological data for these compounds as percent activation relative to 2’3’-cGAMP at the 30µM concentration. Table 9: IFN-β secretion in THP1 cell culture (5h)
Figure imgf000194_0001
[0598] It will be appreciated that various of the above-discussed and other features and functions, or alternatives thereof, may be desirably combined into many other different systems or applications. It also will be appreciated that various presently unforeseen or unanticipated alternatives, modifications, variations or improvements therein may be subsequently made by those skilled in the art and are also intended to be encompassed by the following claims.

Claims

WHAT IS CLAIMED IS: 1. A compound of formula (I):
Figure imgf000195_0001
or a pharmaceutically acceptable salt thereof, wherein
Base1 and Base2 are each independently selected from the group consisting of
Figure imgf000195_0002
Figure imgf000196_0001
at least one of Base1 and Base2 is each independently selected from the
group consisting of
Figure imgf000196_0002
O O O NH
Figure imgf000196_0003
Base1 and Base2 each may be independently substituted by 0-3 substituents R10, where each R10 is independently selected from the group consisting of F, Cl, I, Br, OH, SH, NH2, C1-3 alkyl, C3-6 cycloalkyl, O(C1-3 alkyl), O(C3-6 cycloalkyl), S(C1-3 alkyl), S(C3-6 cycloalkyl), NH(C1-3 alkyl), NH(C3-6 cycloalkyl), N(C1-3 alkyl)2, and N(C3-6 cycloalkyl)2;
Y and Ya are each independently selected from the group consisting of -O-, -S-, -SO2-, -CH2-, and -CF2-; Xa and Xa1 are each independently selected from the group consisting of -O-, -S-, and -CH2-;
Xb and Xb1 are each independently selected from the group consisting of -O-, -S-, and -CH2-;
Xc and Xc1 are each independently selected from the group consisting of -SR9, -OR9, and -NR9R9;
Xd and Xd1 are each independently selected from the group consisting of O and S; R1 and R1a are each independently selected from the group consisting of H, F, Cl, Br, I, OH, CN, N3, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C2-C6
haloalkenyl, C2-C6 haloalkynyl, -O-C1-C6 alkyl, -O-C2-C6 alkenyl, and -O-C2-C6 alkynyl, where said R1 and R1a C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, -O-C1-C6 alkyl, -O-C2-C6 alkenyl, and -O-C2-C6 alkynyl are substituted by 0 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, CN, and N3;
R2 and R2a are each independently selected from the group consisting of H, F, Cl, Br, I, OH, CN, N3, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C2-C6
haloalkenyl, C2-C6 haloalkynyl, -O-C1-C6 alkyl, -O-C2-C6 alkenyl, and -O-C2-C6 alkynyl, where said R2 and R2a C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, -O-C1-C6 alkyl, -O-C2-C6 alkenyl, and -O-C2-C6 alkynyl are substituted by 0 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, CN, and N3;
R3 is selected from the group consisting of H, F, Cl, Br, I, OH, CN, N3, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, -O-C1-C6 alkyl, -O-C2-C6 alkenyl, and -O-C2-C6 alkynyl, where said R3 C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, -O-C1-C6 alkyl, -O-C2-C6 alkenyl, and -O-C2-C6 alkynyl are substituted by 0 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, CN, and N3;
R4 and R4a are each independently selected from the group consisting of H, F, Cl, Br, I, OH, CN, N3, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C2-C6
haloalkenyl, C2-C6 haloalkynyl, -O-C1-C6 alkyl, -O-C2-C6 alkenyl, and -O-C2-C6 alkynyl, where said R4 and R4a C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, -O-C1-C6 alkyl, -O-C2-C6 alkenyl, and -O-C2-C6 alkynyl are substituted by 0 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, CN, and N3; R5 is selected from the group consisting of H, F, Cl, Br, I, OH, CN, N3, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, -O-C1-C6 alkyl, -O-C2-C6 alkenyl, and -O-C2-C6 alkynyl, where said R5 C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, -O-C1-C6 alkyl, -O-C2-C6 alkenyl, and -O-C2-C6 alkynyl are substituted by 0 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, CN, and N3;
R6 and R6a are each independently selected from the group consisting of H, F, Cl, Br, I, OH, CN, N3, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C2-C6
haloalkenyl, C2-C6 haloalkynyl, -O-C1-C6 alkyl, -O-C2-C6 alkenyl, and -O-C2-C6 alkynyl, where said R6 and R6a C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, -O-C1-C6 alkyl, -O-C2-C6 alkenyl, and -O-C2-C6 alkynyl are substituted by 0 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, CN, and N3;
R7 and R7a are each independently selected from the group consisting of H, F, Cl, Br, I, OH, CN, N3, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C2-C6
haloalkenyl, C2-C6 haloalkynyl, -O-C1-C6 alkyl, -O-C2-C6 alkenyl, and -O-C2-C6 alkynyl, where said R7 and R7a C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, -O-C1-C6 alkyl, -O-C2-C6 alkenyl, and -O-C2-C6 alkynyl are substituted by 0 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, CN, and N3;
R8 and R8a are each independently selected from the group consisting of H, F, Cl, Br, I, OH, CN, N3, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C2-C6
haloalkenyl, C2-C6 haloalkynyl, -O-C1-C6 alkyl, -O-C2-C6 alkenyl, and -O-C2-C6 alkynyl, where said R8 and R8a C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, -O-C1-C6 alkyl, -O-C2-C6 alkenyl, and -O-C2-C6 alkynyl are substituted by 0 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, CN, and N3;
each R9 is independently selected from the group consisting of H, C1-C20 alkyl,
Figure imgf000198_0001
where each R9 C1-C20 alkyl is optionally substituted by 0 to 3 substituents independently selected from the group consisting of OH, -O-C1-C20 alkyl,-S-C(O)C1-C6 alkyl, and C(O)OC1-C6 alkyl; optionally R1a and R3 are connected to form C1-C6 alkylene, C2-C6 alkenylene, -O-C1-C6 alkylene, or -O-C2-C6 alkenylene, such that where R1a and R3 are connected to form -O-C1-C6 alkylene, or -O-C2-C6 alkenylene, said O is bound at the R3 position;
optionally R2a and R3 are connected to form C1-C6 alkylene, C2-C6 alkenylene, -O-C1-C6 alkylene, or -O-C2-C6 alkenylene, such that where R2a and R3 are connected to form -O-C1-C6 alkylene, or -O-C2-C6 alkenylene, said O is bound at the R3 position;
optionally R3 and R6a are connected to form C1-C6 alkylene, C2-C6 alkenylene, -O-C1-C6 alkylene, or -O-C2-C6 alkenylene, such that where R3 and R6a are connected to form -O-C1-C6 alkylene, or -O-C2-C6 alkenylene, said O is bound at the R3 position;
optionally R4 and R5 are connected to form C1-C6 alkylene, C2-C6 alkenylene, -O-C1-C6 alkylene, or -O-C2-C6 alkenylene, such that where R4 and R5 are connected to form -O-C1-C6 alkylene, or -O-C2-C6 alkenylene, said O is bound at the R5 position;
optionally R5 and R6 are connected to form -O-C1-C6 alkylene, -O-C2-C6 alkenylene, or -O-C2-C6 alkynylene, such that where R5 and R6 are connected to form -O-C1-C6 alkylene, -O-C2-C6 alkenylene, or -O-C2-C6 alkynylene, said O is bound at the R5 position;
optionally R7 and R8 are connected to form C1-C6 alkylene or C2-C6 alkenylene; and optionally R7a and R8a are connected to form C1-C6 alkylene or C2-C6 alkenylene.
2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein
Y and Ya are each independently selected from the group consisting of -O- and -S-; Xa and Xa1 are each independently selected from the group consisting of -O- and -S-;
Xb and Xb1 are each independently selected from the group consisting of -O and -S-; Xc and Xc1 are each independently selected from the group consisting of -SR9, -OR9, and -NR9R9;
Xd and Xd1 are each independently selected from the group consisting of O and S; R1 and R1a are each H;
R2 and R2a are each independently selected from the group consisting of H, F, Cl, Br, I, OH, CN, N3, C1-C6 alkyl, and C1-C6 haloalkyl, where said R2 and R2a C1-C6 alkyl or C1-C6 haloalkyl are substituted by 0 to 3 substituents selected from the group consisting of OH, CN, and N3; R3 is selected from the group consisting of H, F, Cl, Br, I, OH, CN, N3, C1-C6 alkyl, and C1-C6 haloalkyl, where said R3 C1-C6 alkyl or C1-C6 haloalkyl are substituted by 0 to 3 substituents selected from the group consisting of OH, CN, and N3;
R4 and R4a are each independently selected from the group consisting of H, F, Cl, I, Br, CN, OH, N3, C1-C6 alkyl, and C1-C6 haloalkyl, where said R4 and R4a C1-C6 alkyl or C1-C6 haloalkyl are substituted by 0 to 3 substituents selected from the group consisting of OH, CN, and N3;
R5 is selected from the group consisting of H, F, Cl, Br, I, OH, N3, C1-C6 alkyl, and C1-C6 haloalkyl, where said R5 C1-C6 alkyl or C1-C6 haloalkyl are substituted by 0 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, CN, and N3;
R6 and R6a are each independently selected from the group consisting of H, F, Cl, I, Br, OH, CN, N3, C1-C6 alkyl, C2-C6 alkenyl, and C2-C6 alkynyl, where said R6 and R6a C1-C6 alkyl, C2-C6 alkenyl, and C2-C6 alkynyl are substituted by 0 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, CN, and N3;
R7 and R7a are each independently selected from the group consisting of H, C1-C6 alkyl, and C1-C6 haloalkyl, where said R7 and R7a C1-C6 alkyl or C1-C6 haloalkyl are substituted by 0 to 3 substituents selected from the group consisting of OH, CN, and N3;
R8 and R8a are each independently selected from the group consisting of H, C1-C6 alkyl, and C1-C6 haloalkyl, where said R8 and R8a C1-C6 alkyl or C1-C6 haloalkyl are substituted by 0 to 3 substituents selected from the group consisting of OH, CN, and N3;
each R9 is independently selected from the group consisting of H, C1-C6 alkyl,
Figure imgf000200_0001
where each R9 C1-C6 alkyl is optionally substituted by 1 to 2 substituents independently selected from the group consisting of OH, -O-C1-C20 alkyl,-S-C(O)C1-C6 alkyl, and -C(O)OC1-C6 alkyl;
optionally R3 and R6a are connected to form C2-C6 alkylene, C2-C6 alkenylene, -O-C1-C6 alkylene, or -O-C2-C6 alkenylene, such that where R3 and R6a are connected to form -O-C1-C6 alkylene or -O-C2-C6 alkenylene, said O is bound at the R3 position; and
optionally R5 and R6 are connected to form C1-C6 alkylene, C2-C6 alkenylene, -O-C1-C6 alkylene, or -O-C2-C6 alkenylene, such that where R5 and R6 are connected to form -O-C1-C6 alkylene or -O-C2-C6 alkenylene, said O is bound at the R5 position.
3. The compound according to claim 1 or claim 2, or a pharmaceutically acceptable salt thereof, wherein
Base1 and Base2 are each independently selected from the group consisting of
NH NH
Figure imgf000201_0001
Figure imgf000202_0001
wherein
at least one of Base1 and Base2 is each independently selected from the
group consisting of
Figure imgf000202_0002
Figure imgf000202_0003
and
Base1 and Base2 each may be independently substituted by 0-3 substituents R10, where each R10 is independently selected from the group consisting of F, Cl, I, Br, OH, SH, NH2, C1-3 alkyl, C3-6 cycloalkyl, O(C1-3 alkyl), O(C3-6 cycloalkyl), S(C1-3 alkyl), S(C3-6 cycloalkyl), NH(C1-3 alkyl), NH(C3-6 cycloalkyl), N(C1-3 alkyl)2, and N(C3-6 cycloalkyl)2;
Y and Ya are each independently selected from the group consisting of -O- and -S-; Xa and Xa1 are each independently selected from the group consisting of -O- and -S-;
Xb and Xb1 are each independently selected from the group consisting of -O- and -S-;
Xc and Xc1 are each independently selected from the group consisting of -OH,
Figure imgf000202_0004
Figure imgf000203_0001
Xd and Xd1 are each independently selected from the group consisting of O and S; R1 and R1a are each H;
R2 and R2a are each independently selected from the group consisting of H, F, Cl, I, Br, OH, CN, N3, -CF3, -CH3, -CH2OH, and -CH2CH3;
R3 is selected from the group consisting of H, F, Cl, I, Br, OH, CN, N3, -CF3, -CH3, -CH2OH, and -CH2CH3;
R4 and R4a are each independently selected from the group consisting of H, F, Cl, I, Br, OH, CN, N3, -CF3, -CH3, -CH2OH, and -CH2CH3;
R5 is selected from the group consisting of H, F, Cl, I, Br, OH, CN, N3, -CF3, -CH3, -CH2OH, and -CH2CH3;
R6 and R6a are each independently selected from the group consisting of H, F, Cl, I, Br, OH, CN, N3, -CF3, -CH3, -CH2OH, -CH2CH3, -CH=CH2, -C≡CH, and -C≡C-CH;
R7 and R7a are each independently selected from the group consisting of H, -CF3, -CH3, and -CH2CH3;
R8 and R8a are each independently selected from the group consisting of H, -CF3, -CH3, and -CH2CH3;
optionally R3 and R6a are connected to C2-C6 alkylene, C2-C6 alkenylene, -O-C1-C6 alkylene, or -O-C2-C6 alkenylene, such that where R3 and R6a are connected to form -O-C1-C6 alkylene or -O-C2-C6 alkenylene, said O is bound at the R3 position; and
optionally R5 and R6 are connected to form C1-C6 alkylene, C2-C6 alkenylene, -O-C1-C6 alkylene, or -O-C2-C6 alkenylene, such that where R5 and R6 are connected to form -O-C1-C6 alkylene or -O-C2-C6 alkenylene, said O is bound at the R5 position.
4. The compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein
Base1 and Base2 are each independently selected from the group consisting of
NH NH
Figure imgf000204_0001
at least one of Base1 and Base2 is each independently selected from the group
consisting of
Figure imgf000205_0001
Figure imgf000205_0002
and
Base1 and Base2 each may be independently substituted by 0-3 substituents R10, where each R10 is independently selected from the group consisting of F, Cl, I, Br, OH, SH, NH2, C1-3 alkyl, C3-6 cycloalkyl, O(C1-3 alkyl), O(C3-6 cycloalkyl), S(C1-3 alkyl), S(C3-6 cycloalkyl), NH(C1-3 alkyl), NH(C3-6 cycloalkyl), N(C1-3 alkyl)2, and N(C3-6 cycloalkyl)2;
Y and Ya are each independently selected from the group consisting of -O- and -S-; Xa and Xa1 are each -O-;
Xb and Xb1 are each -O-;
Xc and Xc1 are each independently selected from the group consisting of -OH and -SH;
Xd and Xd1 are each independently selected from the group consisting of O and S; R1 and R1a are each H;
R2 and R2a are each independently selected from the group consisting of H, F, Cl, OH, CN, N3, and -CH3;
R3 is selected from the group consisting of H, F, Cl, OH, CN, N3, and -CH3;
R4 and R4a are each independently selected from the group consisting of H, F, Cl, OH, CN, N3, and -CH3;
R5 is selected from the group consisting of H, F, Cl, OH, CN, N3, and -CH3;
R6 and R6a are each independently selected from the group consisting of H, F, CN, N3, -CH3, -CH=CH2, and -C≡CH;
R7 and R7a are each H;
R8 and R8a are each H;
optionally R3 and R6a are connected to form -O-C1-C6 alkylene or -O-C2-C6 alkenylene, such that O is bound at the R3 position; and optionally R5 and R6 are connected to form C1-C6 alkylene, C2-C6 alkenylene, -O-C1-C6 alkylene, or -O-C2-C6 alkenylene, such that where R5 and R6 are connected to form -O-C1-C6 alkylene or -O-C2-C6 alkenylene, said O is bound at the R5 position.
5. The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein
Base1 and Base2 are each independently selected from the group consisting of
Figure imgf000206_0001
at least one of Base1 and Base2 is each independently selected from the
group consisting of
Figure imgf000207_0001
Figure imgf000207_0002
and
Base1 and Base2 each may be independently substituted by 0-3 substituents R10, where each R10 is independently selected from the group consisting of F, Cl, I, Br, OH, SH, NH2, C1-3 alkyl, C3-6 cycloalkyl, O(C1-3 alkyl), O(C3-6 cycloalkyl), S(C1-3 alkyl), S(C3-6 cycloalkyl), NH(C1-3 alkyl), NH(C3-6 cycloalkyl), N(C1-3 alkyl)2, and N(C3-6 cycloalkyl)2;
Y and Ya are each independently selected from the group consisting of -O- and -S-; Xa and Xa1 are each O;
Xb and Xb1 are each O;
Xc and Xc1 are each independently selected from the group consisting of -OH and -SH;
Xd and Xd1 are each independently selected from the group consisting of O and S; R1 and R1a are each H;
R2 and R2a are each independently selected from the group consisting of H, F, Cl, OH, CN, N3, and -CH3;
R3 is selected from the group consisting of H, F, Cl, OH, CN, N3, and -CH3;
R4 and R4a are each independently selected from the group consisting of H, F, Cl, OH, CN, N3, and CH3;
R5 is selected from the group consisting of H, F, Cl, OH, CN, N3, and -CH3;
R6 and R6a are each independently selected from the group consisting of H, F, CN, N3, -CH3, -CH=CH2, and -C≡CH;
R7 and R7a are each H;
R8 and R8a are each H;
optionally R3 and R6a are connected to form -O-C1-C6 alkylene or -O-C2-C6 alkenylene, such that where R3 and R6a are connected to form -O-C1-C6 alkylene or -O-C2-C6 alkenylene, said O is bound at the R3 position; and optionally R5 and R6 are connected to form C1-C6 alkylene, C2-C6 alkenylene, -O-C1-C6 alkylene, or -O-C2-C6 alkenylene, such that where R5 and R6 are connected to form -O-C1-C6 alkylene or -O-C2-C6 alkenylene, said O is bound at the R5 position.
6. The compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein
Base1 and Base2 are each independently selected from the group consisting of
Figure imgf000208_0001
wherein
at least one of Base1 and Base2 is each independently selected from the
group consisting of
Figure imgf000208_0003
, , , , ,
and
Figure imgf000208_0004
Base1 and Base2 each may be independently substituted by 0-3 substituents R10, where each R10 is independently selected from the group consisting of F, Cl, I, Br, OH, SH, NH2, C1-3 alkyl, C3-6 cycloalkyl, O(C1-3 alkyl), O(C3-6 cycloalkyl), S(C1-3 alkyl), S(C3-6 cycloalkyl), NH(C1-3 alkyl), NH(C3-6 cycloalkyl), N(C1-3 alkyl)2, and N(C3-6 cycloalkyl)2;
Y and Ya are each independently selected from the group consisting of -O- and -S-; Xa and Xa1 are each -O-; Xb and Xb1 are each -O-;
Xc and Xc1 are each independently selected from the group consisting of -SH and -OH;
Xd and Xd1 are each independently selected from the group consisting of O and S; R1 and R1a are each H;
R2 and R2a are each independently selected from the group consisting of H, F, and OH;
R3 is selected from the group consisting of H, F, and OH;
R4 and R4a are each independently selected from the group consisting of H, F, and OH;
R5 is selected from the group consisting of H, F, and OH;
R6 and R6a are each H;
R7 and R7a are each H;
R8 and R8a are each H; and
optionally R3 and R6a are connected to form -O-C1-C6 alkylene or -O-C2-C6 alkenylene, such that where R3 and R6a are connected to form -O-C1-C6 alkylene or -O-C2-C6 alkenylene, said O is bound at the R3 position.
7. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein
Base1 and Base2 are each independently selected from the group consisting of
Figure imgf000209_0001
at least one of Base1 and Base2 is each independently selected from the
group consisting of
Figure imgf000210_0001
Figure imgf000210_0002
and
Base1 and Base2 each may be independently substituted by 0-3 substituents R10, where each R10 is independently selected from the group consisting of F, Cl, I, Br, OH, SH, NH2, C1-3 alkyl, C3-6 cycloalkyl, O(C1-3 alkyl), O(C3-6 cycloalkyl), S(C1-3 alkyl), S(C3-6 cycloalkyl), NH(C1-3 alkyl), NH(C3-6 cycloalkyl), N(C1-3 alkyl)2, and N(C3-6 cycloalkyl)2;
Y and Ya are each independently selected from the group consisting of -O- and -S-; Xa and Xa1 are each -O-;
Xb and Xb1 are each -O-;
Xc and Xc1 are each independently selected from the group consisting of -SH and -OH;
Xd and Xd1 are each independently selected from the group consisting of O and S; R1 and R1a are each H;
R2 is H;
R2a is selected from the group consisting of H, F, and OH;
R3 is selected from the group consisting of H, F, and OH;
R4 is selected from the group consisting of H, F, and OH;
R4a is H;
R5 is selected from the group consisting of H, F, and OH;
R6 and R6a are each H;
R7 and R7a are each H;
R8 and R8a are each H; and
optionally R3 and R6a are connected to form -O-C1-C6 alkylene, such that where R3 and R6a are connected to form -O-C1-C6 alkylene, said O is bound at the R3 position.
8. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein
Base1 and Base2 are each independently selected from the group consisting of
Figure imgf000211_0001
at least one of Base1 and Base2 is each independently selected from the
group consisting of
Figure imgf000211_0002
Figure imgf000211_0003
and
Base1 and Base2 each may be independently substituted by 0-3 substituents R10, where each R10 is independently selected from the group consisting of F, Cl, I, Br, OH, SH, NH2, C1-3 alkyl, C3-6 cycloalkyl, O(C1-3 alkyl), O(C3-6 cycloalkyl), S(C1-3 alkyl), S(C3-6 cycloalkyl), NH(C1-3 alkyl), NH(C3-6 cycloalkyl), N(C1-3 alkyl)2, and N(C3-6 cycloalkyl)2;
Y and Ya are each independently selected from the group consisting of -O- and -S-; Xa and Xa1 are each -O-;
Xb and Xb1 are each -O-;
Xc and Xc1 are each independently selected from the group consisting of -SH and -OH;
Xd and Xd1 are each independently selected from the group consisting of O and S; R1 and R1a are each H;
R2 is H;
R2a is selected from the group consisting of H, F, and OH;
R3 is selected from the group consisting of H, F, and OH;
R4 is selected from the group consisting of H, F, and OH;
R4a is H;
R5 is selected from the group consisting of H, F, and OH;
R6 and R6a are each H;
R7 and R7a are each H; and
R8 and R8a are each H.
9. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein
Base1 is selected from the group consisting of
Figure imgf000212_0001
Figure imgf000212_0002
Base2 is selected from the group consisting of
Figure imgf000213_0001
and
Figure imgf000213_0002
at least one of Base1 and Base2 is each independently selected from the group
consisting of
Figure imgf000213_0003
Figure imgf000213_0004
and Base1 and Base2 each may be independently substituted by 0-3 substituents R10, where each R10 is independently selected from the group consisting of F, Cl, I, Br, OH, SH, NH2, C1-3 alkyl, C3-6 cycloalkyl, O(C1-3 alkyl), O(C3-6 cycloalkyl), S(C1-3 alkyl), S(C3-6 cycloalkyl), NH(C1-3 alkyl), NH(C3-6 cycloalkyl), N(C1-3 alkyl)2, and N(C3-6 cycloalkyl)2;
Y and Ya are each independently selected from the group consisting of -O- and -S-; Xa and Xa1 are each -O-;
Xb and Xb1 are each -O-;
Xc and Xc1 are each independently selected from the group consisting of -SH and -OH;
Xd and Xd1 are each independently selected from the group consisting of O and S; R1 and R1a are each H;
R2 is H;
R2a is selected from the group consisting of H, F, and OH; R3 is selected from the group consisting of H, F, and OH;
R4 is selected from the group consisting of H, F, and OH;
R4a is H;
R5 is selected from the group consisting of H, F, and OH;
R6 and R6a are each H;
R7 and R7a are each H;
R8 and R8a are each H; and
R3 and R6a are connected to form -O-C1-C6 alkylene, such that where R3 and R6a are connected to form -O-C1-C6 alkylene, said O is bound at the R3 position.
10. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein
Base1 is selected from the group consisting of
Figure imgf000214_0001
Figure imgf000214_0002
Base2 is selected from the group consisting of
Figure imgf000215_0001
Figure imgf000215_0002
at least one of Base1 and Base2 is each independently selected from the group
consisting of
Figure imgf000215_0003
Figure imgf000215_0004
and Base1 and Base2 each may be
independently substituted by 0-3 substituents R10, where each R10 is independently selected from the group consisting of F, Cl, I, Br, OH, SH, NH2, C1-3 alkyl, C3-6 cycloalkyl, O(C1-3 alkyl), O(C3-6 cycloalkyl), S(C1-3 alkyl), S(C3-6 cycloalkyl), NH(C1-3 alkyl), NH(C3-6 cycloalkyl), N(C1-3 alkyl)2, and N(C3-6 cycloalkyl)2;
Y and Ya are each independently selected from the group consisting of -O- and -S-; Xa and Xa1 are each -O-;
Xb and Xb1 are each -O-;
Xc and Xc1 are each independently selected from the group consisting of -SH and -OH;
Xd and Xd1 are each independently selected from the group consisting of O and S; R1 and R1a are each H;
R2 is H;
R2a is selected from the group consisting of H, F, and OH; R3 is selected from the group consisting of H, F, and OH; R4 is selected from the group consisting of H, F, and OH; R4a is H;
R5 is selected from the group consisting of H, F, and OH; R6 and R6a are each H;
R7 and R7a are each H; and
R8 and R8a are each H.
11. A compound selected from the group consisting of:
Figure imgf000216_0001
Figure imgf000217_0001
Figure imgf000218_0001
and
Figure imgf000219_0001
pharmaceutically acceptable salts thereof.
12. A pharmaceutical composition, said pharmaceutical composition comprising:
(a) a compound according to any one of claims 1 to 11 or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof; and
(b) a pharmaceutically acceptable carrier.
13. A method of inducing an immune response in a subject, said method comprising administering a therapeutically effective amount of a compound according to any one of claims 1 to 11 to the subject.
14. A method of inducing an immune response in a subject, said method comprising administering a therapeutically effective amount of a pharmaceutical composition according to claim 12 to the subject.
15. A method of inducing a STING-dependent type I interferon production in a subject, said method comprising administering a therapeutically effective amount of a compound according to any one of claims 1 to 11 to the subject.
16. A method of inducing a STING-dependent type I interferon production in a subject, said method comprising administering a therapeutically effective amount of a pharmaceutical composition according to claim 12 to the subject.
17. A method of treating a cell proliferation disorder in a subject, said method comprising administering a therapeutically effective amount of a compound according to any one of claims 1 to 11 to the subject.
18. The method of claim 17, wherein the cell proliferation disorder is cancer.
19. A method of treating a cell proliferation disorder in a subject, said method comprising administering a therapeutically effective amount of a pharmaceutical composition according to claim 1 to the subject.
20. The method of claim 19, wherein the cell proliferation disorder is cancer.
PCT/US2018/065902 2017-12-20 2018-12-17 Cyclic di-nucleotide compounds as sting agonists WO2019125974A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US16/771,814 US11685761B2 (en) 2017-12-20 2018-12-17 Cyclic di-nucleotide compounds as sting agonists
EP18890472.6A EP3727401A4 (en) 2017-12-20 2018-12-17 Cyclic di-nucleotide compounds as sting agonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762608154P 2017-12-20 2017-12-20
US62/608,154 2017-12-20

Publications (1)

Publication Number Publication Date
WO2019125974A1 true WO2019125974A1 (en) 2019-06-27

Family

ID=66993810

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/065902 WO2019125974A1 (en) 2017-12-20 2018-12-17 Cyclic di-nucleotide compounds as sting agonists

Country Status (3)

Country Link
US (1) US11685761B2 (en)
EP (1) EP3727401A4 (en)
WO (1) WO2019125974A1 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021007160A1 (en) 2019-07-05 2021-01-14 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
US10966999B2 (en) 2017-12-20 2021-04-06 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
WO2021206158A1 (en) 2020-04-10 2021-10-14 小野薬品工業株式会社 Method of cancer therapy
US11149052B2 (en) 2018-04-06 2021-10-19 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′-cyclic dinucleotides
US11203610B2 (en) 2017-12-20 2021-12-21 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
WO2022032191A1 (en) 2020-08-07 2022-02-10 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
US11292812B2 (en) 2018-04-06 2022-04-05 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′-cyclic dinucleotides
WO2022220019A1 (en) * 2021-04-16 2022-10-20 国立大学法人東京工業大学 Long-chain dna synthesis using non-natural base
US11638716B2 (en) 2017-08-31 2023-05-02 F-star Therapeutics, Inc. Compounds, compositions, and methods for the treatment of disease
US11697666B2 (en) 2021-04-16 2023-07-11 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
US11767337B2 (en) 2020-02-18 2023-09-26 Gilead Sciences, Inc. Antiviral compounds
US11787833B2 (en) 2019-05-09 2023-10-17 Aligos Therapeutics, Inc. Modified cyclic dinucleoside compounds as sting modulators

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7209697B2 (en) * 2017-08-31 2023-01-20 ブリストル－マイヤーズ スクイブ カンパニー Cyclic dinucleotides as anticancer agents

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170044206A1 (en) * 2015-08-13 2017-02-16 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
WO2017075477A1 (en) * 2015-10-28 2017-05-04 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
WO2017093933A1 (en) * 2015-12-03 2017-06-08 Glaxosmithkline Intellectual Property Development Limited Cyclic purine dinucleotides as modulators of sting
WO2017161349A1 (en) * 2016-03-18 2017-09-21 Immune Sensor, Llc Cyclic di-nucleotide compounds and methods of use
WO2017186711A1 (en) * 2016-04-25 2017-11-02 Invivogen Novel complexes of immunostimulatory compounds, and uses thereof
WO2018100558A2 (en) * 2016-12-01 2018-06-07 Takeda Pharmaceutical Company Limited Cyclic dinucleotide
WO2018208667A1 (en) * 2017-05-12 2018-11-15 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20010306A1 (en) 1999-07-02 2001-03-29 Agouron Pharma INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM USEFUL FOR THE INHIBITION OF PROTEIN KINASE
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
US6310224B1 (en) 2001-01-19 2001-10-30 Arco Chemical Technology, L.P. Epoxidation catalyst and process
US20040175803A1 (en) 2001-02-20 2004-09-09 Jean-Francois Meritet Interferon-alpha induced gene
DK2206517T3 (en) 2002-07-03 2023-11-06 Ono Pharmaceutical Co Immunopotentiating compositions comprising anti-PD-L1 antibodies
CA2508660C (en) 2002-12-23 2013-08-20 Wyeth Antibodies against pd-1 and uses therefor
EP2270051B1 (en) 2003-01-23 2019-05-15 Ono Pharmaceutical Co., Ltd. Antibody specific for human PD-1 and CD3
JPWO2005005450A1 (en) 2003-07-15 2006-08-24 三井化学株式会社 Method for synthesizing cyclic bisdinucleotide
CA2560058C (en) 2004-03-15 2011-10-18 David K.R. Karaolis A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
DK2161336T4 (en) 2005-05-09 2017-04-24 Ono Pharmaceutical Co Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
AU2006265108C1 (en) 2005-07-01 2013-01-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
EP1782826A1 (en) 2005-11-08 2007-05-09 GBF Gesellschaft für Biotechnologische Forschung mbH PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
CA2855098C (en) 2007-06-18 2018-02-27 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme Pd-1 binding proteins
KR20110074850A (en) 2008-08-25 2011-07-04 앰플리뮨, 인크. Pd-1 antagonists and methods of use thereof
EP3530672B1 (en) 2008-09-26 2024-05-01 Dana-Farber Cancer Institute, Inc. Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses thereof
WO2010047774A2 (en) 2008-10-20 2010-04-29 The Texas A & M University System Inhibitors of mycobacterium tuberculosis malate synthase, methods of marking and uses thereof
SG10201708690SA (en) 2008-12-09 2017-12-28 Genentech Inc Anti-pd-l1 antibodies and their use to enhance t-cell function
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
US9156872B2 (en) 2011-04-13 2015-10-13 Merck Sharp & Dohme Corp. 2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
PE20190262A1 (en) 2011-08-01 2019-02-25 Genentech Inc METHODS FOR TREATING CANCER BY USE OF PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS
CA2876150A1 (en) 2012-06-08 2013-12-12 The Johns Hopkins University Compostions and methods for cancer immunotherapy
AU2013358892B2 (en) 2012-12-13 2018-06-21 Aduro Biotech, Inc. Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
US9211300B2 (en) 2012-12-19 2015-12-15 Idenix Pharmaceuticals Llc 4′-fluoro nucleosides for the treatment of HCV
KR102255996B1 (en) 2012-12-19 2021-05-26 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
CN112386604A (en) 2013-04-29 2021-02-23 纪念斯隆-凯特琳癌症中心 Modulators of cGAS
WO2014179760A1 (en) 2013-05-03 2014-11-06 The Regents Of The University Of California Cyclic di-nucleotide induction of type i interferon
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
RS59500B1 (en) 2013-05-18 2019-12-31 Aduro Biotech Inc Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
JP6400082B2 (en) 2013-05-18 2018-10-03 アデュロ バイオテック，インコーポレイテッド Compositions and methods for inhibiting "stimulating factor of interferon gene" dependent signaling
US10176292B2 (en) 2013-07-31 2019-01-08 Memorial Sloan-Kettering Cancer Center STING crystals and modulators
US20160287623A1 (en) 2013-11-19 2016-10-06 The University Of Chicago Use of sting agonist as cancer treatment
CA2931146C (en) 2013-11-22 2022-06-28 Brock University Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
US9315523B2 (en) 2013-12-06 2016-04-19 Rutgers, The State University Of New Jersey Cyclic dinucleosides
WO2015143712A1 (en) 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
EP3131914B1 (en) 2014-04-16 2023-05-10 Idenix Pharmaceuticals LLC 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
CN103908468B (en) 2014-04-21 2017-02-08 上海捌加壹医药科技有限公司 Application of cyclic dinucleotide cGAMP in preparing anti-tumor medicaments
SG11201609021QA (en) 2014-06-04 2016-11-29 Glaxosmithkline Ip Dev Ltd Cyclic di-nucleotides as modulators of sting
US20170121315A1 (en) 2014-06-12 2017-05-04 Bayer Pharma Aktiengesellschaft Heterobicyclically substituted 4-oxobutane acid derivatives and use thereof
US10010607B2 (en) 2014-09-16 2018-07-03 Institut Curie Method for preparing viral particles with cyclic dinucleotide and use of said particles for inducing immune response
US10011630B2 (en) 2014-12-16 2018-07-03 Invivogen Cyclic dinucleotides for cytokine induction
US20170340658A1 (en) 2014-12-16 2017-11-30 Invivogen Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment
CN112626153A (en) 2014-12-17 2021-04-09 立博美华基因科技有限责任公司 Methods of treating cancer with cGAMP or cGAsMP
GB2534573A (en) 2015-01-27 2016-08-03 Bae Systems Plc Reactive materials
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
JP6692826B2 (en) 2015-03-10 2020-05-13 アドゥロ バイオテック，インク． Compositions and methods for activation of "interferon gene stimulator" dependent signaling
WO2017011622A1 (en) 2015-07-14 2017-01-19 Spring Bank Pharmaceuticals, Inc. Compounds and compositions that induce rig-i-and other pattern recongnition receptors
CN107847215A (en) 2015-07-16 2018-03-27 索纳威科斯公司 For strengthening the polymer medical device containing microcavity of ultrasonic echo property
US10844051B2 (en) 2015-07-22 2020-11-24 The Royal Institution For The Advancement Of Learning/Mcgill University Substituted oxazoles for the treatment of cancer
US9809597B2 (en) 2015-08-20 2017-11-07 The Board Of Trustees Of The Leland Stanford Junior University Ganciclovir derivatives for modulating innate and adaptive immunity and for use in immunotherapy
EP3386536A4 (en) 2015-12-07 2019-07-31 Opi Vi- IP Holdco LLC Composition of antibody construct-agonist conjugates and methods of use thereof
WO2017123657A1 (en) 2016-01-11 2017-07-20 Gary Glick Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
AU2017207757B2 (en) 2016-01-11 2021-05-27 Innate Tumor Immunity, Inc. Cyclic dinucleotides for treating conditions associated with STING activity such as cancer
EP3440076B1 (en) 2016-04-07 2022-06-01 GlaxoSmithKline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
EA201892128A1 (en) 2016-04-07 2019-04-30 Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед HETEROCYCLIC AMIDES USEFUL AS MODULATORS
CN109563043B (en) 2016-06-13 2022-05-31 葛兰素史密斯克莱知识产权发展有限公司 Substituted pyridines as inhibitors of DNMT1
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
WO2018156625A1 (en) 2017-02-21 2018-08-30 Board Of Regents,The University Of Texas System Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling
WO2018198084A1 (en) 2017-04-27 2018-11-01 Lupin Limited Cyclic di-nucleotide compounds with tricyclic nucleobases
WO2019046500A1 (en) * 2017-08-31 2019-03-07 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
EP3891165A4 (en) * 2018-12-07 2022-08-24 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
EP3891166A4 (en) * 2018-12-07 2022-08-24 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
EP3891164A4 (en) * 2018-12-07 2022-08-24 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
EP3946370A4 (en) * 2019-03-29 2023-01-04 Merck Sharp & Dohme LLC Stable formulations of cyclic dinucleotide sting agonist compounds and methods of use thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170044206A1 (en) * 2015-08-13 2017-02-16 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
WO2017075477A1 (en) * 2015-10-28 2017-05-04 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
WO2017093933A1 (en) * 2015-12-03 2017-06-08 Glaxosmithkline Intellectual Property Development Limited Cyclic purine dinucleotides as modulators of sting
WO2017161349A1 (en) * 2016-03-18 2017-09-21 Immune Sensor, Llc Cyclic di-nucleotide compounds and methods of use
WO2017186711A1 (en) * 2016-04-25 2017-11-02 Invivogen Novel complexes of immunostimulatory compounds, and uses thereof
WO2018100558A2 (en) * 2016-12-01 2018-06-07 Takeda Pharmaceutical Company Limited Cyclic dinucleotide
WO2018208667A1 (en) * 2017-05-12 2018-11-15 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE PubChem compound 22 April 2017 (2017-04-22), "1-[(1R,6R,8R,9R,10S,15R,17R,18R)-8-(7-Aminoimidazo[4,5-b]pyridin-3-yl)-3,9,12,18-tetrahydroxy-3,12-dioxo-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-5H-imidazo[4,5-c]pyridin-4-one", XP055622119, retrieved from NCBI Database accession no. 126584781 *
See also references of EP3727401A4 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11638716B2 (en) 2017-08-31 2023-05-02 F-star Therapeutics, Inc. Compounds, compositions, and methods for the treatment of disease
US11203610B2 (en) 2017-12-20 2021-12-21 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
US10966999B2 (en) 2017-12-20 2021-04-06 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
US11292812B2 (en) 2018-04-06 2022-04-05 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′-cyclic dinucleotides
US11149052B2 (en) 2018-04-06 2021-10-19 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′-cyclic dinucleotides
US11787833B2 (en) 2019-05-09 2023-10-17 Aligos Therapeutics, Inc. Modified cyclic dinucleoside compounds as sting modulators
WO2021007160A1 (en) 2019-07-05 2021-01-14 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
US11767337B2 (en) 2020-02-18 2023-09-26 Gilead Sciences, Inc. Antiviral compounds
WO2021206158A1 (en) 2020-04-10 2021-10-14 小野薬品工業株式会社 Method of cancer therapy
WO2022032191A1 (en) 2020-08-07 2022-02-10 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
EP4295917A2 (en) 2020-08-07 2023-12-27 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
WO2022220019A1 (en) * 2021-04-16 2022-10-20 国立大学法人東京工業大学 Long-chain dna synthesis using non-natural base
US11697666B2 (en) 2021-04-16 2023-07-11 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides

Also Published As

Publication number Publication date
EP3727401A1 (en) 2020-10-28
US11685761B2 (en) 2023-06-27
EP3727401A4 (en) 2022-04-06
US20210206796A1 (en) 2021-07-08

Similar Documents

Publication Publication Date Title
US11685761B2 (en) Cyclic di-nucleotide compounds as sting agonists
EP3621624B1 (en) Cyclic di-nucleotide compounds as sting agonists
TWI696629B (en) Cyclic di-nucleotide compounds as sting agonists
JP7317014B2 (en) Cyclic dinucleotides as STING agonists
US8859756B2 (en) Stereoselective synthesis of phosphorus containing actives
US20230022922A1 (en) Ectonucleotidase inhibitors and methods of use thereof
EP3752516B1 (en) Cyclic dinucleotides as anticancer agents
EP3891166A1 (en) Cyclic di-nucleotide compounds as sting agonists
WO2020117625A1 (en) Cyclic di-nucleotide compounds as sting agonists
WO2020117623A1 (en) Cyclic di-nucleotide compounds as sting agonists
US11453697B1 (en) Cyclic di-nucleotide compounds as sting agonists
RU2776060C2 (en) Cyclic dinucleotides as sting agonists
EA046381B1 (en) ECTONUCLEOTIDASE INHIBITORS AND METHODS OF THEIR APPLICATION

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18890472

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018890472

Country of ref document: EP

Effective date: 20200720